<SEC-DOCUMENT>0001628280-20-008312.txt : 20200522
<SEC-HEADER>0001628280-20-008312.hdr.sgml : 20200522
<ACCEPTANCE-DATETIME>20200522171317
ACCESSION NUMBER:		0001628280-20-008312
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200522
DATE AS OF CHANGE:		20200522

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		20907011

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cpix-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:1ff53927-8a9f-4642-b593-f74226671984,g:b03cd8a5-37fe-4ab1-a910-c87820aed84d,d:4835ed8a3261445cb0eff023a2e2ca1a--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:cpix="http://www.cumberlandpharma.com/20200331" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGFibGU6OTljYzFiYmIxZDIxNDU3NmI2MDkyOWE3MzZjMzU2NWEvdGFibGVyYW5nZTo5OWNjMWJiYjFkMjE0NTc2YjYwOTI5YTczNmMzNTY1YV81LTEtMS0xLTA_3ba9c003-a2d6-43a5-9310-4cef07c1ad4b">2019</ix:nonNumeric><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGFibGU6OTljYzFiYmIxZDIxNDU3NmI2MDkyOWE3MzZjMzU2NWEvdGFibGVyYW5nZTo5OWNjMWJiYjFkMjE0NTc2YjYwOTI5YTczNmMzNTY1YV82LTEtMS0xLTA_b9a0fdb9-331b-47d7-9330-0500716e5c2f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGFibGU6OTljYzFiYmIxZDIxNDU3NmI2MDkyOWE3MzZjMzU2NWEvdGFibGVyYW5nZTo5OWNjMWJiYjFkMjE0NTc2YjYwOTI5YTczNmMzNTY1YV83LTEtMS0xLTA_1cfe9189-17d4-42f6-9b27-1543fa7a1ed2">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGV4dHJlZ2lvbjo2ZWUyODdlYjAzNjY0MTM3OGVjYWRiNTU2YWQzMmYyZV83OQ_46835ae2-06ee-43ac-baad-fa2f88421bd4">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGV4dHJlZ2lvbjo2ZWUyODdlYjAzNjY0MTM3OGVjYWRiNTU2YWQzMmYyZV84MA_45e8b225-67e0-41d2-9721-4e6a3f07255c">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="ic58199dde0ed4c74a4e8dff3dd65a772_D20200101-20200331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjA0MA_be8c0114-58e3-40ca-8fab-05faba05647c">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cpix-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0088e6b01c024950837d6835253c6edc_I20200518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc8b792be6e54df49d59d6e2ace6a801_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a78868ca68246878f4a228d9e2b4dc5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63aa5c50ea2741fb8570d7b27efeb73a_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2251f12c72da41a0af81132111638b47_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23db2a2a561141ce99aaafe3e6e00e5e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f64be2406764c309799078f75eb3592_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a620a084c74d74898f0dd62e6f7035_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109dbc8d282c4dd2838c55d7a9397435_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87cfdb3f63a74be9b0a92fab69c0e221_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc4ba9e1e0b41b39a3adb37adc6e050_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ecebde61254e95844331383fc92c61_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4880baf56e2047c6a8e04568a2759928_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i249ea7f123574d1fb56baebc9da7f0bc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1118bdd925ed4822a822302514c1ceac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e5be467315b44459b4f1ef5a3b2aff8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf2ca4dfae54e8a8f2062d0b20219bc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b4dd6a5c2e451fb816f8e209689c83_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37bad119d0fa4d7886b1bc8a846a15f6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f51ec8c6cc7448c8ad928a2dd4996f1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:Segment</xbrli:measure></xbrli:unit><xbrli:context id="ie2b2ac84d68d46b6b046398feff08b17_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc21010d4c344e397eec8fd94ae93a3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f6c43b973a9401aaef67992d1c6ca35_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35b3f63ab43f4e26ba10e84c0f0e0561_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie690b89f8a28465da873a92d63700759_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a74522aa1a246c6bb951c12119f378e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d05454a22094fa6aeb2797a74438214_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d8317aacc149c89f316a6abd144f03_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8abae9f8b7f487199521b9e594a9b4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81ff44d18e5471b841b0b5e665a2300_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9cd9a66d5994c338329d9b7f23a56f2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a0bbed12a24e969a3fa6d2c92012a5_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2f0112651b4b5fa2c8fa856efca4e1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16af1e6f767440c0963c81ea17a84134_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b63398db6574d36a6ab44657e1020f8_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e62ba5cdc8846b3a9cbad3ff2f3d0a6_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eff3e3f9b184c99a40826a7fc04fe79_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b53cdae72840e38ccd4cf9b68c791e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a6225e0029425ea693f971f523bd72_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ad73aa4ec4243509dc87099f3f6d521_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34cec4fe802e445f9f9cd20594027f4c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ad0374626954d6a8779a7d539793fd1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dd88465333045ef9fb8d8ae800f1e3c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8bef686ccd4979b9cbc4ee66cf65f8_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579ad134fe1e4cfabef5a5f04f4007a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ab812f8529f40f586ec3f2b6d28d198_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cbff9f699734f4fb0660403bd88bfc3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6ea68976af4647a79518bbe864fb79d2_I20100513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2010-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed406cf09644236bcf2d718718fb69b_I20160131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i273458bd3a91484ca9e99ab2ba12ad5d_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaacbe58946c445c98140de58546b9534_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b33bc113814241ac9ba8c827d1e630_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58199dde0ed4c74a4e8dff3dd65a772_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6cb09a407c649fd83e3903abfc61538_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ade4870a15949a494ead077ed1ab45a_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2c6d15e8144444bdf89f20f0f4edb3_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i292c0e03fcc9444091fffb0964c106d1_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85e4bb036d714dd4a5d3f463aca96009_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b413e2b14ac4e75b23217f08d1a9c8d_I20181017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6629760d5fe04dbda09e1240d59bb8dd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i042b097bef654ed4ac034003fdf2d9e8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad54c0f7e7445c781ab0aa335902d80_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75c26a02dc094045bfcbdd64d34312fe_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76719a5ce10a4d26a917106b3d04b051_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fe3919ad9c7434f9290fae098a242e4_I20181112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaff2de0de98c428d8e8f5eb28397ad66_D20181113-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-13</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6302aef8c83943f7b3951e346f855a91_D20181112-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-12</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ac1f01893a45b9935936208de31383_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a16ef9573464482a030c11307d87377_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecf68fa0fa84ed4ae405f562df6d78e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b25ac7991045ce8e15afc8083e3c2c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8444e0e8293a4f028089960cf516762d_I20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ffe21db330645f5a121ce609572f5f2_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25267995c74748d6b1a05373c4e7820f_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6e5559b01349c0b2cb01a91818807a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f4b8237d2904a1d9dd96818c23f441e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i667d0b68773d46a1a38eecfd7b6b8ff2_D20191001-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46788283ae334d9ea8d12af5a988a06f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81890f83a54f44bc874066750703bfcc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b3abff138f4568b1b90d05aff3cf8d_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic59f3a91d3c34c248c4b7251dabdddec_I20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-20</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_1"></div><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;margin-top:3pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON, DC 20549</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI1_3b5fb19e-ce5b-4f87-acf0-e9f69a4dd979">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6NjQyYmU2MTAyZDM1NDgyNGFjYmEzNGRjYTFkYzMzZWIvdGFibGVyYW5nZTo2NDJiZTYxMDJkMzU0ODI0YWNiYTM0ZGNhMWRjMzNlYl8wLTAtMS0xLTA_ea81863b-2f7d-421a-8996-0813156adcd2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl83MTQ2ODI1NTgyNTk0_0a606212-be42-4e1f-a61e-261b68eef4d7">March 31, 2020</ix:nonNumeric></span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6NTBjMTgwMTM3YjQzNGIwNTk1ZTNjYzlhMmYzOGRkNjIvdGFibGVyYW5nZTo1MGMxODAxMzdiNDM0YjA1OTVlM2NjOWEyZjM4ZGQ2Ml8wLTAtMS0xLTA_00d5a2d4-ee09-4895-8050-fe7a0b6215fb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number: <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIw_54165584-6e84-4b63-9ae5-4df1c5228707">001-33637</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI4_e8ac4503-ad07-4165-a2d5-4a3a6120c79f">Cumberland Pharmaceuticals Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Exact Name of Registrant as Specified In Its Charter)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:47.632%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:45.725%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8wLTAtMS0xLTA_670a0a28-d7f6-421f-87bb-9f126c3a95d1">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8wLTItMS0xLTA_97a2c24e-5493-452b-afb9-71c59fecf54e">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(State or Other Jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Incorporation or Organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Identification No.)</span></div></td></tr><tr><td colspan="3" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:4pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV81_6d8eb251-3e83-4240-b925-36979563e81b">2525 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV85_5393dfa7-006d-42ca-a914-aec5c86929cf">Suite 950</ix:nonNumeric>,</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV8xMw_769c308b-7109-494b-9164-0d97762d418c">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV8xNw_65644fc4-b0fa-4c10-8e09-3a26fe8258fa">Tennessee</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTItMS0xLTA_43a83393-82f5-49a2-b9b2-bafa9803c35c">37203</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIx_862a0016-918d-488f-a564-abfd1274da2c">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIy_bc304cf0-3106-40e4-a139-8e2718bcd451">255-0068</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIz_f4fcf3e3-f6eb-47d1-adaf-14019dfff003">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;"> <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI0_6579eb0b-a0fa-4dc2-9814-033d65af145f">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-align:justify;margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:21.391%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.285%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:40.836%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.431%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:24.023%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.434%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Large&#160;accelerated&#160;filer</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Accelerated&#160;filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6Nzk5Zjc2NmU2NGNkNDE1OGJkZTcyZDEyNWRjNjc0MzAvdGFibGVyYW5nZTo3OTlmNzY2ZTY0Y2Q0MTU4YmRlNzJkMTI1ZGM2NzQzMF8xLTAtMS0xLTA_5d2aff6e-7f30-4679-b413-1aa0eb18c1a7">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt:booleantrue" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6Nzk5Zjc2NmU2NGNkNDE1OGJkZTcyZDEyNWRjNjc0MzAvdGFibGVyYW5nZTo3OTlmNzY2ZTY0Y2Q0MTU4YmRlNzJkMTI1ZGM2NzQzMF8xLTUtMS0xLTMyNTU_38002190-b43a-4711-a43e-609e19236665">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;">Emerging growth company</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9.5pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6Nzk5Zjc2NmU2NGNkNDE1OGJkZTcyZDEyNWRjNjc0MzAvdGFibGVyYW5nZTo3OTlmNzY2ZTY0Y2Q0MTU4YmRlNzJkMTI1ZGM2NzQzMF8yLTItMS0xLTA_aa92856a-d617-4b9b-ac7f-8bee6b6714d9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to&#160;Section 13(a) of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI5_8fa2a3e6-fa15-402e-b313-232c83f7cb7a">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.269%;"><tr><td style="width:1.0%;"></td><td style="width:22.594%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.727%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:32.315%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.389%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:22.597%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Class</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of exchanged on which registered</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding&#160;at May 18, 2020</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTAtMS0xLTA_48b484e4-35e7-4cc7-8a18-9f061008b01e">Common stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTItMS0xLTA_973b1874-2126-48bd-bd10-f9f2fec88417">CPIX</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTQtMS0xLTA_f216097c-c402-49d6-9f45-a2745e902f4d">NASDAQ Global Select Market</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i0088e6b01c024950837d6835253c6edc_I20200518" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTYtMS0xLTA_2979b073-3c52-4b58-9eef-7bfecacbb129">15,230,746</ix:nonFraction></span></td></tr></table></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:9pt;"><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_7"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:81.431%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.569%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_10">PART I &#8211; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_10">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;padding-right:-18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_13">Item&#160;1. Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_13">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_16">1</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_19">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_19">2</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_22">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_22">3</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_25">Condensed Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_25">4</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_28">Notes to the Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_28">5</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_61">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_61">15</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_82">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_82">24</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_85">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_85">24</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_88">PART II &#8211; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_88">25</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_91">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_91">25</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_94">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_94">25</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_97">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_97">31</a></span></div></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_100">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_100">31</a></span></div></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_103">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i4835ed8a3261445cb0eff023a2e2ca1a_103">33</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_10"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I &#8211; FINANCIAL INFORMATION</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_13"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Financial Statements (Unaudited)</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_16"></div><div style="text-align:center;margin-top:18pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:58.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.618%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMy0xLTEtMS0w_19e9ed95-cfec-4966-afd4-3db9c743139f">27,026,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMy0zLTEtMS0w_42bd38e1-bd6f-4ecd-9ce6-ee5f36f9d868">28,212,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNS0xLTEtMS0w_a4edf45d-be2d-45d4-88af-f392b8872305">5,949,910</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNS0zLTEtMS0w_c595d35c-412b-4903-8e80-5dc0cfa5023d">7,843,917</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNi0xLTEtMS0w_d6ef36e4-9aa3-4775-a682-ae1b57b3215b">8,150,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNi0zLTEtMS0w_cb8cd18f-ac78-4d94-a40f-79e7f6611d40">8,871,254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets of discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0xLTEtMS0xODI_36c0f51f-ace4-4059-983a-4ea72cf85126">1,291,359</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0zLTEtMS0xODI_9910b08e-c382-4d2a-b4b6-675f3ad5edd9">2,477,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0xLTEtMS0w_25b96cca-9537-4a70-8c08-20870e991cd2">2,318,862</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0zLTEtMS0w_7cfe2c7a-9c0f-4b5d-932f-0d2f22a4496e">2,757,456</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOC0xLTEtMS0w_8ebd3d75-cecd-45be-a225-0401b3f15954">44,737,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOC0zLTEtMS0w_7969a5f5-bb8a-445f-9ea2-03f73c39d3b2">50,163,075</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-current inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOS0xLTEtMS0w_6185fb66-f72f-4c94-a5a7-d8d3ab0ba2af">15,569,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOS0zLTEtMS0w_8167df16-8bdd-4f2c-8d7a-66a5dbe74233">15,554,992</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTAtMS0xLTEtMA_50e9c3f4-4d34-4279-a51e-cf710b5501c2">694,499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTAtMy0xLTEtMA_a8bc7b75-cae2-4d24-8d28-5334555794e3">747,796</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intangible assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTEtMS0xLTEtMA_70f1520d-fa44-463e-b26e-2b8f646a44dd">30,142,611</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTEtMy0xLTEtMA_33d0577c-76e3-40d5-b55e-18506e2cfc25">30,920,324</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTItMS0xLTEtMA_c77b8456-77b3-4a6c-929e-3bcc0c7cd456">882,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTItMy0xLTEtMA_2596c763-7890-43c2-b83a-52d80eb9fc22">882,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTMtMS0xLTEtMA_0f5b58f4-4f5c-4428-bb78-b8b12ddfc652">21,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTMtMy0xLTEtMA_d05555d4-ab60-4ad8-820a-b5caa331deb2">21,802</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTUtMS0xLTEtMTg5_d10c6e02-ef0d-44fc-b27e-162406cee1f6">2,733,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTQtMy0xLTEtNDA_1d50d22a-7f93-4969-8c67-e5d7ac557076">2,960,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTQtMS0xLTEtMA_0d576cf6-925f-4383-9827-3cda465d5640">2,637,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTQtMy0xLTEtMA_712902fa-adda-4036-9d68-fd0ccebaed90">3,298,725</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTUtMS0xLTEtMA_9bbc2ea2-01e9-4d0c-99a7-3253b7199201">97,419,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTUtMy0xLTEtMA_99e94944-6237-4481-9be5-95f894789dd7">104,549,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTgtMS0xLTEtMA_ce6486f2-3ff0-40be-ae82-1aac3909bc29">8,247,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTgtMy0xLTEtMA_7c23a1d8-6eb3-41ed-b64b-ed3a15fee001">9,993,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities of discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMS0xLTEtMjkwMg_c7385ee6-c02b-42e6-b455-ee75e55c3f8d">1,247,011</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMy0xLTEtMjkwMg_f05c7835-8902-41d9-94ad-f98e6c4ed89d">1,918,868</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMS0xLTEtMTky_e41d19cd-a278-429c-9916-1232437916d7">943,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjAtMy0xLTEtNDQ_2529a059-7622-4fa1-b0e5-dbc5fdecdd38">920,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTktMS0xLTEtMA_b19ec7ce-6d47-4b97-9bec-ce8a92f3f298">8,933,874</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTktMy0xLTEtMA_6d80cc3d-b7bd-44ba-a5e3-2914e071d5ce">11,317,358</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjAtMS0xLTEtMA_d0d51004-095c-496b-895c-dc98cefdda21">19,372,591</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjAtMy0xLTEtMA_4ad97cf4-35f7-41b0-bae3-fc66a4478de8">24,150,235</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMS0xLTEtMA_b758d474-488b-444e-9f6e-89ba42a6e207">18,500,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMy0xLTEtMA_45b10ab4-92a7-4043-b7f3-48ae2c872b77">18,500,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease noncurrent liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjUtMS0xLTEtMTk1_c6bb3086-cadd-4947-8e44-ce2e3988a7a0">1,831,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjQtMy0xLTEtNDg_278e9afc-8eba-4ac1-9e6a-e1e21c7b7c5d">2,076,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjItMS0xLTEtMA_af5a03a1-d2fe-443f-aee4-b80ed44f1566">7,872,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:OtherLongTermObligationsExcludingCurrentPortion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjItMy0xLTEtMA_6c7a6ded-48bc-40c9-8be1-75417c4c8cd9">8,737,323</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjMtMS0xLTEtMA_b70ca04a-a9f3-4132-a89a-b16c6aa7cc9a">47,576,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjMtMy0xLTEtMA_4e702788-e9f3-461e-b759-f033edf41b1c">53,464,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjQtMS0xLTEtMA_ca80d7c3-0a89-4267-bd0d-030fff6d86da"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjQtMy0xLTEtMA_c2f659e8-e745-4d12-bd12-eb8b141815b2"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common stock&#8212;<ix:nonFraction unitRef="usdPerShare" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzE3_040b08ec-4d57-4019-95e0-4d6e6e498d6c"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockNoParValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzE3_9be8a6c5-1a27-45e1-a5d9-62994261bf5b">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzMx_42c1fb39-6bf1-40ce-a9da-2b8ed5364f93"><ix:nonFraction unitRef="shares" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzMx_4fb85efb-b0a3-4dd9-a644-d89364116d24">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzUz_3e74eb26-6398-4792-80ec-32d6bafd2bae"><ix:nonFraction unitRef="shares" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzUz_dc2d469f-d03e-485e-865c-7f7b7e5c5d7a">15,318,529</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzYw_058428c8-5f83-4844-9cf0-1cd84b690f18"><ix:nonFraction unitRef="shares" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzYw_50e74e15-5c9c-4d1d-ba97-0bb082e7c511">15,263,555</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMS0xLTEtMA_70b994f0-e54b-4787-9b3f-c6f4a9bb9af1">49,737,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMy0xLTEtMA_a8a96538-5011-4b87-9302-1c45f016c243">49,914,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjgtMS0xLTEtMA_6eeb6c74-eb27-45c6-9ba4-608a0ac83a98">152,775</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjgtMy0xLTEtMA_9e17a48f-67ed-46dd-aa7b-32094c4ec951">1,208,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total shareholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjktMS0xLTEtMA_424e0c6e-c7fc-4e89-9a21-45586cf635e4">49,890,203</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjktMy0xLTEtMA_53a6d0ba-9840-4bd7-9714-65efd0f5a341">51,122,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzAtMS0xLTEtMA_03781fa6-7104-41d8-b738-ad128fe0e0ba">47,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzAtMy0xLTEtMA_4cfb1349-03bc-4971-94ab-96d6e722ea0d">37,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzEtMS0xLTEtMA_e8d71a1f-828c-46d0-86ad-d0332d6eb374">49,843,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzEtMy0xLTEtMA_ba06814b-7d7a-4260-9deb-187aa0817d35">51,085,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzItMS0xLTEtMA_66a9cb12-aab3-4c9e-99da-ff2f289bb75c">97,419,137</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzItMy0xLTEtMA_625cdb26-63f1-4635-9b90-73ec0e49eebf">104,549,283</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_19"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.415%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.429%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMi01LTEtMS0w_82b71974-bbc7-43a8-a9ab-2529f97d1a78">8,330,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMi03LTEtMS0w_726dcef5-be7c-4d2e-8f98-01a0f930f69d">8,729,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNC01LTEtMS0w_e89ec22d-2d03-4b00-8b65-900527a440cc">1,634,181</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNC03LTEtMS0w_de5f0547-ddcd-47be-b76f-a116a58fcdc0">1,658,789</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNS01LTEtMS0w_974e2a80-bf66-41b8-bc99-e9f980a28b9a">3,707,676</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingAndMarketingExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNS03LTEtMS0w_e5fba390-f2d2-4934-8b90-c2eb671b9b8b">3,436,932</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNi01LTEtMS0w_46c0d7c1-8b93-488d-b21a-aeedfad377ff">1,722,555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNi03LTEtMS0w_82c7c0d1-6d4f-46a6-b14a-3caa3b5efc22">1,399,687</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNy01LTEtMS0w_6142ecd3-16e4-41f0-a49d-9152a0619cc2">2,036,284</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNy03LTEtMS0w_509f4c1c-4b21-4581-aee3-003cc9bf899c">2,536,739</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOC01LTEtMS0w_8bf8ec54-493b-4351-b316-8c2289b92059">1,076,039</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOC03LTEtMS0w_c03dbcf1-cb54-406f-8b9e-6983d7a8df20">1,021,645</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOS01LTEtMS0w_494a60d1-8aac-4bc7-b90b-3c986fc6eba7">10,176,735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOS03LTEtMS0w_96bee36f-3659-4143-a3b0-ac7f5fab68e7">10,053,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTAtNS0xLTEtMA_6ebb6e02-1805-4258-a81d-f6df60b4f0cc">1,846,001</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTAtNy0xLTEtMA_df3c3111-165c-428e-9ac6-03349fa8774a">1,323,932</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTEtNS0xLTEtMA_15f87bcb-a51c-4990-b67e-537b544d65e9">29,888</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTEtNy0xLTEtMA_c1ba5020-cdf0-46d7-8127-2ca916ee7409">115,861</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTItNS0xLTEtMA_d330ab7e-de1d-407c-9aab-8c36dac888e9">33,065</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTItNy0xLTEtMA_5a1a865b-d030-4c21-b3f9-2c81f55a744b">60,911</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations before income taxes</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTMtNS0xLTEtMA_c61b3d0f-805e-4743-a5e5-534ff94ceade">1,849,178</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTMtNy0xLTEtMA_4774d2bc-0c72-4bed-9f31-d72e778484e3">1,268,982</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTQtNS0xLTEtMA_5ec46e00-ca61-48d2-8aa4-e7e7c2f8985a">34,240</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTQtNy0xLTEtMA_aa28da43-8d3b-4fc9-864b-3c441ce26efa">81,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTUtNS0xLTEtMA_5a15a3de-42c7-4e3c-b016-a2356a68365a">1,883,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTUtNy0xLTEtMA_b7552cf2-dd28-4e5b-b3ca-43800042012d">1,187,554</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNS0xLTEtMjA2_c921a35b-bac2-4a72-865d-ede8b1d10878">818,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNy0xLTEtMjA2_6dc9222d-c8ba-444d-a417-77ba59e5dbad">1,147,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNS0xLTEtMjEw_7ecade60-5b0a-4b1e-9364-7a6f34f4b7bb">1,065,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNy0xLTEtMjEw_335b0956-5182-4b35-8f4e-980bbb050922">40,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNS0xLTEtMA_6e47ae3a-4bd0-42e8-8975-9c9ecb006e21">9,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNy0xLTEtMA_67af5d0d-10bc-4b5b-9ebe-5b336e131380">33,460</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNS0xLTEtMA_201d65dc-296d-43c1-b55b-9a96b3da1ed6">1,055,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNy0xLTEtMA_0760383e-6cb8-43ce-98e4-85a07974f201">73,878</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Earnings (loss) per share attributable to common shareholders</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Continuing operations - basic</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTktNS0xLTEtMA_29c6c9aa-ae3c-474a-a156-a3b758ed78ce">0.12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTktNy0xLTEtMA_05bc89e1-6666-4150-9fff-5ffd512a88b5">0.08</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Discontinued operations - basic</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNS0xLTEtMTQ3NA_7afc3bd0-d147-4da5-9d54-85622d5e2be6">0.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNy0xLTEtMTQ3NA_a7e6084d-0ecd-41f5-a2b3-0c7c7a5cbd0c">0.08</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNS0xLTEtMjUzNQ_8c63fde6-33cc-4303-adeb-b6a4ac865b7e">0.07</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNy0xLTEtMjUzNQ_4fda4f47-197a-4005-a43a-22b930f7aa51">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Continuing operations - diluted</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNS0xLTEtMTQ3NA_df66a2e5-706c-4db3-968d-3b5f48cbdce2">0.12</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNy0xLTEtMTQ3NA_861b9dab-25c0-49a8-a94c-3611be725228">0.08</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- Discontinued operations - diluted</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjAtNS0xLTEtMA_890867f3-cb44-479c-8334-f3ac5f510811">0.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjAtNy0xLTEtMA_6c072cb6-e610-4bc4-90f1-bca466ad443b">0.08</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNS0xLTEtMjUzOA_2ca87dd3-67fb-43b6-b15a-d212e7d16ac6">0.07</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNy0xLTEtMjUzOA_6fb763a6-bb38-4642-af0d-7faef7aebd66">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- basic</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNS0xLTEtMA_c9201846-3502-43c4-9def-e34142635d0e">15,240,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNy0xLTEtMA_e6beb0a8-87d9-40d9-a558-412323e0df34">15,472,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">- diluted</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNS0xLTEtMA_72f458c9-7d3f-4f09-af42-35fb6bd29d65">15,578,309</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNy0xLTEtMA_0a29c5aa-3ad4-4e18-95cf-9a2c9f9439a5">15,891,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive income (loss) attributable to common shareholders</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjUtNS0xLTEtMA_9a494a64-3ce1-4d9c-90f3-ef1c82a99083">1,055,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjUtNy0xLTEtMA_e7cb51dd-8fcb-4cbd-8fe5-58052b27d001">73,878</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive (income) loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNS0xLTEtMA_ba4f9c12-c1fe-432f-af4a-79bfeff261c3">9,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNy0xLTEtMA_6350784e-32ff-43da-9c19-7e646f3b1db3">33,460</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total comprehensive income (loss)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjctNS0xLTEtMA_8e8ffbdb-7257-4d00-96c5-8b6e3ae6b0e7">1,065,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjctNy0xLTEtMA_759a4b2d-21af-4697-a769-fc2e99718a23">40,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="margin-top:17pt;margin-bottom:17pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_22"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:65.836%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.789%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.384%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.791%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMy0xLTEtMS0w_fa20f6dd-44bd-4209-a821-359ec49a4343">1,065,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMy0zLTEtMS0w_3cc9bad3-0c6f-42fc-84b7-6e86b87ba09a">40,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNC0xLTEtMS0yMjg_31b78767-1bba-4f97-ad73-578a3d4b76df">818,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNC0zLTEtMS0yMjg_ce26dd63-5385-4595-8fd2-83e269c1574d">1,147,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0xLTEtMS0yMzg_1a67e5b4-14c4-45ff-8dad-a65ffdcbee7e">1,883,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0zLTEtMS0yMzg_7ce2f722-711a-47ba-a1e1-c8e62fa90c8d">1,187,554</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0xLTEtMS0w_474181e2-3521-4b42-a340-df7c61c391e4">1,152,062</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0zLTEtMS0w_482e1cf6-1806-4450-9db9-72aeb08fd715">1,076,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNi0xLTEtMS0w_5b53a811-406b-4117-88f9-0c4f899bbc1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNi0zLTEtMS0w_16093dd0-5b17-41f8-b1c3-b55501197110">43,605</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNy0xLTEtMS0w_67e5ca8b-f7ea-49ed-8cb0-e21c34ab2696">264,574</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNy0zLTEtMS0w_2a339324-deb5-404f-a244-04b145f1f6ae">364,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Decrease in non-cash contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOC0xLTEtMS0w_9da7ae02-3086-40fd-9854-4fc945e931eb">543,006</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOC0zLTEtMS0w_d5ec0759-cd73-4a4e-af15-ceb1592fafc7">269,422</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOS0xLTEtMS0w_823f29b0-141e-479c-96e7-e97dc4dcfae2">11,333</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOS0zLTEtMS0w_acc3e42e-0e3c-4a21-832f-31d8d845f0bd">10,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncash investment gains</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTAtMS0xLTEtMA_95d2a145-181f-40c9-a1f8-213bd4279be0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTAtMy0xLTEtMA_206de4e5-43b4-49a9-bb86-44ab49aad730">44,191</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTItMS0xLTEtMA_b4e4a47b-1848-421e-9874-c816d96da87d">2,014,438</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTItMy0xLTEtMA_cceecebd-c44c-4e00-8952-29d4370e3af3">1,361,692</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTMtMS0xLTEtMA_7f0c16ac-1583-4617-8b90-b652674f83e3">706,102</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTMtMy0xLTEtMA_abc1147a-4887-421b-a02c-d658d3c7a866">494,395</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current assets and other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTQtMS0xLTEtMA_5a34eaee-8fa8-4371-87db-bf782a398cab">1,093,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTQtMy0xLTEtMA_a653e677-4d49-4475-87d8-1f70df70c1bb">134,578</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTUtMS0xLTEtMA_aa4e79a8-6acd-4ecc-83d9-c36828135fc7">2,394,824</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="cpix:IncreaseDecreaseInCurrentOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTUtMy0xLTEtMA_e735203f-8637-40d2-a6d0-ee70437f277d">474,354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:54pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTYtMS0xLTEtMA_917c5392-80e9-49f8-b6f8-967410fe4b40">865,109</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTYtMy0xLTEtMA_bbf063a9-9f7f-43f0-8bd6-7031abcf3536">353,925</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities from continuing operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTctMS0xLTEtMA_5c370e7e-de8b-4f88-9ffa-bab456e94590">444,331</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTctMy0xLTEtMA_5ef95a2d-7f16-48ef-b2f4-4cc964f39200">618,675</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMS0xLTEtMjY0_af2bc935-e343-48a1-aca8-9cb68ac37ee4">1,332,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMy0xLTEtMjY0_f2eb5bdc-6e43-422a-8606-a71d20c9a8b6">232,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMS0xLTEtMjc0_fd3dcdab-a700-4fa0-8f40-8e8da4cb2c7f">888,539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMy0xLTEtMjc0_85edcef2-64f4-42a9-85b5-c29b61a3f414">385,733</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTktMS0xLTEtMA_95b6d3be-ea4a-40bc-9a6b-e3dbec73adf5">22,726</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTktMy0xLTEtMA_69d7380e-a04f-437d-ad2b-b45d1441381d">27,474</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMS0xLTEtMA_aa3fc2f0-4299-4976-836c-78441082bdac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMy0xLTEtMA_4d7b5e3e-922c-4126-a8bb-b97978173944">7,816,191</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from sale of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMS0xLTEtMA_505fc408-c35f-4455-b940-84e8182e4185">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMy0xLTEtMA_913cc7ee-4a29-443a-af3a-11527fef9f2b">6,483,988</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions to intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjMtMS0xLTEtMA_3327c081-c5b2-4106-9e4a-9b3f70ad3eb8">548,435</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjMtMy0xLTEtMA_b7d78711-c508-4995-82b8-7737432ae1c6">363,711</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjQtMS0xLTEtMA_98a561eb-d322-45f1-bf17-87d5ddeece6f">571,161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjQtMy0xLTEtMA_50f0512f-9bc2-4b9d-9297-e7e1570f46cf">1,723,388</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Borrowings on line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjctMS0xLTEtMA_cbe37698-f804-4acf-b645-f4fba4aa6d52">18,500,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjctMy0xLTEtMA_be59cedf-d0a4-4d7e-9178-c5f69c206547">19,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayments on line of credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjgtMS0xLTEtMA_cad697e8-e62b-44f4-bffb-7826281c1fe9">18,500,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjgtMy0xLTEtMA_56de487d-b04f-4836-a3e4-4487fdbc0b20">19,000,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzItMS0xLTEtMA_0fd7bc58-3443-4c0f-bfba-680202a2442c">260,735</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzItMy0xLTEtMA_27990241-be06-47ad-b366-48dfb6cbcddb">507,505</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of subsidiary shares from noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMS0xLTEtMzEy_2e18b2f5-009e-441d-b593-b3fd7587624a">800,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMy0xLTEtMjc4NA_0ae6db37-07d9-4f9f-9e3e-6860030731b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzYtMS0xLTEtMA_b15c6128-193e-43af-a823-95b2469849b8">442,544</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzYtMy0xLTEtMA_e8922f4a-940f-4691-9dcc-7c038ccde9d2">712,919</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMS0xLTEtMA_500f2686-f6ee-41ed-86e7-610cd06127c9">1,503,279</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMy0xLTEtMA_b84ee9ad-4fba-42c6-a6ff-c7f436b0af0a">1,220,424</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzgtMS0xLTEtMA_91445ce8-3c10-417f-9bf5-b921f3a59a0e">1,185,901</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzgtMy0xLTEtMA_4f76efcd-70f7-4451-bd03-dcf6dbef6cbb">3,329,545</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at beginning of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzktMS0xLTEtMA_730479a6-be7e-4cf1-ba9e-60b859458559">28,212,635</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a78868ca68246878f4a228d9e2b4dc5_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzktMy0xLTEtMA_62505c87-8870-4af4-bc3e-0010f302d50a">27,938,960</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDAtMS0xLTEtMA_46950947-b466-4004-a869-b63dd96c75d5">27,026,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63aa5c50ea2741fb8570d7b27efeb73a_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDAtMy0xLTEtMA_4eac3027-d7b4-46d3-ab3c-c13b6e2901a5">24,609,415</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Recognition of operating lease assets and liabilities through adoption of ASC 842</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDUtMS0xLTEtMjc4OA_44364121-78dd-48f5-a407-f810ba626266">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDUtMy0xLTEtMjc5MA_4d39fa45-39a2-4cca-9adc-41cd3be95868">3,629,320</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_25"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:3pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2251f12c72da41a0af81132111638b47_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi0xLTEtMS0w_3195e2aa-dd05-44f4-bbe4-0b78c3fc4b7d">15,481,497</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2251f12c72da41a0af81132111638b47_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi0zLTEtMS0w_c99109f8-2f4b-40f1-8496-60e3b46ae3c0">51,098,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i23db2a2a561141ce99aaafe3e6e00e5e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi01LTEtMS0w_bbb1d8fe-2136-4521-a76f-18e03af155c8">4,746,154</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5f64be2406764c309799078f75eb3592_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi03LTEtMS0w_35564af8-8e04-4fe6-95e3-811748ff6b19">274,266</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a78868ca68246878f4a228d9e2b4dc5_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi05LTEtMS0w_1f280d0e-c9ea-43fe-adc8-82ac0807c303">55,570,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNC0xLTEtMS0w_bcbb14ee-826d-4510-96a7-2d12f64ed6c3">187,486</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNC0zLTEtMS0w_5e8a39e8-abcb-4b72-86b3-fe33e7902e6d">364,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNC05LTEtMS0w_84b96713-6b7f-4ad2-8156-8067e4ee197f">364,434</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNS0xLTEtMS0w_1f1487b0-d770-424e-9a5c-ff8e6bf64004">121,466</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNS0zLTEtMS0w_9e731a73-37d1-4812-806d-5f4213d9719b">703,790</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNS05LTEtMS0w_c5ff3ed8-fba4-4e0a-8230-d7fde8bd6930">703,790</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="id1a620a084c74d74898f0dd62e6f7035_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNi01LTEtMS0w_cf66adfb-7c4d-4d33-a07b-6719fb591578">73,878</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i109dbc8d282c4dd2838c55d7a9397435_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNi03LTEtMS0w_9146f931-fc24-4b87-960b-e234a7508bb3">33,460</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNi05LTEtMS0w_0f5677e4-088f-4e34-b092-4b7e92ab313f">40,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i87cfdb3f63a74be9b0a92fab69c0e221_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy0xLTEtMS0w_522d2069-b5c4-4671-b22f-4ef885de66c3">15,547,517</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87cfdb3f63a74be9b0a92fab69c0e221_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy0zLTEtMS0w_b9be5439-6f70-49f2-aceb-744a31ded004">50,759,257</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iffc4ba9e1e0b41b39a3adb37adc6e050_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy01LTEtMS0w_de07242e-bd17-434c-ab7d-3596786c569f">4,672,276</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if2ecebde61254e95844331383fc92c61_I20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy03LTEtMS0w_74d15fe6-9e1c-46b8-8cdd-cfbf025179a3">240,806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i63aa5c50ea2741fb8570d7b27efeb73a_I20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy05LTEtMS0w_7f127b1c-6670-4dd4-90a3-9cfcc5decb04">55,190,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-bottom:3pt;"><span><br/></span></div><div style="margin-bottom:21pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Retained earnings</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncontrolling interests</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i4880baf56e2047c6a8e04568a2759928_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi0xLTEtMS0w_18cada15-4960-4bf9-b6da-59b1d5d65834"><ix:nonFraction unitRef="shares" contextRef="i4880baf56e2047c6a8e04568a2759928_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi0xLTEtMS0w_a68f769b-58c9-447c-8b03-12214d465587">15,263,555</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4880baf56e2047c6a8e04568a2759928_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi0zLTEtMS0w_f24f185e-46ed-4bdd-9337-8450d5dad8f5">49,914,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i249ea7f123574d1fb56baebc9da7f0bc_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi01LTEtMS0w_9412ba90-14f5-4c01-83cb-290c0cbe9925"><ix:nonFraction unitRef="usd" contextRef="i249ea7f123574d1fb56baebc9da7f0bc_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi01LTEtMS0w_d39780ec-f151-444d-90b2-c0c6d70c27e0">1,208,395</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1118bdd925ed4822a822302514c1ceac_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi03LTEtMS0w_7bebc214-d991-4389-9ef7-86862b6c6dfd"><ix:nonFraction unitRef="usd" contextRef="i1118bdd925ed4822a822302514c1ceac_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi03LTEtMS0w_a8138a96-84cf-42b8-af19-b614c17af3cf">37,620</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi05LTEtMS0w_23736d58-4809-452c-bcb5-3b19502dba8b"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi05LTEtMS0w_b42bc263-3289-4b96-9152-46497be35c91">51,085,253</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0xLTEtMS0w_7e0546fd-5763-4067-954c-9aa27e794346"><ix:nonFraction unitRef="shares" contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0xLTEtMS0w_da188e4b-a6fb-4296-ad64-121a8bd8e220">219,850</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0zLTEtMS0w_55ccde49-f216-4eb7-ba38-f226ac800cb9"><ix:nonFraction unitRef="usd" contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0zLTEtMS0w_636c4ccb-6c71-41da-bd17-16c8b74076d5">264,574</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy05LTEtMS0w_2f30a8fb-22c4-4207-910c-2a4757be2db7"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy05LTEtMS0w_6d4ec49c-0d59-4de8-9897-6e7a8beb17d6">264,574</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repurchase of common shares</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC0xLTEtMS0w_ed093a2d-9e6a-4d59-91ef-89581a379f3d">164,876</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC0zLTEtMS0w_59b675b5-1bed-4329-8f56-f00075e979a6">441,624</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC05LTEtMS0w_614639be-5f0e-481e-94f9-eeaa1af3d00e"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC05LTEtMS0w_78c31d70-0728-4e1c-aa38-277ae85a1f08">441,624</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2e5be467315b44459b4f1ef5a3b2aff8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS01LTEtMS0w_3906e7ee-6810-4e23-9a7a-7a37641bea41"><ix:nonFraction unitRef="usd" contextRef="i2e5be467315b44459b4f1ef5a3b2aff8_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS01LTEtMS0w_8109106b-5133-4584-a975-b138dadcf53d">1,055,620</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iabf2ca4dfae54e8a8f2062d0b20219bc_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS03LTEtMS0w_a57ba4eb-ece8-46b3-902e-8a6dc8d9c8bf"><ix:nonFraction unitRef="usd" contextRef="iabf2ca4dfae54e8a8f2062d0b20219bc_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS03LTEtMS0w_a975fd01-947c-400a-93c1-1a7c56d1ae85">9,525</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS05LTEtMS0w_21e93080-6aae-4544-984d-7c2e8941c7b5"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS05LTEtMS0w_616d9b49-5f17-4fa4-9650-1d94e41718b9">1,065,145</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i10b4dd6a5c2e451fb816f8e209689c83_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi0xLTEtMS0w_feb5ff4a-900c-4aac-9f23-7b83f9db40fb">15,318,529</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i10b4dd6a5c2e451fb816f8e209689c83_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi0zLTEtMS0w_5d0ad019-43bb-4a22-80a6-4792ab6cfd5e">49,737,428</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i37bad119d0fa4d7886b1bc8a846a15f6_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi01LTEtMS0w_9723de5d-d614-49a4-a0eb-68ae77852282">152,775</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i2f51ec8c6cc7448c8ad928a2dd4996f1_I20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi03LTEtMS0w_b2154c77-e288-404e-ab47-a99a5b1d0861">47,145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi05LTEtMS0w_cbf143f1-2579-40ea-834e-a246e949a394">49,843,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.976%;"><tr><td style="width:1.0%;"></td><td style="width:30.496%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.850%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.390%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.857%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="30" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_28"></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_31"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(1) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4MQ_c004b2a2-5cb0-4141-83f8-597b0754b840" continuedAt="ie78414a75cb14cf58aee74160cfaad5a" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ie78414a75cb14cf58aee74160cfaad5a" continuedAt="i35eff76545ac46b2904387ca170c1877"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#8220;2019 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March 31, 2020 and 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Discontinued Operations</span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVID-19 Pandemic </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  The Company is monitoring this situation both in the U.S. and internationally, so Cumberland can maintain employee safety and well-being, while also keeping the business operating and secure.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. All of the Company's corporate and Cumberland Emerging Technologies (&#8220;CET&#8221;) employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  Cumberland's sales organization has continued to make calls on medical professionals, providing information and product samples as requested. However, their contact has largely shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="i35eff76545ac46b2904387ca170c1877" continuedAt="i1f93a490c502453c81402e608cb26a27"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During this national health care and economic crisis, Cumberland understands that the volume of patients seeking health care was negatively impacted by the stay-at-home orders across the country. Declines in hospital admissions, patient visits to physician offices and postponement of elective surgeries have all been reported. As a result, Cumberland is facing the same headwinds that are affecting all companies that rely on these factors to help drive revenue. While the Company expects these dynamics to improve as the country reopens, it cannot be determined at this time when and to what extent that improvement will occur.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given the uncertainty, magnitude and impact of such changes, the Company is unable to fully quantify the impact on the future results as of the date of this filing.</span></div><div style="text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4Mw_234c9790-c647-45d6-883f-383354829e63" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4NA_2da365d8-3f49-4000-9e56-555e70e31e58" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"><ix:continuation id="i1f93a490c502453c81402e608cb26a27" continuedAt="i70ccb86089a144fb8af2e44edc2895a5"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4Ng_f1330eb6-fdd5-455a-92b1-d0f6a3569393" continuedAt="i7fb6b4216b434db98bfed8696ce1ff58" escape="true">Operating Segments</ix:nonNumeric></ix:continuation></span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i70ccb86089a144fb8af2e44edc2895a5"><ix:continuation id="i7fb6b4216b434db98bfed8696ce1ff58">The Company has <ix:nonFraction unitRef="segment" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTA3OA_138173f7-095d-497d-8b16-c27a1702e225">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation></ix:continuation> </span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_34"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(2) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RleHRyZWdpb246YzM2Zjc4ZjE0ZTQxNGM2MWFmZjQzNGYyYWM0MWVkZGZfNjU5NzA2OTc3MDE4NQ_59e34cc2-1d0d-45ed-9d7a-58bad6a075de" continuedAt="i80b11aea03434b558aa50db708ca9e31" escape="true">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i80b11aea03434b558aa50db708ca9e31"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds,  corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of March 31, 2020 and December 31, 2019, all trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RleHRyZWdpb246YzM2Zjc4ZjE0ZTQxNGM2MWFmZjQzNGYyYWM0MWVkZGZfMzIzOA_d21dfadf-eab6-4fe5-a142-f57d262a646e" escape="true"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:27.368%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.160%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.162%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie2b2ac84d68d46b6b046398feff08b17_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC0xLTEtMS0w_a810ef2b-092e-4359-8b7d-6a352e0e1823">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8dc21010d4c344e397eec8fd94ae93a3_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC0zLTEtMS0w_e077c1f6-aef6-4c08-8ff6-d7a0679e4295">498,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f6c43b973a9401aaef67992d1c6ca35_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC01LTEtMS0w_6f8fec2e-d437-443c-9aca-538ba30db882">498,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i35b3f63ab43f4e26ba10e84c0f0e0561_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC03LTEtMS0w_39ae4f98-8c29-44e7-a1ed-3f5cb6b8fb30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie690b89f8a28465da873a92d63700759_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC05LTEtMS0w_ad7e521c-dada-4fd9-9c29-ab76e3726300">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6a74522aa1a246c6bb951c12119f378e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC0xMS0xLTEtMA_82b90619-8749-4800-842d-fd8d9d78128f">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0d05454a22094fa6aeb2797a74438214_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi0xLTEtMS0w_40796ee9-6f47-4762-98e6-2c3aafa1bd86">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5d8317aacc149c89f316a6abd144f03_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi0zLTEtMS0w_af9ef809-e7f9-454a-b13a-958bfecc804f">498,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi01LTEtMS0w_9f3813a0-af73-4904-b815-a09f6d976375">498,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id8abae9f8b7f487199521b9e594a9b4a_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi03LTEtMS0w_a0999a8f-7500-474c-bf5d-bec7054af46f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if81ff44d18e5471b841b0b5e665a2300_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi05LTEtMS0w_791e903a-f011-4e99-afaa-ee5935ad552b">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TradingSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi0xMS0xLTEtMA_a118ea4e-ea07-45c8-8169-3bd5c14f7b10">2,119,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_37"></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(3) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfNDMw_9b2de82c-333e-4da2-b753-c71bba721014" continuedAt="idd9d8073c8ab4546a26f1eebf4363146" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="idd9d8073c8ab4546a26f1eebf4363146"><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfNDMx_cba2b5ea-337e-470c-8094-61abf8a3b1d4" escape="true"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"></td><td style="width:58.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.616%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.537%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.618%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:57.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.883%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.823%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.884%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0xLTEtMS0xNTU0_5a15a3de-42c7-4e3c-b016-a2356a68365a">1,883,418</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0zLTEtMS0xNTU0_b7552cf2-dd28-4e5b-b3ca-43800042012d">1,187,554</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNC0xLTEtMS0xNTU3_2b1ca2ee-c5ed-45c2-897f-70c123c9b226">818,273</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNC0zLTEtMS0xNTU3_2253372f-c8e2-4131-b31d-08084e6f8206">1,147,136</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0xLTEtMS0xNTYx_6e47ae3a-4bd0-42e8-8975-9c9ecb006e21">9,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0zLTEtMS0xNTYx_67af5d0d-10bc-4b5b-9ebe-5b336e131380">33,460</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0xLTEtMS0w_201d65dc-296d-43c1-b55b-9a96b3da1ed6">1,055,620</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0zLTEtMS0w_0760383e-6cb8-43ce-98e4-85a07974f201">73,878</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0xLTEtMS0w_c9201846-3502-43c4-9def-e34142635d0e">15,240,614</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0zLTEtMS0w_e6beb0a8-87d9-40d9-a558-412323e0df34">15,472,952</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfOS0xLTEtMS0yODA1_8c583640-071e-4a03-8cff-ae043290a6d0">337,695</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfOS0zLTEtMS0yODA2_6a561583-bbf8-4d5d-831c-03f1608a510c">418,618</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNy0xLTEtMS0w_72f458c9-7d3f-4f09-af42-35fb6bd29d65">15,578,309</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNy0zLTEtMS0w_0a29c5aa-3ad4-4e18-95cf-9a2c9f9439a5">15,891,570</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020 and 2019, restricted stock awards and options to purchase <ix:nonFraction unitRef="shares" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfMjUz_8039616c-3921-4560-86dd-5e173d01023c">431,226</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfMjYw_efd21adc-78dc-4859-860c-2f69d4038523">263,919</ix:nonFraction> shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div></ix:continuation><div id="i4835ed8a3261445cb0eff023a2e2ca1a_40"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(4) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfNjU5NzA2OTc3NDE4MA_f459a2c8-0e1d-4546-962b-b5fcbf1981a9" continuedAt="i63fd8ebbaa9e4a998673f9d73dcaad09" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="i63fd8ebbaa9e4a998673f9d73dcaad09" continuedAt="icb808d2c94f140419d20f982790004b0"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. </span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfMzAwMQ_cf7f3028-79d4-47a7-84e0-659f45bfaa04" escape="true"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.321%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="width:1.0%;"></td><td style="width:13.058%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.891%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib9cd9a66d5994c338329d9b7f23a56f2_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMy01LTEtMS0w_7fa367d3-878a-4280-a3b3-4a80b01b68cb">713,899</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71a0bbed12a24e969a3fa6d2c92012a5_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMy03LTEtMS0w_d4fb9b2e-3089-453a-a1d9-7465f037d1ea">849,502</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iad2f0112651b4b5fa2c8fa856efca4e1_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNC01LTEtMS0w_cce91490-63c1-479b-8873-75c670a4e931">114,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i16af1e6f767440c0963c81ea17a84134_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNC03LTEtMS0w_aa64d11b-09e0-4711-b742-0e4585ae3582">199,537</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9b63398db6574d36a6ab44657e1020f8_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNS01LTEtMS0w_f7966a2c-b5e8-452f-9dc2-10eb71ad045f">3,311,696</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e62ba5cdc8846b3a9cbad3ff2f3d0a6_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNS03LTEtMS0w_a5bbcf50-8eb1-4265-bfe0-d38c85c2829b">3,307,658</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2eff3e3f9b184c99a40826a7fc04fe79_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNi01LTEtMS0w_a65f64a6-24f0-43b9-bf3f-02fe79fc2eb4">208,763</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i51b53cdae72840e38ccd4cf9b68c791e_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNi03LTEtMS0w_84583510-06ec-4778-9112-649e91c5145b">286,676</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i97a6225e0029425ea693f971f523bd72_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNy01LTEtMS0w_d425e996-d5d9-4063-b3c2-81729655b0b3">1,096,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ad73aa4ec4243509dc87099f3f6d521_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNy03LTEtMS0w_60707775-6bd9-48d5-81c4-242f03e8f59d">1,317,074</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i34cec4fe802e445f9f9cd20594027f4c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTAtNS0xLTEtMA_3007ec29-a695-47bc-90a4-047583e48972">2,425,755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ad0374626954d6a8779a7d539793fd1_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTAtNy0xLTEtMA_d8642756-aba4-4797-adbf-98f2150fedec">2,060,195</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5dd88465333045ef9fb8d8ae800f1e3c_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTEtNS0xLTEtMA_9b28884a-5459-45dc-90a6-c0cfc57265e9">459,560</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4b8bef686ccd4979b9cbc4ee66cf65f8_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTEtNy0xLTEtMA_9a154b3e-5025-4f0e-9375-00c97657005d">709,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTItNS0xLTEtMA_3461e97f-5ebb-48a4-8573-5ca780b69046">8,330,734</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTItNy0xLTEtMA_9648ab7a-8e0b-4c32-a720-7efe62e3678c">8,729,860</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into as a result of providing the distinct intellectual property rights for the respective international territory. These agreements also provide for additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="icb808d2c94f140419d20f982790004b0"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">supplies.  The contractual payments associated with the partners achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues also include revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET&#8217;s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i579ad134fe1e4cfabef5a5f04f4007a2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfNzE0NjgyNTU4OTA3OA_b10aa019-ec0a-4953-abd3-184ac909bd29">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0ab812f8529f40f586ec3f2b6d28d198_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfNzE0NjgyNTU4OTA5Mg_e6f42cbc-cb2d-4686-ba3b-f2b4e1a692bd">0.6</ix:nonFraction>&#160;million for the three months ended March 31, 2020 and 2019, respectively.</span></div></ix:continuation><div id="i4835ed8a3261445cb0eff023a2e2ca1a_43"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(5) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfMjAxMw_a8e1ad1e-2f44-49e4-966d-f07d7c724d00" continuedAt="i5a65874c2833436198d5a2370d88c485" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="i5a65874c2833436198d5a2370d88c485"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  During 2019, Cumberland also obtained $<ix:nonFraction unitRef="usd" contextRef="i1cbff9f699734f4fb0660403bd88bfc3_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfNjU5NzA2OTc2OTYzNw_98e29a73-9a15-469e-bc52-8f2c6bcd0391">0.3</ix:nonFraction>&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. At March 31, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $<ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfNjU5NzA2OTc2OTY2NQ_e53ddfcc-f38a-47fb-bce3-6a0b5710d594"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfNjU5NzA2OTc2OTY2NQ_f10e8d7b-2e69-40e4-be15-e517fd8ed526">15.6</ix:nonFraction></ix:nonFraction>&#160;million. The Company did not have any finished goods included in the non-current inventories at March 31, 2020 or December 31, 2019, respectively.  </span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfMjAxMg_9e4db129-a93a-443b-834b-639f0a34aa7a" escape="true"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:56.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.121%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.530%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.681%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.531%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMi0yLTEtMS0w_d9977d74-d56b-43ed-805a-be125b431c06">19,456,867</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMi00LTEtMS0w_38789efa-3de6-4464-8422-3ff49dc076e9"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMi00LTEtMS0w_7326ce1d-28e1-4196-952f-41944ab25970">19,345,723</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMy0yLTEtMS0w_eac5ce01-bbcb-4f82-9151-a1fbc4e9bb30">245,354</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMy00LTEtMS0w_6861037e-9ff4-4101-980a-e2c7786249dd"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMy00LTEtMS0w_cf915bf5-6d4e-43ba-871b-dc36998e9aac">416,468</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNC0yLTEtMS0w_4381a2b5-32fa-408e-b31b-2cb9e249b242">4,017,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNC00LTEtMS0w_18c7d997-a40f-4182-bcd0-b6398d05b1ae"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNC00LTEtMS0w_609a61d3-4c7b-4f1d-9f81-79e8bd3126c0">4,664,055</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNS0yLTEtMS0w_340e8e60-3ffe-4c34-81a8-ec58bfb25572">23,720,144</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNS00LTEtMS0w_4334909d-17ad-40d6-88d9-3d226c19b409">24,426,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNi0yLTEtMS0w_9cb07d87-d320-4d24-a440-dcb33cea6595">15,569,992</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNi00LTEtMS0w_ccafe397-fd73-4f99-8e21-325acd783009">15,554,992</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNy0yLTEtMS0w_9ee5624f-2372-4669-b2ce-b8b729014a91">8,150,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNy00LTEtMS0w_600031c7-6124-4c9f-a10b-738fe3394fc4">8,871,254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;"><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_46"></div><div style="margin-top:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(6) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjg3Mw_41c14a6c-7169-4130-9586-af6c8a490846" continuedAt="i8bde04ae388046f289753173cf6a6531" escape="true">LEASES</ix:nonNumeric></span></div><div style="text-align:justify;"><span><br/></span></div><ix:continuation id="i8bde04ae388046f289753173cf6a6531"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is <ix:nonFraction unitRef="number" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjc1Nw_858b26f2-5939-474a-8ac6-ac263b4e2156">7.42</ix:nonFraction>%. The weighted-average remaining lease term at March 31, 2020 is <ix:nonNumeric contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfNTQ5NzU1ODE0Mjk1Nw_bc6bb1f3-755e-4183-84af-642a2c8dba8b">2.7</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Lease Position</span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjg3NA_b29027f1-c79f-46a6-8c52-a827606664ef" escape="true"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March 31, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"><tr><td style="width:1.0%;"></td><td style="width:29.316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.464%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:27.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.464%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.187%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.464%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.005%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjkyZWMwNDVmY2E2YTRkN2FiYThlYWVlNzJlNWQ5ODcyL3RhYmxlcmFuZ2U6OTJlYzA0NWZjYTZhNGQ3YWJhOGVhZWU3MmU1ZDk4NzJfMS00LTEtMS0w_d10c6e02-ef0d-44fc-b27e-162406cee1f6">2,733,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjkyZWMwNDVmY2E2YTRkN2FiYThlYWVlNzJlNWQ5ODcyL3RhYmxlcmFuZ2U6OTJlYzA0NWZjYTZhNGQ3YWJhOGVhZWU3MmU1ZDk4NzJfMS02LTEtMS0yODI5_45c43cf3-3a7d-48c6-ad7a-a211399625b8">2,960,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"><tr><td style="width:1.0%;"></td><td style="width:29.316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.464%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:27.500%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.464%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.187%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.464%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:16.005%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfMi00LTEtMS0w_e41d19cd-a278-429c-9916-1232437916d7">943,807</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfMi02LTEtMS0yODMw_59f8e17d-29a4-4049-b64c-33af043c2d0d">920,431</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNC00LTEtMS0w_c6bb3086-cadd-4947-8e44-ce2e3988a7a0">1,831,274</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNC02LTEtMS0yODMy_86eaf861-2046-427f-a06d-cf46c81a79c7">2,076,472</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNS00LTEtMS0w_236f9d3f-9f08-4f29-b9cb-763b85af8efd">2,775,081</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:LeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNS02LTEtMS0yODMy_fa4d721a-aabe-444d-aa25-99d14ede6707">2,996,903</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjg3NQ_a9b5e1f5-48c4-4f24-b80a-e9b425831e6e" escape="true"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"></td><td style="width:76.078%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.751%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.971%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfMi0yLTEtMS0w_77ffd8a4-56db-45ff-8bf9-18c36fe94229">844,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfMy0yLTEtMS0w_61bb7e99-e3bd-45fc-9598-bcae1b6341eb">1,144,889</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNC0yLTEtMS0w_39e796ce-0424-4f3a-a4b3-132b4accf041">1,019,313</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNS0yLTEtMS0w_d63d9641-5913-4e32-a4d4-c1522610d50c">92,478</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:zerodash" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNi0yLTEtMS0w_e85e2c08-3b71-4e82-a848-d06efb75b876">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNy0yLTEtMS0w_9d48d58c-e10d-4646-893a-fee014d88715">3,100,697</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfOC0yLTEtMS0w_32f72fc9-1f6b-47cd-b4d1-0dff24a80b37">325,616</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfOS0yLTEtMS0w_13d400f4-0ea4-4fd3-8eda-f50ca83eb2fb">2,775,081</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_49"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(7) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNjU5NzA2OTc3MjkwMA_d7302848-aa3f-4b17-a37f-f8847d3a4cac" continuedAt="i7041debd042e4ded98e24cff24fa71bc" escape="true">SHAREHOLDERS&#8217; EQUITY AND DEBT</ix:nonNumeric></span></div><ix:continuation id="i7041debd042e4ded98e24cff24fa71bc" continuedAt="ie57e1da3a50440b49aea5bbb670cfe8b"><div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i6ea68976af4647a79518bbe864fb79d2_I20100513" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTMz_15bc9e35-3c25-4ea7-a5dc-a7381ffc2bcd">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i4ed406cf09644236bcf2d718718fb69b_I20160131" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjk0_f703e585-a569-4c57-8a35-e6e06b67d313">10</ix:nonFraction> million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2020 and March 31, 2019, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDE0_63057a8c-bd55-4255-b489-4eea151bc811">164,876</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDk0NzgwMjMzMDMzMQ_7907221d-05d5-4664-a901-1aeb7756b8af">121,466</ix:nonFraction>, respectively, of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDg4_8963f361-b95e-4644-a68e-047b4727fa63">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDk0NzgwMjMzMDM2MA_12aad4ad-b3b6-4458-9249-d81607196aa2">0.7</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i273458bd3a91484ca9e99ab2ba12ad5d_D20171101-20171130" decimals="-6" format="ixt:numdotdecimal" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTQzNA_6252b40f-2c03-4ac8-ba69-e159b862780b">100</ix:nonFraction> million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the three months ended March 31, 2020 or March 31, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, and March 31, 2019, the Company issued <ix:nonFraction unitRef="shares" contextRef="iaacbe58946c445c98140de58546b9534_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTgyMw_0d277c68-5a64-4fe6-8f40-f64060f2eb0c">229,141</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="if9b33bc113814241ac9ba8c827d1e630_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTgzNw_615b197e-1177-4826-b9c0-fdabaa740467">222,269</ix:nonFraction> shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjA0MA_be8c0114-58e3-40ca-8fab-05faba05647c">one</span>-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cumberland Emerging Technologies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">an agreement with WinHealth whereby WinHealth made a $<ix:nonFraction unitRef="usd" contextRef="ib6cb09a407c649fd83e3903abfc61538_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjQ1Ng_a123e240-1c08-49e2-b731-424200437d1c">1</ix:nonFraction>&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="ib6cb09a407c649fd83e3903abfc61538_I20190430" decimals="-6" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPurchaseOfShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjc0Mw_011bab6b-c9e8-4d44-a8d0-cfd0208888f0">1</ix:nonFraction>&#160;million investment in CET.  Cumberland purchased additional CET shares through contribution of $<ix:nonFraction unitRef="usd" contextRef="i4ade4870a15949a494ead077ed1ab45a_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentCashContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjgzMw_ae935652-ba16-4dea-846e-019ff5dbe8ce">0.3</ix:nonFraction>&#160;million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="i2c2c6d15e8144444bdf89f20f0f4edb3_I20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjg2NA_ac385809-5c6f-4089-8f63-ed6b8e63726a">0.7</ix:nonFraction>&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return it's shares in CET in exchange for consideration of  $<ix:nonFraction unitRef="usd" contextRef="i292c0e03fcc9444091fffb0964c106d1_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMzA2Ng_4a18bd9a-dad8-43b5-9868-9c1ab6540439">0.8</ix:nonFraction>&#160;million.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2020.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i85e4bb036d714dd4a5d3f463aca96009_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDM2NA_196feb88-73c8-4328-92bf-c262e5c6d062">12.0</ix:nonFraction> million with the ability to increase the principal amount available for borrowing up to $<ix:nonFraction unitRef="usd" contextRef="i85e4bb036d714dd4a5d3f463aca96009_I20200331" decimals="INF" format="ixt:numdotdecimal" name="cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDQ0Nw_6c9cf929-44dc-463e-b0d1-780a496bb172">20.0</ix:nonFraction> million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $<ix:nonFraction unitRef="usd" contextRef="i2b413e2b14ac4e75b23217f08d1a9c8d_I20181017" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDY4OA_559e2a18-84ce-4736-9623-9a86ea1cac70">20.0</ix:nonFraction> million.   </span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ie57e1da3a50440b49aea5bbb670cfe8b">The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="i6629760d5fe04dbda09e1240d59bb8dd_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDg3NQ_d0993466-265b-44db-9923-666f8c7f3dfb">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i042b097bef654ed4ac034003fdf2d9e8_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDg4MQ_479e6c5f-480e-46ad-8431-5a6c80771e87">2.75</ix:nonFraction>% (representing an interest rate of <ix:nonFraction unitRef="number" contextRef="i85e4bb036d714dd4a5d3f463aca96009_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDkxOA_daf4fdd1-04a9-40fe-81b4-93a50480051f">3.73</ix:nonFraction>% at March 31, 2020).  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="ibad54c0f7e7445c781ab0aa335902d80_D20200101-20200331" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDk1Mg_011822ac-b0d6-43e1-adc6-0af24fb93c79">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of March 31, 2020  and December 31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMzg0ODI5MDcwMzI4NA_b758d474-488b-444e-9f6e-89ba42a6e207">18.5</ix:nonFraction> million in borrowings outstanding under our revolving credit facility.</ix:continuation> </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_52"></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(8) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81Mi9mcmFnOmIxOGFiZDIyOWM4YTRhZmE5M2Q0YzgxZjg1ZDQyMWFiL3RleHRyZWdpb246YjE4YWJkMjI5YzhhNGFmYTkzZDRjODFmODVkNDIxYWJfMTc2OQ_bc11b359-1b4c-4797-98ac-25ac10c0e34a" continuedAt="ia01710911cdd4ce38c4b73a790035b8d" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ia01710911cdd4ce38c4b73a790035b8d" continuedAt="ibe500490bd32474984e80b093c5af9fa"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  </span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ibe500490bd32474984e80b093c5af9fa">As of March 31, 2020, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81Mi9mcmFnOmIxOGFiZDIyOWM4YTRhZmE5M2Q0YzgxZjg1ZDQyMWFiL3RleHRyZWdpb246YjE4YWJkMjI5YzhhNGFmYTkzZDRjODFmODVkNDIxYWJfMTM3Mw_b06b9e84-198b-4f0d-8dad-04d400f8a5e9">44.1</ix:nonFraction> million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations.</ix:continuation> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company does not allocate any portion of its income tax expense (benefit) to discontinued operations. </span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_55"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(9) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NS9mcmFnOjUxZDNhMDk4OTJkZjQwNjU4ZGI0MThjNzg5NDBhNjI5L3RleHRyZWdpb246NTFkM2EwOTg5MmRmNDA2NThkYjQxOGM3ODk0MGE2MjlfOTgx_50e04df6-6af5-44c8-95bf-0d780b66e3ca" continuedAt="i63f2e8c119304152a757a3a3ada25361" escape="true">COLLABORATIVE AGREEMENTS</ix:nonNumeric></span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="i63f2e8c119304152a757a3a3ada25361"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</span></ix:continuation></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_58"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(10) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzA1Mw_a6c57d63-e6a4-4531-b589-f593fea438d8" continuedAt="ib0d1c2fa16c34c4faac0410709a86fcd" escape="true">ADDITIONS AND RETURN OF PRODUCT RIGHTS</ix:nonNumeric></span></div><ix:continuation id="ib0d1c2fa16c34c4faac0410709a86fcd" continuedAt="ibda965bd385e4cc798a6dc40f0891bd8"><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i75c26a02dc094045bfcbdd64d34312fe_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMTgyMw_f76bfd6e-2788-4903-b3a3-43248298deb1">20.0</ix:nonFraction> million at the closing of the transaction and a $<ix:nonFraction unitRef="usd" contextRef="i76719a5ce10a4d26a917106b3d04b051_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMTg2Ng_c4cde30e-6ad2-42c1-9d99-a64749a3ea78">5.0</ix:nonFraction> million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i75c26a02dc094045bfcbdd64d34312fe_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMTk2OQ_98475aa3-85f2-4800-8253-2b31dd63e7e0">20</ix:nonFraction>% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQ5NQ_af2e14e4-78e6-4459-a5fc-c370e02e12b9" escape="true"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.631%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.369%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfMi0xLTEtMS0w_037c8d9c-969f-4164-9aff-116c3e41f666">20,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherPaymentsToAcquireBusinesses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfMy0xLTEtMS0w_58cb77b6-67f4-40b8-90f1-cde1866fa253">5,000,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="cpix:PaymentsForContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfNC0xLTEtMS0w_fc988acc-2fc7-4b08-bfcf-c5f6f8876efd">9,182,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfNS0xLTEtMS0w_738be767-221e-4576-b6bc-4cdf92ca5b19">34,182,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span><br/></span></div><ix:continuation id="ibda965bd385e4cc798a6dc40f0891bd8" continuedAt="i55ca04abbf8f453eb8a7c0db58cd3d8d"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQ5Ng_dc27c937-0bb3-4396-8f22-d81c823828cb" escape="true"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.077%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9fe3919ad9c7434f9290fae098a242e4_I20181112" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMS0xLTEtMS0w_4241d6c2-23a4-4352-8ff6-044c12aa3c01">9,034,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iaff2de0de98c428d8e8f5eb28397ad66_D20181113-20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMi0xLTEtMS0w_8be9d4e9-ae66-4908-b71d-729489950ae0">40,000</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6302aef8c83943f7b3951e346f855a91_D20181112-20181231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMy0xLTEtMS0w_b949bce9-7902-4607-8771-e697d3880db9">508,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i60ac1f01893a45b9935936208de31383_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNC0xLTEtMS0w_b4903222-6b3d-42f1-a306-d5bd2f127a46">9,502,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNS0xLTEtMS0w_6fae2504-82d2-46e0-805a-e117b41f0b8f">148,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNi0xLTEtMS0w_0eeaf128-2547-47dc-8af7-4145bc889e55">1,033,108</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNy0xLTEtMS0w_f5ed547c-787a-420d-a7ec-10d1999df9e9">804,167</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfOC0xLTEtMS0w_6e9550b1-fc9c-4c87-a01c-217ffcc0fa82">820,864</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0ecf68fa0fa84ed4ae405f562df6d78e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfOS0xLTEtMS0w_146d365f-8960-4a71-a599-5f605cf7878e">8,633,589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRoyalties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTAtMS0xLTEtMjg1MQ_8b9c750d-f304-40cb-8043-01b12579bc70">260,735</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTEtMS0xLTEtMjg1MQ_1f825a98-234f-46b7-ab85-0275aaa3a668">543,006</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331" decimals="0" format="ixt:zerodash" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTItMS0xLTEtMjg1MQ_91df443b-83b9-4e96-9f99-85d9c296a8e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i71b25ac7991045ce8e15afc8083e3c2c_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTMtMS0xLTEtMjg1MQ_a623a6dd-2638-4683-9c46-850923fd0c56">7,829,848</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQ5Nw_2a29c494-32ad-40f7-9558-db0cfeec0831" escape="true"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:75.923%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:20.077%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMC0xLTEtMS0w_caee0fb7-405c-4802-adec-a8098d194cf6">6,624,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMS0xLTEtMS0w_0ac9e45b-aa77-4c49-bd4f-5da62f429e62">3,970,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMi0xLTEtMS0w_f221b10a-ed88-413e-acbe-25918b6cbd18">1,827,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMy0xLTEtMS0w_5f09b8ac-5c10-49fb-b3b1-626d4a9eab8e">9,129,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfNC0xLTEtMS0w_1a10a46f-fc80-482f-9388-8fa035de4caf">21,550,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfNi0xLTEtMS0w_70d20038-7f62-4c46-855a-7dfcf9d2f2ed">11,750,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfNy0xLTEtMS0w_392ccfd4-e1ce-47e6-838e-bb5007aa5c58">882,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfOC0xLTEtMS0w_c7283bec-7ce1-4458-b5ff-2b1ee54a97d3">12,632,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8444e0e8293a4f028089960cf516762d_I20181130" decimals="0" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfOS0xLTEtMS0w_8dea7ffd-546a-402c-8975-6284cb31bbaa">34,182,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RediTrex</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, the Company announced an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.&#8217;s ("Nordic") injectable methotrexate product line as an asset purchase. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Agreement, Cumberland is responsible for the products&#8217; FDA submission and registration. As consideration for the license, at closing, Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="i9ffe21db330645f5a121ce609572f5f2_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTE3Nw_cc504ee0-66a9-4ce8-8939-7d1b7244f31c">100,000</ix:nonFraction>.  The Company also recorded a liability of $<ix:nonFraction unitRef="usd" contextRef="i9ffe21db330645f5a121ce609572f5f2_D20161101-20161130" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTIyMw_0c9b58a3-17b8-473f-a020-651c45c296c4">0.9</ix:nonFraction> million that was settled through <ix:nonFraction unitRef="shares" contextRef="i25267995c74748d6b1a05373c4e7820f_D20161101-20161130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTI1NQ_dfdae8b8-4fc1-4ce1-917a-452326042179">180,000</ix:nonFraction> unvested restricted shares of Cumberland common stock.  These shares vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Nordic is responsible for manufacturing and supply of the products. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 27, 2019, Cumberland received FDA approval for the RediTrex product line and brand name. The <ix:nonFraction unitRef="shares" contextRef="i25267995c74748d6b1a05373c4e7820f_D20161101-20161130" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTY3OA_dfdae8b8-4fc1-4ce1-917a-452326042179">180,000</ix:nonFraction> shares of restricted Cumberland common stock vested and were valued at $<ix:nonFraction unitRef="usd" contextRef="i4f6e5559b01349c0b2cb01a91818807a_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTc1Mg_28d03016-f51a-4afc-89c8-d961ddfd51eb">0.9</ix:nonFraction> million on the vesting date. In addition, the FDA approval resulted in Cumberland recording an additional $<ix:nonFraction unitRef="usd" contextRef="i5f4b8237d2904a1d9dd96818c23f441e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTgzMg_69ce8623-bf3f-4e76-ab56-e8d706b9b510">1.0</ix:nonFraction>&#160;million other current liability due to Nordic that will be paid during 2020.    </span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:54pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><ix:continuation id="i55ca04abbf8f453eb8a7c0db58cd3d8d" continuedAt="ibab37f781b93492e88c3449423f54df3"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ethyol and Totect </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. The Dissolution Agreement originally resulted in a transition from the Company's current arrangement with Clinigen effective September 30, 2019.  In early September 2019, Clinigen and Cumberland completed an Amendment to the Dissolution Agreement whereby the transition date was changed to late December 2019. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.  In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $<ix:nonFraction unitRef="usd" contextRef="i667d0b68773d46a1a38eecfd7b6b8ff2_D20191001-20210930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQwOA_0edc9c6e-b733-4691-9228-29c2764823a7">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first installment of $<ix:nonFraction unitRef="usd" contextRef="i46788283ae334d9ea8d12af5a988a06f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMzg0ODI5MDcwOTk2Mw_73998ec1-43a8-42be-9627-dcc06adbaa91">0.8</ix:nonFraction>&#160;million during the quarter ended March 31, 2020 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as discontinued operations and will record each future quarterly installment over the two year period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> There are no expenses associated with the installment payments under the Dissolution Agreement, resulting in $<ix:nonFraction unitRef="usd" contextRef="i46788283ae334d9ea8d12af5a988a06f_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMzg0ODI5MDcxMDk3MA_73998ec1-43a8-42be-9627-dcc06adbaa91">0.8</ix:nonFraction>&#160;million in discontinued operations income during the quarter ended March 31, 2020. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Ethyol and Totect products provided $<ix:nonFraction unitRef="usd" contextRef="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc3OTU1NQ_bb8e330d-2d3b-47ab-b376-cc7da40cc337">3.2</ix:nonFraction>&#160;million in revenue, $<ix:nonFraction unitRef="usd" contextRef="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzAxMg_537b4657-81fd-4355-b217-1316a936ba18">2.0</ix:nonFraction>&#160;million in direct expenses and $<ix:nonFraction unitRef="usd" contextRef="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzAyNg_83ea48cb-698a-4177-addd-d086da72b9da">1.1</ix:nonFraction>&#160;million in discontinued operations income during the three months ended March 31, 2019. These direct expenses do not reflect the selling and marketing costs attributable to the individuals at Cumberland responsible for direct selling and promotion of the Products.  Those selling and marketing individuals who supported the Products continue to support Cumberland's other products.</span></div></ix:continuation><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><ix:continuation id="ibab37f781b93492e88c3449423f54df3" continuedAt="i3db4f6517ae24f1688217eab9e5b3e58"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 31, 2019 current assets of discontinued operations included $<ix:nonFraction unitRef="usd" contextRef="i81890f83a54f44bc874066750703bfcc_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzA0MA_8ae75073-91f0-4537-90ea-fccaaa664d88">0.5</ix:nonFraction>&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">inventory for the products sold back to Clinigen as part of the transaction. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020 and December 31, 2019 </span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i3db4f6517ae24f1688217eab9e5b3e58">the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.</ix:continuation>  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_540"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(11) <ix:nonNumeric contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NDAvZnJhZzo0NjRiYzQ4MmRmNTg0ZWMxYWIzZmEwYzYxNTFkMWUzOC90ZXh0cmVnaW9uOjQ2NGJjNDgyZGY1ODRlYzFhYjNmYTBjNjE1MWQxZTM4XzY1OTcwNjk3NzQ4Njg_50e4cb92-eed4-44a9-ac66-e7b4e727a28d" continuedAt="ifcc1bf3af6c149dcae0e697667c8451e" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="ifcc1bf3af6c149dcae0e697667c8451e"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i92b3abff138f4568b1b90d05aff3cf8d_D20200420-20200420" decimals="0" format="ixt:numdotdecimal" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NDAvZnJhZzo0NjRiYzQ4MmRmNTg0ZWMxYWIzZmEwYzYxNTFkMWUzOC90ZXh0cmVnaW9uOjQ2NGJjNDgyZGY1ODRlYzFhYjNmYTBjNjE1MWQxZTM4XzY1OTcwNjk3NzQ4NTE_8dc2b2e6-a544-4eae-ac47-c05d76b31ccb">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The PPP is administered by the U.S. Small Business Administration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loan matures April 14, 2022, and bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="ic59f3a91d3c34c248c4b7251dabdddec_I20200420" decimals="INF" name="cpix:CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NDAvZnJhZzo0NjRiYzQ4MmRmNTg0ZWMxYWIzZmEwYzYxNTFkMWUzOC90ZXh0cmVnaW9uOjQ2NGJjNDgyZGY1ODRlYzFhYjNmYTBjNjE1MWQxZTM4XzY1OTcwNjk3NzQ4NjM_c82f57e7-fba1-442c-b28a-225c74651316">1.0</ix:nonFraction>% per year, payable monthly commencing during November 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company intends to use the majority of the loan amount for such qualifying expenses.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, thanks to assistance from the PPP loan, the Company currently does not foresee doing so. Cumberland will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.</span></div></ix:continuation><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_61"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Disclosure regarding forward-looking statements</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following discussion contains certain forward-looking statements which reflect management&#8217;s current views of future events and operations. These statements involve certain risks and uncertainties, and actual results may differ materially from them. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that our actual results may differ significantly from the results we discuss in these forward-looking statements. Some important factors which may cause results to differ from expectations include: availability of additional debt and equity capital required to finance the business model; market conditions at the time additional capital is required; our ability to continue to acquire branded products; product sales; management of our growth and integration of our acquisitions and impacts on our business as well as national and international markets and economies resulting from the 2020 COVID-19 pandemic.. While forward-looking statements reflect our beliefs and best judgment based upon current information, they are not guarantees of future performance. Other important factors that may cause actual results to differ materially from forward-looking statements are discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2019 (&#8220;2019 Annual Report on Form 10-K&#8221;) and other filings with the SEC.  We do not undertake to publicly update or revise any of our forward-looking statements, even in the event that experience or future changes indicate that the anticipated results will not be realized. The following presentation of management&#8217;s discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes included in this report on Form 10-Q.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_64"></div><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OVERVIEW</span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Business</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Our primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve the quality of care for patients and address unmet or poorly met medical needs.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We promote our approved products through our hospital and field sales forces in the United States and are establishing a network of international partners to bring our medicines to patients in their countries.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;margin-bottom:8pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our portfolio of FDA approved brands includes:</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Acetadote</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">acetylcysteine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of acetaminophen poisoning; </span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Caldolor</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of pain and fever;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Kristalose</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">lactulose</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Omeclamox</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">-Pak</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">omeprazole, clarithromycin, and amoxicillin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) for the treatment of Helicobacter pylori (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">H. pylori</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) infection and related duodenal ulcer disease;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Vaprisol</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">conivaptan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;</span></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt;">Vibativ</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">telavancin</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections, and</span></div><div style="text-indent:-18pt;padding-left:72pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:14.5pt;">RediTrex</span><sup style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%;">methotrexate</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">) Injection,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we have Phase II clinical programs underway evaluating our ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis, and Aspirin-Exacerbated Respiratory Disease. We have also completed initial Phase II clinical studies with ifetroban in patients with Hepatorenal Syndrome and patients with Portal Hypertension.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has both product development and commercial capabilities, and we believe we can leverage our existing infrastructure to support our expected growth. Our management team consists of pharmaceutical industry veterans experienced in business development, product development, regulatory, manufacturing, sales, marketing, and finance. Our business development team identifies, evaluates and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares all regulatory submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacture, release and shipment of our products. Our marketing and sales team is responsible for our commercial activities, and we work closely with our distribution partners to ensure availability and delivery of our products.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Growth Strategy</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland's growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently market seven FDA-approved products in the United States.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Through our international partners, we are working to bring our medicines to patients in their countries. Our clinical team is developing a pipeline of new product candidates largely to address unmet medical needs. We also look for opportunities to expand the approved use of our products for additional patient populations through clinical trials, through new presentations, and through our support for select, investigator-initiated studies. Through our active business development initiative, we are pursuing the acquisition of additional marketed brands and late-stage development product candidates in our target medical specialties. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, we are supplementing these activities with the earlier stage drug development at Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary. CET partners with academic research institutions to identify and progress promising, new product candidates, which Cumberland has the opportunity to further develop and commercialize.</span></div><div style="text-align:justify;margin-top:8pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Specifically, we are seeking long term sustainable growth by executing on the following:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">        </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Support and expand the use of our marketed products.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will continue to explore opportunities for label expansion to bring our products to new patient populations.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As examples, we have secured pediatric approval, expanding the labeling for both our Acetadote and Caldolor brands. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Selectively add complementary brands.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In addition to our product development activities, we are also seeking to acquire products and late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA approved drugs, as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Vibativ represents the largest product acquisition we have completed.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Progress clinical pipeline and incubate future product opportunities at CET.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We believe it is important to build a pipeline of innovative new product opportunities. Our ifetroban Phase II development programs represent the implementation of this strategy. At CET, we are supplementing our acquisition and late-stage development activities with the early-stage drug development activities. CET partners with universities and other research organizations to develop promising, early-stage product candidates, which Cumberland has the opportunity to further develop and commercialize. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Leverage our infrastructure through co-promotion partnerships.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We believe that our commercial infrastructure can help drive prescription volume and product sales. We also look for strategic co-promotion partners that can complement our capabilities and enhance the opportunity for our brands. Our co-promotion arrangements with Poly Pharmaceuticals, Inc. and Foxland Pharmaceuticals, Inc allow us to expand current promotional support for Kristalose across the U.S.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">     </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Build an international contribution to our business.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We have established our own commercial capabilities, including two sales divisions to support and promote our approved brands in the U.S. We have also established agreements with a group of international partners to register our products and make them available to patients in their countries. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will continue to support and selectively expand our network of international partners while supporting their registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Manage our operations with financial discipline.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. Our goal is to maintain a healthy financial position, with favorable gross margins, and a strong balance sheet. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is www.cumberlandpharma.com. We make available through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all material press releases and other reports as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission, (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="background-color:rgb(255,255,255, 0.0);color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">www.sec.gov</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RECENT DEVELOPMENTS</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Caldolor </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;vertical-align:top;">&#174;</sup></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Next Generation Caldolor Product</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, we launched the next generation of our Caldolor (</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">ibuprofen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">) Injection product. This formulation of Caldolor comes in a ready-to-use bag that may be administered without dilution for pain relief. This launch follows FDA approval in 2019 of the product's new delivery method.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A non-steroidal anti-inflammatory drug (&#8220;NSAID&#8221;), Caldolor may be used as the sole method of treatment for mild-moderate pain or as part of a multimodal treatment for severe pain. The new formulation of Caldolor comes in a pre-mixed bag containing 800 mg of ibuprofen in a 200 mL patented low-sodium formulation for injection that is ready to use. It is the first FDA-approved pre-mixed bag of ibuprofen. Caldolor is still available as an 800 mg/8mL single&#8211;dose vial (100mg/mL) for dilution in addition to the ready-to-use bag (4 mg/mL). The new, premixed presentation provides health care professionals a formulation that is easy to administer, helping to manage the treatment of patient pain and fever, while reducing opioid consumption.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Caldolor Pediatric Study</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We previously received FDA approval for the use of Caldolor in pediatric patients six months of age and older. Caldolor is the first and only injectable NSAID approved for use in children. We then initiated a study to collect data on the use of Caldolor in children ranging in age from birth up to six months of age. Enrollment in that multi-center study was completed in 2019.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, we announced topline results that indicated the use of Caldolor was well tolerated in these young children from birth up to six months of age.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Next steps include finalizing the full study report for submission to the FDA and then determining whether an additional pediatric indication will be available.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVID-19 Pandemic </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2) strain of coronavirus that causes COVID-19, a respiratory illness. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are monitoring this situation both in the U.S. and internationally, so we can maintain our employees&#8217; safety and well-being, while also keeping our business operating and secure.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has remained open for business, as we are considered to be essential by the United States Department of Homeland Security. All of our corporate and CET employees have been given the opportunity to work remotely, and those that wish to work from the office are encouraged to practice the behaviors outlined by the Centers for Disease Control. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our sales organization has continued to make calls on medical professionals, providing information and product samples as requested. However, their contact has largely shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We rely on third-party organizations around the world to supply components, manufacture and distribute our products. We are aware that we may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. Given the uncertainty, magnitude and impact of such changes, the Company is unable to quantify the impact on our future results as of the date of this filing.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Acute Care Product Special Supply Arrangements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2020, Cumberland announced an initiative to expand the availability of Vibativ</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> along with special financial arrangements for hospitals and clinics to help ensure supply during this unprecedented health care crisis. In addition, we sponsored a national program with infectious disease experts to provide information on the management of complicated respiratory infections resulting from COVID-19.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also in March 2020, we announced an initiative to expand the availability of Caldolor with special supply and financial arrangements, including favorable pricing and payment terms for hospitals and clinics to help ensure timely access to Caldolor during this health care crisis.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, in April 2020, the Company announced a third COVID-19-related initiative. This initiative increases the availability of Vaprisol</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> to hospitals and clinics including special supply and financial arrangements, with favorable pricing and payment terms, to help ensure timely access to Vaprisol during this health care crisis.</span></div><div style="text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Paycheck Protection Program</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The PPP is administered by the U.S. Small Business Administration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. The loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company intends to use the majority of the loan amount for such qualifying expenses.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We applied for this loan after carefully considering, with our bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. We evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, thanks to assistance from our PPP loan, we currently do not foresee doing so. The company will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Environmental, Social and Governance (ESG) Activities</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2020, we released our first Sustainability Report. This report describes the Company&#8217;s activities pertaining to Environmental, Social and Governance ("ESG") matters, otherwise known as corporate sustainability. It includes details about Cumberland&#8217;s community involvement, ethical marketing and drug safety.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our board appointed Caroline R. Young, former president of the Nashville Health Care Council, as the company&#8217;s first ESG board director. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The report notes that, during 2019, Cumberland provided nearly 4 million patient doses of products, safely disposed of over 9,700 pounds of expired and damaged products and had no product recalls. We also had no product listings on the FDA&#8217;s Safety Alerts Database and no products identified in the FDA Adverse Event Reporting System during 2019.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Ifetroban Phase II Clinical Programs</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have completed three pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure, 2) patients with Portal Hypertension associated with chronic liver disease and 3) patients suffering from Aspirin-Exacerbated Respiratory Disease, a severe form of asthma. A follow-up Phase II study is currently underway for this asthma indication. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we are currently evaluating ifetroban in two pilot Phase II studies of 1) patients with Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 2) patients with cardiomyopathy associated with Duchenne Muscular Dystrophy. This rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additional pilot studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Enrollment in our clinical studies declined during the first quarter due to the COVID-19 pandemic. While enrollment of new patients is currently limited, we are working to ensure that patients already entered into a trial continue to receive their study drug. We are awaiting further study results before deciding on the best path for approval for ifetroban, our first new chemical entity.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">New Hospital Product Candidate</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol-reducing agent for use in the hospital setting. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During 2017, we completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA. A Phase II study has been initiated and patient enrollment completed. We are now evaluating the results from this study and will then determine the next steps for this product development program.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_67"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:8pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please see a discussion of our critical accounting policies and significant judgments and estimates in Note 1 to the Company's Condensed Consolidated Financial Statements accompanying this report and the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2019 Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Accounting Estimates and Judgments</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that cannot be determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, fair value of marketable securities, inventories, provision for income taxes, fair value of contingent consideration liability, share-based compensation, research and development expenses and intangible assets.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_70"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Three months ended March 31, 2020 compared to the three months ended March 31, 2019 </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the unaudited interim statements of operations for continuing operations for the three months ended March 31, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:47.707%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.643%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.228%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="18" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,330,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,729,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(399,126)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Costs and expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of products sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,634,181&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,658,789&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,608)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling and marketing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,707,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,436,932&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">270,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,722,555&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,399,687&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">322,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,036,284&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,536,739&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(500,455)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,076,039&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,021,645&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">54,394&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total costs and expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,176,735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,053,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">122,943&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating income (loss)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,846,001)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,323,932)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(522,069)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,888&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">115,861&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(85,973)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,065)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(60,911)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,846&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) from continuing operations before income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,849,178)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,268,982)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(580,196)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax (expense) benefit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,240)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81,428&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(115,668)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,883,418)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,187,554)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(695,864)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes net revenues by product for the periods presented: </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:47.780%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.251%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.254%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">713,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">849,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(135,603)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(84,767)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,311,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,307,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,038&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">208,763&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(77,913)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,096,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,317,074&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(220,783)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,425,755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">365,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(249,658)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,330,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,729,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(399,126)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Net revenues.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> Net revenues for the three months ended March 31, 2020 were $8.3 million compared to $8.7 million for the three months ended March 31, 2019.  As detailed in the table above, net revenue increased for two of our marketed products: Kristalose and Vibativ during the quarter. There were decreases in Acetadote, Omeclamox-Pak, Vaprisol and Caldolor net revenue.   We returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen effective January 1, 2020.  As a result, the 2019 revenues and expenses associated with the products are combined and reclassified into discontinued operations in our financial statements. In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $5 million in financial consideration paid over the two-years following the return date. The first installment of $0.8 million due from Clinigen was recorded during the three months ended March 31, 2020 as discontinued operations.  We do not incur expenses associated with these payments from Clinigen.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Kristalose revenue increased slightly during the first quarter of 2020 when compared to the prior year period.  The increase was primarily the result of improved net pricing for the product.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vibativ revenue was $2.4 million for the three months ended March 31, 2020, an increase of $0.4 million over the same period last year.  The increase was a result of improved sales volumes and improved net pricing for the product.</span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Vaprisol revenue was $0.2 million for the first quarter of 2020, a decrease of net sales of $0.1 million compared to the first quarter of 2019 primarily due to lower sales volumes.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Omeclamox-Pak revenue decreased $0.1 million for the first quarter of 2020 compared to the first quarter of 2019 primarily due to a decrease in sales volumes, partially offset by a reduction in expired product returns.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Acetadote revenue includes net sales of our Acetadote brand and our share of net sales from our Authorized Generic. During the quarter, there was a decrease of $0.1 million in the product's revenue when compared to the prior year period as a result of lower sales volumes, partially offset by improved net pricing. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Caldolor revenue was $1.1 million for the first quarter of 2020, a decrease of $0.2 million compared to the same period last year. While there were higher domestic shipments of the product and improved net pricing, these improvements were offset by a reduction in international shipments of Caldolor when compared to the prior year period. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of products sold</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Co</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">st of products sold for the first quarter of 2020 and 2019 were $1.6 million and $1.7 million, respectively. Cost of products sold, as a percentage of net revenues, were 19.6% during the three months ended March 31, 2020 compared to 19.0% during the three months ended March 31, 2019.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix.   </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling and marketing</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Selling and marketing expense for the first quarter of 2020 increased $0.3 million compared to the prior year period.  This increase is primarily attributable to increases in salaries as well as a non-cash expense related to the decrease in the fair value of Cumberland owned life insurance.  These increases were partially offset by decreases in royalty costs during the first quarter of 2020. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and development</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Research and development costs were $1.7 million for the first quarter of 2020 and $1.4 million for the same period last year.  A portion of our research and development costs is variable based on the number of trials, study sites, cost of the per patient study protocol and patients involved in the development of our new product candidates. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  The increase in costs were primarily the result of increased annual FDA user fees.     </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and administrative</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">.  General and administrative expense for the first quarter of 2020 decreased to $2.0 million from  $2.5 million during the first quarter of 2019 as a result of decreases in advisory, legal and professional fees.  We also experienced a reduction in non-cash stock based compensation during the period.  A portion of these decreased costs were related to 2019 expenses related to our acquisition of Vibativ. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Amortization.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Amortization expense is the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for the three months ended March 31, 2020, and three months ended March 31, 2019, totaled approximately $1.1 million and $1.0 million, respectively. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income taxes</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Income tax expense (benefit) for the three months ended March 31, 2020, as a percentage of income (loss) from continuing operations before income taxes, was 1.9% for the three months ended March 31, 2020, compared to (6.4)% for the three months ended March 31, 2019.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, we had approximately $44 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations.  We expect to continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations. </span></div><div><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_73"></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_76"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Working Capital</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our primary sources of liquidity are cash flows provided by our operations, the proceeds from the Paycheck Protection Program loan, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit, including its recent expansion to $20 million, will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We invest a portion of our cash reserves in marketable securities including short-term cash investments, U.S. Treasury notes and bonds, corporate bonds and commercial paper.  At March 31, 2020 and December 31, 2019, all our investments were in commercial paper with original maturities of less than ninety days and as a result were classified as cash equivalents.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our liquidity and working capital as of March 31, 2020 and December 31, 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:57.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.561%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:7pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,026,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,212,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents and marketable securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,026,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,212,635&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Working capital (current assets less current liabilities)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,364,426&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,012,840&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Revolving line of credit availability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,500,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:11pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes our net changes in cash and cash equivalents for the three months ended March 31, 2020 and March 31, 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:57.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.558%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.829%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.561%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">888,539&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(385,733)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(571,161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,723,388)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,503,279)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,220,424)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net decrease in cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,185,901)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,329,545)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net $1.2 million decrease in cash and cash equivalents for the three months ended March 31, 2020 was primarily attributable to cash used in investing and financing activities.  Cash provided by operating activities of $0.9 million was positively impacted by decreases in accounts receivable of $2.0 million and inventory of $0.7 million, as well as the add back of non-cash expenses of depreciation, amortization and share-based compensation expense totaling $1.4 million.  This was partially offset by a decrease in accounts payable of $2.4 million.  Cash used by investing activities was the result of additions to intangibles of $0.5 million.  Our financing activities reflected the $0.4 million in cash used to repurchase shares of our common stock as well as the $0.8 million used for the repurchase of subsidiary shares. </span></div><div style="text-align:justify;margin-top:11pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The net $3.3 million decrease in cash and cash equivalents for the three months ended March 31, 2019 was attributable to cash used in investing, financing and operating activities.  Cash used in operating activities of $0.4 million was primarily impacted by the increase in accounts receivable of  $2.1 million. The use of operating cash was partially offset by the add back of non-cash expenses of depreciation and amortization and share-based compensation expense totaling $1.4 million.  Cash used in investing activities included net cash invested in marketable securities of $1.3 million and additions to intangibles of $0.4 million.  Our financing activities reflected the $0.7 million in cash used to repurchase shares of our common stock. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, we entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants.  On October 17, 2018, we entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.  For a summary of the material terms of the Pinnacle Agreement, as amended, see Note 7 to the accompanying unaudited condensed consolidated financial statements.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Pinnacle Agreement, we were initially subject to one financial covenant, the maintenance of a Funded Debt Ratio. On August 14, 2018 we amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Third Amendment modified the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  We were in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2020. We expect to maintain compliance with the Tangible Capital Ratio financial covenant in future periods. </span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_79"></div><div style="margin-top:12pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020 and 2019, we did not engage in any off-balance sheet arrangements.</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_82"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Interest Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and our revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. The Company did not have any investments classified as marketable securities at March 31, 2020.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on current interest rates, we do not believe we are exposed to significant downside risk related to change in interest on our investment accounts.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 3.73% at March 31, 2020). As of March 31, 2020, we had $18.5 million in borrowings outstanding under our revolving credit facility. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exchange Rate Risk</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we operate primarily in the United States, we are exposed to foreign currency risk.  Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations.  We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice.  Foreign currency exchange gains and losses were immaterial for the three months ended March 31, 2020 and 2019.  Neither a five percent increase nor decrease from current exchange rates would have a material effect on our operating results or financial condition.</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_85"></div><div style="margin-top:6pt;margin-bottom:6pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4. Controls and Procedures</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15-15(e) of the Exchange Act, as of March 31, 2020. Based on that evaluation, our CEO and CFO concluded that, as of March 31, 2020, our disclosure controls and procedures are considered effective to ensure that the information required to be disclosed by the Company in reports filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's CEO and CFO, as appropriate, to allow for timely decisions regarding required disclosure.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, there has not been any change in our internal control over financial reporting that has materially affected, or is likely to materially affect, our internal control over financial reporting. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_88"></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_91"></div><div style="margin-top:14pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1. Legal Proceedings</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_94"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1A. Risk Factors</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are updating the following risk factors that appear in the 2019 Annual Report on Form 10-K under the section titled "Risk Factors." </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">RISKS RELATED TO OUR BUSINESS</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Our business could be adversely affected by natural disasters, public health epidemics, and other events beyond our control.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our business has been adversely impacted by the recent coronavirus (&#8220;COVID-19&#8221;) outbreak which has affected more than 200 countries and has significantly disrupted the day-to-day activities of both individuals and companies. For example, we have been following the recommendations of health authorities to minimize exposure risk for our employees for the past several weeks, including allowing employees to work remotely to the extent possible. This has included our home office employees and our hospital and field based sales representatives. We rely on individuals and third-party organizations around the world to supply components, manufacture and distribute our products and execute our clinical trials. We may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The COVID-19 pandemic&#8217;s impact on global markets could affect our future access to liquidity and materially adversely affect our results of operations and financial condition.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The coronavirus has spread throughout much of the world after initially surfacing in Wuhan, China in December 2019. State and local authorities in the United States, like their counterparts in many other countries, have since forced many businesses to temporarily shut down in an attempt to slow the spread of the virus, and Americans are being told by public officials to practice &#8220;social distancing.&#8221; Global stock markets have reacted very negatively, and economists are projecting a sharp economic slowdown, at least in the near term, even if governments take emergency relief measures. While the economic impact brought by, and the duration of, COVID-19 is difficult to assess or predict, the COVID-19 pandemic could result in significant disruption of global financial markets, reducing our ability to access capital in the future, which could negatively affect our liquidity in the future. The situation is constantly evolving, however, so the extent to which the COVID-19 outbreak will impact businesses and the economy is highly uncertain and cannot be predicted. Accordingly, we cannot predict the extent to which our results of operations, financial condition and cash flows will be affected.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If any manufacturer or partner we rely upon fails to supply our products in the amounts we require on a timely basis, or fails to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may be unable to meet demand for our products and may lose potential revenues.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not manufacture any of our products, and we do not currently plan to develop any capacity to do so. Our dependence upon third parties for the manufacture of our products could adversely affect our profit margins or our ability to develop and deliver products on a timely and competitive basis. If for any reason we are unable to obtain or retain third-party manufacturers on commercially acceptable terms, we may not be able to sell our products as planned. Furthermore, if we encounter delays or difficulties with contract manufacturers in producing our products, the distribution, marketing and subsequent sales of these products could be adversely affected. The recent COVID-19 pandemic may create local issues for our third party-manufacturers and introduce delays in our manufacturing process.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Acetadote</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: We have agreements with two manufacturers, and one manufacturer provided commercial supplies of the product during 2019. If the manufacturer of Acetadote is unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for our product.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Caldolor</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: We have agreements with multiple manufacturers for the supply of Caldolor and during 2019 we obtained commercial supplies from three of these manufacturers for our international and domestic Caldolor requirements. If the manufacturers of Caldolor are unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for our product.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Kristalose</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: The active pharmaceutical ingredient for Kristalose is manufactured at a single facility by an international supplier. We also have manufacturing relationships with two packagers who provided finished supplies of the product for commercial and sampling purposes during 2019. If these facilities are damaged or destroyed, or if local conditions result in a work stoppage, we could suffer an inability to meet demand for our product. Kristalose is manufactured through a complex process. It would be particularly difficult to find a new manufacturer of Kristalose active pharmaceutical ingredient on an expedited basis. As a result of these factors, our ability to manufacture Kristalose may be substantially impaired if the manufacturer is unable or unwilling to supply sufficient quantities of the product.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Omeclamox-Pak</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Prior to our asset purchase agreement with GEL that closed in December 2018, GEL managed the packaging and supply of Omeclamox-Pak commercial and sample units. Following our acquisition of the remaining rights to the brand in late 2018, we assumed responsibility for the packaging and supply of the product. During 2019 we entered into a new packaging arrangement for this product. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vaprisol</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: As part of the acquisition of Vaprisol, we purchased an existing supply of raw material inventory. In addition, as part of this transaction, we were assigned a commercial supply agreement with the historical Vaprisol manufacturer. In 2018, the manufacturer informed us that they would no longer be able to provide the product following the manufacturing of one final batch which is expected to provide us with a multi-year supply. Therefore, we are evaluating alternatives for a new manufacturer to provide us with long term supplies of the product. If we are unable to produce additional marketable inventory in sufficient quantities of Vaprisol, we could suffer an inability to meet demand for our product.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vibativ</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Through our acquisition of Vibativ, we acquired a multi-year supply of raw material, work in process and finished goods inventory. As a result of the agreement, we are now responsible for the future manufacture of the product and completed the transfer of the product&#8217;s manufacturing activities to a new supplier in 2019. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RediTrex</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">: Under our agreement with Nordic, they will be responsible for providing us the packaged and labeled commercial supply of the RediTrex product. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for our product.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, all manufacturers of our products and product candidates must comply with current good manufacturing practices, ("GMPs"), enforced by the FDA through its facilities inspection program. These requirements include quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our products may be unable to comply with GMP requirements and with other FDA, state and foreign regulatory requirements.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have no control over our manufacturers&#8217; compliance with these regulations and standards. If our third-party manufacturers do not comply with these requirements, we could be subject to:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Fines and civil penalties;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Suspension of production or distribution;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Suspension or delay in product approval;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Product seizure or recall; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Withdrawal of product approval.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We are dependent on a variety of other third parties. If these third parties fail to perform as we expect, our operations could be disrupted and our financial results could suffer.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a relatively small internal infrastructure. We rely on a variety of third parties, in addition to our manufacturers, to help us operate our business. Other third parties on which we rely include:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Cardinal Health Specialty Pharmaceutical Services, a logistics and fulfillment company and business unit of Cardinal, which bills for, collects, warehouses and ships our marketed products; and</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Vanderbilt University, WinHealth and the Tennessee Technology Development Corporation, co-owners with us of CET, and the universities that collaborate with us in connection with CET's research and development programs.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If these third parties do not continue to provide services to us, or collaborate with us, we might not be able to obtain others who can serve these functions. This could disrupt our business operations, increase our operating expenses or otherwise adversely affect our operating results. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The recent COVID-19 pandemic may create additional risk and delays at our independent third-party service providers.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We depend on our key personnel, the loss of whom would adversely affect our operations. If we fail to attract and retain the talent required for our business, our business will be materially harmed.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a relatively small company, and we depend to a great extent on principal members of our management, scientific staff, and sales representatives and managers. If we lose the services of any key personnel, in particular, A.J. Kazimi, our Chief Executive Officer, or other members of senior management it could have a material adverse effect on our business prospects. Mr. Kazimi, plays a key role in several operational and strategic decisions such that any loss of his services due to death or disability would adversely impact our day-to-day operations. We have a life insurance policy covering the life of Mr. Kazimi. We have entered into agreements with each of our employees that contain restrictive covenants relating to non-competition and non-solicitation of our customers and suppliers for one year after termination of employment. Nevertheless, each of our officers and key employees may terminate his or her employment at any time without notice and without cause or good reason, and so as a practical matter these agreements do not guarantee the continued service of these employees. Our success depends on our ability to attract and retain highly qualified scientific, technical, sales and managerial personnel and research partners. Competition among pharmaceutical companies for qualified employees is intense, and we may not be able to retain existing personnel or attract and retain qualified staff in the future. If we experience difficulties in hiring and retaining personnel in key positions, we could suffer from delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect operating results. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent COVID-19 pandemic may introduce additional challenges in the retention and hiring of key personnel.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISKS RELATING TO GOVERNMENT REGULATION</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">We are subject to stringent government regulation. All of our products face regulatory challenges.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Virtually all aspects of our business activities are regulated by government agencies. The manufacturing, processing, formulation, packaging, labeling, distribution, promotion and sampling, advertising of our products, and disposal of waste products arising from such activities are subject to governmental regulation. These activities are regulated by one or more of the FDA, the Federal Trade Commission, ("FTC"), the Consumer Product Safety Commission, the U.S. Department of Agriculture and the U.S. Environmental Protection Agency, ("EPA"), as well as by comparable agencies in foreign countries. These activities are also regulated by various agencies of the states and localities in which our products are sold.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Like all pharmaceutical manufacturers, we are subject to regulation by the FDA under the Federal Food, Drug, and Cosmetic Act ("FDCA"). All new drugs must be the subject of an FDA-approved new drug application, ("NDA"), before they may be marketed in the United States. The FDA has the authority to withdraw existing NDA approvals and to review the regulatory status of products marketed under the enforcement policy. The FDA may require an approved NDA for any drug product marketed under the enforcement policy if new information reveals questions about the drug&#8217;s safety and effectiveness. All drugs must be manufactured in conformity with GMP, and drug products subject to an approved NDA must be manufactured, processed, packaged, held and labeled in accordance with information contained in the NDA. Since we rely on third parties to manufacture our products, GMP requirements directly affect our third party manufacturers and indirectly affect us. The manufacturing facilities of our third-party manufacturers are continually subject to inspection by such governmental agencies, and manufacturing operations could be interrupted or halted in any such facilities if such inspections prove unsatisfactory. Our third-party manufacturers are subject to periodic inspection by the FDA to assure such compliance.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even after regulatory approval, certain developments may decrease demand for our products, including the following:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the re-review of products that are already marketed;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">new scientific information and evolution of scientific theories;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the recall or loss of marketing approval of products that are already marketed;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changing government standards or public expectations regarding safety, efficacy or labeling changes; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">greater scrutiny in advertising and promotion.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the past, clinical trials and post-marketing surveillance of certain marketed drugs of competitors within the industry have raised concerns that have led to recalls, withdrawals or adverse labeling of marketed products. If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of our products, it could significantly reduce demand for the product or require us to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, certain health authorities, regulators and agencies have increased their focus on safety when assessing the balance of benefits and risks of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products and are re-reviewing select products that are already marketed, adding further to the uncertainties in the regulatory processes. There is also greater regulatory scrutiny, especially in the U.S., on advertising, and promotion (in particular, direct-to- consumer advertising) and pricing of pharmaceutical products. Certain regulatory changes or decisions could make it more difficult for us to sell our products and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and other applicable regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with a facility where the product is manufactured, a regulatory agency may impose restrictions on that product or the manufacturer, including withdrawal of the product from the market or suspension of manufacturing. If we, our partners or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may take the following actions, among others:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">issue warning letters or untitled letters;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">impose civil or criminal penalties</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspend or withdraw regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspend any ongoing clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">refuse to approve pending applications or supplements to applications submitted by us;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">seize or detain products or require us to initiate a product recall.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any change in the FDA&#8217;s enforcement policy could have a material adverse effect on our business, financial condition and results of operations. We cannot determine what effect changes in regulations or statutes or legal interpretation, when and if promulgated or enacted, may have on our business in the future. Such changes, or new legislation, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent COVID-19 pandemic has introduced additional strain on the FDA. We are unable to fully understand the impact this may cause on regulations or the related timeframes pertaining to communication with the FDA.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We participate in and have certain price reporting obligations to the Medicaid Drug Rebate program and other governmental pricing programs, and we have obligations to report average sales price under the Medicare program.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the Medicaid Drug Rebate program, we are required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and Medicare Part B. Those rebates are based on pricing data reported by us on a monthly and quarterly basis to the Centers for Medicare &amp; Medicaid Services ("CMS"), the federal agency that administers the Medicaid Drug Rebate program. These data include the average manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the US in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Healthcare Reform Act made significant changes to the Medicaid Drug Rebate program, such as expanding rebate liability from fee-for-service Medicaid utilization to include the utilization of Medicaid managed care organizations as well and </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">changing the definition of average manufacturer price. The Healthcare Reform Act also increased the minimum Medicaid rebate; changed the calculation of the rebate for certain innovator products that qualify as line extensions of existing drugs; and capped the total rebate amount at 100% of the average manufacturer price. Finally, the Healthcare Reform Act requires pharmaceutical manufacturers of branded prescription drugs to pay a branded prescription drug fee to the federal government.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CMS issued final regulations to implement the changes to the Medicaid Drug Rebate program under the Healthcare Reform Act. These regulations became effective on April 1, 2016. The issuance of the final regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate program has and will continue to increase our costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS challenges the approach we take in our implementation of the final regulations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Federal law requires that any company that participates in the Medicaid Drug Rebate program also participate in the Public Health Service's 340B drug pricing program in order for federal funds to be available for the manufacturer's drugs under Medicaid and Medicare Part B. The 340B program requires participating manufacturers to agree to charge no more than the 340B "ceiling price" for the manufacturer's covered outpatient drugs to a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The Healthcare Reform Act expanded the list of covered entities to include certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals. The 340B ceiling price is calculated using a statutory formula based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate program. Changes to the definition of average manufacturer price and the Medicaid rebate amount under the Healthcare Reform Act and CMS's final regulations implementing those changes also could affect our 340B ceiling price calculations and negatively impact our results of operations.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Healthcare Reform Act obligates the Secretary of the Department of Health and Human Services ("HHS") to update the agreement that manufacturers must sign to participate in the 340B program to obligate a manufacturer to offer the 340B price to covered entities if the manufacturer makes the drug available to any other purchaser at any price and to report to the government the ceiling prices for its drugs. The Health Resources and Services Administration ("HRSA"), the federal agency that administers the 340B program, recently updated the agreement with participating manufacturers. The Healthcare Reform Act also obligates the Secretary of the HHS to create regulations and processes to improve the integrity of the 340B program. On January 5, 2017, HRSA issued a final regulation regarding the calculation of 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities. The regulation became effective as of January 1, 2019. Implementation of this final rule and the issuance of any other final regulations and guidance could affect our obligations under the 340B program in ways we cannot anticipate. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in the inpatient setting.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Federal law also requires that a company that participates in the Medicaid Drug Rebate program report average sales price information each quarter to CMS for certain categories of drugs that are paid under the Medicare Part B program. Manufacturers calculate the average sales price based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. CMS uses these submissions to determine payment rates for drugs under Medicare Part B. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for our products and the resulting Medicare payment rate, and could negatively impact our results of operations. Also, the Medicare Part B drug payment methodology is subject to change based on potential demonstration projects undertaken by CMS or potential legislation enacted by Congress.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts. In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are liable for errors associated with our submission of pricing data. In addition to retroactive rebates and the potential for 340B program refunds, if we are found to have knowingly submitted any false price information to the government, we may be liable for civil monetary penalties. If we are found to have made a misrepresentation in the reporting of our average sales price, the Medicare statute provides for civil monetary penalties for each misrepresentation for each day in which the </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">misrepresentation was applied. Our failure to submit the required price data on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure also could be grounds for CMS to terminate our Medicaid drug rebate agreement, pursuant to which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">CMS and the Office of Inspector General ("OIG") have pursued manufacturers that were alleged to have failed to report these data to the government in a timely manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In order to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs we are required to participate in the VA Federal Supply Schedule ("FSS") pricing program, established under Section 603 of the Veterans Health Care Act of 1992.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and any response to government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent COVID-19 pandemic may introduce temporary or permanent healthcare reform measures for which we cannot predict the financial implication of on our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISKS RELATED TO OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Our operating results are likely to fluctuate from period to period.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a company actively seeking to deliver significant growth. As we execute our business strategy of adding new products, increasing market share in our existing growth products and striving to maintain market share in our other products, we anticipate that there may be fluctuations in our future operating results. We may not be able to maintain or improve our current levels of revenue or income. Potential causes of future fluctuations in our operating results may include:</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">New product launches, which could increase revenues but also increase sales and marketing expenses;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Acquisition activity and other charges;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Increases in research and development expenses resulting from the acquisition of a product candidate that requires significant additional studies and development;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Ability to utilize unrecognized federal and state net operating loss carryforwards as a result of the exercise of nonqualified options</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Changes in the competitive, regulatory or reimbursement environment, which could drive down revenues or drive up sales and marketing or compliance costs; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Unexpected product liability or intellectual property claims and lawsuits.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">See also &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8212;Liquidity and capital resources.&#8221; Fluctuation in operating results, particularly if not anticipated by investors and other members of the financial community, could add to volatility in our stock price. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent COVID-19 coronavirus has negatively impacted the financial markets and may create additional risk for our customers and their ability to pay for our products.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RISKS RELATED TO OWNING OUR STOCK</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">The market price of our common stock may fluctuate substantially.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The price for the shares of our common stock sold in our initial public offering was determined by negotiation between the representatives of the underwriters and us. This price may not have reflected the market price of our common stock following our initial public offering. Through March 1, 2020, the closing price of our common stock since our initial public offering has ranged from a low of $4.03 to a high of $17.05 per share. Moreover, the market price of our common stock might decline below current levels. In addition, the market price of our common stock is likely to be highly volatile and may fluctuate substantially. </span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales may occur could cause the market price of our common stock to decline.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The realization of any of the risks described in these &#8220;Risk Factors&#8221; could have a dramatic and material adverse impact on the market price of our common stock. In addition, securities class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such securities litigation brought against us could result in substantial costs and a diversion of management&#8217;s attention and resources, which could negatively impact our business, operating results and financial condition. Sales of a substantial number of shares of our common stock in the public market or the perception that these sales may occur could cause the market price of our common stock to decline. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The recent COVID-19 pandemic may cause increased risk to our common stock&#8217;s liquidity and trading price.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Unstable market conditions may have serious adverse consequences on our business.</span></div><div style="text-indent:36pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our general business strategy may be adversely affected by unpredictable and unstable market conditions. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, a radical economic downturn or increase in our expenses could require additional financing on less than attractive rates or on terms that are dilutive to existing shareholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical developments plans. There is a risk that one or more of our current service providers, manufacturers and other partners may encounter difficult economic circumstances, which would directly affect our ability to attain our operating goals on schedule and on budget. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The equity and lending markets have been and will most likely continue to be negatively impacted for an unknown period of time due to the COVID-19 pandemic.</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_97"></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Purchases of Equity Securities</span></div><div style="text-align:justify;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.  </span></div><div style="margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the activity, by month, during the three months ended March 31, 2020:</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.654%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:15.105%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.444%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.449%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Period</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Total</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Shares (or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Purchased (1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Average</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Price&#160;Paid</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">per&#160;Share</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(or Unit)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Total&#160;Number&#160;of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Shares (or Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;as&#160;Part</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">of Publicly</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Announced Plans</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">or Programs</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Maximum&#160;Number</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">(or Approximate</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Dollar Value) of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Shares&#160;(or&#160;Units)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">that May Yet Be</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Purchased&#160;Under</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">the Plans or</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Programs </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;vertical-align:top;">(1)</sup></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">January</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,817</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">180,621</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,820,088&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">February</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,629</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.49&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47,694</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,772,394&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">119,430</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.74&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">446,384</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,326,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">164,876</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">674,699</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-18pt;padding-left:18pt;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) Of this amount, 66,057 shares were repurchased directly through private purchases at the then-current fair market value of common stock.</span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_100"></div><div style="margin-top:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div style="margin-top:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;6. Exhibits</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:6.717%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.461%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:73.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.822%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/a2019-10kxexhibit1011a.htm">Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc., filed  as Exhibit 10.11 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No. 001-33637) and incorporated herein by reference.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/a2019-10kxexhibit1012m.htm">Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between Martin E. Cearnal and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.12 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No. 001-33637) and incorporated herein by reference.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/a2019-10kxexhibit1013l.htm">Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between Leo B. Pavliv and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.13 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No. 001-33637) and incorporated herein by reference.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.4</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/a2019-10kxexhibit1014m.htm">Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between Michael P. Bonner and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.14 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No. 001-33637) and incorporated herein by reference.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.5</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828020003880/a2019-10kxexhibit1015j.htm">Employment Agreement dated March 16, 2020, effective as of January 1, 2020, by and between James L. Herman and Cumberland Pharmaceuticals Inc., filed as Exhibit 10.15 to the Form 10-K of the Company filed with the Securities and Exchange Commission on March 20, 2020 (File No. 001-33637) and incorporated herein by reference.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2020q1-exhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2020q1-exhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1**</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="a2020q1-exhibit321.htm">Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">*</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Filed herewith.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">**</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furnished herewith.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:45pt;width:100%;"><div style="margin-top:12pt;"><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div id="i4835ed8a3261445cb0eff023a2e2ca1a_103"></div><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.099%;"><tr><td style="width:1.0%;"></td><td style="width:7.388%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:24.080%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.184%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:2.769%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.307%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.172%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.184%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:34.516%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cumberland Pharmaceuticals Inc.</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center;"><span><br/></span></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2020q1-exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i24e33f9ff3514e22be5b286bd4be72df_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, A.J. Kazimi, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:49.395%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.698%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.264%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2020q1-exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if74be03f5c134068a903ec60ed8b2f9c_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Michael Bonner, certify that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">I have reviewed this Form 10-Q of Cumberland Pharmaceuticals Inc.&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-18pt;padding-left:30pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:30pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:49.835%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.258%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.443%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:39.264%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2020q1-exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i7d6313c1c2ef4e1abd223ac748fc57c9_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF CHIEF EXECUTIVE AND</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form&#160;10-Q for the fiscal quarter ended March 31, 2020 of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;), as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer and Michael Bonner, Chief Financial Officer of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that&#58;</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.865%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:92.135%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:38.888%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; A. J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2020</font></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:13pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael Bonner</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 22, 2020</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:right;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cpix-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1ff53927-8a9f-4642-b593-f74226671984,g:b03cd8a5-37fe-4ab1-a910-c87820aed84d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquity" roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statement of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationOrganizationDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails">
        <link:definition>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecurities" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities">
        <link:definition>2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecuritiesTables" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables">
        <link:definition>2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>2107103 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails">
        <link:definition>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual">
        <link:definition>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>2111104 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>2312303 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails">
        <link:definition>2413405 - Disclosure - Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>2114105 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>2315304 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>2416406 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>2118106 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>2319305 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>2420408 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>2421409 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1">
        <link:definition>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebt" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt">
        <link:definition>2123107 - Disclosure - Shareholders' Equity and Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtShareholdersEquityDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails">
        <link:definition>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityandDebtDebtDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails">
        <link:definition>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>2126108 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2427413 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements">
        <link:definition>2128109 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRights" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights">
        <link:definition>2129110 - Disclosure - Additions and Returns of Product Rights</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsTables" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables">
        <link:definition>2330306 - Disclosure - Additions and Returns of Product Rights (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails">
        <link:definition>2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails">
        <link:definition>2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsChangeinConsiderationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
        <link:definition>2433416 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails">
        <link:definition>2434417 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents">
        <link:definition>2135111 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.cumberlandpharma.com/role/SubsequentEventsDetails">
        <link:definition>2436418 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" abstract="true" name="CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherLongTermObligationsExcludingCurrentPortion" abstract="false" name="OtherLongTermObligationsExcludingCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductsAbstract" abstract="true" name="ProductsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_EquityAndDebtAbstract" abstract="true" name="EquityAndDebtAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" abstract="false" name="SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ClinigenHealthcareLimitedMember" abstract="true" name="ClinigenHealthcareLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" abstract="false" name="SubsidiaryInvestmentPaymentsForReturnOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PaymentsForContingentConsideration" abstract="false" name="PaymentsForContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInCurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_GloriaPharmaceuticalsMember" abstract="true" name="GloriaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentCashContribution" abstract="false" name="SubsidiaryInvestmentCashContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareholdersEquityTextualAbstract" abstract="true" name="ShareholdersEquityTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_SecondAmendmentMember" abstract="true" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cpix-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1ff53927-8a9f-4642-b593-f74226671984,g:b03cd8a5-37fe-4ab1-a910-c87820aed84d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fc042668-3d5d-40ea-8251-0682764a1e78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1d2884de-bce9-4fd6-9234-dc0d08497082" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fc042668-3d5d-40ea-8251-0682764a1e78" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1d2884de-bce9-4fd6-9234-dc0d08497082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b84f000b-e9aa-458a-8c9e-dd54ef6b018a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fc042668-3d5d-40ea-8251-0682764a1e78" xlink:to="loc_us-gaap_AccountsPayableCurrent_b84f000b-e9aa-458a-8c9e-dd54ef6b018a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_27baaaed-0413-4308-b528-68b8c5c241f5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fc042668-3d5d-40ea-8251-0682764a1e78" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_27baaaed-0413-4308-b528-68b8c5c241f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_66192275-06b3-4bc1-8230-96d2a6761d88" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_fc042668-3d5d-40ea-8251-0682764a1e78" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_66192275-06b3-4bc1-8230-96d2a6761d88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb3764a6-7876-4381-9f3e-29b27cdb500e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fb3764a6-7876-4381-9f3e-29b27cdb500e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_57d3194e-dd38-4d4b-8799-217badbc5d79" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_57d3194e-dd38-4d4b-8799-217badbc5d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2ab9aa87-e352-485e-8741-6db252685f51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_Goodwill_2ab9aa87-e352-485e-8741-6db252685f51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_763ed88b-358d-4065-be6d-055c02377184" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_InventoryNoncurrent_763ed88b-358d-4065-be6d-055c02377184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ada138b-e44b-474d-943c-cf549d4da2d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_AssetsCurrent_6ada138b-e44b-474d-943c-cf549d4da2d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1aa49204-052a-4175-a963-7d47c7ebd8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1aa49204-052a-4175-a963-7d47c7ebd8c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_190703b7-47ef-432e-b5f3-552af00b99bf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_190703b7-47ef-432e-b5f3-552af00b99bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_358b1e1e-2076-41c7-83de-1298f080689f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f02cfcf1-f4a1-4696-b397-4c634e0c2d4b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_358b1e1e-2076-41c7-83de-1298f080689f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_07533d63-c064-4247-8b74-81663c1d233a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_56483a42-1615-4c81-84f5-9899c43b33c0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07533d63-c064-4247-8b74-81663c1d233a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_56483a42-1615-4c81-84f5-9899c43b33c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c248984a-f471-478d-8199-0b3ef4b49915" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07533d63-c064-4247-8b74-81663c1d233a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_c248984a-f471-478d-8199-0b3ef4b49915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ffa64d5b-9fda-42e0-8290-19ce777a31c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07533d63-c064-4247-8b74-81663c1d233a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ffa64d5b-9fda-42e0-8290-19ce777a31c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f2b4f829-541e-42b4-9b10-618e0ae11f90" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07533d63-c064-4247-8b74-81663c1d233a" xlink:to="loc_us-gaap_OtherAssetsCurrent_f2b4f829-541e-42b4-9b10-618e0ae11f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b6fe6188-a510-4dce-a604-f654c50ef9dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_07533d63-c064-4247-8b74-81663c1d233a" xlink:to="loc_us-gaap_InventoryNet_b6fe6188-a510-4dce-a604-f654c50ef9dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fa4daf45-e1ad-49a7-8000-59016907acfe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_076932a2-0802-46c5-a8b2-025d1e445fbc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa4daf45-e1ad-49a7-8000-59016907acfe" xlink:to="loc_us-gaap_LongTermLineOfCredit_076932a2-0802-46c5-a8b2-025d1e445fbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f5a374f-3315-4da4-8be3-ae28b06a9b12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa4daf45-e1ad-49a7-8000-59016907acfe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0f5a374f-3315-4da4-8be3-ae28b06a9b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_43b87fee-2d56-453e-b1cd-c32446309763" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa4daf45-e1ad-49a7-8000-59016907acfe" xlink:to="loc_us-gaap_LiabilitiesCurrent_43b87fee-2d56-453e-b1cd-c32446309763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_4d4e2cd1-6010-4801-9786-d583b97215c7" xlink:href="cpix-20200331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_fa4daf45-e1ad-49a7-8000-59016907acfe" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_4d4e2cd1-6010-4801-9786-d583b97215c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3989bad3-414a-4f4e-8472-89adeb70e4e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7ee8c64e-1b55-41d5-8b29-38496247c971" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3989bad3-414a-4f4e-8472-89adeb70e4e7" xlink:to="loc_us-gaap_CommonStockValue_7ee8c64e-1b55-41d5-8b29-38496247c971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8aa26d64-4235-4046-a53b-77bde506dade" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3989bad3-414a-4f4e-8472-89adeb70e4e7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8aa26d64-4235-4046-a53b-77bde506dade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cd744bf-1e39-417d-bdb8-cf59c4a33245" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_49609ecf-8b85-42d4-bd93-3b947b364af0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cd744bf-1e39-417d-bdb8-cf59c4a33245" xlink:to="loc_us-gaap_Liabilities_49609ecf-8b85-42d4-bd93-3b947b364af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1dfcbc5a-a237-4ef2-aa52-23ffd35db71d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cd744bf-1e39-417d-bdb8-cf59c4a33245" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1dfcbc5a-a237-4ef2-aa52-23ffd35db71d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_1844385f-beb6-489f-ac99-29707eed9321" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cd744bf-1e39-417d-bdb8-cf59c4a33245" xlink:to="loc_us-gaap_CommitmentsAndContingencies_1844385f-beb6-489f-ac99-29707eed9321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b83ffb42-18bf-4d8f-a2ce-5f3cf6c4ce46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6341a4cb-c8d3-45f7-96eb-11521f0fc36e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b83ffb42-18bf-4d8f-a2ce-5f3cf6c4ce46" xlink:to="loc_us-gaap_StockholdersEquity_6341a4cb-c8d3-45f7-96eb-11521f0fc36e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_90058238-bba7-4483-9cbb-431bc8bc1456" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b83ffb42-18bf-4d8f-a2ce-5f3cf6c4ce46" xlink:to="loc_us-gaap_MinorityInterest_90058238-bba7-4483-9cbb-431bc8bc1456" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7283abda-9ca9-47bd-8e27-039dcd553a44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4a804c70-2f28-43d6-982b-30acdb926740" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7283abda-9ca9-47bd-8e27-039dcd553a44" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4a804c70-2f28-43d6-982b-30acdb926740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_00a57492-ee84-4294-a2aa-1e856f4befbe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7283abda-9ca9-47bd-8e27-039dcd553a44" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_00a57492-ee84-4294-a2aa-1e856f4befbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2c5ea23-526f-47a9-b85d-d74c61c36bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e5fbb812-4818-4038-9b23-eb7665ca03b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c2c5ea23-526f-47a9-b85d-d74c61c36bc0" xlink:to="loc_us-gaap_ProfitLoss_e5fbb812-4818-4038-9b23-eb7665ca03b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c4a4c283-f0a0-41c1-b26f-3784684f5325" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c2c5ea23-526f-47a9-b85d-d74c61c36bc0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c4a4c283-f0a0-41c1-b26f-3784684f5325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1fd044ba-c4e2-4d08-ab59-4b413231f6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7ad26b9f-5995-4d4d-a5e6-1e568e1eb8e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1fd044ba-c4e2-4d08-ab59-4b413231f6e5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7ad26b9f-5995-4d4d-a5e6-1e568e1eb8e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_be82a2da-d1f0-47cb-a9e3-a1ccbd86a5b3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_1fd044ba-c4e2-4d08-ab59-4b413231f6e5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_be82a2da-d1f0-47cb-a9e3-a1ccbd86a5b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3360cde6-ee42-4910-8993-0441591f7105" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b020c451-4b57-4f11-a50d-3d9442109355" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3360cde6-ee42-4910-8993-0441591f7105" xlink:to="loc_us-gaap_OperatingIncomeLoss_b020c451-4b57-4f11-a50d-3d9442109355" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_64a091b5-aecc-41de-a99c-ddec8967234c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3360cde6-ee42-4910-8993-0441591f7105" xlink:to="loc_us-gaap_InvestmentIncomeInterest_64a091b5-aecc-41de-a99c-ddec8967234c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c295f5cf-e987-4ad3-aceb-201d54d47169" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3360cde6-ee42-4910-8993-0441591f7105" xlink:to="loc_us-gaap_InterestExpense_c295f5cf-e987-4ad3-aceb-201d54d47169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f446ce4-6ed2-4274-a3fd-8e115852eea9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_59895489-90b5-4768-bdec-f5d8f8fd340c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3f446ce4-6ed2-4274-a3fd-8e115852eea9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_59895489-90b5-4768-bdec-f5d8f8fd340c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d01a8e69-0d46-4bba-a7be-7eea58430d46" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3f446ce4-6ed2-4274-a3fd-8e115852eea9" xlink:to="loc_us-gaap_CostsAndExpenses_d01a8e69-0d46-4bba-a7be-7eea58430d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2ecc36ac-3cb2-4887-801b-e72b2ad04677" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_88827fc8-41e5-4a3a-8b2c-98fc5313ad30" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2ecc36ac-3cb2-4887-801b-e72b2ad04677" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_88827fc8-41e5-4a3a-8b2c-98fc5313ad30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_899c526a-065c-4c97-9cd4-6e9333e1e1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2ecc36ac-3cb2-4887-801b-e72b2ad04677" xlink:to="loc_us-gaap_SellingAndMarketingExpense_899c526a-065c-4c97-9cd4-6e9333e1e1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fba3d87e-1fe3-4ab9-88ec-24f5896bcf8b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2ecc36ac-3cb2-4887-801b-e72b2ad04677" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fba3d87e-1fe3-4ab9-88ec-24f5896bcf8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4fceda2c-f4f1-471f-8716-c61c3ab9a17d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2ecc36ac-3cb2-4887-801b-e72b2ad04677" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4fceda2c-f4f1-471f-8716-c61c3ab9a17d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fb044ea1-df46-4bb6-94da-a5acd2187a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2ecc36ac-3cb2-4887-801b-e72b2ad04677" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fb044ea1-df46-4bb6-94da-a5acd2187a9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_264395b7-b2a5-493a-b5f0-41bb5364a499" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_261275bb-0ee1-4a0e-b798-bda426bc6c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_264395b7-b2a5-493a-b5f0-41bb5364a499" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_261275bb-0ee1-4a0e-b798-bda426bc6c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b3c1a922-da2c-4020-ae47-010620a1b01a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_264395b7-b2a5-493a-b5f0-41bb5364a499" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b3c1a922-da2c-4020-ae47-010620a1b01a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c5e20de9-9511-44c8-a13a-a9c5bfb8a20e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19159da3-a9e2-40be-8088-d289b341f90a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c5e20de9-9511-44c8-a13a-a9c5bfb8a20e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_19159da3-a9e2-40be-8088-d289b341f90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_626a2fa1-b992-441e-90f4-71a411da18e5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c5e20de9-9511-44c8-a13a-a9c5bfb8a20e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_626a2fa1-b992-441e-90f4-71a411da18e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba8aa9-ab14-4e11-9ab4-b0509f33b1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c5e20de9-9511-44c8-a13a-a9c5bfb8a20e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_77ba8aa9-ab14-4e11-9ab4-b0509f33b1dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_810084be-c3a6-4737-98d1-5e74855bcbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f9f80f07-ead6-4d9d-b9fc-c2714f4ef90f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_810084be-c3a6-4737-98d1-5e74855bcbbf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_f9f80f07-ead6-4d9d-b9fc-c2714f4ef90f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_0c1aa727-51b8-4296-b98d-2ffd180ef56f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_810084be-c3a6-4737-98d1-5e74855bcbbf" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_0c1aa727-51b8-4296-b98d-2ffd180ef56f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac9c256b-3262-4838-aee5-e2712e339039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5ae5f26e-2ba5-4fe0-ae9b-9c82a27bde45" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac9c256b-3262-4838-aee5-e2712e339039" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5ae5f26e-2ba5-4fe0-ae9b-9c82a27bde45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5c48b2eb-bdd2-4313-aa61-5ea73d11e338" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac9c256b-3262-4838-aee5-e2712e339039" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5c48b2eb-bdd2-4313-aa61-5ea73d11e338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_87fd6390-d62e-4afb-90f5-aa3eba2cc22c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac9c256b-3262-4838-aee5-e2712e339039" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_87fd6390-d62e-4afb-90f5-aa3eba2cc22c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8dd649bf-e0f9-462e-b883-61e34e35846b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac9c256b-3262-4838-aee5-e2712e339039" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8dd649bf-e0f9-462e-b883-61e34e35846b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81b3c39a-4711-4424-82e2-2a238373b53e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1f4f9e36-21be-4c93-b139-2af008d5d8b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81b3c39a-4711-4424-82e2-2a238373b53e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1f4f9e36-21be-4c93-b139-2af008d5d8b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_82ea206c-3b02-4d9c-9828-76584405bab5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81b3c39a-4711-4424-82e2-2a238373b53e" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_82ea206c-3b02-4d9c-9828-76584405bab5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_ed253be1-c024-45a2-aed5-e50ce8d33d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81b3c39a-4711-4424-82e2-2a238373b53e" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_ed253be1-c024-45a2-aed5-e50ce8d33d0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_92a053d8-41f7-48c8-9a0f-5469a409327d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81b3c39a-4711-4424-82e2-2a238373b53e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_92a053d8-41f7-48c8-9a0f-5469a409327d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_220d0ab1-45dd-4db8-b2cf-4245092e316b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81b3c39a-4711-4424-82e2-2a238373b53e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_220d0ab1-45dd-4db8-b2cf-4245092e316b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_320d33d7-1d3f-4b65-be88-88414d0defd7" xlink:href="cpix-20200331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_320d33d7-1d3f-4b65-be88-88414d0defd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_ef0e9f94-47a1-4833-8088-dfc2042be25d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_ef0e9f94-47a1-4833-8088-dfc2042be25d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e9cd6e98-7eba-4b5f-a32a-bb48d1900599" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e9cd6e98-7eba-4b5f-a32a-bb48d1900599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d94af5d3-7966-46e8-961b-1fc7f14809e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_d94af5d3-7966-46e8-961b-1fc7f14809e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6de71059-67e9-4b4e-a844-e21f1e2bd777" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6de71059-67e9-4b4e-a844-e21f1e2bd777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c7bda435-5ccb-4be0-b4c1-880d7bb0792e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c7bda435-5ccb-4be0-b4c1-880d7bb0792e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0e1cc0c4-247a-4b9d-a355-494b31626c34" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0e1cc0c4-247a-4b9d-a355-494b31626c34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_048cb09f-2c00-4b54-be2d-afad2d600dce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_048cb09f-2c00-4b54-be2d-afad2d600dce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1fd00012-e59a-4b0a-bb96-25e4fc5c154e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1fd00012-e59a-4b0a-bb96-25e4fc5c154e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b79767d0-4daa-4ac9-85f2-1f4e2e0bf84c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b79767d0-4daa-4ac9-85f2-1f4e2e0bf84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_82b56780-48bd-403a-9122-ca215772b9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_ShareBasedCompensation_82b56780-48bd-403a-9122-ca215772b9e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c80e4c0b-7153-4203-905e-f8030adf09b9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_5b3c415b-5bde-4cfb-aa20-85fc062d52d4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_c80e4c0b-7153-4203-905e-f8030adf09b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShare"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97b19b36-cceb-4e6c-89d3-9dcb84cdaf6a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a103074e-5c19-4512-82df-d4b7d20a691c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97b19b36-cceb-4e6c-89d3-9dcb84cdaf6a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a103074e-5c19-4512-82df-d4b7d20a691c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d087865d-95b9-49fd-bb3b-52761b5cf640" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_97b19b36-cceb-4e6c-89d3-9dcb84cdaf6a" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d087865d-95b9-49fd-bb3b-52761b5cf640" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200331.xsd#Revenues"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#RevenuesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#RevenuesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200331.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d3666bcf-756c-4398-aa3d-7c4d4513b344" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3546ac04-0c2c-4061-aa65-daff23978799" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d3666bcf-756c-4398-aa3d-7c4d4513b344" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_3546ac04-0c2c-4061-aa65-daff23978799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_7e9b4502-19db-4f71-a21d-ddc72ce83891" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d3666bcf-756c-4398-aa3d-7c4d4513b344" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_7e9b4502-19db-4f71-a21d-ddc72ce83891" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_adb99a90-da7c-4a33-9ec1-f8614e145857" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_d3666bcf-756c-4398-aa3d-7c4d4513b344" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_adb99a90-da7c-4a33-9ec1-f8614e145857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_275d3946-37c6-44e5-b711-a01b424c9f13" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4a15cad0-f880-4a53-99db-c3a94170d88f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_275d3946-37c6-44e5-b711-a01b424c9f13" xlink:to="loc_us-gaap_InventoryNoncurrent_4a15cad0-f880-4a53-99db-c3a94170d88f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_50d35f48-58a0-49d0-9b44-531051871780" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_275d3946-37c6-44e5-b711-a01b424c9f13" xlink:to="loc_us-gaap_InventoryGross_50d35f48-58a0-49d0-9b44-531051871780" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200331.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f923df2e-8993-449a-81ba-21e935381cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_94d7d8f1-1f92-4059-ad36-71609d56e57d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f923df2e-8993-449a-81ba-21e935381cc2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_94d7d8f1-1f92-4059-ad36-71609d56e57d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3bd243ec-667d-46a5-b490-5255968bae0c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f923df2e-8993-449a-81ba-21e935381cc2" xlink:to="loc_us-gaap_OperatingLeaseLiability_3bd243ec-667d-46a5-b490-5255968bae0c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c363a0c-1d2a-4f09-93d0-9df5b7082d29" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a99b5cbb-cbca-4bba-8d8a-93c27963a69d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c363a0c-1d2a-4f09-93d0-9df5b7082d29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a99b5cbb-cbca-4bba-8d8a-93c27963a69d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a6385f32-1d30-4959-94d2-4100d5b4ed27" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c363a0c-1d2a-4f09-93d0-9df5b7082d29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a6385f32-1d30-4959-94d2-4100d5b4ed27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8a3ae7f-51d7-42c3-9602-20d4194141e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c363a0c-1d2a-4f09-93d0-9df5b7082d29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8a3ae7f-51d7-42c3-9602-20d4194141e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a85c46fd-6ae8-4cc8-b909-771d38aecaff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c363a0c-1d2a-4f09-93d0-9df5b7082d29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_a85c46fd-6ae8-4cc8-b909-771d38aecaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_87560dd0-a523-4828-836e-cc70cb1dd477" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c363a0c-1d2a-4f09-93d0-9df5b7082d29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_87560dd0-a523-4828-836e-cc70cb1dd477" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebt"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200331.xsd#IncomeTaxesDetailsTextual"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200331.xsd#CollaborativeAgreements"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRights"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_25ce18d0-a27f-4a3c-876f-6220de3c41b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_fc2a0ba5-64b3-4046-8fbb-0950f26651b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_25ce18d0-a27f-4a3c-876f-6220de3c41b8" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_fc2a0ba5-64b3-4046-8fbb-0950f26651b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7d0438a8-41b2-47e0-b250-d28f33855c39" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_25ce18d0-a27f-4a3c-876f-6220de3c41b8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7d0438a8-41b2-47e0-b250-d28f33855c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_fc354592-d9de-41e5-b14c-042bfc3daade" xlink:href="cpix-20200331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_25ce18d0-a27f-4a3c-876f-6220de3c41b8" xlink:to="loc_cpix_PaymentsForContingentConsideration_fc354592-d9de-41e5-b14c-042bfc3daade" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cpix-20200331.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cpix-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1ff53927-8a9f-4642-b593-f74226671984,g:b03cd8a5-37fe-4ab1-a910-c87820aed84d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended" id="ic6490d0d0dae4394ac3a9f31c2dbcbd4_CoverPage"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="ib6dc7d030a204aaa8c3ca5a9281f1cfe_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i115b1a0d2509445e9d096a914e83b3fc_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended" id="i67e239ca2e0a4f43b25fbdb0228fa206_CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i618d59dfa89043bb9ac7ef5a61075fbb_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended" id="i4b603ec4a0574d7cae6d7586c194e3bb_CondensedConsolidatedStatementofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a526847-f361-4cc0-9be7-cb4a55a1c085" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4a526847-f361-4cc0-9be7-cb4a55a1c085" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52304b6d-f967-4205-9434-d4d71ea06b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52304b6d-f967-4205-9434-d4d71ea06b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a30e6307-f03a-429b-b540-bcdec13efa83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a30e6307-f03a-429b-b540-bcdec13efa83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ac9a76a6-3469-4165-a9e1-74ecd6b9986b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ac9a76a6-3469-4165-a9e1-74ecd6b9986b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8503b5b-68aa-4507-a3d5-2dabeac9ce06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8503b5b-68aa-4507-a3d5-2dabeac9ce06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_654c8469-e561-4769-a5b6-4959af8dc238" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_654c8469-e561-4769-a5b6-4959af8dc238" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_aa291484-ef4c-4d15-b7e1-dcb4afa279d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_aa291484-ef4c-4d15-b7e1-dcb4afa279d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_829579c5-7f8f-4b33-938f-ff5f2e09b37e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_ProfitLoss_829579c5-7f8f-4b33-938f-ff5f2e09b37e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11fb86dc-a8d0-4ae5-a502-fd88febba795" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f868ed7c-226d-4fdd-bcaa-283861b0e502" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0ff690d-2cab-4b67-bebb-501993ed24d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4a526847-f361-4cc0-9be7-cb4a55a1c085" xlink:to="loc_us-gaap_StatementTable_f0ff690d-2cab-4b67-bebb-501993ed24d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c2796b8-6030-44b2-b7bd-949b67426b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f0ff690d-2cab-4b67-bebb-501993ed24d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c2796b8-6030-44b2-b7bd-949b67426b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8c2796b8-6030-44b2-b7bd-949b67426b7d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c2796b8-6030-44b2-b7bd-949b67426b7d" xlink:to="loc_us-gaap_EquityComponentDomain_8c2796b8-6030-44b2-b7bd-949b67426b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c2796b8-6030-44b2-b7bd-949b67426b7d" xlink:to="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3b2085b3-f61e-43db-b63d-894b67fc0d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:to="loc_us-gaap_CommonStockMember_3b2085b3-f61e-43db-b63d-894b67fc0d5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1734ffa6-8c56-4a51-80ac-cf535f75df6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:to="loc_us-gaap_RetainedEarningsMember_1734ffa6-8c56-4a51-80ac-cf535f75df6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_098fad45-7be7-4e83-bad3-766875b4b50c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:to="loc_us-gaap_NoncontrollingInterestMember_098fad45-7be7-4e83-bad3-766875b4b50c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i9788b1515f7442b6a7e363a14b5f2e8c_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended" id="i4e9c8a673c2d49bca887e08ed62d2ecc_OrganizationandBasisofPresentationPolicies"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended" id="i7d176392c00b40a384bb518ec0902c77_OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended" id="i902c86e68abf4a9f95dd6d13050345c4_InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended" id="idff5eb6210124d97b16c2a89aab9bfc4_InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i37ef61ef5dad45cc99f20f4139e6b93a_InvestmentsinCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2071c43b-3f6e-4f43-861b-d53f4fb161cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_4379c90e-ddc4-4448-b40d-5da1bb95adbb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2071c43b-3f6e-4f43-861b-d53f4fb161cf" xlink:to="loc_us-gaap_TradingSecurities_4379c90e-ddc4-4448-b40d-5da1bb95adbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2071c43b-3f6e-4f43-861b-d53f4fb161cf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08c462fc-8623-46de-a3a0-8493f09dc3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08c462fc-8623-46de-a3a0-8493f09dc3d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_08c462fc-8623-46de-a3a0-8493f09dc3d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08c462fc-8623-46de-a3a0-8493f09dc3d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_08c462fc-8623-46de-a3a0-8493f09dc3d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08c462fc-8623-46de-a3a0-8493f09dc3d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_91c04fbf-0848-45e8-a87e-b05decaf2e66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_91c04fbf-0848-45e8-a87e-b05decaf2e66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3dc856fd-7397-4b11-8826-705b5e50aacf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3dc856fd-7397-4b11-8826-705b5e50aacf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a62cc316-c98b-4d25-8ef5-7747491c0efe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a62cc316-c98b-4d25-8ef5-7747491c0efe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a62cc316-c98b-4d25-8ef5-7747491c0efe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a62cc316-c98b-4d25-8ef5-7747491c0efe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a62cc316-c98b-4d25-8ef5-7747491c0efe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70fa078b-4728-4203-bc1e-25458111233e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a62cc316-c98b-4d25-8ef5-7747491c0efe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70fa078b-4728-4203-bc1e-25458111233e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9a4be758-390f-42bd-b1bd-67d171dabcec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70fa078b-4728-4203-bc1e-25458111233e" xlink:to="loc_us-gaap_CommercialPaperMember_9a4be758-390f-42bd-b1bd-67d171dabcec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShare"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended" id="i218e54e6786847559b390c7a85c656c7_EarningsLossPerShare"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended" id="i7d78f8558e1b4854a355b06367172773_EarningsLossPerShareTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended" id="i5cf58e5ea3314ad19b80c8ace09d7c9b_EarningsLossPerShareDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended" id="i726d6b7b23ef4b0c9fcf38066aaa83ef_EarningsLossPerShareDetailsTextual"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200331.xsd#Revenues"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended" id="i1f4e2c1bdc5d4135bfc6a3a726ccefff_Revenues"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#RevenuesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended" id="ibd395268dc6641c2b33d1e68f878ef59_RevenuesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#RevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended" id="ic8f8756000c340ad8231df5e98a7d0bb_RevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_93dd156c-30f8-4ad0-8761-494bcdaad358" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d37996af-04ab-43b5-aaa2-a4333605ac5f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_93dd156c-30f8-4ad0-8761-494bcdaad358" xlink:to="loc_us-gaap_RevenuesAbstract_d37996af-04ab-43b5-aaa2-a4333605ac5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_02cf0eb9-a87b-4edf-ad8c-d244aa1131d5" xlink:href="cpix-20200331.xsd#cpix_ProductsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d37996af-04ab-43b5-aaa2-a4333605ac5f" xlink:to="loc_cpix_ProductsAbstract_02cf0eb9-a87b-4edf-ad8c-d244aa1131d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac1f4064-e382-4945-87c4-cd021740287c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductsAbstract_02cf0eb9-a87b-4edf-ad8c-d244aa1131d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac1f4064-e382-4945-87c4-cd021740287c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_93dd156c-30f8-4ad0-8761-494bcdaad358" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c218858-ae50-4cde-9e6b-7d79ec40cd78" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:to="loc_srt_ProductOrServiceAxis_6c218858-ae50-4cde-9e6b-7d79ec40cd78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6c218858-ae50-4cde-9e6b-7d79ec40cd78_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6c218858-ae50-4cde-9e6b-7d79ec40cd78" xlink:to="loc_srt_ProductsAndServicesDomain_6c218858-ae50-4cde-9e6b-7d79ec40cd78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6c218858-ae50-4cde-9e6b-7d79ec40cd78" xlink:to="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_113819af-4661-455a-a489-f014aaf2bff7" xlink:href="cpix-20200331.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_AcetadoteMember_113819af-4661-455a-a489-f014aaf2bff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_15341567-e076-49f5-9173-ceaa216e6aaf" xlink:href="cpix-20200331.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_OmeclamoxPakMember_15341567-e076-49f5-9173-ceaa216e6aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_7d539cf8-cee0-443b-915f-508a00a9f279" xlink:href="cpix-20200331.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_KristaloseMember_7d539cf8-cee0-443b-915f-508a00a9f279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_3fbf2201-303e-47d2-90c8-18a9f6fcfd82" xlink:href="cpix-20200331.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_VaprisolMember_3fbf2201-303e-47d2-90c8-18a9f6fcfd82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_cecc0314-298a-4586-8448-d15381faacea" xlink:href="cpix-20200331.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_CaldolorMember_cecc0314-298a-4586-8448-d15381faacea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_94cba62a-41d3-44eb-b579-ce9e6fc83ca9" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_VIBATIVMember_94cba62a-41d3-44eb-b579-ce9e6fc83ca9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_0cdac5e3-856b-4986-9623-196aae622edc" xlink:href="cpix-20200331.xsd#cpix_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_OtherProductsMember_0cdac5e3-856b-4986-9623-196aae622edc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_eb815c8d-7e9a-4bf8-9438-860cf67ed5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_us-gaap_GrantMember_eb815c8d-7e9a-4bf8-9438-860cf67ed5c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b907a3f1-ba9d-48b1-80d8-9f77484e4e50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b907a3f1-ba9d-48b1-80d8-9f77484e4e50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b907a3f1-ba9d-48b1-80d8-9f77484e4e50_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b907a3f1-ba9d-48b1-80d8-9f77484e4e50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b907a3f1-ba9d-48b1-80d8-9f77484e4e50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08150f4a-9c9a-4bd2-b9e1-5bcc55b8ee37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b907a3f1-ba9d-48b1-80d8-9f77484e4e50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08150f4a-9c9a-4bd2-b9e1-5bcc55b8ee37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_8aa50198-581f-474f-a70f-080d98149e74" xlink:href="cpix-20200331.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08150f4a-9c9a-4bd2-b9e1-5bcc55b8ee37" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_8aa50198-581f-474f-a70f-080d98149e74" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200331.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended" id="i424004e331b843459285be738f94a168_Inventories"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended" id="i81a6bc8e2c3b448987eebf80059c3be3_InventoriesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="ib205824aff6a4b64be959cd55830927a_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_70d2249b-7cf4-4aa1-8ce2-0f267fd7fa95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_222dd64d-34d7-4892-ab5a-1eab0119621f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_70d2249b-7cf4-4aa1-8ce2-0f267fd7fa95" xlink:to="loc_us-gaap_InventoryNoncurrent_222dd64d-34d7-4892-ab5a-1eab0119621f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_f77b0666-ff37-4812-a039-737cd81fe5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_70d2249b-7cf4-4aa1-8ce2-0f267fd7fa95" xlink:to="loc_us-gaap_InventoryCurrentTable_f77b0666-ff37-4812-a039-737cd81fe5a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4adee72-9954-4b46-85da-8a9fc9034112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_f77b0666-ff37-4812-a039-737cd81fe5a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4adee72-9954-4b46-85da-8a9fc9034112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4adee72-9954-4b46-85da-8a9fc9034112_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4adee72-9954-4b46-85da-8a9fc9034112" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4adee72-9954-4b46-85da-8a9fc9034112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0ca3489-377a-45e5-b095-004bb12ffb94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4adee72-9954-4b46-85da-8a9fc9034112" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0ca3489-377a-45e5-b095-004bb12ffb94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_e5b413a3-5725-414e-9f51-50cf3bbfc9ce" xlink:href="cpix-20200331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0ca3489-377a-45e5-b095-004bb12ffb94" xlink:to="loc_cpix_IfetrobanClinicalMember_e5b413a3-5725-414e-9f51-50cf3bbfc9ce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended" id="ic93fd90c40e84618b23f2d85a6787e4d_InventoriesScheduleofInventoriesDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200331.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended" id="ie397cfc4cb8841aea4e8cab1831ee0da_Leases"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended" id="i20fdc4bea2344e3bbb93e764134b57be_LeasesTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i4fd8943a307547e7a822d85a58af1d43_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesLeasePositionDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended" id="id8cc7c82d9f348beb11b771dbffeac3b_LeasesLeasePositionDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended" id="ie506bb0f05a6472ca05bdec9844b4d76_LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebt"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended" id="i468193a37e0a44e18ab061fcbbc02edf_ShareholdersEquityandDebt"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended" id="i9e40efabbea84c999e2181884a486a43_ShareholdersEquityandDebtShareholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5506327-9ca6-40cb-b127-1d8cb60ae592" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:href="cpix-20200331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5506327-9ca6-40cb-b127-1d8cb60ae592" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_954bd8ef-b370-4540-9597-4573b93c46c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_954bd8ef-b370-4540-9597-4573b93c46c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_4715a838-4552-4140-84b2-35c324a30ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_4715a838-4552-4140-84b2-35c324a30ee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_944f8913-5bbb-44af-ae39-0aa2bb6baa1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_944f8913-5bbb-44af-ae39-0aa2bb6baa1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e60757df-ad98-4c3d-a52b-14928d3971e0" xlink:href="cpix-20200331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e60757df-ad98-4c3d-a52b-14928d3971e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fb525d86-f644-498d-b907-da6806182e85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fb525d86-f644-498d-b907-da6806182e85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b5b9747-921d-45f8-afee-3c258e4105b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b5b9747-921d-45f8-afee-3c258e4105b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_0042b5a9-c8f3-4bf0-b713-0061d3cb19fa" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_0042b5a9-c8f3-4bf0-b713-0061d3cb19fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_27eb9e0a-98c8-43f5-9b96-1ef3b302283f" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_27eb9e0a-98c8-43f5-9b96-1ef3b302283f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_861a0415-f17d-4a2d-a005-b8a4207bc1bf" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_861a0415-f17d-4a2d-a005-b8a4207bc1bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_92a44d01-cf24-4c19-b4ba-b8d0c42549e8" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_92a44d01-cf24-4c19-b4ba-b8d0c42549e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5506327-9ca6-40cb-b127-1d8cb60ae592" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4bbdffbd-6947-4364-b875-52a85e8432a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4bbdffbd-6947-4364-b875-52a85e8432a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4bbdffbd-6947-4364-b875-52a85e8432a7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4bbdffbd-6947-4364-b875-52a85e8432a7" xlink:to="loc_us-gaap_EquityComponentDomain_4bbdffbd-6947-4364-b875-52a85e8432a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8d5d409c-21b6-4ede-a211-ff4ae843de12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4bbdffbd-6947-4364-b875-52a85e8432a7" xlink:to="loc_us-gaap_EquityComponentDomain_8d5d409c-21b6-4ede-a211-ff4ae843de12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6576b6b0-c75d-4d8a-b50f-4674da3981c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8d5d409c-21b6-4ede-a211-ff4ae843de12" xlink:to="loc_us-gaap_CommonStockMember_6576b6b0-c75d-4d8a-b50f-4674da3981c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_45b10874-1c83-426f-975c-4906972dcb87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_us-gaap_TitleOfIndividualAxis_45b10874-1c83-426f-975c-4906972dcb87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_45b10874-1c83-426f-975c-4906972dcb87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_45b10874-1c83-426f-975c-4906972dcb87" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_45b10874-1c83-426f-975c-4906972dcb87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1b02ae2-8c46-4996-903a-90966ce0ae42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_45b10874-1c83-426f-975c-4906972dcb87" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1b02ae2-8c46-4996-903a-90966ce0ae42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_2eedba58-1b0b-4709-b236-f87366c70039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1b02ae2-8c46-4996-903a-90966ce0ae42" xlink:to="loc_us-gaap_DirectorMember_2eedba58-1b0b-4709-b236-f87366c70039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f139c74-4232-4c6b-934a-821e28ab4f31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_us-gaap_AwardTypeAxis_9f139c74-4232-4c6b-934a-821e28ab4f31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f139c74-4232-4c6b-934a-821e28ab4f31_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9f139c74-4232-4c6b-934a-821e28ab4f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f139c74-4232-4c6b-934a-821e28ab4f31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdee52bf-74c8-41c1-96d8-0918e448fa15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9f139c74-4232-4c6b-934a-821e28ab4f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdee52bf-74c8-41c1-96d8-0918e448fa15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_02dff396-48d0-4bc1-af98-ddfe1ca912b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdee52bf-74c8-41c1-96d8-0918e448fa15" xlink:to="loc_us-gaap_RestrictedStockMember_02dff396-48d0-4bc1-af98-ddfe1ca912b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_srt_CounterpartyNameAxis_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_515f255d-fa21-40cc-80f0-147114f9fa0e" xlink:href="cpix-20200331.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_515f255d-fa21-40cc-80f0-147114f9fa0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_bf791fdd-59f4-4d26-9946-9cf00aad8d26" xlink:href="cpix-20200331.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_bf791fdd-59f4-4d26-9946-9cf00aad8d26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended" id="i2fe2b32bf1a841ff8a77ba99f8ec48ea_ShareholdersEquityandDebtDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf4007bc-4216-4517-9eb1-3d54b407679c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf4007bc-4216-4517-9eb1-3d54b407679c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_abe2d173-4b96-4398-b30d-7476a8704a45" xlink:href="cpix-20200331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_abe2d173-4b96-4398-b30d-7476a8704a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_74fabf9f-9ab8-47bb-b46d-14cbec35b9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_LongTermLineOfCredit_74fabf9f-9ab8-47bb-b46d-14cbec35b9b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ee0cce5-05bb-486c-b79d-9fe7b69e8138" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ee0cce5-05bb-486c-b79d-9fe7b69e8138" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_aa3e31b0-b436-429b-a963-751f06649b93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_aa3e31b0-b436-429b-a963-751f06649b93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_31680202-1295-4a60-abd3-604d05de23fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_31680202-1295-4a60-abd3-604d05de23fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_31680202-1295-4a60-abd3-604d05de23fb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_31680202-1295-4a60-abd3-604d05de23fb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_31680202-1295-4a60-abd3-604d05de23fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_495b59f2-66b5-4ef3-a22e-872ee18f2df3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_31680202-1295-4a60-abd3-604d05de23fb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_495b59f2-66b5-4ef3-a22e-872ee18f2df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_ba4aaf27-157b-4197-af6f-bd3128dae1a7" xlink:href="cpix-20200331.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_495b59f2-66b5-4ef3-a22e-872ee18f2df3" xlink:to="loc_cpix_PinnacleBankMember_ba4aaf27-157b-4197-af6f-bd3128dae1a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_02a7a645-18d7-4f02-b876-906979dbe189" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_us-gaap_DebtInstrumentAxis_02a7a645-18d7-4f02-b876-906979dbe189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_02a7a645-18d7-4f02-b876-906979dbe189_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_02a7a645-18d7-4f02-b876-906979dbe189" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_02a7a645-18d7-4f02-b876-906979dbe189_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_02a7a645-18d7-4f02-b876-906979dbe189" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_519cb078-7faa-40ef-838a-2675b18a44c5" xlink:href="cpix-20200331.xsd#cpix_SecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:to="loc_cpix_SecondAmendmentMember_519cb078-7faa-40ef-838a-2675b18a44c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fd825921-1196-4f40-9fa5-df07c74f97b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:to="loc_us-gaap_LineOfCreditMember_fd825921-1196-4f40-9fa5-df07c74f97b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_49cd919c-08ec-45f9-ac78-e2fb63159715" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_us-gaap_CreditFacilityAxis_49cd919c-08ec-45f9-ac78-e2fb63159715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_49cd919c-08ec-45f9-ac78-e2fb63159715_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_49cd919c-08ec-45f9-ac78-e2fb63159715" xlink:to="loc_us-gaap_CreditFacilityDomain_49cd919c-08ec-45f9-ac78-e2fb63159715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_99a1d0e8-14a4-4e7d-9330-9581a075ed7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_49cd919c-08ec-45f9-ac78-e2fb63159715" xlink:to="loc_us-gaap_CreditFacilityDomain_99a1d0e8-14a4-4e7d-9330-9581a075ed7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d9ee9092-ab81-4082-b9ac-a0b35bb58ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_99a1d0e8-14a4-4e7d-9330-9581a075ed7a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d9ee9092-ab81-4082-b9ac-a0b35bb58ba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_753c58f6-b1a0-4a15-a076-0ff28e744848" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_srt_RangeAxis_753c58f6-b1a0-4a15-a076-0ff28e744848" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_753c58f6-b1a0-4a15-a076-0ff28e744848_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_753c58f6-b1a0-4a15-a076-0ff28e744848" xlink:to="loc_srt_RangeMember_753c58f6-b1a0-4a15-a076-0ff28e744848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_753c58f6-b1a0-4a15-a076-0ff28e744848" xlink:to="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ad4db01-1101-4a81-93ba-e79952eabf19" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:to="loc_srt_MinimumMember_3ad4db01-1101-4a81-93ba-e79952eabf19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8e0c0234-dda1-4564-a9c3-f828821762cc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:to="loc_srt_MaximumMember_8e0c0234-dda1-4564-a9c3-f828821762cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended" id="i103e42d09bd74e53a617d2a0e90e6746_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200331.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="id99bb5e82a5c4085b58b09c574c9b867_IncomeTaxesDetailsTextual"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200331.xsd#CollaborativeAgreements"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended" id="i50a436b138fe494c9415dea7c2a5ddcc_CollaborativeAgreements"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRights"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended" id="i381851ef0c8144d98e1eccaa1f07b468_AdditionsandReturnsofProductRights"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended" id="i51bebe1844a54060a05a54c350e372e8_AdditionsandReturnsofProductRightsTables"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended" id="i9ec9093c98584c498bc649676c7a0e50_AdditionsandReturnsofProductRightsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_546dd540-ca3b-4066-99dc-57bb3b8ea2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_546dd540-ca3b-4066-99dc-57bb3b8ea2a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f549e62b-c446-40ae-b7e3-8ca8040b24e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f549e62b-c446-40ae-b7e3-8ca8040b24e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_a064da7f-98d2-4c5f-96d0-e2c2626d6402" xlink:href="cpix-20200331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_a064da7f-98d2-4c5f-96d0-e2c2626d6402" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_742a631f-b495-467c-a955-e1e96019d065" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_742a631f-b495-467c-a955-e1e96019d065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6856184c-c3ff-440e-9848-56c0092bf850" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6856184c-c3ff-440e-9848-56c0092bf850" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_55fd8267-22cc-4e6b-9757-520291841263" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_55fd8267-22cc-4e6b-9757-520291841263" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2a97103a-4c67-4f49-b575-f51b35bb74d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2a97103a-4c67-4f49-b575-f51b35bb74d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_77cc04b6-9efb-4cb8-9c67-f418868e2430" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_77cc04b6-9efb-4cb8-9c67-f418868e2430" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b29d983-dc78-4184-8422-58f726c39405" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_Revenues_9b29d983-dc78-4184-8422-58f726c39405" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_42f99586-f150-4fa3-b5fc-3af7c2d5bb22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_OperatingExpenses_42f99586-f150-4fa3-b5fc-3af7c2d5bb22" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a751e53c-13dd-4526-9c16-a7a37d420083" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a751e53c-13dd-4526-9c16-a7a37d420083" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_07f82e7b-24ce-4cde-b6d6-18d4e5c473b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_07f82e7b-24ce-4cde-b6d6-18d4e5c473b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_06d92318-c2d2-49d2-93e4-2f4e3b8f8178" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:to="loc_cpix_VIBATIVMember_06d92318-c2d2-49d2-93e4-2f4e3b8f8178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_2d1efc98-68f7-449e-bf46-265bf6d94672" xlink:href="cpix-20200331.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:to="loc_cpix_MethotrexateMember_2d1efc98-68f7-449e-bf46-265bf6d94672" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0704a1b-ac33-4f5c-af53-217abfaaaf6d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_srt_CounterpartyNameAxis_e0704a1b-ac33-4f5c-af53-217abfaaaf6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0704a1b-ac33-4f5c-af53-217abfaaaf6d_default" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e0704a1b-ac33-4f5c-af53-217abfaaaf6d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0704a1b-ac33-4f5c-af53-217abfaaaf6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7aec7e2-385e-498f-bb1f-bb6860d743a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e0704a1b-ac33-4f5c-af53-217abfaaaf6d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7aec7e2-385e-498f-bb1f-bb6860d743a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_2e633fd5-d530-4bed-8508-e11bb063b2d7" xlink:href="cpix-20200331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7aec7e2-385e-498f-bb1f-bb6860d743a8" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_2e633fd5-d530-4bed-8508-e11bb063b2d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis_8f7d3613-171f-44db-bd84-2deba1765803" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_StatementScenarioAxis_8f7d3613-171f-44db-bd84-2deba1765803" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_8f7d3613-171f-44db-bd84-2deba1765803_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_8f7d3613-171f-44db-bd84-2deba1765803" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_8f7d3613-171f-44db-bd84-2deba1765803_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_01c9fb04-ef1c-4a36-afdd-a9c698247450" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_8f7d3613-171f-44db-bd84-2deba1765803" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_01c9fb04-ef1c-4a36-afdd-a9c698247450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember_cd898110-79ba-49c1-bfca-b51eb6c34748" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_01c9fb04-ef1c-4a36-afdd-a9c698247450" xlink:to="loc_us-gaap_ScenarioForecastMember_cd898110-79ba-49c1-bfca-b51eb6c34748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e34caeb-c40e-4c0c-a7c8-da47a960332d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_AwardTypeAxis_8e34caeb-c40e-4c0c-a7c8-da47a960332d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e34caeb-c40e-4c0c-a7c8-da47a960332d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8e34caeb-c40e-4c0c-a7c8-da47a960332d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8e34caeb-c40e-4c0c-a7c8-da47a960332d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50e806dc-2a23-40f3-ba47-3865f7fbfd33" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8e34caeb-c40e-4c0c-a7c8-da47a960332d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50e806dc-2a23-40f3-ba47-3865f7fbfd33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ea6d483d-ae29-4323-8223-8f728a0f9586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50e806dc-2a23-40f3-ba47-3865f7fbfd33" xlink:to="loc_us-gaap_RestrictedStockMember_ea6d483d-ae29-4323-8223-8f728a0f9586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d5bbaf03-009e-47d2-941b-be809e3f6259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d5bbaf03-009e-47d2-941b-be809e3f6259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f48d6b03-f649-485d-8c86-6fa2b43543d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d5bbaf03-009e-47d2-941b-be809e3f6259" xlink:to="loc_us-gaap_SubsequentEventMember_f48d6b03-f649-485d-8c86-6fa2b43543d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_07a7dbf9-9008-4e46-8c88-fb96ffe1a8a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_07a7dbf9-9008-4e46-8c88-fb96ffe1a8a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_7968a305-954b-40d3-b56b-85d21a2fac56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_07a7dbf9-9008-4e46-8c88-fb96ffe1a8a8" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_7968a305-954b-40d3-b56b-85d21a2fac56" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended" id="i7d2c00ba39a241dd87fa3761d1394a91_AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a928f86-3052-4525-bda0-c10b397254a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a928f86-3052-4525-bda0-c10b397254a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_db19f68d-0864-45bf-9f60-c678068016a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_db19f68d-0864-45bf-9f60-c678068016a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_4165e692-3d79-4ffb-b1cf-fad6ce5b97a5" xlink:href="cpix-20200331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_cpix_PaymentsForContingentConsideration_4165e692-3d79-4ffb-b1cf-fad6ce5b97a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7ec984c-5588-4a03-a36c-22cc13c59b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7ec984c-5588-4a03-a36c-22cc13c59b7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0e66801-7759-44eb-aabd-07a897399597" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0e66801-7759-44eb-aabd-07a897399597" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38995e08-6a15-401a-8cfe-4c0ee035c85f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0e66801-7759-44eb-aabd-07a897399597" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38995e08-6a15-401a-8cfe-4c0ee035c85f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_38995e08-6a15-401a-8cfe-4c0ee035c85f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38995e08-6a15-401a-8cfe-4c0ee035c85f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_38995e08-6a15-401a-8cfe-4c0ee035c85f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4ceb5d9-cfdf-43d2-8760-dc205287314a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38995e08-6a15-401a-8cfe-4c0ee035c85f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4ceb5d9-cfdf-43d2-8760-dc205287314a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_6d02a1b8-1e62-4dac-b0dc-0435dda227da" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4ceb5d9-cfdf-43d2-8760-dc205287314a" xlink:to="loc_cpix_VIBATIVMember_6d02a1b8-1e62-4dac-b0dc-0435dda227da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended" id="i57b3ae0c270343e9a460598adeacfa92_AdditionsandReturnsofProductRightsChangeinConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f82a16a8-893d-480f-bda6-693086b48d92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f82a16a8-893d-480f-bda6-693086b48d92" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e5f6ba2-ba17-405d-8af3-e666e62eb55a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e5f6ba2-ba17-405d-8af3-e666e62eb55a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_ee3e19e3-aeff-460b-a20d-899b5dd3eadc" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_ee3e19e3-aeff-460b-a20d-899b5dd3eadc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_60819052-d884-4696-ae23-edeac337cca5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_us-gaap_PaymentsForRoyalties_60819052-d884-4696-ae23-edeac337cca5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5ce13d0b-0188-43b1-ba37-5ae2809fc7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5ce13d0b-0188-43b1-ba37-5ae2809fc7f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_08310f0d-b8e4-413e-8cf9-1867da177215" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_08310f0d-b8e4-413e-8cf9-1867da177215" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_103c278a-1cea-497f-91cf-a2c4c718f0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6a74642-6cd6-4516-b1cf-cb3b4ffc02fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f82a16a8-893d-480f-bda6-693086b48d92" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6a74642-6cd6-4516-b1cf-cb3b4ffc02fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11f6dda6-9bdf-44ed-b87b-6ddda561d882" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6a74642-6cd6-4516-b1cf-cb3b4ffc02fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11f6dda6-9bdf-44ed-b87b-6ddda561d882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f6dda6-9bdf-44ed-b87b-6ddda561d882_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11f6dda6-9bdf-44ed-b87b-6ddda561d882" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f6dda6-9bdf-44ed-b87b-6ddda561d882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c067b193-c718-4c7a-a0be-f122b9754646" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11f6dda6-9bdf-44ed-b87b-6ddda561d882" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c067b193-c718-4c7a-a0be-f122b9754646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_92ba29f3-2864-48a1-b000-0a0454f3fe14" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c067b193-c718-4c7a-a0be-f122b9754646" xlink:to="loc_cpix_VIBATIVMember_92ba29f3-2864-48a1-b000-0a0454f3fe14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended" id="i4f2a808dfcdb466e8d327c12082ea7ea_AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_488d3bdd-b795-4c33-bb8c-674f3c6d0dba" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_488d3bdd-b795-4c33-bb8c-674f3c6d0dba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_0863323f-0a67-4fbb-81db-230cf5da76df" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_0863323f-0a67-4fbb-81db-230cf5da76df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_ffce3e75-85b2-4420-883b-6df7a08533da" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_ffce3e75-85b2-4420-883b-6df7a08533da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8ae2be1d-3ebc-48fb-8b43-555d2e49869d" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8ae2be1d-3ebc-48fb-8b43-555d2e49869d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_384b199e-7f29-41f6-843a-db464355b113" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_384b199e-7f29-41f6-843a-db464355b113" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_67b4d7d9-15d9-4604-b4c9-65d383cf8e58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_67b4d7d9-15d9-4604-b4c9-65d383cf8e58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_968ed405-0f85-4fa9-ac0d-bbab4ad73703" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_Goodwill_968ed405-0f85-4fa9-ac0d-bbab4ad73703" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8c79301a-cd6f-42e3-b12e-9a973278b679" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8c79301a-cd6f-42e3-b12e-9a973278b679" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d2660ca9-0a33-40f1-95c2-25fb3b515bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d2660ca9-0a33-40f1-95c2-25fb3b515bfb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e265817-fcfb-4698-a15f-eb8f6b886a76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e265817-fcfb-4698-a15f-eb8f6b886a76" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_66dfdab9-5e81-4079-a55a-94452ae9da5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e265817-fcfb-4698-a15f-eb8f6b886a76" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_66dfdab9-5e81-4079-a55a-94452ae9da5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66dfdab9-5e81-4079-a55a-94452ae9da5b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_66dfdab9-5e81-4079-a55a-94452ae9da5b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_66dfdab9-5e81-4079-a55a-94452ae9da5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cd5fd2d-9fca-4a07-b526-0676a91e8ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_66dfdab9-5e81-4079-a55a-94452ae9da5b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cd5fd2d-9fca-4a07-b526-0676a91e8ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_76fc9383-eab9-487b-8542-c0257ededaac" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cd5fd2d-9fca-4a07-b526-0676a91e8ce6" xlink:to="loc_cpix_VIBATIVMember_76fc9383-eab9-487b-8542-c0257ededaac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cpix-20200331.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="extended" id="i55b7fa96f4ef4556a251f22acf511f8e_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEventsDetails" xlink:type="extended" id="i60f374b9b4a14330b3bab52014c95588_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_f508906e-1824-4f58-97a8-f32831286198" xlink:href="cpix-20200331.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_f508906e-1824-4f58-97a8-f32831286198" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage_ba72b4d8-119e-4182-87e5-000547304545" xlink:href="cpix-20200331.xsd#cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:to="loc_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage_ba72b4d8-119e-4182-87e5-000547304545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4035b532-9846-45bc-8353-a92707143cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:to="loc_us-gaap_SubsequentEventTable_4035b532-9846-45bc-8353-a92707143cb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_45be3d0c-3915-49f4-97c5-f44c57332dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4035b532-9846-45bc-8353-a92707143cb3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_45be3d0c-3915-49f4-97c5-f44c57332dc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_45be3d0c-3915-49f4-97c5-f44c57332dc5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_45be3d0c-3915-49f4-97c5-f44c57332dc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_45be3d0c-3915-49f4-97c5-f44c57332dc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9c7fd423-8020-4fd2-8944-7b7508083c11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_45be3d0c-3915-49f4-97c5-f44c57332dc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9c7fd423-8020-4fd2-8944-7b7508083c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d97195a8-a205-4315-a56c-bbc1b228e518" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9c7fd423-8020-4fd2-8944-7b7508083c11" xlink:to="loc_us-gaap_SubsequentEventMember_d97195a8-a205-4315-a56c-bbc1b228e518" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cpix-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1ff53927-8a9f-4642-b593-f74226671984,g:b03cd8a5-37fe-4ab1-a910-c87820aed84d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_111c4bf9-3e68-482c-a4b1-e348c967ad2b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_6d425f68-0544-4f99-b356-7e2327d4bbe0_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20200331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_67688d2e-ba82-491c-b4a6-0e9dc604f204_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cbcd5f33-3beb-4c61-87dd-238c6ecf60a1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_62ec6c67-b3cf-4c01-9ba0-3daa0b11d3eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_01de51cc-691d-4312-9bef-88cfe02dbffb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_a07e5a4a-0128-4ee5-b5dc-68aec4611591_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_ce703657-1e94-42c1-be6a-6237bb9aaffb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b69ddd4a-66e7-4b74-84a3-65a7e9ea68de_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_11003beb-24a2-4cf1-8a90-6eb3bf129554_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7935a573-ae46-448f-9c97-2241b7ab278a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock granted in period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_44847c1e-7e1c-4dfc-bc80-ba7e82bb8270_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c58b7eb2-eedd-44c3-8abb-97f7d786d41e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cacb8c92-01b3-47af-a6e2-1d1f13fda2c9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6edfdaef-4809-438c-b446-2deecf4dc2e2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_113257f6-7b37-4a77-b8d0-be843985cb37_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_85eed42c-b421-4177-8801-2846b60a38aa_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_545e17f1-8a1d-4b64-ae58-5573fc659d2a_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - unlabeled vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_720721ca-d5fe-429d-b1c1-cb5c9ed5ed78_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_4a592d8e-e4b1-469d-9a3f-b1c3ddea094b_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20200331.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d5989e64-7fcd-45ae-ac48-352509055204_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ecfa7f7d-f53b-4657-8268-b67af1254453_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_b2a3f9c6-102f-428c-9e44-8889afbd3be4_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20200331.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_4814db11-0a83-43d9-858e-e24368d8fb99_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_95b16873-d4b1-47fa-b28c-335b1840988a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_193a9628-294b-4fe0-a6fc-30cfa7d22206_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ce0d7a6b-e032-4c7c-9922-74231207cfff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f9e5119b-120b-4b08-9585-456575874f42_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_423b1647-5596-4bc3-a35c-686cad909c0c_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of cash</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentCashContribution_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Cash Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentCashContribution" xlink:to="lab_cpix_SubsidiaryInvestmentCashContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_228a273c-ce7e-4ac4-a5ef-68c666e1664c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e9c8780e-f259-417f-af96-ad2404d3f16a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of marketable securities, by type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_3934ab8d-0532-41be-a3bb-0f8d49ff2440_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations income</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_539ed560-4878-420a-be0c-261b453405d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8e9aee57-6abb-48f2-a85c-7e4902f51bdf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_273acc25-91a2-42cd-ac2f-36ea03acbdfd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b8c46c0a-ee37-444f-a951-0ce71783b1e1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_ccc612fb-b0a1-4f18-974c-f0e619447c7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_ddd8306c-99c1-43ea-a048-cf0414f3fa76_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_79fa26ee-9683-4bfb-a4db-ac61e0d5a666_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_9d415872-8f84-47f8-9d05-939f2c190b50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_66462042-c858-4eec-8f4e-800b4f88589f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1319e6c8-26d8-4c11-b4d0-3c6bbcfaf669_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1f6096a6-c034-46a9-8529-165c7de9f49c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_363fb7d6-8be5-4c02-bcbf-dc074a1cb6bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductsAbstract_c8599f43-3bb5-49ae-b372-0643cad24c7e_verboseLabel_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products:</link:label>
    <link:label id="lab_cpix_ProductsAbstract_label_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products [Abstract]</link:label>
    <link:label id="lab_cpix_ProductsAbstract_documentation_en-US" xlink:label="lab_cpix_ProductsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract" xlink:href="cpix-20200331.xsd#cpix_ProductsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductsAbstract" xlink:to="lab_cpix_ProductsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_32f3a776-4c3c-4072-acde-57adde16dd07_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:href="cpix-20200331.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:to="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_fe30c18e-78da-4d06-8991-b87f0f8245cf_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to initial fair value of the contingent consideration liability</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_4c63e87f-00fd-4f0a-8eba-f0ef13ab4e6e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_e35dc742-7862-4373-9bfc-86d60856df9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5451404e-b402-453e-adc9-1e717ae11490_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7e1f129f-1336-407e-b4a7-7c3aecc4d0f0_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_34972f28-0f2f-4d86-b1a6-520d91306eef_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9b46cf9b-2a6a-43f1-b146-dec1fe5f8079_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c7b111f0-a08d-4159-80b0-1a3af8ddede7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ff3712a5-b25a-40eb-a286-204b852cfd61_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7c6fc03a-e423-4db9-b495-7065db8aa8dd_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_ef57d965-cc2f-4266-b1e5-e996f5340db4_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a5eca818-d4a4-4231-98e0-297152cadb2a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_0acffe5a-74f1-42ec-965f-8310d3d443a2_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_039161a8-6a25-49d3-8535-1eb0e3390d7d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_49d685d5-b948-497b-b2b7-2c2f3681a14f_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20200331.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_051a7aa8-bbab-4a8d-b4bb-21ca1457f4f3_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_151249bf-befd-425f-aa2d-1a1bfdfd8eed_terseLabel_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_label_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited [Member]</link:label>
    <link:label id="lab_cpix_ClinigenHealthcareLimitedMember_documentation_en-US" xlink:label="lab_cpix_ClinigenHealthcareLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigen Healthcare Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember" xlink:href="cpix-20200331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ClinigenHealthcareLimitedMember" xlink:to="lab_cpix_ClinigenHealthcareLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f95de159-62e8-4341-9291-47a7cbef9a2f_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d7e03602-bd38-48e6-a57f-4a18d2849564_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_802c146e-3186-484b-b5eb-9cfbc67000fe_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_71dcb4c2-b2e8-4392-aef8-93ca358ab5cf_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_3825f66e-4b39-4691-bdbe-dbea5af358bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration received in exchange for product license rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_f6f73924-e404-42d0-9b30-d5028708b378_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_8c73b4a3-7073-45a8-b50c-255159e2cc4c_terseLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_250ff990-3493-465a-9dee-82fe9adafbd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6d051b4c-9541-4415-adbf-8b971c7a8037_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_07a2d050-4e7b-4f27-81a6-3417f754fdfa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment during early 2019</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_056d9138-b1d9-40b1-a0d5-d699cea5578d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_01cae66e-92d1-4a9e-bcdd-c009979d53ee_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_7530d287-fccf-4749-ba8f-a18e722064c7_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20200331.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_245bd927-fa0c-4e37-8def-6528a048c2b5_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment through purchase of shares of CET Stock</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_d2fff17b-6cb1-4aa3-ac20-5f4f130a707f_terseLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20200331.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_40893415-900d-4e67-a383-cbf67f9b58c4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_90654345-c00e-40f7-af3d-8054f31a4085_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherProductsMember_d5dbeef9-c38f-4588-b570-9be89c785121_terseLabel_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_cpix_OtherProductsMember_label_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_cpix_OtherProductsMember_documentation_en-US" xlink:label="lab_cpix_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember" xlink:href="cpix-20200331.xsd#cpix_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherProductsMember" xlink:to="lab_cpix_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1ebcb578-08d4-47b0-ad77-20c459b3805e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SecondAmendmentMember_aeaa6fe0-23f8-48db-95cc-62e6c10d992e_terseLabel_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_label_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment [Member]</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember" xlink:href="cpix-20200331.xsd#cpix_SecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SecondAmendmentMember" xlink:to="lab_cpix_SecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b3857edf-293a-4448-9e3f-59cb9d4b5bfd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_72736b54-dc43-4ee3-9c31-405026c9c389_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_7f3bd129-056d-4af6-b92c-2a6c9330de64_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories classified as current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ca4bcb08-d90e-4296-a88d-324f8d3fbdc0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_83f7fe76-4900-41c8-8745-1c715ba30890_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_242d3f07-6a8f-4b9f-ba22-c83d1c0e8bdc_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a60ea8e4-d5c7-4693-acc5-8f636987a3a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_22e79e73-844c-4262-b8f8-5f2010e2f43d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability recorded</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f152d8d5-c91a-49c7-8eb6-59e264a6d791_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_25273d3c-f614-4d17-9ba5-396c31ee8ad9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_f6251bed-ddcf-4ba5-8304-a8156e13c204_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_bb68738c-5cf7-4b2b-a6ab-e0117bad071e_terseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20200331.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0f557128-b532-427f-8771-c6f69181c70f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b953e08c-a44a-4772-9b81-d2f3e333946c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b4125873-ab05-47ba-96a8-8960ff78a480_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_42ae6254-7148-41b7-87e2-bf680d67d149_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4b2a6497-f738-4443-aebb-68d039135903_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_bf3962ef-7af3-4270-95ee-020d47233090_verboseLabel_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_label_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity (Textual) [Abstract]</link:label>
    <link:label id="lab_cpix_ShareholdersEquityTextualAbstract_documentation_en-US" xlink:label="lab_cpix_ShareholdersEquityTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders Equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract" xlink:href="cpix-20200331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract" xlink:to="lab_cpix_ShareholdersEquityTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3adb8557-9d1d-4799-b7ff-b91dd13d29b5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_9138f1b0-d283-4676-9a10-7c35d669900c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_362fc38b-14bd-40ce-a3f0-5a91059bf3ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cc733aa2-4052-40c9-893a-04a49ab96ab8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_12c18a32-a53c-4f90-979f-2d30a2fe67ea_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d40cc202-571b-472f-9e43-c5c27ba91718_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_28b8b8a6-5c2f-4d81-b4c0-d3dc6329543a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2f25a4ee-8e1f-4aa0-b302-e030d2190e53_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f914ea6d-a8dc-4f95-be54-8cd9d148d9a1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e7655203-c600-4d51-b41f-767aa78a9dd8_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_47720d40-adef-4ceb-af0d-fa999c012eb7_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f372cd38-d9e0-4b95-b460-267edb464e16_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2d26acbc-906e-442a-9af1-59eaa95a69ac_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d46f9936-138b-4557-a9dd-60fd4223fa76_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_57023c1d-89e0-4495-a1ea-1704c5f42b92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d13e86de-06a6-4654-a825-116aaee37abe_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHAREHOLDERS' EQUITY AND DEBT</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_52e5ea9b-1baa-4709-8d82-325c675fcbcf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_4d82eb3a-563e-4d27-87c3-da56ebb71630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of net revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8327b2e5-9061-41a7-bedb-cf61047de408_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_a7e011be-5132-4855-92dd-a1aef13e22ff_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_c33434b3-8ee9-456e-aa3a-e9d8f9581e26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_de824d77-be64-402c-b826-cdc5497840fb_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_abe2b9a8-0b49-4638-9590-f64f30cbd57c_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20200331.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_3434e77a-c22b-4548-8b2c-08b185631f00_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_69a08ec2-6fc5-4979-a5b2-1ce04449a6ea_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a1f6fb5d-64f9-4611-8d20-cff6f44be942_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f2fa1cf0-d719-413d-9914-6780c191186c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a7261367-7302-4dd3-b1e9-3790359ce11b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_90f011cd-3ae7-411a-ac77-8486bef415b1_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42a4b91c-2516-473b-be6c-c6354008799b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37b805c3-7961-4dd3-a9e4-6d89ac02108b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, Beginning of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a991f10a-1f11-49af-ba47-5bc2e996fe5d_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, End of Period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_8c0cf950-d120-4a99-82d4-11c9211ca178_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_42f876f6-34cd-49ac-8f9d-a29d3f1bc864_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_cee4dfc9-7456-49fc-a6b0-d41c3d1a3718_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20200331.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2abfdaa1-4346-40c7-bd49-44c3ea8140bd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_fecd2607-d998-4a9c-be43-4df9c7ebf9af_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7c283281-984f-4e35-b5c0-c8e3232886be_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_e9303a76-3618-4251-9c6c-8e487663872f_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementScenarioAxis_08fec7ec-4d0d-44aa-9b24-19affb00cce7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0c0b3df0-4b74-4e2a-be5e-7fb67c151245_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0a7e9efd-71c2-4245-b46d-aee0ca9df77d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of operating lease assets and liabilities through adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_91cd34e0-6d0d-4124-88b1-544562d5b177_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_9d001609-cff1-4465-9dcf-3728e11b716e_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of tiered royalty payments (up to)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20200331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_35d6cc2e-9ca3-46bd-b52c-58917432ce08_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4b3aa7ee-ec47-4255-b0d0-5bd59a7a71c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_eb070271-08ba-4cf2-8435-ce95ed7290c9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATIVE AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5f6a17dd-5562-40ae-b19e-639933387bfc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8f06d76b-a719-4cf3-a5f9-98bc4c155b2f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c108ba70-fb22-48c4-a8ce-c3c89bc689a1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b13a645f-1ac3-4bcf-baaa-d748e2cbfea5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e5bcaf2a-390e-4fdd-8170-d785aa748ac5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ea6c008c-47e3-4509-9f6e-3eccedbfcda9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b22124ef-f932-43c0-b61e-bfe9f0d05875_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9458844e-10e0-4848-9817-2ae03d1b3b00_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_08b55fe7-63cb-494e-bb7b-428e4aa0fefc_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_5111e930-ce1a-44e4-89a1-62ffe619fadc_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:href="cpix-20200331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:to="lab_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_c74de564-f9e8-4b54-b38a-a4beff3fc464_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20200331.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_47853f8f-37b5-42df-b461-5935785afc24_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_730abf5c-0f3b-48fe-a7e0-9cc13df550d0_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for purchase through restricted stock awards and options (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d6032979-eaea-45b2-911c-6e53a54d89a2_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_93fe9d64-7cf2-4e46-b74d-b4b07bf0c151_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c4da2b06-aacf-4dab-906e-9bd302138370_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_e39cd800-f8a7-4c38-a0b5-49abf1c00697_verboseLabel_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_label_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:label id="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion_documentation_en-US" xlink:label="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Obligations, Excluding Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:href="cpix-20200331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:to="lab_cpix_OtherLongTermObligationsExcludingCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5f33c0d7-d0e5-4b52-abcb-e6c206f06848_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_23351b6f-e7de-407a-9a5b-b893bf9f42df_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_015ab9d1-7478-4114-bb86-0ed2f3b91ae0_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_75b915e7-360b-4648-a6f1-902a2d1304ae_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_2b1fcd1c-e289-4f21-97b1-17d509715585_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_5246ecc6-fa8e-4132-80a7-cd88497941d2_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20200331.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_095704f2-4de5-4f9d-9fbd-dc2ed92cebc1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioForecastMember_f1fbb01e-03ca-4bbd-8af9-18fdafa59a13_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember" xlink:to="lab_us-gaap_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_35a5f74a-93ca-425e-8793-4f991b8795f7_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_259b8142-b256-4ff9-b239-fb6029a8b8f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_73610488-2565-4fa4-a956-eaa72c0c2912_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_59a7e707-e477-4e7d-8326-9b18c9f105e8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a1ab5e48-fcd0-4d6d-b5d9-774a4a01f6f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4a28a08-3aa4-457b-b104-aa895769f2f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_be43c256-7f49-4b2a-98b5-1fce33bef123_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of other securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8dcedcc1-15d6-42b5-a69c-5fa5a02cf467_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_57ba0770-a7a3-4770-ae4a-5330aa078913_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_95193aa0-656c-496e-bf64-f1df1bce016d_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangibles and goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_78325009-e02f-479f-aaad-6c943d7310a2_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Position</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20200331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_7001063d-f6ae-4ed6-adab-4b24ea242c15_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_20cd5e31-fc8c-4fc8-bf6a-0b60234e751a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_529c5c76-c7f7-4bd7-816a-9bc8d14eef30_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_163de7c9-26f8-42c0-a0af-2d7ccc679097_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of subsidiary shares from noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_3311e380-3677-4a6e-9ce3-f374d4cf3492_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_5ee80532-0bc6-49bc-bb2c-f02198419065_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a9a5389b-2f43-447d-b25a-4fc1e8751ccc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_ed960f6b-a9c7-4594-a3b9-e38eabbcbb3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_df79b62a-5fb1-4568-9f3f-d0c823f2fa2b_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross, Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a4732bb8-a1f8-4747-941f-3d15306fcf9e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a916f91b-5154-446a-8d54-fd407d9f33ff_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage_836a5ecb-9d77-47c8-a3be-cddb0b9b36a0_terseLabel_en-US" xlink:label="lab_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act, Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act, Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" xlink:href="cpix-20200331.xsd#cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_33b0fd71-dc33-4c9f-8df8-0540b74e8ba0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_fff0a4e9-9c09-4d82-9fda-ffa407e86d8e_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_b1490b8b-82a7-4584-bb99-9c9aaa740ff9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_08913d6d-3622-4934-b7d9-d04f99c8291c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_beb7fe71-5b47-4086-9c0c-5c979ce35aa7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_f4016380-2068-4551-ad66-20b2f05e8e8c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_953e6be6-8d46-4905-b557-487fa1f7b2a8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6b51f1fd-42e0-4117-9049-438070f584a7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_88fc8a1c-e7cf-442e-83a7-3dcf218d1f81_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_c5d988a0-fafa-4a7d-ac18-cade90151602_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_196815e7-1b5f-4d5d-b663-a8bd332e2b86_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7c6de5c0-35c4-4d45-9103-133b283a4e2e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e9209d93-55c5-4f3e-83f0-55df0206d820_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f85f78ea-be24-402c-b80e-fdeee5fc5b36_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (income) loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4baacdf5-3a6d-4646-8b76-5b67b74d8ad9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_f96a7909-714b-48f4-b809-9b4db0930379_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_91a84869-58fa-44ab-8cbd-55c10379a56c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2ef4039c-07bb-4534-ac1e-17e85c7ea349_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f7e2da90-ffa7-4354-a5d7-0919059a29ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_00cbce58-1b25-4c81-88ad-25063b35e111_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1e7c57cb-55b4-4bc0-b918-8d6fd5e23f62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of numerator and denominator</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_03b6212f-987e-493e-a0ad-a9bfe22b5d87_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_09d0d401-ff9b-4dbc-b7b6-44eeae7f6877_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6890a849-71e5-415c-8af3-920f244907e9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_e200c78f-be82-474e-908e-8af7e3fc43c0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_321c5ef7-3c75-4c8f-b544-90c311acfee5_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">- basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19283154-e58b-4f4c-a919-0f2b3663859e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_b22c52f8-ffe6-416f-99ee-38d5cdaf3093_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase outstanding common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_33e9d5ef-9c23-400b-b5ef-af39fe9003f2_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for return of shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:to="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e1b7ee80-57f7-4ed3-92eb-8f539ec516db_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested common stock, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_268501cd-ca9c-40ce-9c23-960107340515_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3464c69b-7240-4102-b3b3-8af4aa2fa75f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_db42250e-9160-4f86-8b73-ce228038e7b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_4565eff2-f9a3-4146-a61d-773b262b57bf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f39960c0-7ff6-4d81-a041-645e9af7cca0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_74ab2ef4-b209-4633-b06d-c5c21929670f_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_d13ca9bc-30b3-4c23-9e68-b8cbe6eb3dda_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f12df6c8-df09-49c8-a09e-1b72e70cd7ff_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_b53785ca-d363-4dc0-84a9-0a94a3494003_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_fcb9ffa1-50db-40c5-a934-d104f140e001_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_5fc64e3f-0ab2-4d38-98a1-92c2cb634433_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADDITIONS AND RETURN OF PRODUCT RIGHTS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c8218c6d-8375-44af-b304-45f577b678ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_aaf02283-c45e-40a6-9ef7-7c4f59d50cc6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_15874586-8786-4ff6-b64c-c0f9d265d43e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_15465e4c-834d-4306-8c8e-ed7040949e8b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_897e3cd3-e54f-43f0-bde4-098c518fcb02_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5ab257da-f690-4231-a658-54069b803cfe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_1c73a2c9-6441-4b3c-bfc3-3e40adf1b60a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_ccf2b615-a42c-4e89-abe1-0f200cb86ed2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d3428254-a149-49d9-b8e7-f97d732179e6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_871d4250-6268-47dd-afbf-b3963fc48e41_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_957af67f-cb2a-4ceb-8ab7-7d9afb42d11b_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_26c8d775-30d2-4a1e-bacc-5c4ee2747997_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_5c0f2346-0e10-4999-818d-dd859005203a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_4a8d35a3-f7bb-4377-bcc2-a61c8cd2efbb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_828b54fb-f0fc-4e0e-960b-5185e1eea6fe_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_2125ca9b-918a-469b-8788-13b65f37b620_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_f3a4b73d-32c2-4c20-a3ed-f8c562c590e1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_2439390f-78a9-4125-ac07-400b9135a60c_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued in operating expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0fa17b5d-d433-46af-bc6e-3d0ff127fa9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_aaee64d9-5f40-4bb4-9ede-e27bf52999ab_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualRollForward_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward" xlink:to="lab_us-gaap_LossContingencyAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4afa768e-992d-4665-ae30-3d50501de661_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate spread</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_7fdd3183-9e6b-4fbd-a7a8-b14699568d8d_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20200331.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_14151317-e681-42fd-b347-9f1a324ccfe4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_53e83bdc-7aaf-40a0-8b43-69539b04e58e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1a0fef89-e21c-4c2d-b723-f13f529318cb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ab31cc74-6994-424f-9f62-80decbf9465d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3e04b91b-d0e9-49fb-8738-5bc695a9734d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_77511d29-270e-467c-b23a-c35b6ff3ad39_negatedLabel_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Tax Benefit from Share-based Compensation, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:to="lab_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6c0e9b3e-15e5-4aed-9cfb-a2fc74ca4303_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_8cd57c8d-2652-4394-8fe2-47dd5c25fc86_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process - validation vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_label_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:label id="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:to="lab_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_9a6746c1-f202-452c-910f-e6cc8fa87be7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_a2bb0140-1ae8-4cec-8be9-c4a6430b1c3a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_91928d2f-bf80-40e4-aee7-a1dadd189f47_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_74b71a94-3fc9-4b09-bae4-c3eb45d69664_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7301fc19-1d88-4044-92e0-e629482bf183_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b5153237-7566-44a0-b339-2e3fd315d8a3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration included in operating expenses</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_af736f15-e852-47c3-99c5-f3179ba1f66e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a32759e4-0810-4e29-99cc-caefd4e61ff4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_1dbc8db3-139e-48b9-b31c-129dc42ae310_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_91a83889-d3b0-425a-a951-a577b70d247e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EquityAndDebtAbstract_label_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:label id="lab_cpix_EquityAndDebtAbstract_documentation_en-US" xlink:label="lab_cpix_EquityAndDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity and Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract" xlink:href="cpix-20200331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EquityAndDebtAbstract" xlink:to="lab_cpix_EquityAndDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_030ae1f3-9661-4aac-a8d4-b78a5428804b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Leases Liabilities at March 31, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_ad87fbff-1cfb-4a08-8e7c-a6d0b2f1821c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_63344fb2-e630-4779-97c0-a0a17ce7f1b4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_827881bf-60c7-414f-b66e-89133d4aebda_terseLabel_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration - net sales royalty</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_label_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:label id="lab_cpix_PaymentsForContingentConsideration_documentation_en-US" xlink:label="lab_cpix_PaymentsForContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration" xlink:href="cpix-20200331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentsForContingentConsideration" xlink:to="lab_cpix_PaymentsForContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ce6b4e53-97e7-4078-b429-9658ca4386c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_3448e705-fa56-4ad7-808f-9199c9e8fc5d_verboseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncreaseDecreaseInCurrentOperatingLiabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:href="cpix-20200331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:to="lab_cpix_IncreaseDecreaseInCurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_558acbfb-ccd3-42e5-bd9c-119c4c02418e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_272359ba-22dc-4417-8a03-41dc97b329a0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_6454b162-47ce-4897-8095-9aca9d9ca430_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_abdd0137-94c1-4eaf-abdd-ec32fd467511_terseLabel_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_label_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember" xlink:href="cpix-20200331.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GloriaPharmaceuticalsMember" xlink:to="lab_cpix_GloriaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a46c7cd-b44c-4217-990f-de429b02af39_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_f97a2e01-3222-47ef-ba9e-6eafb46d5db3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_90d06385-f9cf-438e-923b-c06a22a941fc_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_64b722f6-fb94-4002-9f94-079317299a49_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_aabfc27a-c351-436a-9f6d-f3b7ec5b5e0f_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to acquire business upon closing</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_00879574-9741-4770-b76e-2d5289d06a6e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_bc037148-4de7-4f1f-b882-cfa8a7c4143a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net, Items Net of Reserve Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:to="lab_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a5868753-4eb9-4188-babc-132a1226f26c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2d308867-5fd6-4c0a-8700-31e37b34737a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a4e2d5a7-93f1-4db6-b500-1a3aff92b9cb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_26e3d501-5fa8-4059-a0b1-c6ffe4103fc6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_9111b3a4-a71d-48d1-8e31-76297cb6bbc4_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_20afdb49-7be7-46da-9696-14e3911f449e_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_aa4c61f5-8192-4b1a-907d-e6e1583e7317_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash operating, investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_29c7de33-aa83-4ab1-84c0-67f325057c00_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f9033350-2a60-4522-bad0-e9678b531f89_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_9f2bc908-63fa-4744-b09d-b2df8ce384d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f69cd5f6-b2b1-46a1-b6f8-707fd3529e97_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_50770c4d-2e6b-4fd5-b4d9-0f5f08bdf9da_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_403a5fc2-f951-45d7-869b-9236eef32f75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c8ba7852-05fa-4786-8daf-0f80bb586818_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e00f0807-0e4d-4051-8daa-44caeabb1dff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_d3a27da2-b51c-4d6c-a7d1-0f79b762e8bb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_81984434-cce6-4499-aedd-5450b51b9ccb_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_21b27687-ae00-424c-b42b-85ed1bc29456_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_f51d6312-9bc2-486d-8284-215e01f4c87a_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20200331.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1566b933-bb3e-4041-b61f-b769dd5e8c0a_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ea81d5fe-a601-42b2-8d1e-e0998b050361_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual property amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_2a1b7971-25d4-415a-87a2-c5cf831526a0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_8fca8d34-6eab-41e9-b8a7-0b9e2e609346_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bac60958-dded-4801-83de-11e07d678c84_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_19560746-fb69-4b95-ab49-ee2926a0b444_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ef56ff5f-e584-4e4b-8653-da46b0f7ac61_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ca353c7a-1fae-47a7-b3c7-ca09d94cab62_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_b3c71ec6-b244-4f31-a987-0ff07b2efac7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_673e98c2-1a3a-4bdc-8b83-b1165e978ee6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_16d70918-4fe5-435c-895d-0499108de964_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_08f24ee4-3e9c-4e3c-90bd-956f4ffd4b96_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_1faa5ead-fe85-4eb8-b227-3627c20805ac_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20200331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_857e5251-6184-4256-8127-ddf88ee8ead9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_3ab03bbc-08ce-4714-ae17-42855b52fc00_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of intercompany loans payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Conversion Of Intercompany Loans Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:to="lab_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DirectorMember_9691a150-9a87-4cac-b514-a53c10de8fb0_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_label_en-US" xlink:label="lab_us-gaap_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember" xlink:to="lab_us-gaap_DirectorMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cpix-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1ff53927-8a9f-4642-b593-f74226671984,g:b03cd8a5-37fe-4ab1-a910-c87820aed84d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20200331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_4dc38517-c145-4fee-b423-9dc0d760695d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_DocumentType_4dc38517-c145-4fee-b423-9dc0d760695d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_548abbe7-6039-436e-98b3-3d26f3010f49" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_DocumentQuarterlyReport_548abbe7-6039-436e-98b3-3d26f3010f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_42490507-4730-49d2-869a-4ad231b84adb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_DocumentPeriodEndDate_42490507-4730-49d2-869a-4ad231b84adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_83e41796-ccf3-443c-824b-6678b9472428" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_DocumentTransitionReport_83e41796-ccf3-443c-824b-6678b9472428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_04093cf4-ae6d-4ed8-9140-111c173c61fa" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityFileNumber_04093cf4-ae6d-4ed8-9140-111c173c61fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_688050aa-b413-44eb-8036-ea4e1a81bdf0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityRegistrantName_688050aa-b413-44eb-8036-ea4e1a81bdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_991f52ca-aaa7-4f39-9a49-6024600aa27a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityCentralIndexKey_991f52ca-aaa7-4f39-9a49-6024600aa27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9c7eb205-c688-4c04-bca7-e66995af1650" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_CurrentFiscalYearEndDate_9c7eb205-c688-4c04-bca7-e66995af1650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5c41f7e1-1ca5-457c-a5ab-c32e3106ce3a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_DocumentFiscalYearFocus_5c41f7e1-1ca5-457c-a5ab-c32e3106ce3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8842299a-816d-460d-83db-f29d95db7c81" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8842299a-816d-460d-83db-f29d95db7c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4da94f14-a822-41df-b229-baf79083e5ce" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_AmendmentFlag_4da94f14-a822-41df-b229-baf79083e5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bc95da6f-9a91-4aa5-98db-2325bdcf3047" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bc95da6f-9a91-4aa5-98db-2325bdcf3047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_17fec474-a876-4b3e-a271-ec96088849f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityTaxIdentificationNumber_17fec474-a876-4b3e-a271-ec96088849f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7c44c431-0af6-4360-9900-dc61f640ac90" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityAddressAddressLine1_7c44c431-0af6-4360-9900-dc61f640ac90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_f3c628c2-f651-4f3c-aed5-6d71ed447cce" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityAddressAddressLine2_f3c628c2-f651-4f3c-aed5-6d71ed447cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b1ac0e0b-5fef-4d1e-b9c0-caa3165e4578" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityAddressCityOrTown_b1ac0e0b-5fef-4d1e-b9c0-caa3165e4578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_b3cbc38d-40ac-433a-95f4-9f0c9fdb0422" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityAddressStateOrProvince_b3cbc38d-40ac-433a-95f4-9f0c9fdb0422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f78b5441-f6c9-4c8c-afc1-d68a1960817f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityAddressPostalZipCode_f78b5441-f6c9-4c8c-afc1-d68a1960817f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_60535296-3d63-49a0-b226-b132a77c6dde" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_CityAreaCode_60535296-3d63-49a0-b226-b132a77c6dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_c3c88136-3c7e-4cf9-bc40-68d5ef27da7e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_LocalPhoneNumber_c3c88136-3c7e-4cf9-bc40-68d5ef27da7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_dc39fa72-63a5-43b5-b40c-cb197bda07ac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityCurrentReportingStatus_dc39fa72-63a5-43b5-b40c-cb197bda07ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_377e9a26-3703-45b8-91b4-be1dc3176bcb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityInteractiveDataCurrent_377e9a26-3703-45b8-91b4-be1dc3176bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e112f6ef-6dfa-448e-93c2-01ca4f6c7962" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityFilerCategory_e112f6ef-6dfa-448e-93c2-01ca4f6c7962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b264f211-a793-4279-a5ed-a7b26f6b193f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntitySmallBusiness_b264f211-a793-4279-a5ed-a7b26f6b193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bcee29aa-6ff6-484e-bada-6734d9f16ae7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityEmergingGrowthCompany_bcee29aa-6ff6-484e-bada-6734d9f16ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_3af18027-7834-4020-8353-ed868f6d2630" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityShellCompany_3af18027-7834-4020-8353-ed868f6d2630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_202fa789-59ae-4c15-a894-57ea2bd1199f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_Security12bTitle_202fa789-59ae-4c15-a894-57ea2bd1199f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f1297c12-00a5-494a-b0f4-afcde2412851" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_TradingSymbol_f1297c12-00a5-494a-b0f4-afcde2412851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7041bfca-ae44-4b62-95b6-a3e19ca02625" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_SecurityExchangeName_7041bfca-ae44-4b62-95b6-a3e19ca02625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cfcdaa71-a653-499c-9aae-512dd9b76ed6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c9d4b752-23b7-4b0b-95b0-46f38a395318" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cfcdaa71-a653-499c-9aae-512dd9b76ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f0859ba6-da6d-428c-98d0-f62dc87b9ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0859ba6-da6d-428c-98d0-f62dc87b9ecf" xlink:to="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f071edd-cbea-49ca-8141-fe36c8f6b355" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f071edd-cbea-49ca-8141-fe36c8f6b355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ee88f0b5-a96d-4575-ad97-f225063cbee8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ee88f0b5-a96d-4575-ad97-f225063cbee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_72cd80bb-ce22-4008-99f9-504067cfe8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:to="loc_us-gaap_InventoryNet_72cd80bb-ce22-4008-99f9-504067cfe8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_da21b034-539b-4d82-8cfc-d03b2c1409a9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_da21b034-539b-4d82-8cfc-d03b2c1409a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_5dfe646d-7007-48df-9795-9e6de48a2132" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:to="loc_us-gaap_OtherAssetsCurrent_5dfe646d-7007-48df-9795-9e6de48a2132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_44cab1aa-d937-407b-bd62-cd57e017a453" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f5666528-d0d7-440c-abae-29edcdf2d1b2" xlink:to="loc_us-gaap_AssetsCurrent_44cab1aa-d937-407b-bd62-cd57e017a453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e8c7641c-1ebc-4dd9-92fd-8f9b5701145f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_InventoryNoncurrent_e8c7641c-1ebc-4dd9-92fd-8f9b5701145f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_777df371-1622-4480-a415-7f7082653da8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_777df371-1622-4480-a415-7f7082653da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82e435fc-f541-43bf-a229-0755f63b52a0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82e435fc-f541-43bf-a229-0755f63b52a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5e7d3860-9b12-4b71-ad7a-70360bb89604" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_Goodwill_5e7d3860-9b12-4b71-ad7a-70360bb89604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_cea76f03-5aa6-400e-95ef-0c7dfb430765" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_cea76f03-5aa6-400e-95ef-0c7dfb430765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4d7af721-bc15-4808-839b-f906677a3b35" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4d7af721-bc15-4808-839b-f906677a3b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f5586e17-488d-4858-ac30-f762bd409d77" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f5586e17-488d-4858-ac30-f762bd409d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_670f04a2-321d-4782-ab3a-5f491eaa6751" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6bdb7e68-cb49-4ac7-a872-88386b191300" xlink:to="loc_us-gaap_Assets_670f04a2-321d-4782-ab3a-5f491eaa6751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0859ba6-da6d-428c-98d0-f62dc87b9ecf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8a3776fb-fbbc-486a-a555-2396b451bace" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8a3776fb-fbbc-486a-a555-2396b451bace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0a840a21-b445-406f-94d0-8560eb81304b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a3776fb-fbbc-486a-a555-2396b451bace" xlink:to="loc_us-gaap_AccountsPayableCurrent_0a840a21-b445-406f-94d0-8560eb81304b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1235b373-80bd-436f-aee5-e05dad97015d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a3776fb-fbbc-486a-a555-2396b451bace" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_1235b373-80bd-436f-aee5-e05dad97015d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_40500483-c5f6-43e5-ba43-e5154d936c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a3776fb-fbbc-486a-a555-2396b451bace" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_40500483-c5f6-43e5-ba43-e5154d936c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b17f3d16-d441-40b4-b76e-2a5ade475098" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a3776fb-fbbc-486a-a555-2396b451bace" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b17f3d16-d441-40b4-b76e-2a5ade475098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_81f1e1cc-ef3b-4878-b9c5-ccfcd148a200" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8a3776fb-fbbc-486a-a555-2396b451bace" xlink:to="loc_us-gaap_LiabilitiesCurrent_81f1e1cc-ef3b-4878-b9c5-ccfcd148a200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_78916969-5950-4716-8e92-496e4dc92847" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_us-gaap_LongTermLineOfCredit_78916969-5950-4716-8e92-496e4dc92847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b587898f-2d80-4011-bcdf-1aa6680a9e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b587898f-2d80-4011-bcdf-1aa6680a9e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_c3c3b704-0f6a-42c8-aff8-48961421aa7e" xlink:href="cpix-20200331.xsd#cpix_OtherLongTermObligationsExcludingCurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_cpix_OtherLongTermObligationsExcludingCurrentPortion_c3c3b704-0f6a-42c8-aff8-48961421aa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_66ba098c-989d-4555-8089-b872a3aac984" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_us-gaap_Liabilities_66ba098c-989d-4555-8089-b872a3aac984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b1bc8e5b-8267-40e6-ba17-b0e094b9e613" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b1bc8e5b-8267-40e6-ba17-b0e094b9e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_73690764-afe3-4c4d-a05e-23005504b72e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_73690764-afe3-4c4d-a05e-23005504b72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_43f588bb-1722-417d-b0f0-1502b2432b51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_73690764-afe3-4c4d-a05e-23005504b72e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_43f588bb-1722-417d-b0f0-1502b2432b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_14a1bde2-6dc2-4297-b6d1-32ed177dbcfe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43f588bb-1722-417d-b0f0-1502b2432b51" xlink:to="loc_us-gaap_CommonStockValue_14a1bde2-6dc2-4297-b6d1-32ed177dbcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45569be0-8401-4880-b33c-11a92c28829e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43f588bb-1722-417d-b0f0-1502b2432b51" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_45569be0-8401-4880-b33c-11a92c28829e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c1f85cd4-70dd-48cb-bc0a-b031d98c97f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_43f588bb-1722-417d-b0f0-1502b2432b51" xlink:to="loc_us-gaap_StockholdersEquity_c1f85cd4-70dd-48cb-bc0a-b031d98c97f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b4bceaea-4f0b-433c-afec-0baf682e534e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_73690764-afe3-4c4d-a05e-23005504b72e" xlink:to="loc_us-gaap_MinorityInterest_b4bceaea-4f0b-433c-afec-0baf682e534e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e9f8f71d-d4f6-40b0-9494-036acb075e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_73690764-afe3-4c4d-a05e-23005504b72e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e9f8f71d-d4f6-40b0-9494-036acb075e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f06ff341-0054-4c1d-a1db-7abbeaf70204" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_83ed2f3a-d40c-4edc-84d4-89df47760bbb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f06ff341-0054-4c1d-a1db-7abbeaf70204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e6c85215-cee0-4380-bc63-13af83a2524e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_ea635630-d26c-43da-ac6f-17a2853cf479" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6c85215-cee0-4380-bc63-13af83a2524e" xlink:to="loc_us-gaap_CommonStockNoParValue_ea635630-d26c-43da-ac6f-17a2853cf479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a853f0ba-0761-4b72-bedd-d6c5b0dac73f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6c85215-cee0-4380-bc63-13af83a2524e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a853f0ba-0761-4b72-bedd-d6c5b0dac73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_91a4a9d6-e7a9-4576-b112-7c4516637c7e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6c85215-cee0-4380-bc63-13af83a2524e" xlink:to="loc_us-gaap_CommonStockSharesIssued_91a4a9d6-e7a9-4576-b112-7c4516637c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_be0e355d-0582-494a-8d71-f00087cf7f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e6c85215-cee0-4380-bc63-13af83a2524e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_be0e355d-0582-494a-8d71-f00087cf7f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da1b754d-6f88-472c-849f-56898c9c966f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da1b754d-6f88-472c-849f-56898c9c966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ca42bdef-51be-4213-bb5e-96a137626b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ca42bdef-51be-4213-bb5e-96a137626b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_88e55c08-b542-4b49-b316-3d0af54627fc" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:to="loc_us-gaap_SellingAndMarketingExpense_88e55c08-b542-4b49-b316-3d0af54627fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_881fa2ea-ffb4-43a5-b4ce-18e1bb90c722" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_881fa2ea-ffb4-43a5-b4ce-18e1bb90c722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8e149bd8-b807-4ffd-aa4e-3cf33d8534d5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8e149bd8-b807-4ffd-aa4e-3cf33d8534d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4a8facc8-e9eb-406b-8f00-1776ac944933" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4a8facc8-e9eb-406b-8f00-1776ac944933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6d5f5847-dd8f-4b5c-b172-12fcdaaed0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:to="loc_us-gaap_CostsAndExpenses_6d5f5847-dd8f-4b5c-b172-12fcdaaed0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_30b06e26-9960-4d55-891f-ddb1ca3e110a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_99c36cb6-1898-41c6-8e4b-73e71578f3b5" xlink:to="loc_us-gaap_OperatingIncomeLoss_30b06e26-9960-4d55-891f-ddb1ca3e110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7e8061c9-28aa-443a-9141-ac8ca94e5bb1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7e8061c9-28aa-443a-9141-ac8ca94e5bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fb16427b-7e0b-4de5-8b13-e47285260f24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_InterestExpense_fb16427b-7e0b-4de5-8b13-e47285260f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_080f9369-5aa9-47ac-aa91-4550bfd121b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_080f9369-5aa9-47ac-aa91-4550bfd121b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b4b58741-6042-4a25-b536-e7a89cf59eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b4b58741-6042-4a25-b536-e7a89cf59eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ca09a616-7a1f-4bfe-89cd-d602212cb528" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ca09a616-7a1f-4bfe-89cd-d602212cb528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_202c5428-aff7-4691-a3e0-29cfbf81f231" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_202c5428-aff7-4691-a3e0-29cfbf81f231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c17d8bb2-89a2-4e61-a7eb-c9d2aa650e58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_ProfitLoss_c17d8bb2-89a2-4e61-a7eb-c9d2aa650e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5e7d8376-8b70-465e-a1a1-e164b58612fd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5e7d8376-8b70-465e-a1a1-e164b58612fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3c730306-2344-43ad-ac16-ba8744ffbdc7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_NetIncomeLoss_3c730306-2344-43ad-ac16-ba8744ffbdc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bb6a3bef-8889-4dc6-9319-b7ba6ce2efef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_bb6a3bef-8889-4dc6-9319-b7ba6ce2efef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c55c4b20-902a-4b8f-a530-bbcaf0d3c1ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c55c4b20-902a-4b8f-a530-bbcaf0d3c1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d9a9055-c520-4b3d-a56d-a519da5c82c4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d9a9055-c520-4b3d-a56d-a519da5c82c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_81f8e19f-0fae-40df-807e-5e10e3f02218" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_81f8e19f-0fae-40df-807e-5e10e3f02218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1720846a-71a9-4a7c-90e0-ba0b9e8da48d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1720846a-71a9-4a7c-90e0-ba0b9e8da48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_19e293d9-0327-479d-8115-7bb618905789" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_de3ba7c0-9b6a-41c3-8776-935e29b68388" xlink:to="loc_us-gaap_EarningsPerShareDiluted_19e293d9-0327-479d-8115-7bb618905789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0a9ff451-990b-4b80-9775-a8b9412cfa96" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0a9ff451-990b-4b80-9775-a8b9412cfa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f4b6365b-2f14-4466-9bce-590494153890" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0a9ff451-990b-4b80-9775-a8b9412cfa96" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f4b6365b-2f14-4466-9bce-590494153890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98a8d69c-a459-45e0-8285-4d78df478355" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0a9ff451-990b-4b80-9775-a8b9412cfa96" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98a8d69c-a459-45e0-8285-4d78df478355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1e43d455-7c56-44e8-98f4-3c2b40942aad" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1e43d455-7c56-44e8-98f4-3c2b40942aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6e35a591-1490-45ee-ba2b-d528582f3c74" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6e35a591-1490-45ee-ba2b-d528582f3c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_177a708e-ba8a-40a9-8c8a-2a2e4bbcc3f7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1151f431-4eff-4f97-bddd-e5723d1202a3" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_177a708e-ba8a-40a9-8c8a-2a2e4bbcc3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_61de8070-4871-4ac1-aa37-269be62739bb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61de8070-4871-4ac1-aa37-269be62739bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_df0b16bd-39ee-4517-a068-2427fcdf89b0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:to="loc_us-gaap_ProfitLoss_df0b16bd-39ee-4517-a068-2427fcdf89b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0bec7af6-58bd-4aab-a865-8e4490dd26f6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0bec7af6-58bd-4aab-a865-8e4490dd26f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2ab4df00-bda8-4874-b17f-aacd4cd7bba3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2ab4df00-bda8-4874-b17f-aacd4cd7bba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_275eee88-c5f0-4b8e-953b-023a7708b445" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_275eee88-c5f0-4b8e-953b-023a7708b445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93441729-7048-490c-a45e-46bab27e56ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93441729-7048-490c-a45e-46bab27e56ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7a855c71-f37d-4fb7-8f56-1990fd5f76cd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:to="loc_us-gaap_ShareBasedCompensation_7a855c71-f37d-4fb7-8f56-1990fd5f76cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_aaeab52f-d193-44b0-9773-1e36617ca6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:to="loc_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities_aaeab52f-d193-44b0-9773-1e36617ca6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_b809d42f-3441-4bed-850f-a520c955b739" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_b809d42f-3441-4bed-850f-a520c955b739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c3f4baaf-1e1a-4035-9a85-e8c5e5176e07" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c3f4baaf-1e1a-4035-9a85-e8c5e5176e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_db38d8b2-a3c8-44f7-8634-50692dffd81b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f375b4-9227-4562-bbdc-1287bfedb137" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_db38d8b2-a3c8-44f7-8634-50692dffd81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f02157d-5e76-4bf8-a38b-eb84760c906d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_db38d8b2-a3c8-44f7-8634-50692dffd81b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f02157d-5e76-4bf8-a38b-eb84760c906d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_af659985-4018-4b6f-88ef-8d26a418ebff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_db38d8b2-a3c8-44f7-8634-50692dffd81b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_af659985-4018-4b6f-88ef-8d26a418ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0b93ccee-55be-40ee-843e-9622b389aa3a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_db38d8b2-a3c8-44f7-8634-50692dffd81b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0b93ccee-55be-40ee-843e-9622b389aa3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_59d004bc-649c-4182-9e85-c403f1a8cead" xlink:href="cpix-20200331.xsd#cpix_IncreaseDecreaseInCurrentOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_db38d8b2-a3c8-44f7-8634-50692dffd81b" xlink:to="loc_cpix_IncreaseDecreaseInCurrentOperatingLiabilities_59d004bc-649c-4182-9e85-c403f1a8cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c4b28107-7c40-4ec4-b115-b2111a9e220d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_db38d8b2-a3c8-44f7-8634-50692dffd81b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_c4b28107-7c40-4ec4-b115-b2111a9e220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_234650c3-d3f9-4d59-bd94-798370e9afc0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_234650c3-d3f9-4d59-bd94-798370e9afc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1c2b3c6c-1cd3-4adb-b24b-8df5e275ebb8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1c2b3c6c-1cd3-4adb-b24b-8df5e275ebb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c50505cb-7703-4508-873c-7fc401e1dc78" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2e41f962-3360-40fe-9587-eb8c98c2c488" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c50505cb-7703-4508-873c-7fc401e1dc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_efe20552-2a97-4a79-97bd-78223b43e6ab" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61de8070-4871-4ac1-aa37-269be62739bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_efe20552-2a97-4a79-97bd-78223b43e6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d486110-a469-496c-90e8-92f09970b152" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_efe20552-2a97-4a79-97bd-78223b43e6ab" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d486110-a469-496c-90e8-92f09970b152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4120b41c-cccf-4636-bf77-9dd5777bae8a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_efe20552-2a97-4a79-97bd-78223b43e6ab" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4120b41c-cccf-4636-bf77-9dd5777bae8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_25ef304f-8701-4f05-be63-226b4f99b022" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_efe20552-2a97-4a79-97bd-78223b43e6ab" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_25ef304f-8701-4f05-be63-226b4f99b022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_20dfa03a-880e-426a-a9da-79e9a0058fbf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_efe20552-2a97-4a79-97bd-78223b43e6ab" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_20dfa03a-880e-426a-a9da-79e9a0058fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a3786789-86ca-453f-9434-18e97ca0b466" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_efe20552-2a97-4a79-97bd-78223b43e6ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a3786789-86ca-453f-9434-18e97ca0b466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61de8070-4871-4ac1-aa37-269be62739bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_7f2f2ecc-55d9-4530-8fec-ae1cac36a216" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_7f2f2ecc-55d9-4530-8fec-ae1cac36a216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_ea05e8d3-108a-4caa-8b3a-3b438b24597d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_ea05e8d3-108a-4caa-8b3a-3b438b24597d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ff376fd8-2d28-4896-8c39-cd59270e22a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ff376fd8-2d28-4896-8c39-cd59270e22a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_873b9ed9-dc65-4070-a225-672cc89fd906" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_873b9ed9-dc65-4070-a225-672cc89fd906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cce6b1b6-a967-437f-bf1b-0991c75d6825" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_cce6b1b6-a967-437f-bf1b-0991c75d6825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e95ac2f-03af-4f10-a318-096e1d1f8494" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3e95ac2f-03af-4f10-a318-096e1d1f8494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70a82755-5f1f-4ae9-a55e-fe73c5a00961" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_70a82755-5f1f-4ae9-a55e-fe73c5a00961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d519190-0f87-4332-912b-7c67daee1882" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d519190-0f87-4332-912b-7c67daee1882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84936b4a-6d34-4bc5-b1c8-830fe56ee246" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_53425c9a-4062-4563-bd3f-9698f547dd41" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_84936b4a-6d34-4bc5-b1c8-830fe56ee246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7424424d-9c86-48ba-bb39-ebfe76294ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61de8070-4871-4ac1-aa37-269be62739bb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7424424d-9c86-48ba-bb39-ebfe76294ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_44f2f0ee-fd3c-4332-bb81-e5a2685eec40" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7424424d-9c86-48ba-bb39-ebfe76294ec8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_44f2f0ee-fd3c-4332-bb81-e5a2685eec40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="simple" xlink:href="cpix-20200331.xsd#CondensedConsolidatedStatementofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_489d18a6-c02c-4603-aef1-3639b19f4ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0ff690d-2cab-4b67-bebb-501993ed24d2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_489d18a6-c02c-4603-aef1-3639b19f4ac1" xlink:to="loc_us-gaap_StatementTable_f0ff690d-2cab-4b67-bebb-501993ed24d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8c2796b8-6030-44b2-b7bd-949b67426b7d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0ff690d-2cab-4b67-bebb-501993ed24d2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8c2796b8-6030-44b2-b7bd-949b67426b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8c2796b8-6030-44b2-b7bd-949b67426b7d" xlink:to="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3b2085b3-f61e-43db-b63d-894b67fc0d5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:to="loc_us-gaap_CommonStockMember_3b2085b3-f61e-43db-b63d-894b67fc0d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1734ffa6-8c56-4a51-80ac-cf535f75df6e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:to="loc_us-gaap_RetainedEarningsMember_1734ffa6-8c56-4a51-80ac-cf535f75df6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_098fad45-7be7-4e83-bad3-766875b4b50c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef4b40bb-97da-4e73-923d-c8a2b1546144" xlink:to="loc_us-gaap_NoncontrollingInterestMember_098fad45-7be7-4e83-bad3-766875b4b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4a526847-f361-4cc0-9be7-cb4a55a1c085" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0ff690d-2cab-4b67-bebb-501993ed24d2" xlink:to="loc_us-gaap_StatementLineItems_4a526847-f361-4cc0-9be7-cb4a55a1c085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4a526847-f361-4cc0-9be7-cb4a55a1c085" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52304b6d-f967-4205-9434-d4d71ea06b4c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_52304b6d-f967-4205-9434-d4d71ea06b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a30e6307-f03a-429b-b540-bcdec13efa83" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a30e6307-f03a-429b-b540-bcdec13efa83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ac9a76a6-3469-4165-a9e1-74ecd6b9986b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ac9a76a6-3469-4165-a9e1-74ecd6b9986b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8503b5b-68aa-4507-a3d5-2dabeac9ce06" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_b8503b5b-68aa-4507-a3d5-2dabeac9ce06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_654c8469-e561-4769-a5b6-4959af8dc238" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_654c8469-e561-4769-a5b6-4959af8dc238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_aa291484-ef4c-4d15-b7e1-dcb4afa279d0" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_aa291484-ef4c-4d15-b7e1-dcb4afa279d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_829579c5-7f8f-4b33-938f-ff5f2e09b37e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_ProfitLoss_829579c5-7f8f-4b33-938f-ff5f2e09b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11fb86dc-a8d0-4ae5-a502-fd88febba795" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11fb86dc-a8d0-4ae5-a502-fd88febba795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f868ed7c-226d-4fdd-bcaa-283861b0e502" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4fbf44e4-92f7-4ad7-b5af-22e49d7a4449" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f868ed7c-226d-4fdd-bcaa-283861b0e502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41fa00f1-d546-41c6-a1e0-5abe6caa0374" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_71dae55b-9fd6-4325-8836-893d5ee229b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41fa00f1-d546-41c6-a1e0-5abe6caa0374" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_71dae55b-9fd6-4325-8836-893d5ee229b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c80f6c4b-b0bb-4a5d-a1b2-482629c5f149" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9dd9fe81-c126-4773-8990-a8d9169232b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c80f6c4b-b0bb-4a5d-a1b2-482629c5f149" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9dd9fe81-c126-4773-8990-a8d9169232b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_4f47c89b-b386-4d6a-8ace-eb577cb76bb9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c80f6c4b-b0bb-4a5d-a1b2-482629c5f149" xlink:to="loc_us-gaap_UseOfEstimates_4f47c89b-b386-4d6a-8ace-eb577cb76bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_99b1debf-cd27-41ee-a8ed-864501ae455a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c80f6c4b-b0bb-4a5d-a1b2-482629c5f149" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_99b1debf-cd27-41ee-a8ed-864501ae455a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#OrganizationandBasisofPresentationOrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a6c5caf-8aaa-4b39-b4b8-4c35ef05a364" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a6d3a05a-e970-4804-b081-5d95c80bffcb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a6c5caf-8aaa-4b39-b4b8-4c35ef05a364" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a6d3a05a-e970-4804-b081-5d95c80bffcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e55807b1-1abe-4be1-9616-41b8909ebfca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0c3ad9be-8d3d-443b-815c-0ebcf44a4877" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e55807b1-1abe-4be1-9616-41b8909ebfca" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0c3ad9be-8d3d-443b-815c-0ebcf44a4877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5792b1be-c7e3-412f-9173-c0456d1583b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f80a82b8-9feb-4232-87c3-83068c286135" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5792b1be-c7e3-412f-9173-c0456d1583b8" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f80a82b8-9feb-4232-87c3-83068c286135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2477de1-9df4-450e-905f-3e7186f1b39a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2477de1-9df4-450e-905f-3e7186f1b39a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08c462fc-8623-46de-a3a0-8493f09dc3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08c462fc-8623-46de-a3a0-8493f09dc3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_08c462fc-8623-46de-a3a0-8493f09dc3d8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_91c04fbf-0848-45e8-a87e-b05decaf2e66" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_91c04fbf-0848-45e8-a87e-b05decaf2e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3dc856fd-7397-4b11-8826-705b5e50aacf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc22e9e9-4cb8-467e-b4ca-748750f2e4ae" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3dc856fd-7397-4b11-8826-705b5e50aacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a62cc316-c98b-4d25-8ef5-7747491c0efe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a62cc316-c98b-4d25-8ef5-7747491c0efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70fa078b-4728-4203-bc1e-25458111233e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a62cc316-c98b-4d25-8ef5-7747491c0efe" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70fa078b-4728-4203-bc1e-25458111233e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_9a4be758-390f-42bd-b1bd-67d171dabcec" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_70fa078b-4728-4203-bc1e-25458111233e" xlink:to="loc_us-gaap_CommercialPaperMember_9a4be758-390f-42bd-b1bd-67d171dabcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2071c43b-3f6e-4f43-861b-d53f4fb161cf" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_21238c2e-2f76-44cf-83d1-80851da9411d" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2071c43b-3f6e-4f43-861b-d53f4fb161cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_4379c90e-ddc4-4448-b40d-5da1bb95adbb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2071c43b-3f6e-4f43-861b-d53f4fb161cf" xlink:to="loc_us-gaap_TradingSecurities_4379c90e-ddc4-4448-b40d-5da1bb95adbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e9c23420-ae70-43d3-813a-181121c9945e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_20a64908-423a-4b5c-b3dc-b62178a9ee41" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e9c23420-ae70-43d3-813a-181121c9945e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_20a64908-423a-4b5c-b3dc-b62178a9ee41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fed0beba-3aa8-4016-bd38-a4f2d08ba708" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3de4d18a-937a-462f-a900-2697eaaba213" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fed0beba-3aa8-4016-bd38-a4f2d08ba708" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3de4d18a-937a-462f-a900-2697eaaba213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0ad23405-f886-4cd5-a2d8-da34524846ff" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_1ce64889-7ab0-4601-a6ae-1126d2568699" xlink:href="cpix-20200331.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ad23405-f886-4cd5-a2d8-da34524846ff" xlink:to="loc_cpix_NumeratorAbstract_1ce64889-7ab0-4601-a6ae-1126d2568699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e7cf75c1-90e9-4118-832a-666761f08364" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1ce64889-7ab0-4601-a6ae-1126d2568699" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_e7cf75c1-90e9-4118-832a-666761f08364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_716bb11f-0b88-4fbf-b6b9-5f2bfe3671a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1ce64889-7ab0-4601-a6ae-1126d2568699" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_716bb11f-0b88-4fbf-b6b9-5f2bfe3671a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d482bd1-b3f8-4575-ba7d-f260d74da943" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1ce64889-7ab0-4601-a6ae-1126d2568699" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1d482bd1-b3f8-4575-ba7d-f260d74da943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9f14109d-2834-404a-b7c8-9709e9e90723" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_1ce64889-7ab0-4601-a6ae-1126d2568699" xlink:to="loc_us-gaap_NetIncomeLoss_9f14109d-2834-404a-b7c8-9709e9e90723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_c5737b1e-83d5-4397-b2a5-bb0c0a6fc578" xlink:href="cpix-20200331.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ad23405-f886-4cd5-a2d8-da34524846ff" xlink:to="loc_cpix_DenominatorAbstract_c5737b1e-83d5-4397-b2a5-bb0c0a6fc578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b57ca8aa-2d7c-48da-8729-66b817548c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_c5737b1e-83d5-4397-b2a5-bb0c0a6fc578" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b57ca8aa-2d7c-48da-8729-66b817548c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_81411e37-3b05-4b3b-ae6b-337f636da48e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_c5737b1e-83d5-4397-b2a5-bb0c0a6fc578" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_81411e37-3b05-4b3b-ae6b-337f636da48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bfde6bf3-3608-4764-b11f-9565524ec03c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_c5737b1e-83d5-4397-b2a5-bb0c0a6fc578" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bfde6bf3-3608-4764-b11f-9565524ec03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="simple" xlink:href="cpix-20200331.xsd#EarningsLossPerShareDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c35cfd2d-51d6-4260-9252-618314e191c2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bf7b3dcf-a3a8-4a62-bbbd-9490a762df2e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c35cfd2d-51d6-4260-9252-618314e191c2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bf7b3dcf-a3a8-4a62-bbbd-9490a762df2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20200331.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e4212c9e-eb31-47c3-b8fe-31d0822f222f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_54d68fad-1ada-4980-a1e3-778aaa135a9b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e4212c9e-eb31-47c3-b8fe-31d0822f222f" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_54d68fad-1ada-4980-a1e3-778aaa135a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b398cf84-bebc-452a-91c8-3e7af3a17d02" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2d9a86db-3a03-4b8a-8b4f-0308c761c387" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b398cf84-bebc-452a-91c8-3e7af3a17d02" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_2d9a86db-3a03-4b8a-8b4f-0308c761c387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#RevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a362065d-2623-4e30-bc9e-9f6f107381ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a362065d-2623-4e30-bc9e-9f6f107381ef" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c218858-ae50-4cde-9e6b-7d79ec40cd78" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:to="loc_srt_ProductOrServiceAxis_6c218858-ae50-4cde-9e6b-7d79ec40cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6c218858-ae50-4cde-9e6b-7d79ec40cd78" xlink:to="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_113819af-4661-455a-a489-f014aaf2bff7" xlink:href="cpix-20200331.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_AcetadoteMember_113819af-4661-455a-a489-f014aaf2bff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_15341567-e076-49f5-9173-ceaa216e6aaf" xlink:href="cpix-20200331.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_OmeclamoxPakMember_15341567-e076-49f5-9173-ceaa216e6aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_7d539cf8-cee0-443b-915f-508a00a9f279" xlink:href="cpix-20200331.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_KristaloseMember_7d539cf8-cee0-443b-915f-508a00a9f279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_3fbf2201-303e-47d2-90c8-18a9f6fcfd82" xlink:href="cpix-20200331.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_VaprisolMember_3fbf2201-303e-47d2-90c8-18a9f6fcfd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_cecc0314-298a-4586-8448-d15381faacea" xlink:href="cpix-20200331.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_CaldolorMember_cecc0314-298a-4586-8448-d15381faacea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_94cba62a-41d3-44eb-b579-ce9e6fc83ca9" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_VIBATIVMember_94cba62a-41d3-44eb-b579-ce9e6fc83ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherProductsMember_0cdac5e3-856b-4986-9623-196aae622edc" xlink:href="cpix-20200331.xsd#cpix_OtherProductsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_cpix_OtherProductsMember_0cdac5e3-856b-4986-9623-196aae622edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_eb815c8d-7e9a-4bf8-9438-860cf67ed5c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_567bfea8-1b63-48bd-8dbe-415e0bfdbfaa" xlink:to="loc_us-gaap_GrantMember_eb815c8d-7e9a-4bf8-9438-860cf67ed5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b907a3f1-ba9d-48b1-80d8-9f77484e4e50" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b907a3f1-ba9d-48b1-80d8-9f77484e4e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08150f4a-9c9a-4bd2-b9e1-5bcc55b8ee37" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b907a3f1-ba9d-48b1-80d8-9f77484e4e50" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08150f4a-9c9a-4bd2-b9e1-5bcc55b8ee37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_8aa50198-581f-474f-a70f-080d98149e74" xlink:href="cpix-20200331.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_08150f4a-9c9a-4bd2-b9e1-5bcc55b8ee37" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_8aa50198-581f-474f-a70f-080d98149e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_93dd156c-30f8-4ad0-8761-494bcdaad358" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_4ba0f3fc-1f64-427b-98ef-9158d12eeb59" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_93dd156c-30f8-4ad0-8761-494bcdaad358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d37996af-04ab-43b5-aaa2-a4333605ac5f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_93dd156c-30f8-4ad0-8761-494bcdaad358" xlink:to="loc_us-gaap_RevenuesAbstract_d37996af-04ab-43b5-aaa2-a4333605ac5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductsAbstract_02cf0eb9-a87b-4edf-ad8c-d244aa1131d5" xlink:href="cpix-20200331.xsd#cpix_ProductsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d37996af-04ab-43b5-aaa2-a4333605ac5f" xlink:to="loc_cpix_ProductsAbstract_02cf0eb9-a87b-4edf-ad8c-d244aa1131d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac1f4064-e382-4945-87c4-cd021740287c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductsAbstract_02cf0eb9-a87b-4edf-ad8c-d244aa1131d5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac1f4064-e382-4945-87c4-cd021740287c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20200331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_614219f8-76dd-4fbb-bc20-2791ec5d80a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_930c1e62-17e6-4ba3-ad4a-8104e0d6ee24" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_614219f8-76dd-4fbb-bc20-2791ec5d80a8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_930c1e62-17e6-4ba3-ad4a-8104e0d6ee24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_f49d448a-076c-4d4f-ab0d-82ed4ce0f640" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3042efdc-d1c7-4e28-a1f3-dc50453249ef" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_f49d448a-076c-4d4f-ab0d-82ed4ce0f640" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_3042efdc-d1c7-4e28-a1f3-dc50453249ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ad0a1d2a-87b5-4ae4-8c57-6b4610b957ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_f77b0666-ff37-4812-a039-737cd81fe5a1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ad0a1d2a-87b5-4ae4-8c57-6b4610b957ac" xlink:to="loc_us-gaap_InventoryCurrentTable_f77b0666-ff37-4812-a039-737cd81fe5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4adee72-9954-4b46-85da-8a9fc9034112" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_f77b0666-ff37-4812-a039-737cd81fe5a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4adee72-9954-4b46-85da-8a9fc9034112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0ca3489-377a-45e5-b095-004bb12ffb94" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4adee72-9954-4b46-85da-8a9fc9034112" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0ca3489-377a-45e5-b095-004bb12ffb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_e5b413a3-5725-414e-9f51-50cf3bbfc9ce" xlink:href="cpix-20200331.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0ca3489-377a-45e5-b095-004bb12ffb94" xlink:to="loc_cpix_IfetrobanClinicalMember_e5b413a3-5725-414e-9f51-50cf3bbfc9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_70d2249b-7cf4-4aa1-8ce2-0f267fd7fa95" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_f77b0666-ff37-4812-a039-737cd81fe5a1" xlink:to="loc_us-gaap_InventoryLineItems_70d2249b-7cf4-4aa1-8ce2-0f267fd7fa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_222dd64d-34d7-4892-ab5a-1eab0119621f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_70d2249b-7cf4-4aa1-8ce2-0f267fd7fa95" xlink:to="loc_us-gaap_InventoryNoncurrent_222dd64d-34d7-4892-ab5a-1eab0119621f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ca63680a-0a18-4f5f-a363-7e76d8129dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ca63680a-0a18-4f5f-a363-7e76d8129dcd" xlink:to="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_838cfb59-6c4d-4840-ae75-e360effb656c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_838cfb59-6c4d-4840-ae75-e360effb656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_450b50fe-816c-4802-9e62-eb0c95108681" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_450b50fe-816c-4802-9e62-eb0c95108681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9a4fa2f9-054a-40cc-8c76-3d1b5c72f79d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_9a4fa2f9-054a-40cc-8c76-3d1b5c72f79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c298c66d-fff7-46a3-9f4a-af352938145d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:to="loc_us-gaap_InventoryGross_c298c66d-fff7-46a3-9f4a-af352938145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_a81e5e39-d3d1-4478-ba2f-1c695d2c948f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:to="loc_us-gaap_InventoryNoncurrent_a81e5e39-d3d1-4478-ba2f-1c695d2c948f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3f9a55c6-6a03-4cfe-99c8-8e9bf1f9e22a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract_386b54b1-76a7-47d1-88a7-0c9026dd0379" xlink:to="loc_us-gaap_InventoryNet_3f9a55c6-6a03-4cfe-99c8-8e9bf1f9e22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20200331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d77eec8e-d018-48ec-9185-1a23fd9c2e51" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d3d80715-f867-4f4d-8747-37d8a9414704" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d77eec8e-d018-48ec-9185-1a23fd9c2e51" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d3d80715-f867-4f4d-8747-37d8a9414704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a7776922-945b-4447-a29b-7538be883b6f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_9f4e0f8e-4116-48e9-a4c8-c0ddbcd8bc04" xlink:href="cpix-20200331.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a7776922-945b-4447-a29b-7538be883b6f" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_9f4e0f8e-4116-48e9-a4c8-c0ddbcd8bc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d2bf25d1-f9cd-4d5f-b760-aa2031c12965" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a7776922-945b-4447-a29b-7538be883b6f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d2bf25d1-f9cd-4d5f-b760-aa2031c12965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6d86792f-25c9-4bae-a89a-e885e46c668c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d585351e-7a70-4e1e-85a6-789725375849" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6d86792f-25c9-4bae-a89a-e885e46c668c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d585351e-7a70-4e1e-85a6-789725375849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c8248c4e-4333-4c8a-b316-d78e6d043f55" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6d86792f-25c9-4bae-a89a-e885e46c668c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c8248c4e-4333-4c8a-b316-d78e6d043f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a9738cfb-cf63-4051-ae11-01785cc241eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b466956-9a2c-4f96-82f6-e78f938a73eb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9738cfb-cf63-4051-ae11-01785cc241eb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6b466956-9a2c-4f96-82f6-e78f938a73eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1c7ccb8e-3a37-4c44-ba49-10a06e0aa6e1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9738cfb-cf63-4051-ae11-01785cc241eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1c7ccb8e-3a37-4c44-ba49-10a06e0aa6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_04a2b9f8-f434-4c77-a3a2-5f3d1581755a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9738cfb-cf63-4051-ae11-01785cc241eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_04a2b9f8-f434-4c77-a3a2-5f3d1581755a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_8176b8fd-4986-4c17-9af9-b9da381a5362" xlink:href="cpix-20200331.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9738cfb-cf63-4051-ae11-01785cc241eb" xlink:to="loc_cpix_LeaseLiability_8176b8fd-4986-4c17-9af9-b9da381a5362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a934f0f3-0b05-4296-94e2-f7269c41da2c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a934f0f3-0b05-4296-94e2-f7269c41da2c" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8f33040b-f4b2-4c24-80a6-d3b753ee7f71" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_8f33040b-f4b2-4c24-80a6-d3b753ee7f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d370c732-ea0c-49bc-951f-abcc1d8f3767" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d370c732-ea0c-49bc-951f-abcc1d8f3767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b32a2c7f-f5ad-4f75-9174-0f10ed8d7fda" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b32a2c7f-f5ad-4f75-9174-0f10ed8d7fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4297f288-496c-4228-82ee-885c759efcba" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_4297f288-496c-4228-82ee-885c759efcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_72bd8f01-dd64-41e9-a759-ec2d16a5692d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_72bd8f01-dd64-41e9-a759-ec2d16a5692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9952220-d836-4c4b-847b-cd3d42988545" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b9952220-d836-4c4b-847b-cd3d42988545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43220155-a1b8-4394-be47-567c87b75f44" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43220155-a1b8-4394-be47-567c87b75f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a5053826-fe8a-4c63-bb75-685c141cb3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_30fd081b-4409-4eed-94e3-840ed96d114a" xlink:to="loc_us-gaap_OperatingLeaseLiability_a5053826-fe8a-4c63-bb75-685c141cb3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="simple" xlink:href="cpix-20200331.xsd#LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_d72830a4-2298-47b2-9392-9a56d3103ef4" xlink:href="cpix-20200331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c6243e02-8bcf-44c6-9f94-5438b17ae0a4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_d72830a4-2298-47b2-9392-9a56d3103ef4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c6243e02-8bcf-44c6-9f94-5438b17ae0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebtShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_6074a1d5-20c5-4867-b210-89b6027cffcc" xlink:href="cpix-20200331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_6074a1d5-20c5-4867-b210-89b6027cffcc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4bbdffbd-6947-4364-b875-52a85e8432a7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4bbdffbd-6947-4364-b875-52a85e8432a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8d5d409c-21b6-4ede-a211-ff4ae843de12" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4bbdffbd-6947-4364-b875-52a85e8432a7" xlink:to="loc_us-gaap_EquityComponentDomain_8d5d409c-21b6-4ede-a211-ff4ae843de12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6576b6b0-c75d-4d8a-b50f-4674da3981c6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8d5d409c-21b6-4ede-a211-ff4ae843de12" xlink:to="loc_us-gaap_CommonStockMember_6576b6b0-c75d-4d8a-b50f-4674da3981c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualAxis_45b10874-1c83-426f-975c-4906972dcb87" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_us-gaap_TitleOfIndividualAxis_45b10874-1c83-426f-975c-4906972dcb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1b02ae2-8c46-4996-903a-90966ce0ae42" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_45b10874-1c83-426f-975c-4906972dcb87" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1b02ae2-8c46-4996-903a-90966ce0ae42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DirectorMember_2eedba58-1b0b-4709-b236-f87366c70039" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_a1b02ae2-8c46-4996-903a-90966ce0ae42" xlink:to="loc_us-gaap_DirectorMember_2eedba58-1b0b-4709-b236-f87366c70039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9f139c74-4232-4c6b-934a-821e28ab4f31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_us-gaap_AwardTypeAxis_9f139c74-4232-4c6b-934a-821e28ab4f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdee52bf-74c8-41c1-96d8-0918e448fa15" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9f139c74-4232-4c6b-934a-821e28ab4f31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdee52bf-74c8-41c1-96d8-0918e448fa15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_02dff396-48d0-4bc1-af98-ddfe1ca912b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cdee52bf-74c8-41c1-96d8-0918e448fa15" xlink:to="loc_us-gaap_RestrictedStockMember_02dff396-48d0-4bc1-af98-ddfe1ca912b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_srt_CounterpartyNameAxis_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bf8f20e6-6e1b-4d8f-8a22-e9a02f727e29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_515f255d-fa21-40cc-80f0-147114f9fa0e" xlink:href="cpix-20200331.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_515f255d-fa21-40cc-80f0-147114f9fa0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_bf791fdd-59f4-4d26-9946-9cf00aad8d26" xlink:href="cpix-20200331.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_845c571e-64c6-4f3d-a765-1e83e8b6955e" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_bf791fdd-59f4-4d26-9946-9cf00aad8d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5506327-9ca6-40cb-b127-1d8cb60ae592" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2fb4e671-da96-4121-a8f1-adb8b7a08247" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5506327-9ca6-40cb-b127-1d8cb60ae592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:href="cpix-20200331.xsd#cpix_ShareholdersEquityTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e5506327-9ca6-40cb-b127-1d8cb60ae592" xlink:to="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_954bd8ef-b370-4540-9597-4573b93c46c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_954bd8ef-b370-4540-9597-4573b93c46c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_4715a838-4552-4140-84b2-35c324a30ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_4715a838-4552-4140-84b2-35c324a30ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_944f8913-5bbb-44af-ae39-0aa2bb6baa1f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_944f8913-5bbb-44af-ae39-0aa2bb6baa1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e60757df-ad98-4c3d-a52b-14928d3971e0" xlink:href="cpix-20200331.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e60757df-ad98-4c3d-a52b-14928d3971e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fb525d86-f644-498d-b907-da6806182e85" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fb525d86-f644-498d-b907-da6806182e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b5b9747-921d-45f8-afee-3c258e4105b7" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3b5b9747-921d-45f8-afee-3c258e4105b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_0042b5a9-c8f3-4bf0-b713-0061d3cb19fa" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_0042b5a9-c8f3-4bf0-b713-0061d3cb19fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentCashContribution_27eb9e0a-98c8-43f5-9b96-1ef3b302283f" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentCashContribution"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentCashContribution_27eb9e0a-98c8-43f5-9b96-1ef3b302283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_861a0415-f17d-4a2d-a005-b8a4207bc1bf" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable_861a0415-f17d-4a2d-a005-b8a4207bc1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_92a44d01-cf24-4c19-b4ba-b8d0c42549e8" xlink:href="cpix-20200331.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ShareholdersEquityTextualAbstract_51cbb218-10be-4629-8906-96129706a805" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_92a44d01-cf24-4c19-b4ba-b8d0c42549e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#ShareholdersEquityandDebtDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EquityAndDebtAbstract_7594b74d-6bb8-43b9-a595-a1d7665c3845" xlink:href="cpix-20200331.xsd#cpix_EquityAndDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EquityAndDebtAbstract_7594b74d-6bb8-43b9-a595-a1d7665c3845" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_31680202-1295-4a60-abd3-604d05de23fb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_31680202-1295-4a60-abd3-604d05de23fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_495b59f2-66b5-4ef3-a22e-872ee18f2df3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_31680202-1295-4a60-abd3-604d05de23fb" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_495b59f2-66b5-4ef3-a22e-872ee18f2df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_ba4aaf27-157b-4197-af6f-bd3128dae1a7" xlink:href="cpix-20200331.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_495b59f2-66b5-4ef3-a22e-872ee18f2df3" xlink:to="loc_cpix_PinnacleBankMember_ba4aaf27-157b-4197-af6f-bd3128dae1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_02a7a645-18d7-4f02-b876-906979dbe189" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_us-gaap_DebtInstrumentAxis_02a7a645-18d7-4f02-b876-906979dbe189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_02a7a645-18d7-4f02-b876-906979dbe189" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_519cb078-7faa-40ef-838a-2675b18a44c5" xlink:href="cpix-20200331.xsd#cpix_SecondAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:to="loc_cpix_SecondAmendmentMember_519cb078-7faa-40ef-838a-2675b18a44c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_fd825921-1196-4f40-9fa5-df07c74f97b5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d3f43d4e-1502-40b2-92a9-294f45624402" xlink:to="loc_us-gaap_LineOfCreditMember_fd825921-1196-4f40-9fa5-df07c74f97b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_49cd919c-08ec-45f9-ac78-e2fb63159715" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_us-gaap_CreditFacilityAxis_49cd919c-08ec-45f9-ac78-e2fb63159715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_99a1d0e8-14a4-4e7d-9330-9581a075ed7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_49cd919c-08ec-45f9-ac78-e2fb63159715" xlink:to="loc_us-gaap_CreditFacilityDomain_99a1d0e8-14a4-4e7d-9330-9581a075ed7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d9ee9092-ab81-4082-b9ac-a0b35bb58ba2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_99a1d0e8-14a4-4e7d-9330-9581a075ed7a" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d9ee9092-ab81-4082-b9ac-a0b35bb58ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_753c58f6-b1a0-4a15-a076-0ff28e744848" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_srt_RangeAxis_753c58f6-b1a0-4a15-a076-0ff28e744848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_753c58f6-b1a0-4a15-a076-0ff28e744848" xlink:to="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ad4db01-1101-4a81-93ba-e79952eabf19" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:to="loc_srt_MinimumMember_3ad4db01-1101-4a81-93ba-e79952eabf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8e0c0234-dda1-4564-a9c3-f828821762cc" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_182edd5c-b419-419b-8153-bd32e98d29c3" xlink:to="loc_srt_MaximumMember_8e0c0234-dda1-4564-a9c3-f828821762cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_fd98e5a8-c4e0-40ca-a93c-03fdeb2037ca" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf4007bc-4216-4517-9eb1-3d54b407679c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bf4007bc-4216-4517-9eb1-3d54b407679c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_abe2d173-4b96-4398-b30d-7476a8704a45" xlink:href="cpix-20200331.xsd#cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions_abe2d173-4b96-4398-b30d-7476a8704a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_74fabf9f-9ab8-47bb-b46d-14cbec35b9b6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_LongTermLineOfCredit_74fabf9f-9ab8-47bb-b46d-14cbec35b9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ee0cce5-05bb-486c-b79d-9fe7b69e8138" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5ee0cce5-05bb-486c-b79d-9fe7b69e8138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_aa3e31b0-b436-429b-a963-751f06649b93" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_bf438e91-fe8b-4d5f-a0ac-ce1f2846de31" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_aa3e31b0-b436-429b-a963-751f06649b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20200331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4d8ad8ed-a22d-40cd-b20b-08c200377445" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3f09d90c-71da-4ec2-a5c9-6f13c6e23177" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4d8ad8ed-a22d-40cd-b20b-08c200377445" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3f09d90c-71da-4ec2-a5c9-6f13c6e23177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="cpix-20200331.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7b34e31b-fc7b-4814-b574-ab4b9695ca5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_5d1ffa9e-276d-433b-a65b-2ad614cf24ee" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7b34e31b-fc7b-4814-b574-ab4b9695ca5b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_5d1ffa9e-276d-433b-a65b-2ad614cf24ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="cpix-20200331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac58eeec-5506-41c8-9f68-60865d02fc36" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5456bd78-4ae2-416a-b89e-bec204830d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ac58eeec-5506-41c8-9f68-60865d02fc36" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5456bd78-4ae2-416a-b89e-bec204830d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRights"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_334d90fd-7707-4867-a6aa-3741274c321c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_14634bb9-7b6e-4d33-a113-3ab124e38f0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_334d90fd-7707-4867-a6aa-3741274c321c" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_14634bb9-7b6e-4d33-a113-3ab124e38f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_aef6f1e6-4e62-4613-94d0-9ad05fabf827" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_6bde533b-6f74-418c-9ac3-5e9cfb4252e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_aef6f1e6-4e62-4613-94d0-9ad05fabf827" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_6bde533b-6f74-418c-9ac3-5e9cfb4252e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_fb967f15-53ec-4ad1-ba62-05ac99a82bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_aef6f1e6-4e62-4613-94d0-9ad05fabf827" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_fb967f15-53ec-4ad1-ba62-05ac99a82bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_f232d127-05e8-4862-904f-52d9382576f9" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_aef6f1e6-4e62-4613-94d0-9ad05fabf827" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_f232d127-05e8-4862-904f-52d9382576f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_81651a4d-f25b-414b-a2bc-c877f9827348" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_81651a4d-f25b-414b-a2bc-c877f9827348" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8cbd63a6-8c0d-45d2-ae1e-f1d204fa7633" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_06d92318-c2d2-49d2-93e4-2f4e3b8f8178" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:to="loc_cpix_VIBATIVMember_06d92318-c2d2-49d2-93e4-2f4e3b8f8178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_2d1efc98-68f7-449e-bf46-265bf6d94672" xlink:href="cpix-20200331.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e65734e8-62e1-4f24-9255-b58621cf873b" xlink:to="loc_cpix_MethotrexateMember_2d1efc98-68f7-449e-bf46-265bf6d94672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0704a1b-ac33-4f5c-af53-217abfaaaf6d" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_srt_CounterpartyNameAxis_e0704a1b-ac33-4f5c-af53-217abfaaaf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7aec7e2-385e-498f-bb1f-bb6860d743a8" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e0704a1b-ac33-4f5c-af53-217abfaaaf6d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7aec7e2-385e-498f-bb1f-bb6860d743a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ClinigenHealthcareLimitedMember_2e633fd5-d530-4bed-8508-e11bb063b2d7" xlink:href="cpix-20200331.xsd#cpix_ClinigenHealthcareLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d7aec7e2-385e-498f-bb1f-bb6860d743a8" xlink:to="loc_cpix_ClinigenHealthcareLimitedMember_2e633fd5-d530-4bed-8508-e11bb063b2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementScenarioAxis_8f7d3613-171f-44db-bd84-2deba1765803" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_StatementScenarioAxis_8f7d3613-171f-44db-bd84-2deba1765803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_01c9fb04-ef1c-4a36-afdd-a9c698247450" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_8f7d3613-171f-44db-bd84-2deba1765803" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_01c9fb04-ef1c-4a36-afdd-a9c698247450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioForecastMember_cd898110-79ba-49c1-bfca-b51eb6c34748" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_01c9fb04-ef1c-4a36-afdd-a9c698247450" xlink:to="loc_us-gaap_ScenarioForecastMember_cd898110-79ba-49c1-bfca-b51eb6c34748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8e34caeb-c40e-4c0c-a7c8-da47a960332d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_AwardTypeAxis_8e34caeb-c40e-4c0c-a7c8-da47a960332d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50e806dc-2a23-40f3-ba47-3865f7fbfd33" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8e34caeb-c40e-4c0c-a7c8-da47a960332d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50e806dc-2a23-40f3-ba47-3865f7fbfd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_ea6d483d-ae29-4323-8223-8f728a0f9586" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50e806dc-2a23-40f3-ba47-3865f7fbfd33" xlink:to="loc_us-gaap_RestrictedStockMember_ea6d483d-ae29-4323-8223-8f728a0f9586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d5bbaf03-009e-47d2-941b-be809e3f6259" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b6d10b0f-2581-41d2-99a1-ff3250e2c4ac" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d5bbaf03-009e-47d2-941b-be809e3f6259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f48d6b03-f649-485d-8c86-6fa2b43543d6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d5bbaf03-009e-47d2-941b-be809e3f6259" xlink:to="loc_us-gaap_SubsequentEventMember_f48d6b03-f649-485d-8c86-6fa2b43543d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_07a7dbf9-9008-4e46-8c88-fb96ffe1a8a8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_ce1f8c33-8a87-43fc-b3d9-ce88895cb10e" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_07a7dbf9-9008-4e46-8c88-fb96ffe1a8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_7968a305-954b-40d3-b56b-85d21a2fac56" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_07a7dbf9-9008-4e46-8c88-fb96ffe1a8a8" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_7968a305-954b-40d3-b56b-85d21a2fac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6c97174-f2e5-45fe-961c-99fd75a1361a" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_546dd540-ca3b-4066-99dc-57bb3b8ea2a2" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_546dd540-ca3b-4066-99dc-57bb3b8ea2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f549e62b-c446-40ae-b7e3-8ca8040b24e6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_f549e62b-c446-40ae-b7e3-8ca8040b24e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_a064da7f-98d2-4c5f-96d0-e2c2626d6402" xlink:href="cpix-20200331.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_a064da7f-98d2-4c5f-96d0-e2c2626d6402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_742a631f-b495-467c-a955-e1e96019d065" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_742a631f-b495-467c-a955-e1e96019d065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6856184c-c3ff-440e-9848-56c0092bf850" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_6856184c-c3ff-440e-9848-56c0092bf850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_55fd8267-22cc-4e6b-9757-520291841263" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_55fd8267-22cc-4e6b-9757-520291841263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2a97103a-4c67-4f49-b575-f51b35bb74d1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2a97103a-4c67-4f49-b575-f51b35bb74d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_77cc04b6-9efb-4cb8-9c67-f418868e2430" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_77cc04b6-9efb-4cb8-9c67-f418868e2430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9b29d983-dc78-4184-8422-58f726c39405" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_Revenues_9b29d983-dc78-4184-8422-58f726c39405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_42f99586-f150-4fa3-b5fc-3af7c2d5bb22" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_OperatingExpenses_42f99586-f150-4fa3-b5fc-3af7c2d5bb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a751e53c-13dd-4526-9c16-a7a37d420083" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_a751e53c-13dd-4526-9c16-a7a37d420083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_07f82e7b-24ce-4cde-b6d6-18d4e5c473b8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_374acb4c-1315-493f-81df-dd88df0a0521" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_07f82e7b-24ce-4cde-b6d6-18d4e5c473b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_982f6e13-4e0f-414c-a078-e35e00d9eb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0e66801-7759-44eb-aabd-07a897399597" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_982f6e13-4e0f-414c-a078-e35e00d9eb8c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0e66801-7759-44eb-aabd-07a897399597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_38995e08-6a15-401a-8cfe-4c0ee035c85f" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0e66801-7759-44eb-aabd-07a897399597" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_38995e08-6a15-401a-8cfe-4c0ee035c85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4ceb5d9-cfdf-43d2-8760-dc205287314a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_38995e08-6a15-401a-8cfe-4c0ee035c85f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4ceb5d9-cfdf-43d2-8760-dc205287314a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_6d02a1b8-1e62-4dac-b0dc-0435dda227da" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c4ceb5d9-cfdf-43d2-8760-dc205287314a" xlink:to="loc_cpix_VIBATIVMember_6d02a1b8-1e62-4dac-b0dc-0435dda227da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c0e66801-7759-44eb-aabd-07a897399597" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a928f86-3052-4525-bda0-c10b397254a3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_4a928f86-3052-4525-bda0-c10b397254a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_db19f68d-0864-45bf-9f60-c678068016a5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_db19f68d-0864-45bf-9f60-c678068016a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentsForContingentConsideration_4165e692-3d79-4ffb-b1cf-fad6ce5b97a5" xlink:href="cpix-20200331.xsd#cpix_PaymentsForContingentConsideration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_cpix_PaymentsForContingentConsideration_4165e692-3d79-4ffb-b1cf-fad6ce5b97a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7ec984c-5588-4a03-a36c-22cc13c59b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_010696c5-776f-4907-8894-1a0108c67705" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7ec984c-5588-4a03-a36c-22cc13c59b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsChangeinConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_31a16a21-be05-4543-82af-cbfea7bac7c8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6a74642-6cd6-4516-b1cf-cb3b4ffc02fe" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_31a16a21-be05-4543-82af-cbfea7bac7c8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6a74642-6cd6-4516-b1cf-cb3b4ffc02fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11f6dda6-9bdf-44ed-b87b-6ddda561d882" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6a74642-6cd6-4516-b1cf-cb3b4ffc02fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11f6dda6-9bdf-44ed-b87b-6ddda561d882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c067b193-c718-4c7a-a0be-f122b9754646" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11f6dda6-9bdf-44ed-b87b-6ddda561d882" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c067b193-c718-4c7a-a0be-f122b9754646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_92ba29f3-2864-48a1-b000-0a0454f3fe14" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c067b193-c718-4c7a-a0be-f122b9754646" xlink:to="loc_cpix_VIBATIVMember_92ba29f3-2864-48a1-b000-0a0454f3fe14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f82a16a8-893d-480f-bda6-693086b48d92" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f6a74642-6cd6-4516-b1cf-cb3b4ffc02fe" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f82a16a8-893d-480f-bda6-693086b48d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f82a16a8-893d-480f-bda6-693086b48d92" xlink:to="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e5f6ba2-ba17-405d-8af3-e666e62eb55a" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0e5f6ba2-ba17-405d-8af3-e666e62eb55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_ee3e19e3-aeff-460b-a20d-899b5dd3eadc" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment_ee3e19e3-aeff-460b-a20d-899b5dd3eadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_60819052-d884-4696-ae23-edeac337cca5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_us-gaap_PaymentsForRoyalties_60819052-d884-4696-ae23-edeac337cca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5ce13d0b-0188-43b1-ba37-5ae2809fc7f8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5ce13d0b-0188-43b1-ba37-5ae2809fc7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_08310f0d-b8e4-413e-8cf9-1867da177215" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_08310f0d-b8e4-413e-8cf9-1867da177215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_103c278a-1cea-497f-91cf-a2c4c718f0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyAccrualRollForward_6a5aa134-595d-4cd1-bf96-30f1a3a5a13d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_103c278a-1cea-497f-91cf-a2c4c718f0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_acab9575-b742-4709-902b-19ff06df5ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e265817-fcfb-4698-a15f-eb8f6b886a76" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_acab9575-b742-4709-902b-19ff06df5ee8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e265817-fcfb-4698-a15f-eb8f6b886a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_66dfdab9-5e81-4079-a55a-94452ae9da5b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e265817-fcfb-4698-a15f-eb8f6b886a76" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_66dfdab9-5e81-4079-a55a-94452ae9da5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cd5fd2d-9fca-4a07-b526-0676a91e8ce6" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_66dfdab9-5e81-4079-a55a-94452ae9da5b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cd5fd2d-9fca-4a07-b526-0676a91e8ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_76fc9383-eab9-487b-8542-c0257ededaac" xlink:href="cpix-20200331.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7cd5fd2d-9fca-4a07-b526-0676a91e8ce6" xlink:to="loc_cpix_VIBATIVMember_76fc9383-eab9-487b-8542-c0257ededaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8e265817-fcfb-4698-a15f-eb8f6b886a76" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_488d3bdd-b795-4c33-bb8c-674f3c6d0dba" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory_488d3bdd-b795-4c33-bb8c-674f3c6d0dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_0863323f-0a67-4fbb-81db-230cf5da76df" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials_0863323f-0a67-4fbb-81db-230cf5da76df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_ffce3e75-85b2-4420-883b-6df7a08533da" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials_ffce3e75-85b2-4420-883b-6df7a08533da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8ae2be1d-3ebc-48fb-8b43-555d2e49869d" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory_8ae2be1d-3ebc-48fb-8b43-555d2e49869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_384b199e-7f29-41f6-843a-db464355b113" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_384b199e-7f29-41f6-843a-db464355b113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_67b4d7d9-15d9-4604-b4c9-65d383cf8e58" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_67b4d7d9-15d9-4604-b4c9-65d383cf8e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_968ed405-0f85-4fa9-ac0d-bbab4ad73703" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_Goodwill_968ed405-0f85-4fa9-ac0d-bbab4ad73703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8c79301a-cd6f-42e3-b12e-9a973278b679" xlink:href="cpix-20200331.xsd#cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill_8c79301a-cd6f-42e3-b12e-9a973278b679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d2660ca9-0a33-40f1-95c2-25fb3b515bfb" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_dafaa395-5969-48e6-9a9d-d7b252a4f280" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_d2660ca9-0a33-40f1-95c2-25fb3b515bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cpix-20200331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_29b793b4-f621-4b67-887f-44d3e604c9b1" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_6a60822c-adf7-4b23-9830-6b51a593a811" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_29b793b4-f621-4b67-887f-44d3e604c9b1" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_6a60822c-adf7-4b23-9830-6b51a593a811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="cpix-20200331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_d4a2718e-b5c6-48d4-981d-831252880d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4035b532-9846-45bc-8353-a92707143cb3" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_d4a2718e-b5c6-48d4-981d-831252880d0b" xlink:to="loc_us-gaap_SubsequentEventTable_4035b532-9846-45bc-8353-a92707143cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_45be3d0c-3915-49f4-97c5-f44c57332dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4035b532-9846-45bc-8353-a92707143cb3" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_45be3d0c-3915-49f4-97c5-f44c57332dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9c7fd423-8020-4fd2-8944-7b7508083c11" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_45be3d0c-3915-49f4-97c5-f44c57332dc5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9c7fd423-8020-4fd2-8944-7b7508083c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d97195a8-a205-4315-a56c-bbc1b228e518" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9c7fd423-8020-4fd2-8944-7b7508083c11" xlink:to="loc_us-gaap_SubsequentEventMember_d97195a8-a205-4315-a56c-bbc1b228e518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4035b532-9846-45bc-8353-a92707143cb3" xlink:to="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_f508906e-1824-4f58-97a8-f32831286198" xlink:href="cpix-20200331.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_f508906e-1824-4f58-97a8-f32831286198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage_ba72b4d8-119e-4182-87e5-000547304545" xlink:href="cpix-20200331.xsd#cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_bc7d14ad-9c08-481b-b142-e64460359a3c" xlink:to="loc_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage_ba72b4d8-119e-4182-87e5-000547304545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6605612832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:56.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.531%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,456,867&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,345,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,354&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,017,923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,664,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,720,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,426,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,569,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,554,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,150,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,871,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6746213136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 498,008<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">498,008<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">498,008<span></span>
</td>
<td class="nump">2,119,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 498,008<span></span>
</td>
<td class="nump">$ 2,119,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6759265968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 8,330,734<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">1,634,181<span></span>
</td>
<td class="nump">1,658,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">3,707,676<span></span>
</td>
<td class="nump">3,436,932<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,722,555<span></span>
</td>
<td class="nump">1,399,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,036,284<span></span>
</td>
<td class="nump">2,536,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">1,076,039<span></span>
</td>
<td class="nump">1,021,645<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">10,176,735<span></span>
</td>
<td class="nump">10,053,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(1,846,001)<span></span>
</td>
<td class="num">(1,323,932)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">29,888<span></span>
</td>
<td class="nump">115,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(33,065)<span></span>
</td>
<td class="num">(60,911)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) from continuing operations before income taxes</a></td>
<td class="num">(1,849,178)<span></span>
</td>
<td class="num">(1,268,982)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(34,240)<span></span>
</td>
<td class="nump">81,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total</a></td>
<td class="num">(1,883,418)<span></span>
</td>
<td class="num">(1,187,554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">818,273<span></span>
</td>
<td class="nump">1,147,136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,065,145)<span></span>
</td>
<td class="num">(40,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">9,525<span></span>
</td>
<td class="num">(33,460)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (1,055,620)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)</a></td>
<td class="num">(0.07)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)</a></td>
<td class="num">(0.12)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)</a></td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- basic (in shares)</a></td>
<td class="nump">15,240,614<span></span>
</td>
<td class="nump">15,472,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- diluted (in shares)</a></td>
<td class="nump">15,578,309<span></span>
</td>
<td class="nump">15,891,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to common shareholders</a></td>
<td class="num">$ (1,055,620)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">9,525<span></span>
</td>
<td class="num">(33,460)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="num">$ (1,065,145)<span></span>
</td>
<td class="num">$ (40,418)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868656-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868656-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1278-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636578320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds,  corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of March 31, 2020 and December 31, 2019, all trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 -   Significant inputs to the valuation model are unobservable.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:27.368%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.162%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001628280-20-008312-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-008312-xbrl.zip
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MKF;B79G$SC ,H1@HI('1X*"4(OQE$45B!&89)18Y'XRP&>1RX@OO/(8=@;O
M>!9LX"HO*Q"\9Q<(-:>U(0ZV1M*U<-@>@[>."HBD"0_0V:D2B>&A5$&@8/D"
M(X#*H/!&B ]./1YQ/4-ZO6E:C$WCN,8G;5BM=%TJ?Y@S[38W*,UD"C&A3#K@
M^\!OC0*F$#)B";#\"$(#6EB*,8==LD1;]X?8Y"D<*R\^ /QG%P#SDZ _H5%F
MX!+=@X4AI'A\ ANK-J1J<Y:T!?S;R\W9FW%X& C0K6R.Z(E,WZ_!-@<4G?=F
MF "'C]?FB%>DUB:&F5T)T,?X*T[PDGTV>'8^.P=MZPWK7H45YIS2FI:-KOL$
MJ$9"(GP_D^@[2Z?_!JFQ4!KNX_,4($M!QD3^R( \@.C#>X:$$ 0 HG=ZYXK[
MX)JF.(YU\R2;Z_7::C6F:DZ5$'Y-T+# G$MF/?(S8T8B?L.BO%)^IW_Y+R_1
MXX&RKZKLJRJ[6%5I[:LJ.U15,<\S! 6LEQ<',_*$96A=G-$(CD_@ZVN9XUPU
M"MFC%E+-*;*Y 2+CF&O-V ,LR!- PK$]X*"?$7((  RD0R&I@;^8PQ:G!OLC
MXZ"^.2&RQ#?%\=?[XLD.:WD/93Z/(%V"N.7@PE@(PY*:SQGX7$Y[YT6,*:,W
MR&-M^F28K$G\S&?<Q2<D3_+DO-Y@RY ;#GD:P$#%YF?\O5Z?IXLP!%P7SM>R
M)=,*F+1]JAF6R1B3<ZN-GR7]$$3Y^58WSH$/AQ+PK QNPPP$@^.91QIR#RU;
M.LF3B8@F##EE0D?YDQDR1VT6IY&8,6B=CH6%:KKB_^"OWX1P._=ZT;K/[#*O
M;!W5OXY7-MM.H_U=B*7K'+5/OG)LS:D_)+C9;'SEV(<Y=MMQCYK?A@H7D8)1
M\6T8F_6[+4G; Q1SK]GSU.S_D7O9[Q_]%=5W*/_ZE<Z(ZY;-=\.>9RJV0XOY
M=K::1MR_CKL5R?M=?6A77QTT@3Z9U^5O!JWL\B,XM%O;O==F1T(AY[TX%VA&
MS"?FI/#/9Q<G^]AXX=K\;;'Q7,E4;\Q92/JWS,_PDU-R98NKZ]'P50_&IL+^
M;D#'/H8S8<O?IU_^FGUI\S#J <!DFG7S_:H]^?OX^:O]70#S"P5G_P-02P,$
M%     @ IXFV4+)(R%CH"   !4$  !8   !A,C R,'$Q+65X:&EB:70S,3(N
M:'1M[5QM<QJW$W_?3Z'B:>K,\' \^0$<SV",)\PD=NJ02?OJ/[H['6BL.UTE
M'9A^^NY*!P:#;9RF_6.'S 1S)VFU*^W^]-OEX.3G\ZONX(]//3(RL2"?OIQ]
MZ'=)H52I?*UW*Y7SP3EY/_CX@33*7I4,%$TT-UPF5%0JO<L"*8R,25N5RF0R
M*4_J9:F&E<%U!44U*D)*S<JA"0NG)W@'7AD-3W\Z^;E4(N<RR&*6&!(H1@T+
M2:9Y,B1?0Z9O2*F4]^K*=*KX<&1(S:MYY*M4-WQ,7;OA1K#3F9R3BKL^J=A)
M3GP93D]/0CXF/'Q7X-%APV=>/6H&U7K#.SBBQUZ=!0<>"X_\6G0<_*\*2E:@
MNQNCS52P=X41P[E;C69JVA,>FE&KZGF_M NVT^E))!,#,RD8Z=XZ 2MB#+LU
M)2KX,&E98]HES8(2W%0T,"V=Q3%54Y2*4F:#?!K<#)7,DK 42"%52PW]_5JS
M69S])U[9>]MV;7N>_==& :6(QEQ,6[\.>,PTN603<BUCFOQ:U+![,+7BD>NH
M^5\,+ +C[.7$67L(<@1/6"FWOEJS)O=N1]SGAM2KY=JRO>LM#6!3F&J#:4.>
ME(Q,6\<PT98;V>U=#_H7_6YGT+^Z)%<7I/N^W[L@%_W+SF6WW_D MZ"U=_V,
M!=ARBS]]N?[\I7,Y((,K\KG71;O?[%4/O';=JX&UK\?0P?L>^=RY/NM<]CZ7
MKG[_T/N#=+H#W..:YSWLT5OJOXWU1O:+Y",/1I0)<B:3A*DB"9@R/)H2,Z+F
MS5[SJ/V4J;XT1L:M V>MH;Y@]WH(%ID6S8R<1;=%-7?'ERID"E=#T%2SUNQ-
M>\%A<+R[YDD(SM-"ZT*N4T&G+9Y8N^R\.>@>'Y</O4.+NP; UH0S?7),+CM,
MKIAPM;%>/CIH/MS\Z-A'&X]KY6I]4\D5J[?3'59$IS1Y5Z@79B-2&H9P^EDO
MJZ6W[=EUOA5X:T-/N[_*8]S]@(K\'DPP%VYWL0HK/[OA=K&ZZN5/^.'&_KP<
M!AM:5#BMSCTV7^>7L8)SBK!]8.%(3)^,Z)@1Q<:<38"!F1'7Y$*JF%2]TF]$
M1J2;Q3Y3@B8A^32B*J8!R^QB:-)/@C+ R?$].+GS]HJ-X 68>9 O[2!H!T%;
M#D&U'03]*Q!T1C4 CTQ(/"4WB9P(%@Y9T2&18JE4AH02YDLD)(H@CO*$T&1*
MLL2H##$!4D>;10)841+#E>)4D CR*B(5D3$D+$:Z?BL=$A8PK2'UPBXQO6$P
M[X),#?="4 :F%#8%A3FP0\ 5I)S0+8'AH E@#9F,@'41G>'+W?@)4RP7@@;$
M7 O(33'-G7 S @-UR@*K(,I-036)G@7;#8OB3Q>780>U.ZC],:"VOH/:_Q9J
M&8EX F"&N'@'7D6"K$]"LUIHYTD$_)!B!1#>!R(+028 Y )2%0%<N1)3D@*^
M(30C9 MQA[TY[.E[4P.\A[:T6,0>F8 . +@24-%.IZT^ =4C$@DYT3,T5FS(
MM5$4)J)XT^D-6A870%7/E%G1=H>K.US],7"UL</5?P57!TL@]&;OJ%8];.L<
M.?/B&U(^&44<+BT\]0E5S (A !M': # (DQCN'(]PN[8+0:ZBY07KR&P R%U
M!N.0""O8/-LG53)@(=S69!\ ,&2 J [E>K?!B"9#1CK ,:\S 3VJ=5JJ-O?9
M6SNTV@S=E;OD6,5-'!*C?()$= &@'6"B+AM/%"U-%,%$:.=]V(8>6(A84YQ\
M!(J7ZM Y ):J1PMN9/VJ[FU_T9:69U9OKY;+P0JH?&C7]9QI"&=P YOZ/.VC
M1<S* IKIS8=@>N0S\+=\)I=PR4R! #C=QUQ;S@"]6&+E8*'[CFTL,A;%!+4.
MG&=<=TY8S-D,-G)@'J"+EH*']I-)G?F:AYPJC@9PEQ=:#I6@I$QCKF;C7=O$
MSC(,J1DH9(#1X*"4(OQE@B(Q K.L$G<Y'XQP&>1BX@OO?(8=@;O >!:NX2JO
M*Q#\%Q<(7KFY)@XV1M*5<-@<@S>."HBD,0_1V:F6B>6A5$.@8/D"(X"J<.:-
M$!^<^EQP,T5ZO6Y:C$WKN-8G75@M=5TH?]@S[38W*,U4"C&A;3H0!,!OK0*V
M$#)D";!\ :$!+2S%F,,N66*<^T-L\A2.E5<? ,&+"X#Y2= ;4Y%9N$3W8%$$
M*1X?P\;J-:G:G"5M /_N<GWV9AT>!@)T:Y<C^C(S#VNPR0%%Y[T9)L#1T[4Y
MXL]2:QO#S*T$Z&/]%2=XS3X;OCB?G8.V\X95K\(*<TYI;<M:UWT&5",AD4&0
M*?2=A=-_C=18:@/W\9$*D*4A8R)_9D >0/3^ T,B" ( T7N]<\4#<$U;',>Z
M>9+-]7KKM!I1/:=*"+\V:%AHSR6['OF9,26"WS"15\KO]2_^XR5Z.E!V595=
M564;JRK-755EBZHJ]GF&< ;KQ;N#&7G"(K3>G=$(CL_@ZRN9XUPU"MFCD4K/
M*;*] 2+CF!O#V",LR)= PK$]Y*"?%;(/  RD0R.I@;^8P\Y.#?9GQD%]>T)D
M26"+XV]WQ9,MUO(!RMP1D"Y!W')P82R$84DMX Q\+J>]\R+&A-$;Y+$N?;),
MUB9^]C/NV2<DS_+DO-[@RI!K#GD:PD#-YF?\@UZ?IXLP!%P7SM>B(],:F+1[
ML!F6R1J3<ZNUGR7]$$3YY58W.L"'(P5X5@2W81:"P?'L(PVYAQ8=G>3)6(HQ
M0TZ9T&'^9(;*49O%J9!3!JV3D71039?\'_SUNQ#N\H->M.HSV\PKFP?5;^.5
MC>/RT<;T[UF-M7*M>?2-8[UR]3'!C4;]&\<^SK&/R[6#QO>APK-(P:CX/HS-
M^=V&I.T1BKG3[&5J]O_(O=Q7D/Z)ZEN4?WVD4U*K%>W7PUYF*K9%BWDV74XC
M'E['[8KDW:X^MJMO]AI G^SKO2\'+6WT$U"T73N^TV9+HB&GOC@7:$;LA^9D
MYJ(O+E1VX?'ZM?G/PN.E4JKNB+.(7,SSZBM78EV-AF]Z/#:5[@<$6NYAG#%;
M_&+]XO?M"^N'41\P)C.LG>^7]^POYN>O[@<"[$\5G/X-4$L#!!0    ( *>)
MME /_BY+E 4  #,D   6    83(P,C!Q,2UE>&AI8FET,S(Q+FAT;>U:ZU/;
M.!#_?G_%-LRU="9^)Y#$*3.I,=/T(*'$7-M/-XJM))KZ55DFI'_]K?Q(@98V
MW*,-% 8\UFM7O]7JMROA_I/#L>.]/W5A(:(03L]?'@\=:"B:]M9R-.W0.X17
MWLDQM%3= (^3.&.")3$)-<T=-:"Q$"+M:=IRN527EIKPN>:=:5)42PN3)*-J
M((+&05_6X).2X."W_A-%@</$SR,:"_ Y)8(&D&<LGL/;@&8?0%&J7DZ2KCB;
M+P28NJG#VX1_8!>D;!=,A/2@EM/7RG)?*Y3TITFP.N@'[ )8\*+!]H,]R[!\
MPS?IK$4-,@U,TR+^?JLS\]O[?O<O R>I8?=R3"96(7W16%"IN]=JI\)>LD L
M>H:N_VXWBDX'_5D2"]3$<63Y6@KX0HR@ET(A(9O'O0*,K6345["2$U_TLCR*
M"%])J5)*/6A*_ ]SGN1QH/A)F/ >GT]WS7:[6?^!KNK/[;)M1R]^;"E F9&(
MA:O>,X]%-(,17<)9$I'X63/#U4/5G,W*CAG[1!$1@BN*RQ+M/LH)64R5"KUA
M%I#=RP6;,@&6J1K7\7X=J8^+0KF-T.8L5D22]KJH:,M!.NZ9-SP:.@-O.![!
M^ B<5T/W"-QWKG/N#?]T83 ZO /X;4=;@#L:C@8C9S@X1KP(W3U[. !/S\\F
MYX.1!]X8C Z<JQ/546'B.G)YG^X8>[IM6&V]^7 0#R8P.!R?>NXA7 5_#7)7
MWWLX@'&/>J]<F S.7@Y&[D09OSMVW\/ \>3N-77=O!7JEC)3Z^LXAS'X21Q3
M7T9?6#*Q +&@\"8G'%<I7,$931,N !N/$AY5SJTK;V"6\*+KC&4^">%C.0)H
M'&#4/2'<7X!E-,L F\S R:,I"B1Q *<+PB/BTUPP')G!,/95V)6RGNYT3%.W
MG21*2;PJ2H;]O DD0S4AREU/<$+]G&/*@*:0(MU+?T'B.<7('D4LRR08_)4]
M TP#8$$YQ4E<55("^ZQCV(2!^EJ%/\@G%K$F. M&9R@8%0EV06$\FS$? 4IU
M)PS5T1!>2M/QNN\1BTGL,S1&W1=52HT5GB9@G6 S?$ESGN4$W4(D$HHT_GH3
MU:,FA$])3#-E?!G2%0Q\(5ND[\'N9];)JJ63A(,HQ((@IG;'_IY_3A,ADJBW
M5[JH(-.0WN@1TIGHD5PD=; MDHRR9IKP@'+IPB%),]JK7^PK&UV.+\L,?2(6
M/>F2 <O2D*QZ+"Z<L=!;Y4#=KKJO[Q=ID,#<1P3U?*H422U3)$T$7S9::F>O
M?7OS-\=^L[&+:8FUJ62MF'<Y=[1(AHO^HF$UZA$I"0),1@MJ,--+NRY72R&K
M-J2'FU:^D'Z%>ZFJ0P5KX<4J&FCYNJ)<1>-+:OH.>6Q,0M>Y:T-$C8//V5]E
MY_MAP77&OGT,7YXI/*22BL1G>8B,[B,;A9(XUV3*Z<><<2K/.YGDF&N,9%B[
MY'GYBHQOM'>#NC2[R<1K%JZXRNA:+22CKBU)\\9A9KU?M((#KA#5K0>@1Q)[
M)+$M)S'SD<3^-Q)C,::<$2FR'<Q9!<%N =86+%0S'&$R:4TYS229-64S"4/
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M()WQ5D>Y5U?M+@>GG<61$$%'+:'4$R5\Q(K@%(W.#=$+8%<?0DMPUI(?F_C
M+25&":(5A4AK'[A0"CL4K8HF; &T9$D%P\832X:20#WF1B/H);4P0 \9GV/.
M9P;YZL:O/%?02!4BZ8NDG#DMTT#&CA,!H6#J>6C)4H+\ VH)UX(RC+5&&E-N
MN3&*(8MP=.T"$=(O@)8LIV"@@XRF%0T8*AHTU]Y@H404%R42([H UG<.(%\5
MDVR8DP0)K:U%5-D(NP3Q*#3C$*4!9D9=*6DYJ4WT=((T(E ID%(,(Z,\BPZ0
M,E0O .A5?6P](!(&B4*@U"'I&17(2(H,-,QSSC0F$#X/:3WJV'I :1EEG=*<
M.Z84M81(@I53<:!AHAD/-ZYCKIC8AH/1R[>#OCNQHYW!GA]\*:P?"ZB,S:U;
M/]*N/_++..4BD(;&>(=PY(-><:5))!\.6Q6U!.M%R$FMAOB>)NU4.QP@0I@S
M9*AA06,K@Y:,^V U]6CQ1]].U]N.[O9/W^JES%*(M#&@E-;/(].'%BI.K$1>
M1W(9#1^ABS\ YR?!IQF#RG!"E'2&I_0[4KH!E,8O'D5%68@\DY](\'\&1>S*
M3G^XE":0>HZ-9M99*2DW1"MKM",AX$ <U$^QM'I!Y?<TXP_[$(@G01DDJ55*
M4R@QUR)82(,7BY"X]Q/Y?=#'48+]SC*.ODA<&+%.>X$EA9Y(:QVU49A<6J&0
M7_S1-Q_I/9'M$YICS#R$L2_COYJK.! %"@P3XVZN8K58TGNE.Z[?Z3]"&/GI
MQQ[43A =_01+,24,JF@"!50JD!#]>8P6?^S-1WI/,_8(M5%PP4N(/:4LJ*"L
MPY I"K$(=!$R87^&G-M_K[>V/RSCT"/:02(HQUPQZKB60B@M'"-*1 1U2S#T
MYB*\IQEYS+GD*C!""*3,QY%GI),ZCD08?7FR!"-O9W3H!Y/C2[F,@!II?."2
M)[H9QYR)3I^EWG-N V=CIWVQQ]\<1?A$HS BID,D6D#DH\>@35K;PT)T^BB$
M0B\"]YQ. *4J_#MAIG+K+(7I=SK:] =Z5'SQ,Z>\]LX/=&>OJSN=OT^&1<\/
MAUOQZ"C*_&"@NS^3^2_HU[39Y>.6$1V@-A+A(!E649D"D]Q;$K#A#DN'U"*@
M0U:M:J(6LB9$PL"5$A&Z:#"0<TAA]):E-,&2ZL]N3S5BW?[GI!@69<WI"YW:
M#GXTZ!O=>]4I>H75CQ#V>/"RHKURNY;O%/X]CA^G-[CUN@SN-9=*<!THIT(+
MQ9 TQDL>!2Z4&]=-2V5_2;6*+H[+_I+[]>>5J+JC,)(IJ#BEF'!C W8"R?A_
M,%R9L@<X1%4K.\G'6^D\0 _@.,"9-(YHA:BD5JM4WM!@HQ'6CKG2B @T,2+Q
M X$5Z(I+""D NBU"EJ<2^  (J;4UGDE%N4U[=2F)*'3Q!T:Y46P\([H@O*XL
MM)\L\-4UAL/1H+ C[Y9V\7U0AA!CHU)'\6&*M%5&2RNQ<,AS A>(055!B$_#
M5>ZS1T5%A=A*>Y;MA.U>67#[1%_)P-LH!MZ.?AHG7BB=>9J!;[@U,,W!"LNI
M"DX23^+PUI';<L3(I$X4I(]O[.ZJ*LDI>=4_22N*CV-/G35U=S:>\J]^[^!_
MXI^/1>]?7G=&AV_+K?VV!OV3XU?]-T6WB&)]9+(+Z8R)_15RIIVG4D"-F*)1
M6(IZ[: 0WB%M*-,3=*93=)Z#M.X!B/3V@$@?AII@BRUWB/EHU-)_Q@6I H8!
MALAW#9F?<C^5YF"%+?20!&M5[ "H4 C1AXTDWR+(O\U;S%-S'GB<;W7Z@T*/
M![?U)Z/DP\XA?CI_99;,4V,@X=$MH\Y1S1R)[BK1T5/A$*KJKV%Y4_2B37\U
M\*X8O=:VZ,3&S4CR;='K:=OQ?^O>STSMK1]YT\,NK/N7?N=+T3NX?-)#/7K#
MF]'WUKS-]L2"+,K!AB+B<2JV9JD7S&""D0A01ANDK'23TO+1L\SJ5U7UF]0N
MB7)UW[;I?%0*) &" (D'4#_.L1(<.A8\I,XX#95'F,8?E#'2N8Q^U5"_9*UW
MT\3$^&GI:Z/H%=V3;L;5F^>N*(Y\3*39;9:"L-I"0J,B!Q>P4UYFQ:ZN8NO3
MK-C?CRQHQU+1$^%%B@L+&7U5J#4A3$'L)%R@:-3ST/"GU\.G#X<)9C'743\M
M5!129H(USG'J""4(AW%ZNYQ. LEY3 +=5VE_/.\[GW0_>?L)*?E@$U*""Z0T
MLQY!35T4IT("06Z(@]1 M@@QCRK)\$F"'3 XQ3PWPOI I6;2&ND59-I(&(@C
M"V0\*B##I\%2%3Q1<20Z904E-"BL8- >*JDQQ9Y.(@8(X2RZ'SC0""#\ '1,
MA^A/>.B\DI9BZ:27@7F#)5%".\ZGE@T14/4] BLPHB:"(;>T;/AA1A0G$&L?
MI(U"HR0(0Q1#GE >)&/1S'V3(<XRO+4,\9QE"+5%(=Y1$1WYI5+1'R(<0^E\
MN8M2];?HK 0J/M1>+QIQ'Q03<1!1*K&&!*8L&"B<%.3:5IQ9+#_EBK=/>WFH
M$06]#5P&'<F%+"-HGD(6&,<N<+<0-1*??D0]7($I@0QFV@JE4/2?K9<>,1VL
MA"FSQ&);_7CFDTOC(4N)4TH]]!(G:Q,@CF)0BD,;&.(BCI I!\\N\$\X^(-D
M8Z@0/$;.$ (YC1"E$4;6<QCM#PYL7'P-\6ETB2^N6!I^=-@?#?RI?O0Z7OSV
M(2;^8"$FS'"JM<ZB8RNH=-P@#1D1),V,2PS#<Q3DK9]8A63+IU$;&KAGC"D#
M$:'*0H-M_!@=-XFDA$(O351K?N/_B:K@!&HD)L)A!:E&3CFG>!2BQ210BOR8
MY"PNY7R,8;]W8H;^/R>QF9M?XE_7 >#*"8_,L!ZL0CL7#AHNA2 N;:ZEB?31
M(7'"<"/#Q*9'+CP>TPBJZIF"GV18EBL##_PDC=KJ@;]=]O3M-6.ZE=2>]3T=
M>_Z*7DQ^?=T?>*OGL!]]6E9W*T")P*,>R#)P(2661'M"J%->RU3B-3)$):6&
M/"R 9:B,%NW$?M>CHG>P;D?%EPAM?CC9K^N*7HU_W"B&211%[\2[R:7]WE(6
MT8AL0V$1@@E1Y%&OHJ-.M#',Z0A@2.(%6.3U2$HVU[C70XDS\@T%0\0,1B/I
M,%8*"J,U8E! 8H*M\#[5U9'BHX3 %#9I 55 1 ;*N#3(J+1?B Z!V"#=!,QI
M'-K3#U634'5(VU78I+'/;@F;LZ?^TK)*%=*B<$<LH193::D1F"&GC7/.3R.:
M68JW#F[."N:VX^Q%!(:!'_9/!M8/QU\/O79E>USQ9>W/^->$2TG"O).:8(Y2
MYJ&!:7M-3#3VV$:"_BGAX<4UP]%9)TG$%P>'HY>4'8_^^%JXT>'+R-G_]Q\K
MET[JZL%!T0.C_O%+A..)\>CP6/?6_C2#%_&>X\_C6U][0'H-H#O%0>]E)+01
M^OZ8N1N)-P-1$T \::#MZ.7PI!L/GTV?,+V)T?;SP2!"IP,V%4I\.3@POV'&
MZM,_-;@*?_]C?.R_8/G?'R'V(0BZ6W3.7O[?5E2/8:WIO]9V^UW=^[_UH>X-
MXZ,'11B?."S._4LD8X/*KU_'_2+B?2(L>S#I)X3+SGG?W&YM;M3V6NNMS;W+
M'?##5Z_X:^UMOGJ_N]W:WMRKK3<W:IO_?O6O]>;69NW53J.QO;>WO=-<@'?%
MMWO7C^M[_]IN;K5VFO7:QJL:AHRJZ=L]2;OAE7;3F]O]?_X+<?C''>1P9;A5
M7 5?[^PV:G]&E.OU>\V3;KR+K4W <->'Q#*LMYY[3I/$TNZPR$A/(.5.8,W=
MC76T:SV=K(_SQ<N-OBWS>Y,Q6)GLNT0^G)F-_I<W>/=+FS1.W-'FE_TM=;1S
M](XVSC]T]C<.#QOGV[C1>@>;'YM%8^M#=_]H_:R!-\_V6_\<M5NO#]^09J=]
MWH<[&PVT__$=;;<:9\VC3=C<^'#4/OJ[L]]M?VT<-0\;W?=G;;QYVOX@3]_@
M_;/V1\N;YP=G.Q_W#]M'EK5;AY^;&YVBN;5]NG^T37<^-ECC:!W'?\G^5ON+
MV_I W;_^Z>SCSA=SU"<[&]MLO_NZ:)YW#G>VWL&=C]NP??2ZVS@Z8.WSSV>-
MC7;\UWW>[\CX>1M](H8%@Y0'UC,#:) ":!L@\*G8DZ;.*:%6UA $[TI;<R&%
MM=IW=6Y&P]@3:MC5 ?0=#?NMH0>?:SL]__O/7LCT1Z-^]R4?O]-(FXZ_<D;'
MA]%+?3+J3T?9H'Q2^8OI#Z*93N_<T<=#_W+ZX8^9(9JN'W\O>HGPO$SOX(KA
M<4>?18I0MKY\[L0V*[4JH"C-\R@R@)&;MF=BNE?'IOO%R%T_2%8E9]\__,-K
M?WA0X55$;GOG%V6[QVV//9($\-<*69E><:R=*WH'I2[AX],_IM\GHD@_W5*?
MKO;R%S\H%TE/?HL/^';S4HHH]OSTA[$4T75=_H&9H5>U]F.\4[K;\)*^7E;S
M6[Y+;,5#(V+H#[IZ%*\^';TT_7['1S(Z./$W0>6[D^AN^$'G;-<?]P>CA43-
MUX79>L^;1^_.VMWWL4WK9_OQF<V-@[/FUNNC=G?SO+FUF]KTN7W>.-__N#VY
MYD-\%NOMM_JXN?%/L=]JGS8V_OG<.'\?VQR1-KY7;#/<WXIM_+A[U#B/[].1
M7]^TUD>-/7@:__WDM422$P-P$ Y0C#1(N0@ 2D00X]I9AY-55X+R/ZYB[C>$
MFHRKQ1@Q)9P^B0E /S,!8]_FW?OUW=;F[IMV;7?S[<YNJ_;V_>[>^_5FJ];:
MJ442W(I,MX9(;6>WAMAO[O?:SNM:ZU^;M1E^_(T;K[]JI<-($7K%$_H&=R]*
M"+\K65/5-Z6O^X/:Z-#7_C-%B-K8C:WY:,W<P].X6=!R*>P=[WCH]-F9UP/?
MNPF[WI;MV1Q'0182N>[-]TAL/X[GHV8KHESK,_P$-8<<(PR,IQA0CP+0''F
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M0V&DDF;N)9:Y5[9BQGV+@H\2B:?##!6W@(KV-ZC 2B@#!0'$L@@5AD5R[WT
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MV>^!*=,N<OKU$G'HBWS$?L]FT+\[Z,^N.>1(LF X!T'@ *A-:8E,"^"D(]I
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M_\B5P7)48GZ5P:92?I.$O)LZ82>\'X[GTC*ZWPG=WU\PV]8!^^00M-Q##'R
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M)*B.YY+HL/2I:SF=.:<S+[]E>+)TYFP9[FD99G?T._B$A?1*!QO-@=& :HN
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MOUX/>K&AN5+"XC/7J4PW)R)=M_:D>]+1(^\V?"ALKH5Y1U0_F.6RW'O#K:#
MFW+.TW*0ZO\"#J6&VDJBTTYPB.&Z$/.H]K[TBX&?.I<I@^ B$MD,@@\/@A?4
M5GDD-)4!<)$*(W#G@-;" (*AHI9ZJU@*Q]4QE'6B,@Q6E-DN?TV$X7<3AG.)
MA.5FP64,8R+Y\<J'#/AW OQ+^Q]33#VTW ,K@@742P64QBCR7R:Y#9PP3\M8
MAE0PHOX\JN \[^6_SS:\^UP1\_$I<T;,7T?,"XK,B.8.&@V4I!!0XP10 E'
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MM;*6ZJ)+6?'X5=4Q-<\!/'NPG&.8/X/E0X'E!;NWR&@6C1BP+D"03!R0" N
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M2LPZ3 W=K')>F+KHDN^$EC[-YNM.YJM]X6L<K>-/5F&D23);VF) M<! <N:
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M?7<'0GYK-F*[^JZ-]>T>5Q&[F[%Q+F+7=M9>[% 3" M8EAXQ[AWH<,XA1:E
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MP:HLB#-:FBPR660:(F- ;;.$4T0)J/[,@#:G<$D0XTR!;4!+J_#&5HF[A8S
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MN3B83I^]TXD>'?4&%=3KZ63X:_U#U0GIE[K7H'%]?3KVSV8?+K!0^MX;.#\
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MB+ >Q>N[G2_'/7N<3@1)&8V]'\23%GTSO^E,B.K%LZE5BWO'-X3'!I BF,:
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M%2=?E*=#;X\'T;\<#>BY'__5X=R=/A/=)@L=@?XS\]Q$DHL5]))+(CK*8D<
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M#5U7];#FM#D>/VGR/MUWM;X;G(7.K>%8AO</G#N%(PF?'XW:>MCKQP[)\"A
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M.,,\S82ETA)U5^A&12+/0R))X^C0"<^IR0PR&;6("RE0IEF&8+>X(UHHFME
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M"9-AI3D&N88K;R5S# 0(G7D# ,5DT14-\P?;$2;KO=T-P!$F\D]ILMOQ"_[
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MYR<X-,/@^^X_H[PTOT7S4=[)X"04EX=!%(.*-Q4+X$>%2ZJL%##MP# HBM:
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M[6B".9(T% D4#B.)$XT<(6G&01+)I%][1_AJJC 5(%7*S345 0"*QG&<97&
M6'<P=NM<14WGI2'.,AZ79X"<Q0(Q'WO]HJ9G7AFWED.&N:(PSFG04"2B"4\1
M3ZU!4GOXB8!>:J14+G21(W7,6)U@63E&5AL*7K-N\C*<\J_<3?*\H%"YX5\%
MX,QZ4WSB+$"-0:E,->(46Z139Q#!EBBEK%>A6:_$O$Y$^J1P4SE2*EWC!?KA
MWY0.LEHJ2.65_Z4XLC/K<Q%.)0G."/)&A7QZF2*-B4&4I-X;@[V6%'"$XKH4
M?,4]+JO."BO=Y0F]\BM2R/)->DJP,UY(KP.WX,YR[3A.?"*H]<*FTD4__$]9
MJRH__!-CPJR;@W!AF4@\DDI@Q'5*D$Z40HD7.#$>- [I !/J@K%Z(E7EZ'AI
M".'C?Z\2(7ZU:^.:M7T;<+&,1>L7U,&OW!P/C>%M;0PG&8@G1Z3Q^5!FRJ0)
MML@S'(HAFPQ)S!G")",T255FTM#I3.!ZRI*GM3T]]FE;5;96J0Z5V^,5V*&>
M%R0JM\?K *"M10 B7M)$*XDHXQYQH!$$5)$@3$,'3LVT$*%9*V=UC$7E_%@Y
MF'G-^L>*NCN6E)1>&K#\,N7CTO5[%G3.RK>Q(F"QO0@6BEC/.0,=A64*<:<$
M4EXI)!.K#%5"2\<#YY.4T#^?P9;UL(.XJORN4DP>T:?1T'US7#HT0J/PE2O)
M?V5Q5VLI5[+H_NM!SI1D(':;5"F">6*<="31WD@LF6.&FN#F>8IJ^I6;Y_'@
ML;$(CUI0T)>L150P";J49$@9+@ >L:+,6VP2L?8NK4NJZI)?C5RNG#W/!YVW
M]A6_IU;U+#W.GVPL]V@N\%P5N'>=Z1UU@7KL=BCV&PN&;\1JY&7?Q2#6C]E4
M[@;P'8S)ML+8WW05[O-#JBGP&,41H]HBCGV*5))(9#-LO',& (7<5H7[Y9?<
M!E* 2<!3RLKZ ';MFH9K3&$M*/.#IZ;J29G\LN"]+FDLE*@_T_WAY.MI!?CP
MT=<\"[TOI@WM[]%<X>KJ5L6RGZ58=J49S0/DQ[R;#X#=UHYZ/1LJTG\'.NGU
MK^3$/YMB5*D_]S-3O&0E1W+.'78@[C+-/::@W2@E )<2(E)![;A>,L./%?9\
M59 (;.\>HL3X?'P*QV-[?#I>B4*T==&X?)_O=SZS)FVV86R@"&TG.ZWW'?@W
M"!/'3;I[TFA-[QDK1(W6]F7CTU_YP:9A^_3+C^9FN]TX.4T:GP[@WX_'!]^V
MV,&GQH\&""2-V5AHHYW#/DM!(DD,XA)3I&$/D99824L4-QY4(5$7=,5J*U>V
MPC?B7?K6ZY\&M]%9OV> B=00<+*VSEP;0/)[#IRH\AY5\#"&AT LV]U_"E*9
MP,.7,<%\#?12@<4R8#$;)(VU48XG&=(Z!<0 =19EEGN46"VHYU0Y0=?>L;I*
MKR^%7#F65@(L7K'Z=!4LOL-L;&%@>%*T>-U!;&\)+;Y.**:"BZ7A8K9 C*>4
M9 1KY*R4B!/FD#:90S111&;"9);(4"!&TK32+587+EZQ;K&KSVO <^ 1E1Y1
M(<,,,@!A-,9T45F9'H0$LY5;$H]5)K5!B2$8<>4SE+&,($&%Y5HYG87L2E4G
M5%6*P^HBP4,5!_H"H*#5&^KV"OA;JD"T*A#M><'SED"T!^-GA9D/P<RYS@!$
M@^K$A4<AVA!Q23U2#/2H4'.")=9QH_W:.TKJ2?)<UK8J2FVU(L.>?"PS6\A@
M"VUO%()B[I.K?R6 ;45$D1<@B6P#UV^WG1F.0" YZX=TJ>%%37=Z,+7+&)64
M=X>Z>Y2''XO0J,JH6:'O'/J.Z:.R7BZ%O[/6RQ3;$ XK4>H%#<ZN$!^>:)1:
M;[RRU%-GU]X14D]7%']7G<]5YLN?7<$0!'6>M]N5Y?+%L__Q5E;\>AE^/6MC
M9.K_9^]-F]LVLH7AOX+RS;PC5X$<[HM];ZH464XT8\L>28Z?F2^I)M D$8,
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M"75GKFW&EO6-Q@H"N4B QL<R 976TF=/(B_'GPPN]9XU+ITLWE_]T?"&H^Y
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M8%<:S^=A8)JS@'[#X*'<8N0<XSPD-LBIG-2]@Y@7\I(1&#M<#0;R;!*H>AU
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M6 :ZR24F#NX"%UOO$]##5K'#?H[5E!YG^!9:F []8A1=<[J:2N3FJD=,,0U
M2XN3FM7DJWC5/)(YUKP)UTZ_IKD[*A$D_:*<J/0']AWP*#NU6 09#-_%);<H
M[-[LWI7'/5DJ&RYU/<?3 V.WC>7ABK^3Y3V9\&/$N"4#?/3<I-NS0U[W3&;3
M&-C+5Y'=SHOZQ'"VV>-V0/P&O-@%H&Z(VE->7S(%00!R EL__9F#V, :F< /
M8E":ITI'3C&,)IUY&F-9,_Z89%,L\TI+T@/L?\P$PWH#NC,-]KE7PJ$IN0H7
M+B9F3@6 \^-4@%%R<N)XV-L5,QM5T;@:*G,E3'\"G0(7C&66Q"-ALE$QM=.G
M*@@R9<K6BX=U-O%L0>>S6.G@^2;WIC**I/,^3[T\%(GS9H$9JO,I+/(<$TVH
MG9<7RB1. U4_> @:1 *0/_XJ0/D8T=O.)/XHJ(OM&W;L4-$>[9+&T!=#^F"G
M&2H5JYM/,U!2I%IZL=&57?TFY_@I<B:=+R(_P>(\;DECW_81:Z1"YS>TV3(9
MI78#K?W#,+NG!?9: %-Q:G!D<\XS5@":GK"N&NQMTH:O.',8+>5$3#@[5'X-
M4M4%?IR(0M6SFKSS;5CS".?-=7^<,VU5!692S+@C2,I504NIW* ,PCD /EUB
M-PV!)6>F_(ERRDU%H+4Y=]V.<0#3)"?U=H'3$Z,<J^9R;D-"J:O63$57I;5&
MJM[.+CVTH4C+#U!?#<8$.=T'0DT_E),X"^B?>D6E)'0>F*@[ZWMQK6C%+W1/
M6Y-GOGJ&##QDT/R!.< E$]Q">H9;98V;P9W2>2Q3F<MMH[#UF:#A7AI$<(JC
M69"FIA(SS<1XG!8)N(0TV!&#$MEYD3JMF^<$6!!V*#F$WH85!3@:#/ML<$L=
M?9_$(PJ1:_ 'I\'<KAPMY]V7QU]RZC&?1KHR\X V7N Z2;$RIE/Z,5:_2SUP
M$Y^Q!VZ6<I'AT!#72Z6[W($F!/F8+%:6O,)PKJT8VA(6LR&D]BM7\)Y3!<%D
ML;^\M#2D0M4MIVK7NM@>J\V_!K/@FYX",H\SY : 9@H'#*-4"=A75%&LJJGI
MJ1AX2Q#ZF 9@9V]SK2Z]++.R\+D,WO2N437>*16+OGUS6%M-VU^7BE^533R@
MR"VJ(M:7+Y"JAW4/R&;TD=^]G('XGF'@FMDI@<"5%/-@+G&)B#\1[&^-=AAB
M;4]()?WE(IMR60UB&:EL6)G,7)2D.C:X#'BM((EU9WF#=%AVOL3\Z&&KV8#:
M(B#[7,LH4UE2[ X]3JEK+O!FBHIDQ;KMBA2M=E ?-HE%^2Y2J4RIIT2<U%CE
M)#\5"S\LO"J>5\;-6CFO'J6D''66U.Q"4[TEU9=Z.#!]%O47N&J,A()5CJJ4
M_9'UJCPN31>7K1:([7/;L+=Y@F7WLS@IH(Z''))>I$#/;0Z4/"\J\W%V>( -
M0!C*23XI:[^EYG#'V),+WW<AO6F$-7GXKH,71\<7V*R8B%0U_JO%5SB)'92C
M% Q>;,WEP%V%<D +$)[@WF2(L-37&">&!EFND#W6*N-"=YN;$!VB]A>DI'ZN
M)U[=.'FIH1INN*!.(NTQPTYO>J7$43Z #;2IWKFJD[]GG7QO;^KD=X"[4"\2
M; VD?3'$7J0D 1W&R%V ]P"EIQA9H4:^2@<<+4#T22]G;PPK5Z9OQJO=4*SX
M__9 =FPP4LZ5,D"=?PH]Q5)/C&!>,=*V8E^;3NZS+'5B,GTGES0N:]H]Z)!%
M(2BJ5G9KTJ"DK!CU"Z2-0,TSM*$7:*!Q3[%45D;$0]9>K_07!<C#U^62XHWJ
M;2A&,N23H>X[)7NB*->.68U8U;>K@WO(,6;RJT"O=EIX]%-L:8>L!11VD>%D
M)$U]KJ(G;3C02:I&B^RLI3Y7NK27*$U7U"D38B]4_DULF^PV;D<!?$G%"U!E
M1[>FVO\NH(5S$AG&BH08;W#AVKY(I8.0U:T5$:O9GJ'KNYF02ZW[UKJ:UH(9
M10UU4'%HKH4O$^6>EKY;;BV YE4YK'?]\E1#$.U^V-C:PUG'%94MO,:?7MHU
M?0";I\#6)-A>C%-EGYK+U$HB%/4[]-Z$B( YQ^ P8K3 YB-F0FW&V.F,)<\+
M4?GO*&U!(.+R;A,D84_.DL] 99YA+S+V<Z2*0<!VT_7[U>S&1-7V(;"U@3-\
MU$9R$235OB[N^^CE&(0T[1(5N,JR$\W^XXO=8""?B_A;D*&CKVCW:).QY?"S
M.N_8[H,2"!CUBJBJ";\ND2F'GPTN\I!IPR2*8=&P+NT2KSN'!-X-OIJE]I[7
M<;%-#IU%;9,[QSRPSAT#6\=XDT(!T\W1.&?B9"(BU?5)=>YGIXGEC[$__[A^
MF3V6[N]LWK@<-]8>8#L(JL]Q&LQW1.Q;5&O:$UNAQZ5-8U1]*L,Y8#3WR[*J
M0"_C,-<)#793W36>>46!-(!S#?1X)?BM0L[SPJR@/UO*T=0T$[815P=1M69
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M\>F%\^;X]^-W'SZ^A[_/]T \;]BLB>;=IN#RD=;:KP\>IN+\$8YG"^K!3W%
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MS>!,8\OQ&ZSJ@GT6!\NI&Q2H,\"Q\+PT7Q/[T6W 3_0*+J/)ZFA0-(M2^@=
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MNFGTD79.+;.TKG?ZM%NX?L&.O6(S<">[9D2%@]W_G2N92.>G0;WMP*K"((Y
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M2-FS3#B T$DNV0W%82,"%0@&T/JR0-IF>SJ%%]3@P&;\++]XQN;ZI_IYW;E
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MSXMI2"V.987=CK@%QD^MNIG(2HO#I499G"S4E_K%O%:!DS1#FMI(4V]]^(K
MF?0TJ;[&H,19JRFOTY=S^%A $W9=')(+I*@&P..7TJE(9&TD$$8XN1:>XXOJ
M'0#%#/ 2M@_'V-'+ $!=3(.4]RT2')!;#+>'38O2.9M=S\7"VK+]MB-S4/!T
ML";J0I_"#:N1G_ *Y $T-QA/.H@R$4T">+L^G:[U>IQ1O.[ X6WC4-)1X;OA
M*;,H@Z"T*OA"(N<YH![NB8"6FDFM]AC@I>.!-P[,&^E-&K6MU\%[TGR4!GY
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M!C_@!]+Z/6EV8_GQ-E/QIVO.CK#L"G#,(=PE10O4]C]!84!HQY%<@[&N.DW
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M!A"&0XW2CF2R<^=31,[$\\RPNR7F!M@.K]0,TEL0<6)4D!EFN+!YI%8'U^N
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M/%^#$ZJ%;@.GAPNS$>*B!0(FH+<@3%*>(34R]S8IC!5V;"=V4#0>-,S42T
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M/:.8GT9^K'G"Z3B%ZH1,^<V8!NA"3[TXAT;1.9YYD[C)DXGE<%1"I;>&;XM
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M7+>]PE_;I1T6ZY:[ U,#.)G%DC,D^!6\,L1B09CNQ)^E[+W\P[0IX/ECT^B
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MSK5_/PGOOT/A:UN%SRI\=F16]+ZPZ*T"95FU^/O4XKJ =UB%SRI\/U?AZ_P
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MQ$#X+$'DIEN.K)5DT<78HD8[4Q=3((9?!/.(JZ8#E\A3U?U^C+$4Q0%8R]&
MC*V1:0 <]V!2/(<FXFDEF5H15RMD>T M8>,^XM"],98$%-X\A,OLS7BJY% &
M3^O]DI1?]AW?N0$%&]Y"&M<Z"H"ORWSH[A@(R"/NP;S?QQX3FPG<PD+-OM"L
MUUOY?&$AV&)#:R': MG6DG KE&Z]5_(/7I( K(O$^,IC3YMWA05G,]ZM>OVX
M#-Z*OZ4%'/",[,*&GW\&1,XVB^6<JQG'XWK]I""."L:0]QY!>,M'B)*_M1:
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M0RE:XCS-1$GMO*1.\#8I\G=#NZ?E^6=:M&HIK#61WD$".%F^7WU#:ARGB?J
M8E IX3(:+ D\YO)TKJ(.#7'6R,W9#>\]L^[_S)2KJMH'.+#=>':E4$R2J4!4
M2,7>S(%XW.:)53E2S9/BJ4E1Z9IGE-L+;?DBX_6C_O43C-\>;+WP+)- I>)6
M9 A+ E49M"(!K"762B8339#3=@]AWJO;QWD(NS?#+KV<V4Y/-5/.KT \>].\
M0(),P64G2\U.5B(N8IT(ER.GD@?@JHDA<2NJQ^#XM*16?=4-_=(5N)@T./34
M(/A2JRL3+[@G(4B;6'G\X_%>NAJD.W4@^CXT5QJNHLM'D[\]E'YQG4].^JR2
M(,9I3:0&-/8U"X3E:#*3ECIH$KV\#\A'<$+P,$ML);TVN@A][D<LK_>.=()2
M4<P1;6!9.Q6(MU(2X"PSX"&9-M5E;@,UI$O0#\BL:GIKO89]$\;J+#::<@52
M**)B#(@-* DR,K12:3(A4(-NX@%7KROPMF&7_H^T#?=69D.B'<4X6RQ3WB.,
M/RU/D2BP&&F4A*/]BLA<PFV\O+ON9!!,<QU%$Z]^&W#;D,S\1Y)L3T56H]C+
M+Q'Z_H/_LKYZNSSU/_8=_.27%T-/RKW<U=J[(=V52AL#=9GP2&DQ(24ZXAQQ
M9Y]XTI2FV&2)VPOU-J2T_P&D/)SJJ['U!9QV$,=+4/C?$UBJ;9HNV@C+BOB4
M,DY E9APH,6E<9IP!3)'%9F234BY#;AMN.?^_#9==3U68]AO4UR@)^-_0_J'
M'T^+S_UF>K':13#.:).0\<DC*!]=&3!'UT4"!QJR;5-Y_ Y<6\60Z7_ HE93
M?_6J.VY<54>6!Z6-12PVI/*NER>.<4ZBYTP9PT.C\,9F.%M1Z$]\#E%1617W
MNPQ=!^FF.BG14I"1!F*8$D1R*HBC"DBV5%"?,G5M'M^[ ]=65!K>[:T&VUP]
M]0V@S,TLKVI 7894H\3-><N'*V^S>3#U7MQ^TWWTT[4I@_^,"\JXG^6W'?38
M^6K!W4&,6[1:4X3W'<0AQ?<651J+.]=$C.>M'U:<FP=U2+%>_,0+F/OQI)&$
M-W5T6&'?.=1Z<K]@@HZG5XI2^+-RTU>NGNP@]5VZJ2GSO8?YH!+_4'X\E-S7
MG3VP]#<-^4%UL,>2LT=O#ZR%QHO/2]]-T:CMBS?\%KJE@[.+@#>V4U-T=P-M
M*Y3=%X!;6FLMH+93>%./>\S1VYIK+:C;9]E^COKO2T\6TM$G=!P_PJ]+8&_R
MB_%D49R.TGW_9C'OYX@5<8V<"<P%H4DL#Y%)T)%8E]#]2S%8&9//NDGMQ'OB
MW#=^<4-WU_HIQED<>89NKY% 5&2.2,4XL3QEDF0PB5.O'6L26[T7RB%EZ[9D
MW=581CM55HN6;81XDS".TO\M5MOT*%%KK%:).!40K,N)A" "4=QH%E3,6C9Y
M=VE'O$,JC?3@#*RLWH-$V6[9G#[@?K3PD\I;ZUFK!]IA-PZBGDFR?K]P)_OC
M_+LU1;$94/T![VZ>7FFAQ>#;FJ%GO>QA>EYMHH40#A!%.KO:L:.#?.EF2$6/
M=R.L)B/?+TISN9%&4F@?55EW]*OO5D],[1DVN:FY1O*Y'7832;V/QY 6$YCE
M"[^L([5;FVXDP>V'4\G!/>OFZS^Z\L!L$EJ75^V(46C"2>%L*3&5B(DRH;4O
M@I"-DDXOPM@_OW;=VCO_^1<_AV[L)_VO,"_W?WOH/I6KADIJ'ZDD-"Y?(M&L
ME&53!"W5S(4SUK2Z4'47M"$YHGNPXWJJ;%6=U'O/O62%GX,[1_9^<7HZP;E7
MJF1!N3V.WD</O^&,ZY;E5CY.ESZ( 1>DHIPPE]#OR08A<Y9(2M'P"%98QUK0
M:"_40W(T*S+L<)JL>!%@C?95>582E_[ER\679X5/P3E?2O]Y$\N[Q>A50V0D
M6\TD,*FL:G*%:0ML0[K'V6*IJJ25^G1!+"-N5!).:B),U$1*4"24.AF>LB"Y
MC"XST907"*+>@,[O$XZD9RKZ1%&4)2O/*Y1LF9)1>">9H<G:)H6@-F 9Y%9\
M7]W?R.X=95Z?S:L9JV@2*DM+E/6(P2$:7)$E48)1Q:QAQC:)UMYF>@YD;ZRF
M\OM+^B"!T]?E[M1.[MKZFS6]L4U@ZKFNJ]9WCW5<^G[]8;>-<*SZJ!'<N*&E
M^@(Y5$ACU=ORS[>S?KQGEMXMK=47T=V@:XOI6Y1D^?.%$@1G%8WQJZ\6^)_P
M"YIP)XN3Y>=*O;GQ*H-G;]G6@U!?(8W$4RGB]!KZ'N!;_:>+$+^>E6U[L8!1
M=ERDS(%8YP3N>,X3RX(GG($32E@6(V]A$&P+<%_[Y]9^?BM>ZO(J,:35A<ZC
MD_+3R,EDDLV,L%Q>O2LU$CPZ.\0P35U2&E2;RI8[H1V2 =V$=U<MK?8ZK1?X
MV@QR)$+B4D D6IM$I/9H:$IT=!57RFD;/- FV3HWX!F207X0"M70RP&M]FJ;
MS8@-8#=&$ />CZ^*Z- [LHM""T\C88E[(C-UQ(GB/::L@J&6)][DT&00._*%
M?OX7?/?A\VSDG0LJAD!BB.4F.\YPFZQ'H41N'(I*N\/OQ==Q/LI=^#Y<N]<N
MO*<>J^V_VX(\RG/H"M)7Z(6.O!969<%+B=02NT%3 :T'-!H8I4D%"8DW.0W8
M">VCW+L/0;S==7IP^BWG"#()1M%ZX<%DHE@R1/(HB-.4(V.29$XRR>!!J7>.
M=$C'4H.BW6ZZ/"SEWL&)'Y?#V5(3L$?E%= C;U64.B>B/5@B8[0D.!21,3AG
MK(?H<Y-#H=TA#ZE^Z'!(N+]V'V0!?#5;="-KE*8)I>$51Z>NO)MCA082HZ$Q
ML)1DFUJB]P4ZI/JBPV'>KIH\B"N]S+(_GDU0-_VJ? 5^Z 6$^2XN\<V-U71M
MMX1<+_1_8X?7_V&/Z/X.O1Q$JEL.\@#B7OV_OH OMGL0D=XXD)J)RNL"0;LF
MMG_[>MV$XQM@-1GY_E>@;FZLD50.<^'I^6R"=LEL=;Y\]!'M\E7-OQTD=%-3
M=>LN;0&WGG2.4EJ>*)?B"N]@ONBFRS(OL[2(\W?%=-E)4%NT6E-F]QW$(<6W
M>Q+*UFT?5I1MDU?N[K]&8LL.O1Q6R(=*B+D;R<6[,OA1/SDS]?$;EYY$;:J.
M>Z,XK+KV$U*E Z:?%GUY-;1_/CL)X^FRNTM]?^C\M%^55&0CKB(P6YPS;G+)
MK([$&IV)+D_S02G:&&P+-_L^(*M<.CG3Q(?9442[M(,S!-"/<N2>!J^(E@$]
M5"HUL3D$0IVBF6NM6&AWK^068$,Z2FK&JHT72VIIJUK\ZA9 JS1?DZ@4UI<G
M50,GTI2G+;BB)'&;A;!*1='DM/8N8$,Z%3H8AZIJ:V\.+=]FO/!$Z@UOB2.Q
MA9+*<9)<*9++2M(YDY&4Y_/PWY+WZ<XM=,N^AG1HTYP5+>1_D$#EW0;'\V./
M QE/#V>!W=KC8:VM[0?_,(;RVPXFXQ.D=/?U[?I-Y*/)<IDXG)F\%8:',I+O
M+Z"*$==%Z.%?"UP$7G[:-0YTK8VJD=1; ;83Q#[1YAN::BF6.VFR7IK+'P$)
M]N-?_A]02P,$%     @ IXFV4$(<<\E8+P  0N8! !4   !C<&EX+3(P,C P
M,S,Q7V1E9BYX;6SM?5MW6S>2[OO\"I_,ZT$']TNO2<^RG;C':YR.E^U.SQM7
M 2C8/$UQNTG*L>?7GP)%74R1TB:Y0<I*5A)%X@7[0WT%H #4Y3_^\_/9Y,DG
MG,W'W?2'[\2?^'=/<)JZ/)Z^_^&[O[][P?QW__F7?_NW__@_C/W/LS>OGOS8
MI?,SG"Z>/)\A+# _^6V\^/#D'QGG_WQ29MW9DW]TLW^./P%C?UE^Z7GW\<ML
M_/[#XHGDDJ^_._NS*,6H(!WS$ K35DL635"L."VEM4X$K__O^S]'KE+V8)AR
M!9F&*!@$P5GRSDL.F+W.RT8GX^D__UQ_1)CC$^K<=+[\\X?O/BP6'__\_?>_
M_?;;GS['V>1/W>S]]Y)S]?WEI[];??SSK<__II:?%B&$[Y?O7GUT/M[T06I6
M?/\_/[]ZFS[@&;#Q=+Z :;I^ #T^+ZZ^>!.-^?[B3?KH?/SG^?+[K[H$BR4]
M]W;AR=9/U+_8Y<=8?8D)R93XT^=Y_NXO__;DR87D8)9FW03?8'FR^O7O;U[>
M1CJ>+K[/X[/O5Y_Y'B830KQL8?'E(_[PW7Q\]G&"EZ]]F&'9BOZRRQ64J7#^
MO;;V_<&8/A"063J/R.A5G%8%'Q#CIM8/QWS5%LM8X'RR&!#Q[;8'Q=N=P7A(
M =]J>@"TRX;8&9Y%G T)]:MV;^"\!+F.L#9)TRA]>@+3_/$#S,[@3ZD[^WX)
M\WE'\_%K>(_W0TP?QY]9G5BYNAC*_W[]Y1LXB/#Q=%SGD%?TYZJ%^JS#$.'G
M!4XSYN^>C/,/WXV3U8'G^@^@5D%#4C2G*Y%DCBEF/=J(;5\9T8.G<\STR[R;
MC'-=BY[!I$ZS;S\@+N;[">_>5@>5ZFY]6!-WM#FYS!4'R34 ^*02& C2BR)2
MP=%NO6G%PVN8D;GP 1?C!#T6B7U(^?H11V7HCMZMT26$B0)XEH8'K0V&S(,E
M&T:C5U&5U(.NK?T<D+NW"_I9#;QY5WZA)6YI><SIV\^[LX\S_%#GY$_XDDS$
M,YQT\^&&V<X/;LWS89)88]\ZE"HDD,A!%ZVB-"7FR*7TA<:OW<S^(3)II!//
M8?[AQ:3[K0WQUZT?D]TM?5JG4/AL0B[@ R<"8X#DL!BP@CLB,]Y/X<;>M>"I
M*S_]ZWR\^#(\1U<M'XV?S7U9XT9'RQ4F#=PXG5T"M-D9;Y,(&M6]W%P]HW;J
MLEN3+GWUR$G=AG57=N,$(DZ6KX[.Y^P]P,?157LD!WQ)O\Y'&HRT7CM6E!5,
MI\19B.A8BO2. 9&X-QNMSJ7%66 >EV;GZ@ED?@K_/4X6\\M76'V%<;':R?W[
M=B@7C.W?.9IE:,<_QQ_QXO\OIV\77?KGAVZ2<3:_D-^;;C)YT<U^@UD>Z1*+
MUJA9D,71CCT[VMA#85*B#MF!UCJTZ/F..+\6R[4J/YU="FBU>]AS>U'/1 ;5
MDD5W/%XN=(/Z]]V3;D;-_? =/U2-;H.C#DS.ZWG3ZVZVE/QB,1O'\P7$";[K
M_M;1ZC9=D("IQ?<OIPN<X7PQ,E)Q&O29E6"I%Y(;%K32+-/H%PC<1IW:C*LA
MX!]?Z9IJ27=RBF\KJCA44<G$.NLNI/26%BR<_W*^J,=XM1LC4!RMXC1@N0+"
M%B*)1W,64\8D%)*1H%JHWUV@'K=2#4;';561@\QI+^?S<\P_GL^JFN-LW.5?
M87*.2[#/8&EYG'TD$V1IPX\@!7 6+%/:!J:%-0P""N8TIFQC"-[&9O/73E ?
MMUHUINZVLJE&RG8Q*+9 CMYP%4UDU@.-#T,C!50V3&9JG_J3D-LC:MM=6'^7
MZC88>;?U30^B;V_PX_DL?:C8;@V3D34Z^3H6T%3KU=%O8*)E.I@ Q><DE6^F
M77<A^QWHTF#$W-8<TU)S+C1^!""#T%XS+#HQG85AT=%<FNO.IX!T(?-CJ\X%
MM-^O[NQ!S6WEL8<JS^M95\:+5]U\/O(R&!>28:[XPG14B@5%OY5BBD0>HG*;
M;^X.5))K"(];&?84]6W2W0,Y'!"B1&]S8N S)V$@66B&2U:R]P5C!!<:';H-
M?S@P\,:U>.LQNT2*03MK77*F31*9%=(K;T7D2'(Z[<;U@&/7=U6LH\)+L8%G
M)A-$TF%+0X%(9X:+$!1FJ7.3+GX-8\ IXX9S3?/3Q -DN>D,YLF%J\2?TZ2C
M5>:'[Q:S<[Q^D70?/R]^FBP?^,-W<WQ??QE,'2Z&8+6ENVF]@'GZ>4PS7**5
MRT;/+%<T-^@H:5F+F04=J'=:VNAR4^W8A&I 9;G#Z^D.Y=F#[6V*<[#4&YSE
MK6'Z<;D&]P(U6O/#&E(E-J(:TM38YDQVAR(<SE[72O1'TPLR>*/FI/?!9=IP
MHR,C2*K,D@<9A=%6:/V-Z\-7SGJG5X==)-[VJ/_GI5T^4E'2(AD5*U8@TRI'
M%BT!\J'.BB7Q;)H<S]Y"<OR=QP ,;3^ZWT.\#>X@W^""^H3Y)YA-R?Z<KU )
MIW0I8)E/QM*VP0CF.226BE&F.).+;;+/W SG,3 _@* ;#/?-VZX5-AY\@:QI
M!UQ-YNJ<QR)DQ9RUWIFHH^%-+I;O O485&$PH6^]O_N/[]?$0SNB?Q[J9_7+
M[#U,Q_^[/(FGMY_!?#SORFO"3F*YN+#8P\>J1ZL#^E?MVH<UWZK@O"=V!8U,
MK66TX%!9!8)8*1)]&NW6FU8\O.XFXS3&O?P2=VC]J+QL[M.Z[QL&&H#6J20S
M66 )O'?(/68KL\34AY]-O6O%T\U/_%C7ATDCRC8]Z*CLW=O3-2)=%LZJ(!/G
M-,V"\CI&(SPF'KA,SO4@\IX^[\?IR^DGFJJ7/JSC:?5AK:O#)YC4%^CC/\/L
MG[@\T7R+Z7Q&(MUO$.[SF 'Y/+B7Z],F<>8M6@^Q: @EF)QM%HH;KK1)>G1@
M?X_&Y?)LZ%B,KAYV6EXW]7B-W5R*P6BEX$+J'%P4-DGP 2"&6/9C]W;?C\;Q
M 1/Q 4\[+<M]IF3EL&Y1B\G5/$TIA")YT4(%M#$HV(?FR^<>>,J=/F ^G^ O
MY>DG:JX^XD4W>PLWGW1])2"Y$TFKR!1MK5@-0&'UNH=EHXHNI+PBE2:GWKN@
M/'1?]VX&]3KINN615BZDP)'EG#336GM&*VMF1*>(,1C(L<DQSBTD)_ R;Z8?
MZSN[P\3>PL6\1]<O+CRDD,HGB4P69PEH*LRK7$\CO!$9@A:BS6507X1'NT4\
MFK:T(>>AW#V^@/%LZ7OU[,O5K_\UQADA^_#E%7["R?($G?NDK2R)Q"85TS8C
M P6<>1U4X2$GE9MXS/6#=[+;R#:JT36GJ,$9Y16TGQ'FY[.+",+;>%<'<WW
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M[STSM,FAC:HN#!RO8;(\!R]T0*=[V:T' CF^3TE3EKL3473<0(>:%&Q*RGE
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MMG'Q[8GOR&DR!J9U/0=! TY:Y,KX&F;^D>RFZ?O7.!MW>2F@^4@[8<"K6B_
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MFA-]JQSLH2P-:-'5+/[/:Q@-SC[";/&E]O$B[W'Q17*TS**(]0RM, ]2,@S
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M17IT6GO=Q\6A7[3!Y5,?QX*_OR"'#D>J(%9*U0?&X %'U\\_?DC1G@RL<WB
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MNH.8M;EDB($9K.GAN2,KQ1A@06N2&X8,INGL]ZTZB.VD ST=Q';AXB2N/GT
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M254R4R6L 4GP@I7++EG63+3C93NV9B8Y4Z>Z<)5Z3ZNI=+<\=G[] 7CI.]D
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MJ\&S[4QO47A3S?(,SBOP3%?@BP'J919WGFH[>>E-W\"24O'VN>3M?0XT1E"
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MMF=N!?I]G[/S)W '>96OP(WO%98G9@<J+]H)TFM5'^W#7TMQTEZ/[:;'M3_
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M>_CXJ1W:[@W- M\5*"*B.M85+!FTD[CNO RL6<>4#%!(\,#D06H(EBV\3OG
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MS\TUK$__@L8G;OM+SX?QP'^JZ=.7M9*WWPR]/*D/&VNY?=0GU= JE]8$YIG
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MLL0 IC('B&76TR,$P (IE9>HI+3T\CZ>FVEL)^^MH#?)@:B!";GGX77T(<8
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M+TTX-ENHD==^;5DM<,*W58DWS^:;;,N3FX^O'W%<A)TQKD5>,B @S@PM%\S
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M!2U AA0TJZ41HJI9D;NY'-%Z;*7I\?9P+@=="K>S<,_@]OSU]6LP_LI=PD\
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M(K_"LER3)5.$F%AMRBAYIC#*V[*C85V+_7#< [5&*#I2XAT$J+].YXOEQ70
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MC[#,$U5B40IK:]Y2*W0R24N' D*@\MD&I523%O*/I+,3K_I 6'RW\]AP.NH
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M(3=.*PHC>#(0.#+0]$)#V&+2-LDI&X3Z8^W@4434(0VSQ>ILB>])HS_-:EL
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MQ:=(N-Q0<(E&*15Y\26#M<S6DRQ+>VD((*WBPJHD!6]RT_<04<<:O1W/WK5
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M2L(8%BD3,)02%"L<O(X"A"Y!!LUU*$V!"=,MI>-12KT4"2-LWONHAY?L[F.
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M,C R,'$Q+65X:&EB:70S,3$N:'1M4$L! A0#%     @ IXFV4+)(R%CH"
M!4$  !8              ( !( D  &$R,#(P<3$M97AH:6)I=#,Q,BYH=&U0
M2P$"% ,4    " "GB;90#_XN2Y0%   S)   %@              @ $\$@
M83(P,C!Q,2UE>&AI8FET,S(Q+FAT;5!+ 0(4 Q0    ( *>)ME#LGU->2( !
M *>)$0 1              "  008  !C<&EX+3(P,C P,S,Q+FAT;5!+ 0(4
M Q0    ( *>)ME!=N&(1Q0P  %Y_   1              "  7N8 0!C<&EX
M+3(P,C P,S,Q+GAS9%!+ 0(4 Q0    ( *>)ME#VIT4SW!L  .<> 0 5
M          "  6^E 0!C<&EX+3(P,C P,S,Q7V-A;"YX;6Q02P$"% ,4
M" "GB;900AQSR5@O  !"Y@$ %0              @ %^P0$ 8W!I>"TR,#(P
M,#,S,5]D968N>&UL4$L! A0#%     @ IXFV4 P3+>D_D0  B L& !4
M         ( !"?$! &-P:7@M,C R,# S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M *>)ME!=AVVL-E@  #;@ P 5              "  7N" @!C<&EX+3(P,C P
A,S,Q7W!R92YX;6Q02P4&      D "0!6 @  Y-H"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6631902416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 44,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6614946928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,733,782<span></span>
</td>
<td class="nump">$ 2,960,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">943,807<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,831,274<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,775,081<span></span>
</td>
<td class="nump">$ 2,996,903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cpix-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20200331.xsd" xlink:type="simple"/>
    <context id="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0088e6b01c024950837d6835253c6edc_I20200518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-05-18</instant>
        </period>
    </context>
    <context id="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idc8b792be6e54df49d59d6e2ace6a801_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1a78868ca68246878f4a228d9e2b4dc5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i63aa5c50ea2741fb8570d7b27efeb73a_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i2251f12c72da41a0af81132111638b47_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i23db2a2a561141ce99aaafe3e6e00e5e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5f64be2406764c309799078f75eb3592_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id1a620a084c74d74898f0dd62e6f7035_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i109dbc8d282c4dd2838c55d7a9397435_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i87cfdb3f63a74be9b0a92fab69c0e221_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iffc4ba9e1e0b41b39a3adb37adc6e050_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="if2ecebde61254e95844331383fc92c61_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4880baf56e2047c6a8e04568a2759928_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i249ea7f123574d1fb56baebc9da7f0bc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1118bdd925ed4822a822302514c1ceac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2e5be467315b44459b4f1ef5a3b2aff8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iabf2ca4dfae54e8a8f2062d0b20219bc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i10b4dd6a5c2e451fb816f8e209689c83_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i37bad119d0fa4d7886b1bc8a846a15f6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2f51ec8c6cc7448c8ad928a2dd4996f1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie2b2ac84d68d46b6b046398feff08b17_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8dc21010d4c344e397eec8fd94ae93a3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3f6c43b973a9401aaef67992d1c6ca35_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i35b3f63ab43f4e26ba10e84c0f0e0561_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie690b89f8a28465da873a92d63700759_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6a74522aa1a246c6bb951c12119f378e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0d05454a22094fa6aeb2797a74438214_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib5d8317aacc149c89f316a6abd144f03_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id8abae9f8b7f487199521b9e594a9b4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if81ff44d18e5471b841b0b5e665a2300_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9cd9a66d5994c338329d9b7f23a56f2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i71a0bbed12a24e969a3fa6d2c92012a5_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iad2f0112651b4b5fa2c8fa856efca4e1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i16af1e6f767440c0963c81ea17a84134_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9b63398db6574d36a6ab44657e1020f8_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4e62ba5cdc8846b3a9cbad3ff2f3d0a6_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2eff3e3f9b184c99a40826a7fc04fe79_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i51b53cdae72840e38ccd4cf9b68c791e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i97a6225e0029425ea693f971f523bd72_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0ad73aa4ec4243509dc87099f3f6d521_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i34cec4fe802e445f9f9cd20594027f4c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3ad0374626954d6a8779a7d539793fd1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5dd88465333045ef9fb8d8ae800f1e3c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4b8bef686ccd4979b9cbc4ee66cf65f8_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i579ad134fe1e4cfabef5a5f04f4007a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0ab812f8529f40f586ec3f2b6d28d198_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1cbff9f699734f4fb0660403bd88bfc3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ea68976af4647a79518bbe864fb79d2_I20100513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2010-05-13</instant>
        </period>
    </context>
    <context id="i4ed406cf09644236bcf2d718718fb69b_I20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="i273458bd3a91484ca9e99ab2ba12ad5d_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="iaacbe58946c445c98140de58546b9534_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if9b33bc113814241ac9ba8c827d1e630_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic58199dde0ed4c74a4e8dff3dd65a772_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib6cb09a407c649fd83e3903abfc61538_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i4ade4870a15949a494ead077ed1ab45a_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i2c2c6d15e8144444bdf89f20f0f4edb3_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i292c0e03fcc9444091fffb0964c106d1_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i85e4bb036d714dd4a5d3f463aca96009_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2b413e2b14ac4e75b23217f08d1a9c8d_I20181017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-17</instant>
        </period>
    </context>
    <context id="i6629760d5fe04dbda09e1240d59bb8dd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i042b097bef654ed4ac034003fdf2d9e8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibad54c0f7e7445c781ab0aa335902d80_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i75c26a02dc094045bfcbdd64d34312fe_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i76719a5ce10a4d26a917106b3d04b051_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9fe3919ad9c7434f9290fae098a242e4_I20181112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-12</instant>
        </period>
    </context>
    <context id="iaff2de0de98c428d8e8f5eb28397ad66_D20181113-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-13</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6302aef8c83943f7b3951e346f855a91_D20181112-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-12</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i60ac1f01893a45b9935936208de31383_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1a16ef9573464482a030c11307d87377_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0ecf68fa0fa84ed4ae405f562df6d78e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71b25ac7991045ce8e15afc8083e3c2c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8444e0e8293a4f028089960cf516762d_I20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="i9ffe21db330645f5a121ce609572f5f2_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i25267995c74748d6b1a05373c4e7820f_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i4f6e5559b01349c0b2cb01a91818807a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5f4b8237d2904a1d9dd96818c23f441e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i667d0b68773d46a1a38eecfd7b6b8ff2_D20191001-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i46788283ae334d9ea8d12af5a988a06f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i81890f83a54f44bc874066750703bfcc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:ClinigenHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92b3abff138f4568b1b90d05aff3cf8d_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="ic59f3a91d3c34c248c4b7251dabdddec_I20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-20</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>cpix:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGFibGU6OTljYzFiYmIxZDIxNDU3NmI2MDkyOWE3MzZjMzU2NWEvdGFibGVyYW5nZTo5OWNjMWJiYjFkMjE0NTc2YjYwOTI5YTczNmMzNTY1YV81LTEtMS0xLTA_3ba9c003-a2d6-43a5-9310-4cef07c1ad4b">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGFibGU6OTljYzFiYmIxZDIxNDU3NmI2MDkyOWE3MzZjMzU2NWEvdGFibGVyYW5nZTo5OWNjMWJiYjFkMjE0NTc2YjYwOTI5YTczNmMzNTY1YV82LTEtMS0xLTA_b9a0fdb9-331b-47d7-9330-0500716e5c2f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGFibGU6OTljYzFiYmIxZDIxNDU3NmI2MDkyOWE3MzZjMzU2NWEvdGFibGVyYW5nZTo5OWNjMWJiYjFkMjE0NTc2YjYwOTI5YTczNmMzNTY1YV83LTEtMS0xLTA_1cfe9189-17d4-42f6-9b27-1543fa7a1ed2">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGV4dHJlZ2lvbjo2ZWUyODdlYjAzNjY0MTM3OGVjYWRiNTU2YWQzMmYyZV83OQ_46835ae2-06ee-43ac-baad-fa2f88421bd4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80L2ZyYWc6NmVlMjg3ZWIwMzY2NDEzNzhlY2FkYjU1NmFkMzJmMmUvdGV4dHJlZ2lvbjo2ZWUyODdlYjAzNjY0MTM3OGVjYWRiNTU2YWQzMmYyZV84MA_45e8b225-67e0-41d2-9721-4e6a3f07255c">0001087294</dei:EntityCentralIndexKey>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic58199dde0ed4c74a4e8dff3dd65a772_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjA0MA_be8c0114-58e3-40ca-8fab-05faba05647c">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI1_3b5fb19e-ce5b-4f87-acf0-e9f69a4dd979">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6NjQyYmU2MTAyZDM1NDgyNGFjYmEzNGRjYTFkYzMzZWIvdGFibGVyYW5nZTo2NDJiZTYxMDJkMzU0ODI0YWNiYTM0ZGNhMWRjMzNlYl8wLTAtMS0xLTA_ea81863b-2f7d-421a-8996-0813156adcd2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl83MTQ2ODI1NTgyNTk0_0a606212-be42-4e1f-a61e-261b68eef4d7">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6NTBjMTgwMTM3YjQzNGIwNTk1ZTNjYzlhMmYzOGRkNjIvdGFibGVyYW5nZTo1MGMxODAxMzdiNDM0YjA1OTVlM2NjOWEyZjM4ZGQ2Ml8wLTAtMS0xLTA_00d5a2d4-ee09-4895-8050-fe7a0b6215fb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIw_54165584-6e84-4b63-9ae5-4df1c5228707">001-33637</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI4_e8ac4503-ad07-4165-a2d5-4a3a6120c79f">Cumberland Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8wLTAtMS0xLTA_670a0a28-d7f6-421f-87bb-9f126c3a95d1">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8wLTItMS0xLTA_97a2c24e-5493-452b-afb9-71c59fecf54e">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV81_6d8eb251-3e83-4240-b925-36979563e81b">2525 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV85_5393dfa7-006d-42ca-a914-aec5c86929cf">Suite 950</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV8xMw_769c308b-7109-494b-9164-0d97762d418c">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTAtMS0xLTAvdGV4dHJlZ2lvbjoyN2I1YjBjOTcxZWQ0M2QwODYxYjVlMDIxYTZiMmI0MV8xNw_65644fc4-b0fa-4c10-8e09-3a26fe8258fa">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTE1NWNmM2Y3ZGUxNDM4OWJmOGMzNzBiZDIwNTc5NGQvdGFibGVyYW5nZTplMTU1Y2YzZjdkZTE0Mzg5YmY4YzM3MGJkMjA1Nzk0ZF8zLTItMS0xLTA_43a83393-82f5-49a2-b9b2-bafa9803c35c">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIx_862a0016-918d-488f-a564-abfd1274da2c">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIy_bc304cf0-3106-40e4-a139-8e2718bcd451">255-0068</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDIz_f4fcf3e3-f6eb-47d1-adaf-14019dfff003">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI0_6579eb0b-a0fa-4dc2-9814-033d65af145f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6Nzk5Zjc2NmU2NGNkNDE1OGJkZTcyZDEyNWRjNjc0MzAvdGFibGVyYW5nZTo3OTlmNzY2ZTY0Y2Q0MTU4YmRlNzJkMTI1ZGM2NzQzMF8xLTAtMS0xLTA_5d2aff6e-7f30-4679-b413-1aa0eb18c1a7">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6Nzk5Zjc2NmU2NGNkNDE1OGJkZTcyZDEyNWRjNjc0MzAvdGFibGVyYW5nZTo3OTlmNzY2ZTY0Y2Q0MTU4YmRlNzJkMTI1ZGM2NzQzMF8xLTUtMS0xLTMyNTU_38002190-b43a-4711-a43e-609e19236665">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6Nzk5Zjc2NmU2NGNkNDE1OGJkZTcyZDEyNWRjNjc0MzAvdGFibGVyYW5nZTo3OTlmNzY2ZTY0Y2Q0MTU4YmRlNzJkMTI1ZGM2NzQzMF8yLTItMS0xLTA_aa92856a-d617-4b9b-ac7f-8bee6b6714d9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGV4dHJlZ2lvbjo3ODI5ZmFiNzlhOGQ0OWI0YjFmMjg5YzkyMDY5YzdkZl8yMDI5_8fa2a3e6-fa15-402e-b313-232c83f7cb7a">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTAtMS0xLTA_48b484e4-35e7-4cc7-8a18-9f061008b01e">Common stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTItMS0xLTA_973b1874-2126-48bd-bd10-f9f2fec88417">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTQtMS0xLTA_f216097c-c402-49d6-9f45-a2745e902f4d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0088e6b01c024950837d6835253c6edc_I20200518"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xL2ZyYWc6NzgyOWZhYjc5YThkNDliNGIxZjI4OWM5MjA2OWM3ZGYvdGFibGU6ZTk3ZWVhMWQ3MmMwNDkzODljMGU4YzA0M2NiYzcxYzUvdGFibGVyYW5nZTplOTdlZWExZDcyYzA0OTM4OWMwZThjMDQzY2JjNzFjNV8xLTYtMS0xLTA_2979b073-3c52-4b58-9eef-7bfecacbb129"
      unitRef="shares">15230746</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMy0xLTEtMS0w_19e9ed95-cfec-4966-afd4-3db9c743139f"
      unitRef="usd">27026734</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMy0zLTEtMS0w_42bd38e1-bd6f-4ecd-9ce6-ee5f36f9d868"
      unitRef="usd">28212635</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNS0xLTEtMS0w_a4edf45d-be2d-45d4-88af-f392b8872305"
      unitRef="usd">5949910</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNS0zLTEtMS0w_c595d35c-412b-4903-8e80-5dc0cfa5023d"
      unitRef="usd">7843917</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNi0xLTEtMS0w_d6ef36e4-9aa3-4775-a682-ae1b57b3215b"
      unitRef="usd">8150152</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNi0zLTEtMS0w_cb8cd18f-ac78-4d94-a40f-79e7f6611d40"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0xLTEtMS0xODI_36c0f51f-ace4-4059-983a-4ea72cf85126"
      unitRef="usd">1291359</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0zLTEtMS0xODI_9910b08e-c382-4d2a-b4b6-675f3ad5edd9"
      unitRef="usd">2477813</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0xLTEtMS0w_25b96cca-9537-4a70-8c08-20870e991cd2"
      unitRef="usd">2318862</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfNy0zLTEtMS0w_7cfe2c7a-9c0f-4b5d-932f-0d2f22a4496e"
      unitRef="usd">2757456</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOC0xLTEtMS0w_8ebd3d75-cecd-45be-a225-0401b3f15954"
      unitRef="usd">44737017</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOC0zLTEtMS0w_7969a5f5-bb8a-445f-9ea2-03f73c39d3b2"
      unitRef="usd">50163075</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOS0xLTEtMS0w_6185fb66-f72f-4c94-a5a7-d8d3ab0ba2af"
      unitRef="usd">15569992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfOS0zLTEtMS0w_8167df16-8bdd-4f2c-8d7a-66a5dbe74233"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTAtMS0xLTEtMA_50e9c3f4-4d34-4279-a51e-cf710b5501c2"
      unitRef="usd">694499</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTAtMy0xLTEtMA_a8bc7b75-cae2-4d24-8d28-5334555794e3"
      unitRef="usd">747796</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTEtMS0xLTEtMA_70f1520d-fa44-463e-b26e-2b8f646a44dd"
      unitRef="usd">30142611</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTEtMy0xLTEtMA_33d0577c-76e3-40d5-b55e-18506e2cfc25"
      unitRef="usd">30920324</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTItMS0xLTEtMA_c77b8456-77b3-4a6c-929e-3bcc0c7cd456"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTItMy0xLTEtMA_2596c763-7890-43c2-b83a-52d80eb9fc22"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTMtMS0xLTEtMA_0f5b58f4-4f5c-4428-bb78-b8b12ddfc652"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTMtMy0xLTEtMA_d05555d4-ab60-4ad8-820a-b5caa331deb2"
      unitRef="usd">21802</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTUtMS0xLTEtMTg5_d10c6e02-ef0d-44fc-b27e-162406cee1f6"
      unitRef="usd">2733782</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTQtMy0xLTEtNDA_1d50d22a-7f93-4969-8c67-e5d7ac557076"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTQtMS0xLTEtMA_0d576cf6-925f-4383-9827-3cda465d5640"
      unitRef="usd">2637434</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTQtMy0xLTEtMA_712902fa-adda-4036-9d68-fd0ccebaed90"
      unitRef="usd">3298725</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTUtMS0xLTEtMA_9bbc2ea2-01e9-4d0c-99a7-3253b7199201"
      unitRef="usd">97419137</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTUtMy0xLTEtMA_99e94944-6237-4481-9be5-95f894789dd7"
      unitRef="usd">104549283</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTgtMS0xLTEtMA_ce6486f2-3ff0-40be-ae82-1aac3909bc29"
      unitRef="usd">8247899</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTgtMy0xLTEtMA_7c23a1d8-6eb3-41ed-b64b-ed3a15fee001"
      unitRef="usd">9993578</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMS0xLTEtMjkwMg_c7385ee6-c02b-42e6-b455-ee75e55c3f8d"
      unitRef="usd">1247011</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMy0xLTEtMjkwMg_f05c7835-8902-41d9-94ad-f98e6c4ed89d"
      unitRef="usd">1918868</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMS0xLTEtMTky_e41d19cd-a278-429c-9916-1232437916d7"
      unitRef="usd">943807</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjAtMy0xLTEtNDQ_2529a059-7622-4fa1-b0e5-dbc5fdecdd38"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTktMS0xLTEtMA_b19ec7ce-6d47-4b97-9bec-ce8a92f3f298"
      unitRef="usd">8933874</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMTktMy0xLTEtMA_6d80cc3d-b7bd-44ba-a5e3-2914e071d5ce"
      unitRef="usd">11317358</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjAtMS0xLTEtMA_d0d51004-095c-496b-895c-dc98cefdda21"
      unitRef="usd">19372591</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjAtMy0xLTEtMA_4ad97cf4-35f7-41b0-bae3-fc66a4478de8"
      unitRef="usd">24150235</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMS0xLTEtMA_b758d474-488b-444e-9f6e-89ba42a6e207"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjEtMy0xLTEtMA_45b10ab4-92a7-4043-b7f3-48ae2c872b77"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjUtMS0xLTEtMTk1_c6bb3086-cadd-4947-8e44-ce2e3988a7a0"
      unitRef="usd">1831274</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjQtMy0xLTEtNDg_278e9afc-8eba-4ac1-9e6a-e1e21c7b7c5d"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjItMS0xLTEtMA_af5a03a1-d2fe-443f-aee4-b80ed44f1566"
      unitRef="usd">7872214</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <cpix:OtherLongTermObligationsExcludingCurrentPortion
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjItMy0xLTEtMA_6c7a6ded-48bc-40c9-8be1-75417c4c8cd9"
      unitRef="usd">8737323</cpix:OtherLongTermObligationsExcludingCurrentPortion>
    <us-gaap:Liabilities
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjMtMS0xLTEtMA_b70ca04a-a9f3-4132-a89a-b16c6aa7cc9a"
      unitRef="usd">47576079</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjMtMy0xLTEtMA_4e702788-e9f3-461e-b759-f033edf41b1c"
      unitRef="usd">53464030</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjQtMS0xLTEtMA_ca80d7c3-0a89-4267-bd0d-030fff6d86da"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjQtMy0xLTEtMA_c2f659e8-e745-4d12-bd12-eb8b141815b2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzE3_040b08ec-4d57-4019-95e0-4d6e6e498d6c"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzE3_9be8a6c5-1a27-45e1-a5d9-62994261bf5b"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzMx_42c1fb39-6bf1-40ce-a9da-2b8ed5364f93"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzMx_4fb85efb-b0a3-4dd9-a644-d89364116d24"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzUz_3e74eb26-6398-4792-80ec-32d6bafd2bae"
      unitRef="shares">15318529</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzUz_dc2d469f-d03e-485e-865c-7f7b7e5c5d7a"
      unitRef="shares">15318529</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzYw_058428c8-5f83-4844-9cf0-1cd84b690f18"
      unitRef="shares">15263555</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMC0xLTEtMC90ZXh0cmVnaW9uOjU2ZGEzZTM5ZTk3YTQ0ZjFiYjY5ZDhlZGU4MjQ0YjE0XzYw_50e74e15-5c9c-4d1d-ba97-0bb082e7c511"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMS0xLTEtMA_70b994f0-e54b-4787-9b3f-c6f4a9bb9af1"
      unitRef="usd">49737428</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjctMy0xLTEtMA_a8a96538-5011-4b87-9302-1c45f016c243"
      unitRef="usd">49914478</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjgtMS0xLTEtMA_6eeb6c74-eb27-45c6-9ba4-608a0ac83a98"
      unitRef="usd">152775</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjgtMy0xLTEtMA_9e17a48f-67ed-46dd-aa7b-32094c4ec951"
      unitRef="usd">1208395</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjktMS0xLTEtMA_424e0c6e-c7fc-4e89-9a21-45586cf635e4"
      unitRef="usd">49890203</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMjktMy0xLTEtMA_53a6d0ba-9840-4bd7-9714-65efd0f5a341"
      unitRef="usd">51122873</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzAtMS0xLTEtMA_03781fa6-7104-41d8-b738-ad128fe0e0ba"
      unitRef="usd">-47145</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzAtMy0xLTEtMA_4cfb1349-03bc-4971-94ab-96d6e722ea0d"
      unitRef="usd">-37620</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzEtMS0xLTEtMA_e8d71a1f-828c-46d0-86ad-d0332d6eb374"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzEtMy0xLTEtMA_ba06814b-7d7a-4260-9deb-187aa0817d35"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzItMS0xLTEtMA_66a9cb12-aab3-4c9e-99da-ff2f289bb75c"
      unitRef="usd">97419137</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xNi9mcmFnOjBjMzg1NGM1OGNkZTRkNjg5MGI4MDcyOWNmOWE3Y2VjL3RhYmxlOmNmZTIxZDVmMDA4NTQ0MGY4MDFkYmRjMmFlZWQ0ZWJiL3RhYmxlcmFuZ2U6Y2ZlMjFkNWYwMDg1NDQwZjgwMWRiZGMyYWVlZDRlYmJfMzItMy0xLTEtMA_625cdb26-63f1-4635-9b90-73ec0e49eebf"
      unitRef="usd">104549283</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMi01LTEtMS0w_82b71974-bbc7-43a8-a9ab-2529f97d1a78"
      unitRef="usd">8330734</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMi03LTEtMS0w_726dcef5-be7c-4d2e-8f98-01a0f930f69d"
      unitRef="usd">8729860</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNC01LTEtMS0w_e89ec22d-2d03-4b00-8b65-900527a440cc"
      unitRef="usd">1634181</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNC03LTEtMS0w_de5f0547-ddcd-47be-b76f-a116a58fcdc0"
      unitRef="usd">1658789</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNS01LTEtMS0w_974e2a80-bf66-41b8-bc99-e9f980a28b9a"
      unitRef="usd">3707676</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNS03LTEtMS0w_e5fba390-f2d2-4934-8b90-c2eb671b9b8b"
      unitRef="usd">3436932</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNi01LTEtMS0w_46c0d7c1-8b93-488d-b21a-aeedfad377ff"
      unitRef="usd">1722555</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNi03LTEtMS0w_82c7c0d1-6d4f-46a6-b14a-3caa3b5efc22"
      unitRef="usd">1399687</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNy01LTEtMS0w_6142ecd3-16e4-41f0-a49d-9152a0619cc2"
      unitRef="usd">2036284</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfNy03LTEtMS0w_509f4c1c-4b21-4581-aee3-003cc9bf899c"
      unitRef="usd">2536739</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOC01LTEtMS0w_8bf8ec54-493b-4351-b316-8c2289b92059"
      unitRef="usd">1076039</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOC03LTEtMS0w_c03dbcf1-cb54-406f-8b9e-6983d7a8df20"
      unitRef="usd">1021645</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOS01LTEtMS0w_494a60d1-8aac-4bc7-b90b-3c986fc6eba7"
      unitRef="usd">10176735</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfOS03LTEtMS0w_96bee36f-3659-4143-a3b0-ac7f5fab68e7"
      unitRef="usd">10053792</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTAtNS0xLTEtMA_6ebb6e02-1805-4258-a81d-f6df60b4f0cc"
      unitRef="usd">-1846001</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTAtNy0xLTEtMA_df3c3111-165c-428e-9ac6-03349fa8774a"
      unitRef="usd">-1323932</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTEtNS0xLTEtMA_15f87bcb-a51c-4990-b67e-537b544d65e9"
      unitRef="usd">29888</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTEtNy0xLTEtMA_c1ba5020-cdf0-46d7-8127-2ca916ee7409"
      unitRef="usd">115861</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTItNS0xLTEtMA_d330ab7e-de1d-407c-9aab-8c36dac888e9"
      unitRef="usd">33065</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTItNy0xLTEtMA_5a1a865b-d030-4c21-b3f9-2c81f55a744b"
      unitRef="usd">60911</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTMtNS0xLTEtMA_c61b3d0f-805e-4743-a5e5-534ff94ceade"
      unitRef="usd">-1849178</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTMtNy0xLTEtMA_4774d2bc-0c72-4bed-9f31-d72e778484e3"
      unitRef="usd">-1268982</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTQtNS0xLTEtMA_5ec46e00-ca61-48d2-8aa4-e7e7c2f8985a"
      unitRef="usd">34240</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTQtNy0xLTEtMA_aa28da43-8d3b-4fc9-864b-3c441ce26efa"
      unitRef="usd">-81428</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTUtNS0xLTEtMA_5a15a3de-42c7-4e3c-b016-a2356a68365a"
      unitRef="usd">-1883418</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTUtNy0xLTEtMA_b7552cf2-dd28-4e5b-b3ca-43800042012d"
      unitRef="usd">-1187554</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNS0xLTEtMjA2_c921a35b-bac2-4a72-865d-ede8b1d10878"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNy0xLTEtMjA2_6dc9222d-c8ba-444d-a417-77ba59e5dbad"
      unitRef="usd">1147136</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNS0xLTEtMjEw_7ecade60-5b0a-4b1e-9364-7a6f34f4b7bb"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNy0xLTEtMjEw_335b0956-5182-4b35-8f4e-980bbb050922"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNS0xLTEtMA_6e47ae3a-4bd0-42e8-8975-9c9ecb006e21"
      unitRef="usd">-9525</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTYtNy0xLTEtMA_67af5d0d-10bc-4b5b-9ebe-5b336e131380"
      unitRef="usd">33460</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNS0xLTEtMA_201d65dc-296d-43c1-b55b-9a96b3da1ed6"
      unitRef="usd">-1055620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTctNy0xLTEtMA_0760383e-6cb8-43ce-98e4-85a07974f201"
      unitRef="usd">-73878</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTktNS0xLTEtMA_29c6c9aa-ae3c-474a-a156-a3b758ed78ce"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMTktNy0xLTEtMA_05bc89e1-6666-4150-9fff-5ffd512a88b5"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNS0xLTEtMTQ3NA_7afc3bd0-d147-4da5-9d54-85622d5e2be6"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNy0xLTEtMTQ3NA_a7e6084d-0ecd-41f5-a2b3-0c7c7a5cbd0c"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNS0xLTEtMjUzNQ_8c63fde6-33cc-4303-adeb-b6a4ac865b7e"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNy0xLTEtMjUzNQ_4fda4f47-197a-4005-a43a-22b930f7aa51"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNS0xLTEtMTQ3NA_df66a2e5-706c-4db3-968d-3b5f48cbdce2"
      unitRef="usdPerShare">-0.12</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNy0xLTEtMTQ3NA_861b9dab-25c0-49a8-a94c-3611be725228"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjAtNS0xLTEtMA_890867f3-cb44-479c-8334-f3ac5f510811"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjAtNy0xLTEtMA_6c072cb6-e610-4bc4-90f1-bca466ad443b"
      unitRef="usdPerShare">0.08</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNS0xLTEtMjUzOA_2ca87dd3-67fb-43b6-b15a-d212e7d16ac6"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNy0xLTEtMjUzOA_6fb763a6-bb38-4642-af0d-7faef7aebd66"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNS0xLTEtMA_c9201846-3502-43c4-9def-e34142635d0e"
      unitRef="shares">15240614</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjItNy0xLTEtMA_e6beb0a8-87d9-40d9-a558-412323e0df34"
      unitRef="shares">15472952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNS0xLTEtMA_72f458c9-7d3f-4f09-af42-35fb6bd29d65"
      unitRef="shares">15578309</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjMtNy0xLTEtMA_0a29c5aa-3ad4-4e18-95cf-9a2c9f9439a5"
      unitRef="shares">15891570</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjUtNS0xLTEtMA_9a494a64-3ce1-4d9c-90f3-ef1c82a99083"
      unitRef="usd">-1055620</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjUtNy0xLTEtMA_e7cb51dd-8fcb-4cbd-8fe5-58052b27d001"
      unitRef="usd">-73878</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNS0xLTEtMA_ba4f9c12-c1fe-432f-af4a-79bfeff261c3"
      unitRef="usd">9525</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjYtNy0xLTEtMA_6350784e-32ff-43da-9c19-7e646f3b1db3"
      unitRef="usd">-33460</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjctNS0xLTEtMA_8e8ffbdb-7257-4d00-96c5-8b6e3ae6b0e7"
      unitRef="usd">-1065145</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8xOS9mcmFnOjlkYTY0NjVlYTc0MDQ0ZTFiZWRjODYyYjFjMzYzOTcwL3RhYmxlOmVhOWZmOWNmOWQwZjRmM2JiZWJhODNhZDM4YTQ4NmM1L3RhYmxlcmFuZ2U6ZWE5ZmY5Y2Y5ZDBmNGYzYmJlYmE4M2FkMzhhNDg2YzVfMjctNy0xLTEtMA_759a4b2d-21af-4697-a769-fc2e99718a23"
      unitRef="usd">-40418</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMy0xLTEtMS0w_fa20f6dd-44bd-4209-a821-359ec49a4343"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMy0zLTEtMS0w_3cc9bad3-0c6f-42fc-84b7-6e86b87ba09a"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNC0xLTEtMS0yMjg_31b78767-1bba-4f97-ad73-578a3d4b76df"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNC0zLTEtMS0yMjg_ce26dd63-5385-4595-8fd2-83e269c1574d"
      unitRef="usd">1147136</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0xLTEtMS0yMzg_1a67e5b4-14c4-45ff-8dad-a65ffdcbee7e"
      unitRef="usd">-1883418</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0zLTEtMS0yMzg_7ce2f722-711a-47ba-a1e1-c8e62fa90c8d"
      unitRef="usd">-1187554</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0xLTEtMS0w_474181e2-3521-4b42-a340-df7c61c391e4"
      unitRef="usd">1152062</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNS0zLTEtMS0w_482e1cf6-1806-4450-9db9-72aeb08fd715"
      unitRef="usd">1076246</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNi0xLTEtMS0w_5b53a811-406b-4117-88f9-0c4f899bbc1e"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNi0zLTEtMS0w_16093dd0-5b17-41f8-b1c3-b55501197110"
      unitRef="usd">43605</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNy0xLTEtMS0w_67e5ca8b-f7ea-49ed-8cb0-e21c34ab2696"
      unitRef="usd">264574</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNy0zLTEtMS0w_2a339324-deb5-404f-a244-04b145f1f6ae"
      unitRef="usd">364434</us-gaap:ShareBasedCompensation>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOC0xLTEtMS0w_9da7ae02-3086-40fd-9854-4fc945e931eb"
      unitRef="usd">543006</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOC0zLTEtMS0w_d5ec0759-cd73-4a4e-af15-ceb1592fafc7"
      unitRef="usd">269422</us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOS0xLTEtMS0w_823f29b0-141e-479c-96e7-e97dc4dcfae2"
      unitRef="usd">11333</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfOS0zLTEtMS0w_acc3e42e-0e3c-4a21-832f-31d8d845f0bd"
      unitRef="usd">10497</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTAtMS0xLTEtMA_95d2a145-181f-40c9-a1f8-213bd4279be0"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTAtMy0xLTEtMA_206de4e5-43b4-49a9-bb86-44ab49aad730"
      unitRef="usd">44191</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTItMS0xLTEtMA_b4e4a47b-1848-421e-9874-c816d96da87d"
      unitRef="usd">-2014438</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTItMy0xLTEtMA_cceecebd-c44c-4e00-8952-29d4370e3af3"
      unitRef="usd">1361692</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTMtMS0xLTEtMA_7f0c16ac-1583-4617-8b90-b652674f83e3"
      unitRef="usd">-706102</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTMtMy0xLTEtMA_abc1147a-4887-421b-a02c-d658d3c7a866"
      unitRef="usd">-494395</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTQtMS0xLTEtMA_5a34eaee-8fa8-4371-87db-bf782a398cab"
      unitRef="usd">-1093517</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTQtMy0xLTEtMA_a653e677-4d49-4475-87d8-1f70df70c1bb"
      unitRef="usd">-134578</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTUtMS0xLTEtMA_aa4e79a8-6acd-4ecc-83d9-c36828135fc7"
      unitRef="usd">-2394824</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <cpix:IncreaseDecreaseInCurrentOperatingLiabilities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTUtMy0xLTEtMA_e735203f-8637-40d2-a6d0-ee70437f277d"
      unitRef="usd">474354</cpix:IncreaseDecreaseInCurrentOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTYtMS0xLTEtMA_917c5392-80e9-49f8-b6f8-967410fe4b40"
      unitRef="usd">-865109</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTYtMy0xLTEtMA_bbf063a9-9f7f-43f0-8bd6-7031abcf3536"
      unitRef="usd">-353925</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTctMS0xLTEtMA_5c370e7e-de8b-4f88-9ffa-bab456e94590"
      unitRef="usd">-444331</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTctMy0xLTEtMA_5ef95a2d-7f16-48ef-b2f4-4cc964f39200"
      unitRef="usd">-618675</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMS0xLTEtMjY0_af2bc935-e343-48a1-aca8-9cb68ac37ee4"
      unitRef="usd">1332870</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMy0xLTEtMjY0_f2eb5bdc-6e43-422a-8606-a71d20c9a8b6"
      unitRef="usd">232942</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMS0xLTEtMjc0_fd3dcdab-a700-4fa0-8f40-8e8da4cb2c7f"
      unitRef="usd">888539</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMy0xLTEtMjc0_85edcef2-64f4-42a9-85b5-c29b61a3f414"
      unitRef="usd">-385733</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTktMS0xLTEtMA_95b6d3be-ea4a-40bc-9a6b-e3dbec73adf5"
      unitRef="usd">22726</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMTktMy0xLTEtMA_69d7380e-a04f-437d-ad2b-b45d1441381d"
      unitRef="usd">27474</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMS0xLTEtMA_aa3fc2f0-4299-4976-836c-78441082bdac"
      unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjAtMy0xLTEtMA_4d7b5e3e-922c-4126-a8bb-b97978173944"
      unitRef="usd">7816191</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMS0xLTEtMA_505fc408-c35f-4455-b940-84e8182e4185"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjEtMy0xLTEtMA_913cc7ee-4a29-443a-af3a-11527fef9f2b"
      unitRef="usd">6483988</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjMtMS0xLTEtMA_3327c081-c5b2-4106-9e4a-9b3f70ad3eb8"
      unitRef="usd">548435</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjMtMy0xLTEtMA_b7d78711-c508-4995-82b8-7737432ae1c6"
      unitRef="usd">363711</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjQtMS0xLTEtMA_98a561eb-d322-45f1-bf17-87d5ddeece6f"
      unitRef="usd">-571161</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjQtMy0xLTEtMA_50f0512f-9bc2-4b9d-9297-e7e1570f46cf"
      unitRef="usd">-1723388</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjctMS0xLTEtMA_cbe37698-f804-4acf-b645-f4fba4aa6d52"
      unitRef="usd">18500000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjctMy0xLTEtMA_be59cedf-d0a4-4d7e-9178-c5f69c206547"
      unitRef="usd">19000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjgtMS0xLTEtMA_cad697e8-e62b-44f4-bffb-7826281c1fe9"
      unitRef="usd">18500000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMjgtMy0xLTEtMA_56de487d-b04f-4836-a3e4-4487fdbc0b20"
      unitRef="usd">19000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzItMS0xLTEtMA_0fd7bc58-3443-4c0f-bfba-680202a2442c"
      unitRef="usd">260735</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzItMy0xLTEtMA_27990241-be06-47ad-b366-48dfb6cbcddb"
      unitRef="usd">507505</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMS0xLTEtMzEy_2e18b2f5-009e-441d-b593-b3fd7587624a"
      unitRef="usd">800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMy0xLTEtMjc4NA_0ae6db37-07d9-4f9f-9e3e-6860030731b4"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzYtMS0xLTEtMA_b15c6128-193e-43af-a823-95b2469849b8"
      unitRef="usd">442544</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzYtMy0xLTEtMA_e8922f4a-940f-4691-9dcc-7c038ccde9d2"
      unitRef="usd">712919</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMS0xLTEtMA_500f2686-f6ee-41ed-86e7-610cd06127c9"
      unitRef="usd">-1503279</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzctMy0xLTEtMA_b84ee9ad-4fba-42c6-a6ff-c7f436b0af0a"
      unitRef="usd">-1220424</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzgtMS0xLTEtMA_91445ce8-3c10-417f-9bf5-b921f3a59a0e"
      unitRef="usd">-1185901</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzgtMy0xLTEtMA_4f76efcd-70f7-4451-bd03-dcf6dbef6cbb"
      unitRef="usd">-3329545</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzktMS0xLTEtMA_730479a6-be7e-4cf1-ba9e-60b859458559"
      unitRef="usd">28212635</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1a78868ca68246878f4a228d9e2b4dc5_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfMzktMy0xLTEtMA_62505c87-8870-4af4-bc3e-0010f302d50a"
      unitRef="usd">27938960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDAtMS0xLTEtMA_46950947-b466-4004-a869-b63dd96c75d5"
      unitRef="usd">27026734</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63aa5c50ea2741fb8570d7b27efeb73a_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDAtMy0xLTEtMA_4eac3027-d7b4-46d3-ab3c-c13b6e2901a5"
      unitRef="usd">24609415</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDUtMS0xLTEtMjc4OA_44364121-78dd-48f5-a407-f810ba626266"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yMi9mcmFnOjA4NDM2Y2FlNjlhZjRlZDlhNjg5NGI1Y2FkNDE5ODExL3RhYmxlOjg2ZWEyZDY0ZGRkNzQ2Y2I4MDhjZWRiMjcyMDQyZGM2L3RhYmxlcmFuZ2U6ODZlYTJkNjRkZGQ3NDZjYjgwOGNlZGIyNzIwNDJkYzZfNDUtMy0xLTEtMjc5MA_4d39fa45-39a2-4cca-9adc-41cd3be95868"
      unitRef="usd">3629320</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2251f12c72da41a0af81132111638b47_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi0xLTEtMS0w_3195e2aa-dd05-44f4-bbe4-0b78c3fc4b7d"
      unitRef="shares">15481497</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2251f12c72da41a0af81132111638b47_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi0zLTEtMS0w_c99109f8-2f4b-40f1-8496-60e3b46ae3c0"
      unitRef="usd">51098613</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i23db2a2a561141ce99aaafe3e6e00e5e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi01LTEtMS0w_bbb1d8fe-2136-4521-a76f-18e03af155c8"
      unitRef="usd">4746154</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f64be2406764c309799078f75eb3592_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi03LTEtMS0w_35564af8-8e04-4fe6-95e3-811748ff6b19"
      unitRef="usd">-274266</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a78868ca68246878f4a228d9e2b4dc5_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfMi05LTEtMS0w_1f280d0e-c9ea-43fe-adc8-82ac0807c303"
      unitRef="usd">55570501</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNC0xLTEtMS0w_bcbb14ee-826d-4510-96a7-2d12f64ed6c3"
      unitRef="shares">187486</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNC0zLTEtMS0w_5e8a39e8-abcb-4b72-86b3-fe33e7902e6d"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNC05LTEtMS0w_84b96713-6b7f-4ad2-8156-8067e4ee197f"
      unitRef="usd">364434</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNS0xLTEtMS0w_1f1487b0-d770-424e-9a5c-ff8e6bf64004"
      unitRef="shares">121466</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNS0zLTEtMS0w_9e731a73-37d1-4812-806d-5f4213d9719b"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNS05LTEtMS0w_c5ff3ed8-fba4-4e0a-8230-d7fde8bd6930"
      unitRef="usd">703790</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="id1a620a084c74d74898f0dd62e6f7035_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNi01LTEtMS0w_cf66adfb-7c4d-4d33-a07b-6719fb591578"
      unitRef="usd">-73878</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i109dbc8d282c4dd2838c55d7a9397435_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNi03LTEtMS0w_9146f931-fc24-4b87-960b-e234a7508bb3"
      unitRef="usd">33460</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNi05LTEtMS0w_0f5677e4-088f-4e34-b092-4b7e92ab313f"
      unitRef="usd">-40418</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i87cfdb3f63a74be9b0a92fab69c0e221_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy0xLTEtMS0w_522d2069-b5c4-4671-b22f-4ef885de66c3"
      unitRef="shares">15547517</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87cfdb3f63a74be9b0a92fab69c0e221_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy0zLTEtMS0w_b9be5439-6f70-49f2-aceb-744a31ded004"
      unitRef="usd">50759257</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffc4ba9e1e0b41b39a3adb37adc6e050_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy01LTEtMS0w_de07242e-bd17-434c-ab7d-3596786c569f"
      unitRef="usd">4672276</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2ecebde61254e95844331383fc92c61_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy03LTEtMS0w_74d15fe6-9e1c-46b8-8cdd-cfbf025179a3"
      unitRef="usd">-240806</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63aa5c50ea2741fb8570d7b27efeb73a_I20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjVlN2ZkNWNmZjkwYzQ3OWU5MmNkY2UwZTcyMDdmNzQwL3RhYmxlcmFuZ2U6NWU3ZmQ1Y2ZmOTBjNDc5ZTkyY2RjZTBlNzIwN2Y3NDBfNy05LTEtMS0w_7f127b1c-6670-4dd4-90a3-9cfcc5decb04"
      unitRef="usd">55190727</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4880baf56e2047c6a8e04568a2759928_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi0xLTEtMS0w_18cada15-4960-4bf9-b6da-59b1d5d65834"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i4880baf56e2047c6a8e04568a2759928_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi0xLTEtMS0w_a68f769b-58c9-447c-8b03-12214d465587"
      unitRef="shares">15263555</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4880baf56e2047c6a8e04568a2759928_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi0zLTEtMS0w_f24f185e-46ed-4bdd-9337-8450d5dad8f5"
      unitRef="usd">49914478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i249ea7f123574d1fb56baebc9da7f0bc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi01LTEtMS0w_9412ba90-14f5-4c01-83cb-290c0cbe9925"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i249ea7f123574d1fb56baebc9da7f0bc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi01LTEtMS0w_d39780ec-f151-444d-90b2-c0c6d70c27e0"
      unitRef="usd">1208395</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1118bdd925ed4822a822302514c1ceac_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi03LTEtMS0w_7bebc214-d991-4389-9ef7-86862b6c6dfd"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1118bdd925ed4822a822302514c1ceac_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi03LTEtMS0w_a8138a96-84cf-42b8-af19-b614c17af3cf"
      unitRef="usd">-37620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi05LTEtMS0w_23736d58-4809-452c-bcb5-3b19502dba8b"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMi05LTEtMS0w_b42bc263-3289-4b96-9152-46497be35c91"
      unitRef="usd">51085253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0xLTEtMS0w_7e0546fd-5763-4067-954c-9aa27e794346"
      unitRef="shares">219850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0xLTEtMS0w_da188e4b-a6fb-4296-ad64-121a8bd8e220"
      unitRef="shares">219850</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0zLTEtMS0w_55ccde49-f216-4eb7-ba38-f226ac800cb9"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy0zLTEtMS0w_636c4ccb-6c71-41da-bd17-16c8b74076d5"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy05LTEtMS0w_2f30a8fb-22c4-4207-910c-2a4757be2db7"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfMy05LTEtMS0w_6d4ec49c-0d59-4de8-9897-6e7a8beb17d6"
      unitRef="usd">264574</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC0xLTEtMS0w_ed093a2d-9e6a-4d59-91ef-89581a379f3d"
      unitRef="shares">164876</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC0zLTEtMS0w_59b675b5-1bed-4329-8f56-f00075e979a6"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC05LTEtMS0w_614639be-5f0e-481e-94f9-eeaa1af3d00e"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNC05LTEtMS0w_78c31d70-0728-4e1c-aa38-277ae85a1f08"
      unitRef="usd">441624</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ProfitLoss
      contextRef="i2e5be467315b44459b4f1ef5a3b2aff8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS01LTEtMS0w_3906e7ee-6810-4e23-9a7a-7a37641bea41"
      unitRef="usd">-1055620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2e5be467315b44459b4f1ef5a3b2aff8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS01LTEtMS0w_8109106b-5133-4584-a975-b138dadcf53d"
      unitRef="usd">-1055620</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iabf2ca4dfae54e8a8f2062d0b20219bc_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS03LTEtMS0w_a57ba4eb-ece8-46b3-902e-8a6dc8d9c8bf"
      unitRef="usd">-9525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iabf2ca4dfae54e8a8f2062d0b20219bc_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS03LTEtMS0w_a975fd01-947c-400a-93c1-1a7c56d1ae85"
      unitRef="usd">-9525</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS05LTEtMS0w_21e93080-6aae-4544-984d-7c2e8941c7b5"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNS05LTEtMS0w_616d9b49-5f17-4fa4-9650-1d94e41718b9"
      unitRef="usd">-1065145</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i10b4dd6a5c2e451fb816f8e209689c83_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi0xLTEtMS0w_feb5ff4a-900c-4aac-9f23-7b83f9db40fb"
      unitRef="shares">15318529</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10b4dd6a5c2e451fb816f8e209689c83_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi0zLTEtMS0w_5d0ad019-43bb-4a22-80a6-4792ab6cfd5e"
      unitRef="usd">49737428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i37bad119d0fa4d7886b1bc8a846a15f6_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi01LTEtMS0w_9723de5d-d614-49a4-a0eb-68ae77852282"
      unitRef="usd">152775</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f51ec8c6cc7448c8ad928a2dd4996f1_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi03LTEtMS0w_b2154c77-e288-404e-ab47-a99a5b1d0861"
      unitRef="usd">-47145</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8yNS9mcmFnOmJiMmQ2Y2YxMjhjMzRmNzJiYTI4MGRjZGRkMmYwNzYwL3RhYmxlOjU4ZWRiNWIxMzUzODQ3YmRhYmYyYzZmM2JjZjYwOGIyL3RhYmxlcmFuZ2U6NThlZGI1YjEzNTM4NDdiZGFiZjJjNmYzYmNmNjA4YjJfNi05LTEtMS0w_cbf143f1-2579-40ea-834e-a246e949a394"
      unitRef="usd">49843058</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4MQ_c004b2a2-5cb0-4141-83f8-597b0754b840">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#x201c;2019 Annual Report on Form 10-K&#x201d;). The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March 31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;COVID-19 Pandemic &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  The Company is monitoring this situation both in the U.S. and internationally, so Cumberland can maintain employee safety and well-being, while also keeping the business operating and secure.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. All of the Company's corporate and Cumberland Emerging Technologies (&#x201c;CET&#x201d;) employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  Cumberland's sales organization has continued to make calls on medical professionals, providing information and product samples as requested. However, their contact has largely shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During this national health care and economic crisis, Cumberland understands that the volume of patients seeking health care was negatively impacted by the stay-at-home orders across the country. Declines in hospital admissions, patient visits to physician offices and postponement of elective surgeries have all been reported. As a result, Cumberland is facing the same headwinds that are affecting all companies that rely on these factors to help drive revenue. While the Company expects these dynamics to improve as the country reopens, it cannot be determined at this time when and to what extent that improvement will occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Given the uncertainty, magnitude and impact of such changes, the Company is unable to fully quantify the impact on the future results as of the date of this filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accounting Policies:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4Mw_234c9790-c647-45d6-883f-383354829e63">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &#x201c;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#x201d; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &#x201c;Simplifying the Test for Goodwill Impairment&#x201d; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4NA_2da365d8-3f49-4000-9e56-555e70e31e58">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTg4Ng_f1330eb6-fdd5-455a-92b1-d0f6a3569393">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zMS9mcmFnOmViY2NkYmE3ZmJlOTRmODQ5YzYwMTA3NDQwZTc5Y2Q2L3RleHRyZWdpb246ZWJjY2RiYTdmYmU5NGY4NDljNjAxMDc0NDBlNzljZDZfOTA3OA_138173f7-095d-497d-8b16-c27a1702e225"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RleHRyZWdpb246YzM2Zjc4ZjE0ZTQxNGM2MWFmZjQzNGYyYWM0MWVkZGZfNjU5NzA2OTc3MDE4NQ_59e34cc2-1d0d-45ed-9d7a-58bad6a075de">INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company invests in marketable securities in order to maximize its return on cash. Marketable securities consist of short-term cash investments, U.S. Treasury notes and bonds,  corporate bonds and commercial paper.  At the time of purchase, the Company classifies marketable securities as either trading securities or available-for-sale securities, depending on the intent at that time.  As of March 31, 2020 and December 31, 2019, marketable securities were comprised solely of trading securities.  Trading securities are carried at fair value with unrealized gains and losses recognized as a component of interest income in the consolidated statements of operations.  As of March 31, 2020 and December 31, 2019, all trading securities were commercial paper with original maturities of less than ninety days and as a result, were classified as cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 2 -   Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-45pt;padding-left:81pt;text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Level 3 -   Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's fair values of marketable securities are determined based on valuations provided by a third-party pricing service, as derived from such service's pricing models, and are considered either Level 1 or Level 2 measurements, depending on the nature of the investment.  The Company has no marketable securities in which the fair value is determined based on Level 3 measurements.  The level of management judgment required in evaluating fair value for Level 1 investments is minimal.  Similarly, there is little subjectivity or judgment required for Level 2 investments valued using valuation models that are standard across the industry and whose parameter inputs are quoted in active markets.  Inputs to the models may include, but are not limited to, reported trades, executable bid and ask prices, broker/dealer quotations, prices or yields of securities with similar characteristics, benchmark curves or information pertaining to the issuer, as well as industry and economic events. Based on the information available, the Company believes that the valuations provided by the third-party pricing service, as derived from such service's pricing models, are representative of prices that would be received to sell the assets at the measurement date (exit prices).  There were no transfers of assets between levels within the fair value hierarchy.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.162%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RleHRyZWdpb246YzM2Zjc4ZjE0ZTQxNGM2MWFmZjQzNGYyYWM0MWVkZGZfMzIzOA_d21dfadf-eab6-4fe5-a142-f57d262a646e">&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.368%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.160%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.162%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total fair value of marketable  securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;498,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,119,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:TradingSecurities
      contextRef="ie2b2ac84d68d46b6b046398feff08b17_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC0xLTEtMS0w_a810ef2b-092e-4359-8b7d-6a352e0e1823"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i8dc21010d4c344e397eec8fd94ae93a3_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC0zLTEtMS0w_e077c1f6-aef6-4c08-8ff6-d7a0679e4295"
      unitRef="usd">498008</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i3f6c43b973a9401aaef67992d1c6ca35_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC01LTEtMS0w_6f8fec2e-d437-443c-9aca-538ba30db882"
      unitRef="usd">498008</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i35b3f63ab43f4e26ba10e84c0f0e0561_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC03LTEtMS0w_39ae4f98-8c29-44e7-a1ed-3f5cb6b8fb30"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ie690b89f8a28465da873a92d63700759_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC05LTEtMS0w_ad7e521c-dada-4fd9-9c29-ab76e3726300"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6a74522aa1a246c6bb951c12119f378e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNC0xMS0xLTEtMA_82b90619-8749-4800-842d-fd8d9d78128f"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i0d05454a22094fa6aeb2797a74438214_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi0xLTEtMS0w_40796ee9-6f47-4762-98e6-2c3aafa1bd86"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ib5d8317aacc149c89f316a6abd144f03_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi0zLTEtMS0w_af9ef809-e7f9-454a-b13a-958bfecc804f"
      unitRef="usd">498008</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi01LTEtMS0w_9f3813a0-af73-4904-b815-a09f6d976375"
      unitRef="usd">498008</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="id8abae9f8b7f487199521b9e594a9b4a_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi03LTEtMS0w_a0999a8f-7500-474c-bf5d-bec7054af46f"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="if81ff44d18e5471b841b0b5e665a2300_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi05LTEtMS0w_791e903a-f011-4e99-afaa-ee5935ad552b"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNC9mcmFnOmMzNmY3OGYxNGU0MTRjNjFhZmY0MzRmMmFjNDFlZGRmL3RhYmxlOjM0YWVjNDc3ZmM3NzQ3YTk4MDk5MjllYzRiYTNhNDhlL3RhYmxlcmFuZ2U6MzRhZWM0NzdmYzc3NDdhOTgwOTkyOWVjNGJhM2E0OGVfNi0xMS0xLTEtMA_a118ea4e-ea07-45c8-8169-3bd5c14f7b10"
      unitRef="usd">2119607</us-gaap:TradingSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfNDMw_9b2de82c-333e-4da2-b753-c71bba721014">EARNINGS (LOSS) PER SHARE&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.618%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.210%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,883,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,187,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,147,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,055,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,240,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,472,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;418,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,578,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,891,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March 31, 2020 and 2019, restricted stock awards and options to purchase 431,226 and 263,919 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfNDMx_cba2b5ea-337e-470c-8094-61abf8a3b1d4">&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.616%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.537%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.618%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:57.210%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.883%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.823%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.884%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,883,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,187,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;818,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,147,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) at subsidiary attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,055,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(73,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,240,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,472,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Dilutive effect of other securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;337,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;418,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,578,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,891,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0xLTEtMS0xNTU0_5a15a3de-42c7-4e3c-b016-a2356a68365a"
      unitRef="usd">-1883418</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0zLTEtMS0xNTU0_b7552cf2-dd28-4e5b-b3ca-43800042012d"
      unitRef="usd">-1187554</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNC0xLTEtMS0xNTU3_2b1ca2ee-c5ed-45c2-897f-70c123c9b226"
      unitRef="usd">818273</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNC0zLTEtMS0xNTU3_2253372f-c8e2-4131-b31d-08084e6f8206"
      unitRef="usd">1147136</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0xLTEtMS0xNTYx_6e47ae3a-4bd0-42e8-8975-9c9ecb006e21"
      unitRef="usd">-9525</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0zLTEtMS0xNTYx_67af5d0d-10bc-4b5b-9ebe-5b336e131380"
      unitRef="usd">33460</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0xLTEtMS0w_201d65dc-296d-43c1-b55b-9a96b3da1ed6"
      unitRef="usd">-1055620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfMy0zLTEtMS0w_0760383e-6cb8-43ce-98e4-85a07974f201"
      unitRef="usd">-73878</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0xLTEtMS0w_c9201846-3502-43c4-9def-e34142635d0e"
      unitRef="shares">15240614</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNS0zLTEtMS0w_e6beb0a8-87d9-40d9-a558-412323e0df34"
      unitRef="shares">15472952</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfOS0xLTEtMS0yODA1_8c583640-071e-4a03-8cff-ae043290a6d0"
      unitRef="shares">337695</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfOS0zLTEtMS0yODA2_6a561583-bbf8-4d5d-831c-03f1608a510c"
      unitRef="shares">418618</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNy0xLTEtMS0w_72f458c9-7d3f-4f09-af42-35fb6bd29d65"
      unitRef="shares">15578309</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RhYmxlOjk4YjhlMzNhZDdhMTQyYTg4YmE0MDEzNDNmNjJmZWQwL3RhYmxlcmFuZ2U6OThiOGUzM2FkN2ExNDJhODhiYTQwMTM0M2Y2MmZlZDBfNy0zLTEtMS0w_0a29c5aa-3ad4-4e18-95cf-9a2c9f9439a5"
      unitRef="shares">15891570</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfMjUz_8039616c-3921-4560-86dd-5e173d01023c"
      unitRef="shares">431226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV8zNy9mcmFnOjI2YTFiZjY4MjUwYTRjY2FhZmYxODJhZTQ0YzRjYmU5L3RleHRyZWdpb246MjZhMWJmNjgyNTBhNGNjYWFmZjE4MmFlNDRjNGNiZTlfMjYw_efd21adc-78dc-4859-860c-2f69d4038523"
      unitRef="shares">263919</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfNjU5NzA2OTc3NDE4MA_f459a2c8-0e1d-4546-962b-b5fcbf1981a9">REVENUES&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.321%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.058%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.891%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;713,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;849,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;114,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,311,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,307,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;208,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,096,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,317,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,425,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;459,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,330,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,729,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into as a result of providing the distinct intellectual property rights for the respective international territory. These agreements also provide for additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;supplies.  The contractual payments associated with the partners achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Other revenues also include revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET&#x2019;s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.2&#160;million and $0.6&#160;million for the three months ended March 31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfMzAwMQ_cf7f3028-79d4-47a7-84e0-659f45bfaa04">&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s net revenues consisted of the following for the three months ended March 31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.321%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.058%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.891%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three months ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;713,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;849,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;114,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;199,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,311,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,307,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;208,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,096,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,317,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,425,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,060,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;459,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;709,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,330,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,729,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib9cd9a66d5994c338329d9b7f23a56f2_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMy01LTEtMS0w_7fa367d3-878a-4280-a3b3-4a80b01b68cb"
      unitRef="usd">713899</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71a0bbed12a24e969a3fa6d2c92012a5_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMy03LTEtMS0w_d4fb9b2e-3089-453a-a1d9-7465f037d1ea"
      unitRef="usd">849502</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad2f0112651b4b5fa2c8fa856efca4e1_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNC01LTEtMS0w_cce91490-63c1-479b-8873-75c670a4e931"
      unitRef="usd">114770</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16af1e6f767440c0963c81ea17a84134_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNC03LTEtMS0w_aa64d11b-09e0-4711-b742-0e4585ae3582"
      unitRef="usd">199537</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b63398db6574d36a6ab44657e1020f8_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNS01LTEtMS0w_f7966a2c-b5e8-452f-9dc2-10eb71ad045f"
      unitRef="usd">3311696</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e62ba5cdc8846b3a9cbad3ff2f3d0a6_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNS03LTEtMS0w_a5bbcf50-8eb1-4265-bfe0-d38c85c2829b"
      unitRef="usd">3307658</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2eff3e3f9b184c99a40826a7fc04fe79_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNi01LTEtMS0w_a65f64a6-24f0-43b9-bf3f-02fe79fc2eb4"
      unitRef="usd">208763</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51b53cdae72840e38ccd4cf9b68c791e_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNi03LTEtMS0w_84583510-06ec-4778-9112-649e91c5145b"
      unitRef="usd">286676</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97a6225e0029425ea693f971f523bd72_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNy01LTEtMS0w_d425e996-d5d9-4063-b3c2-81729655b0b3"
      unitRef="usd">1096291</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ad73aa4ec4243509dc87099f3f6d521_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfNy03LTEtMS0w_60707775-6bd9-48d5-81c4-242f03e8f59d"
      unitRef="usd">1317074</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34cec4fe802e445f9f9cd20594027f4c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTAtNS0xLTEtMA_3007ec29-a695-47bc-90a4-047583e48972"
      unitRef="usd">2425755</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ad0374626954d6a8779a7d539793fd1_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTAtNy0xLTEtMA_d8642756-aba4-4797-adbf-98f2150fedec"
      unitRef="usd">2060195</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5dd88465333045ef9fb8d8ae800f1e3c_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTEtNS0xLTEtMA_9b28884a-5459-45dc-90a6-c0cfc57265e9"
      unitRef="usd">459560</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4b8bef686ccd4979b9cbc4ee66cf65f8_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTEtNy0xLTEtMA_9a154b3e-5025-4f0e-9375-00c97657005d"
      unitRef="usd">709218</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTItNS0xLTEtMA_3461e97f-5ebb-48a4-8573-5ca780b69046"
      unitRef="usd">8330734</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a7bb43ebb9648959c442c69ba175516_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RhYmxlOjM4MzI2YTBjZDUzMzQ2ZjI4OWQ4NjVhNzVmY2FkNjEyL3RhYmxlcmFuZ2U6MzgzMjZhMGNkNTMzNDZmMjg5ZDg2NWE3NWZjYWQ2MTJfMTItNy0xLTEtMA_9648ab7a-8e0b-4c32-a720-7efe62e3678c"
      unitRef="usd">8729860</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i579ad134fe1e4cfabef5a5f04f4007a2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfNzE0NjgyNTU4OTA3OA_b10aa019-ec0a-4953-abd3-184ac909bd29"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ab812f8529f40f586ec3f2b6d28d198_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80MC9mcmFnOjU3ZWQ4ZTgyNzllZTQ4ZWZhMmJiNWNiODE4MjEwNmExL3RleHRyZWdpb246NTdlZDhlODI3OWVlNDhlZmEyYmI1Y2I4MTgyMTA2YTFfNzE0NjgyNTU4OTA5Mg_e6f42cbc-cb2d-4686-ba3b-f2b4e1a692bd"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfMjAxMw_a8e1ad1e-2f44-49e4-966d-f07d7c724d00">INVENTORIES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  During 2019, Cumberland also obtained $0.3&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. At March 31, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $15.6&#160;million. The Company did not have any finished goods included in the non-current inventories at March 31, 2020 or December 31, 2019, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.531%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,456,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,017,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,720,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,569,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,150,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryNoncurrent
      contextRef="i1cbff9f699734f4fb0660403bd88bfc3_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfNjU5NzA2OTc2OTYzNw_98e29a73-9a15-469e-bc52-8f2c6bcd0391"
      unitRef="usd">300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfNjU5NzA2OTc2OTY2NQ_e53ddfcc-f38a-47fb-bce3-6a0b5710d594"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfNjU5NzA2OTc2OTY2NQ_f10e8d7b-2e69-40e4-be15-e517fd8ed526"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RleHRyZWdpb246OTQ5MWQ2YTJkZTQwNDIyNjgyZjE3OTk5YmQ2ZTNjY2ZfMjAxMg_9e4db129-a93a-443b-834b-639f0a34aa7a">&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-top:7pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:56.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.121%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.530%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.681%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.531%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,456,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,345,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;245,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;416,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,017,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,664,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,720,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,426,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,569,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15,554,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,150,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,871,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMi0yLTEtMS0w_d9977d74-d56b-43ed-805a-be125b431c06"
      unitRef="usd">19456867</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMi00LTEtMS0w_38789efa-3de6-4464-8422-3ff49dc076e9"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMi00LTEtMS0w_7326ce1d-28e1-4196-952f-41944ab25970"
      unitRef="usd">19345723</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMy0yLTEtMS0w_eac5ce01-bbcb-4f82-9151-a1fbc4e9bb30"
      unitRef="usd">245354</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMy00LTEtMS0w_6861037e-9ff4-4101-980a-e2c7786249dd"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfMy00LTEtMS0w_cf915bf5-6d4e-43ba-871b-dc36998e9aac"
      unitRef="usd">416468</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNC0yLTEtMS0w_4381a2b5-32fa-408e-b31b-2cb9e249b242"
      unitRef="usd">4017923</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNC00LTEtMS0w_18c7d997-a40f-4182-bcd0-b6398d05b1ae"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNC00LTEtMS0w_609a61d3-4c7b-4f1d-9f81-79e8bd3126c0"
      unitRef="usd">4664055</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNS0yLTEtMS0w_340e8e60-3ffe-4c34-81a8-ec58bfb25572"
      unitRef="usd">23720144</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNS00LTEtMS0w_4334909d-17ad-40d6-88d9-3d226c19b409"
      unitRef="usd">24426246</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNi0yLTEtMS0w_9cb07d87-d320-4d24-a440-dcb33cea6595"
      unitRef="usd">15569992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNi00LTEtMS0w_ccafe397-fd73-4f99-8e21-325acd783009"
      unitRef="usd">15554992</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNy0yLTEtMS0w_9ee5624f-2372-4669-b2ce-b8b729014a91"
      unitRef="usd">8150152</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80My9mcmFnOjk0OTFkNmEyZGU0MDQyMjY4MmYxNzk5OWJkNmUzY2NmL3RhYmxlOjkwMzYwYzM2Y2I3MzQ4NzA4NmU4OWJlNjUwMjg2YWM2L3RhYmxlcmFuZ2U6OTAzNjBjMzZjYjczNDg3MDg2ZTg5YmU2NTAyODZhYzZfNy00LTEtMS0w_600031c7-6124-4c9f-a10b-738fe3394fc4"
      unitRef="usd">8871254</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjg3Mw_41c14a6c-7169-4130-9586-af6c8a490846">LEASES&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company&#x2019;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2020 is 2.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At March 31, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.187%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.005%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other non-current assets&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,733,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.187%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.005%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;943,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,831,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,775,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.971%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity of Leases Liabilities at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;844,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,100,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(325,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,775,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjc1Nw_858b26f2-5939-474a-8ac6-ac263b4e2156"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfNTQ5NzU1ODE0Mjk1Nw_bc6bb1f3-755e-4183-84af-642a2c8dba8b">P2Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjg3NA_b29027f1-c79f-46a6-8c52-a827606664ef">&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;At March 31, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.187%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.005%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other non-current assets&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,733,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,960,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:29.316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:27.500%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:14.187%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.464%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:16.005%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other current liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;943,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;920,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other long-term liabilities&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,831,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,076,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,775,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,996,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjkyZWMwNDVmY2E2YTRkN2FiYThlYWVlNzJlNWQ5ODcyL3RhYmxlcmFuZ2U6OTJlYzA0NWZjYTZhNGQ3YWJhOGVhZWU3MmU1ZDk4NzJfMS00LTEtMS0w_d10c6e02-ef0d-44fc-b27e-162406cee1f6"
      unitRef="usd">2733782</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjkyZWMwNDVmY2E2YTRkN2FiYThlYWVlNzJlNWQ5ODcyL3RhYmxlcmFuZ2U6OTJlYzA0NWZjYTZhNGQ3YWJhOGVhZWU3MmU1ZDk4NzJfMS02LTEtMS0yODI5_45c43cf3-3a7d-48c6-ad7a-a211399625b8"
      unitRef="usd">2960569</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfMi00LTEtMS0w_e41d19cd-a278-429c-9916-1232437916d7"
      unitRef="usd">943807</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfMi02LTEtMS0yODMw_59f8e17d-29a4-4049-b64c-33af043c2d0d"
      unitRef="usd">920431</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNC00LTEtMS0w_c6bb3086-cadd-4947-8e44-ce2e3988a7a0"
      unitRef="usd">1831274</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNC02LTEtMS0yODMy_86eaf861-2046-427f-a06d-cf46c81a79c7"
      unitRef="usd">2076472</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNS00LTEtMS0w_236f9d3f-9f08-4f29-b9cb-763b85af8efd"
      unitRef="usd">2775081</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="idc8b792be6e54df49d59d6e2ace6a801_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOjNkYmE1N2M0OWIyYjRiMDQ4YzY0YjNkYTc3ZjE0MjVjL3RhYmxlcmFuZ2U6M2RiYTU3YzQ5YjJiNGIwNDhjNjRiM2RhNzdmMTQyNWNfNS02LTEtMS0yODMy_fa4d721a-aabe-444d-aa25-99d14ede6707"
      unitRef="usd">2996903</cpix:LeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RleHRyZWdpb246ZjZlNWYwZDFlMmQ5NDhmYzhkOWE0ZTQ2YjdhNWI4M2FfMjg3NQ_a9b5e1f5-48c4-4f24-b80a-e9b425831e6e">&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:76.078%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.751%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.971%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Maturity of Leases Liabilities at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;844,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,144,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,019,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;92,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;After 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,100,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(325,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,775,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfMi0yLTEtMS0w_77ffd8a4-56db-45ff-8bf9-18c36fe94229"
      unitRef="usd">844017</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfMy0yLTEtMS0w_61bb7e99-e3bd-45fc-9598-bcae1b6341eb"
      unitRef="usd">1144889</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNC0yLTEtMS0w_39e796ce-0424-4f3a-a4b3-132b4accf041"
      unitRef="usd">1019313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNS0yLTEtMS0w_d63d9641-5913-4e32-a4d4-c1522610d50c"
      unitRef="usd">92478</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNi0yLTEtMS0w_e85e2c08-3b71-4e82-a848-d06efb75b876"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfNy0yLTEtMS0w_9d48d58c-e10d-4646-893a-fee014d88715"
      unitRef="usd">3100697</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfOC0yLTEtMS0w_32f72fc9-1f6b-47cd-b4d1-0dff24a80b37"
      unitRef="usd">325616</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80Ni9mcmFnOmY2ZTVmMGQxZTJkOTQ4ZmM4ZDlhNGU0NmI3YTViODNhL3RhYmxlOmQxZWNkN2I2MzQ4NDQzOGE5Zjk1OWUxMzJmZjNiMjNkL3RhYmxlcmFuZ2U6ZDFlY2Q3YjYzNDg0NDM4YTlmOTU5ZTEzMmZmM2IyM2RfOS0yLTEtMS0w_13d400f4-0ea4-4fd3-8eda-f50ca83eb2fb"
      unitRef="usd">2775081</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNjU5NzA2OTc3MjkwMA_d7302848-aa3f-4b17-a37f-f8847d3a4cac">SHAREHOLDERS&#x2019; EQUITY AND DEBT&lt;div style="margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2020 and March 31, 2019, the Company repurchased 164,876 shares and 121,466, respectively, of common stock for approximately $0.7 million and $0.7 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share purchases and sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Share Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the three months ended March 31, 2020 or March 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Restricted Share Grants &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During the three months ended March 31, 2020, and March 31, 2019, the Company issued 229,141 shares and 222,269 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjA0MA_be8c0114-58e3-40ca-8fab-05faba05647c"&gt;one&lt;/span&gt;-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Cumberland Emerging Technologies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;an agreement with WinHealth whereby WinHealth made a $1&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return it's shares in CET in exchange for consideration of  $0.8&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Debt Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#x201c;Pinnacle Agreement&#x201d;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#x201c;Second Amendment&#x201d;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.   &lt;/span&gt;&lt;/div&gt;The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 3.73% at March 31, 2020).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of March 31, 2020  and December 31, 2019, the Company had $18.5 million in borrowings outstanding under our revolving credit facility.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i6ea68976af4647a79518bbe864fb79d2_I20100513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTMz_15bc9e35-3c25-4ea7-a5dc-a7381ffc2bcd"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4ed406cf09644236bcf2d718718fb69b_I20160131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjk0_f703e585-a569-4c57-8a35-e6e06b67d313"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3699eff10cb14a69867fd346ae97c6a9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDE0_63057a8c-bd55-4255-b489-4eea151bc811"
      unitRef="shares">164876</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDk0NzgwMjMzMDMzMQ_7907221d-05d5-4664-a901-1aeb7756b8af"
      unitRef="shares">121466</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDg4_8963f361-b95e-4644-a68e-047b4727fa63"
      unitRef="usd">700000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2e3ea184f5154505be3fe97b7cb56777_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDk0NzgwMjMzMDM2MA_12aad4ad-b3b6-4458-9249-d81607196aa2"
      unitRef="usd">700000</us-gaap:StockRepurchasedDuringPeriodValue>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i273458bd3a91484ca9e99ab2ba12ad5d_D20171101-20171130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTQzNA_6252b40f-2c03-4ac8-ba69-e159b862780b"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iaacbe58946c445c98140de58546b9534_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTgyMw_0d277c68-5a64-4fe6-8f40-f64060f2eb0c"
      unitRef="shares">229141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if9b33bc113814241ac9ba8c827d1e630_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMTgzNw_615b197e-1177-4826-b9c0-fdabaa740467"
      unitRef="shares">222269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="ib6cb09a407c649fd83e3903abfc61538_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjQ1Ng_a123e240-1c08-49e2-b731-424200437d1c"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="ib6cb09a407c649fd83e3903abfc61538_I20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjc0Mw_011bab6b-c9e8-4d44-a8d0-cfd0208888f0"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentCashContribution
      contextRef="i4ade4870a15949a494ead077ed1ab45a_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjgzMw_ae935652-ba16-4dea-846e-019ff5dbe8ce"
      unitRef="usd">300000</cpix:SubsidiaryInvestmentCashContribution>
    <cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable
      contextRef="i2c2c6d15e8144444bdf89f20f0f4edb3_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjg2NA_ac385809-5c6f-4089-8f63-ed6b8e63726a"
      unitRef="usd">700000</cpix:SubsidiaryInvestmentConversionOfIntercompanyLoansPayable>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="i292c0e03fcc9444091fffb0964c106d1_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMzA2Ng_4a18bd9a-dad8-43b5-9868-9c1ab6540439"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i85e4bb036d714dd4a5d3f463aca96009_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDM2NA_196feb88-73c8-4328-92bf-c262e5c6d062"
      unitRef="usd">12000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions
      contextRef="i85e4bb036d714dd4a5d3f463aca96009_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDQ0Nw_6c9cf929-44dc-463e-b0d1-780a496bb172"
      unitRef="usd">20000000.0</cpix:LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2b413e2b14ac4e75b23217f08d1a9c8d_I20181017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDY4OA_559e2a18-84ce-4736-9623-9a86ea1cac70"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6629760d5fe04dbda09e1240d59bb8dd_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDg3NQ_d0993466-265b-44db-9923-666f8c7f3dfb"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i042b097bef654ed4ac034003fdf2d9e8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDg4MQ_479e6c5f-480e-46ad-8431-5a6c80771e87"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85e4bb036d714dd4a5d3f463aca96009_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDkxOA_daf4fdd1-04a9-40fe-81b4-93a50480051f"
      unitRef="number">0.0373</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ibad54c0f7e7445c781ab0aa335902d80_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfNDk1Mg_011822ac-b0d6-43e1-adc6-0af24fb93c79"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LongTermLineOfCredit
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMzg0ODI5MDcwMzI4NA_b758d474-488b-444e-9f6e-89ba42a6e207"
      unitRef="usd">18500000</us-gaap:LongTermLineOfCredit>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81Mi9mcmFnOmIxOGFiZDIyOWM4YTRhZmE5M2Q0YzgxZjg1ZDQyMWFiL3RleHRyZWdpb246YjE4YWJkMjI5YzhhNGFmYTkzZDRjODFmODVkNDIxYWJfMTc2OQ_bc11b359-1b4c-4797-98ac-25ac10c0e34a">INCOME TAXES&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#x201c;the Tax Act&#x201d;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#x201c;AMT&#x201d;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The SEC staff issued Staff Accounting Bulletin (&#x201c;SAB&#x201d;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  &lt;/span&gt;&lt;/div&gt;As of March 31, 2020, the Company has approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ifa55cb7eb5474354a2473e4ed21c98ea_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81Mi9mcmFnOmIxOGFiZDIyOWM4YTRhZmE5M2Q0YzgxZjg1ZDQyMWFiL3RleHRyZWdpb246YjE4YWJkMjI5YzhhNGFmYTkzZDRjODFmODVkNDIxYWJfMTM3Mw_b06b9e84-198b-4f0d-8dad-04d400f8a5e9"
      unitRef="usd">44100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NS9mcmFnOjUxZDNhMDk4OTJkZjQwNjU4ZGI0MThjNzg5NDBhNjI5L3RleHRyZWdpb246NTFkM2EwOTg5MmRmNDA2NThkYjQxOGM3ODk0MGE2MjlfOTgx_50e04df6-6af5-44c8-95bf-0d780b66e3ca">COLLABORATIVE AGREEMENTS&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzA1Mw_a6c57d63-e6a4-4531-b589-f593fea438d8">ADDITIONS AND RETURN OF PRODUCT RIGHTS&lt;div style="text-align:justify;margin-top:7pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.369%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,033,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(804,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;820,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(260,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(543,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,829,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In November 2016, the Company announced an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.&#x2019;s ("Nordic") injectable methotrexate product line as an asset purchase. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the Agreement, Cumberland is responsible for the products&#x2019; FDA submission and registration. As consideration for the license, at closing, Cumberland paid a deposit of $100,000.  The Company also recorded a liability of $0.9 million that was settled through 180,000 unvested restricted shares of Cumberland common stock.  These shares vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Nordic is responsible for manufacturing and supply of the products. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On November 27, 2019, Cumberland received FDA approval for the RediTrex product line and brand name. The 180,000 shares of restricted Cumberland common stock vested and were valued at $0.9 million on the vesting date. In addition, the FDA approval resulted in Cumberland recording an additional $1.0&#160;million other current liability due to Nordic that will be paid during 2020.    &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Ethyol and Totect &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. The Dissolution Agreement originally resulted in a transition from the Company's current arrangement with Clinigen effective September 30, 2019.  In early September 2019, Clinigen and Cumberland completed an Amendment to the Dissolution Agreement whereby the transition date was changed to late December 2019. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.  In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first installment of $0.8&#160;million during the quarter ended March 31, 2020 &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;as discontinued operations and will record each future quarterly installment over the two year period.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; There are no expenses associated with the installment payments under the Dissolution Agreement, resulting in $0.8&#160;million in discontinued operations income during the quarter ended March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Ethyol and Totect products provided $3.2&#160;million in revenue, $2.0&#160;million in direct expenses and $1.1&#160;million in discontinued operations income during the three months ended March 31, 2019. These direct expenses do not reflect the selling and marketing costs attributable to the individuals at Cumberland responsible for direct selling and promotion of the Products.  Those selling and marketing individuals who supported the Products continue to support Cumberland's other products.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;December 31, 2019 current assets of discontinued operations included $0.5&#160;million in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;inventory for the products sold back to Clinigen as part of the transaction. &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March 31, 2020 and December 31, 2019 &lt;/span&gt;the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i75c26a02dc094045bfcbdd64d34312fe_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMTgyMw_f76bfd6e-2788-4903-b3a3-43248298deb1"
      unitRef="usd">20000000.0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i76719a5ce10a4d26a917106b3d04b051_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMTg2Ng_c4cde30e-6ad2-42c1-9d99-a64749a3ea78"
      unitRef="usd">5000000.0</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i75c26a02dc094045bfcbdd64d34312fe_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMTk2OQ_98475aa3-85f2-4800-8253-2b31dd63e7e0"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQ5NQ_af2e14e4-78e6-4459-a5fc-c370e02e12b9">&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the initial payments and consideration for the business combination:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.631%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.369%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash paid at closing&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment during early 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair value of contingent consideration - net sales royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfMi0xLTEtMS0w_037c8d9c-969f-4164-9aff-116c3e41f666"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfMy0xLTEtMS0w_58cb77b6-67f4-40b8-90f1-cde1866fa253"
      unitRef="usd">5000000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <cpix:PaymentsForContingentConsideration
      contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfNC0xLTEtMS0w_fc988acc-2fc7-4b08-bfcf-c5f6f8876efd"
      unitRef="usd">9182000</cpix:PaymentsForContingentConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjRkZTk3NzNhMWE4MjRhOTM4NmQwZDU3OWRmMjlkNWVjL3RhYmxlcmFuZ2U6NGRlOTc3M2ExYTgyNGE5Mzg2ZDBkNTc5ZGYyOWQ1ZWNfNS0xLTEtMS0w_738be767-221e-4576-b6bc-4cdf92ca5b19"
      unitRef="usd">34182000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQ5Ng_dc27c937-0bb3-4396-8f22-d81c823828cb">&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at November 12, 2018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,034,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;508,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,502,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment to initial fair value of the contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;148,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,033,108)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(804,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;820,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,633,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(260,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Change in fair value of contingent consideration included in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(543,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration earned and accrued in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,829,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9fe3919ad9c7434f9290fae098a242e4_I20181112"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMS0xLTEtMS0w_4241d6c2-23a4-4352-8ff6-044c12aa3c01"
      unitRef="usd">9034000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iaff2de0de98c428d8e8f5eb28397ad66_D20181113-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMi0xLTEtMS0w_8be9d4e9-ae66-4908-b71d-729489950ae0"
      unitRef="usd">-40000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i6302aef8c83943f7b3951e346f855a91_D20181112-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMy0xLTEtMS0w_b949bce9-7902-4607-8771-e697d3880db9"
      unitRef="usd">508000</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i60ac1f01893a45b9935936208de31383_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNC0xLTEtMS0w_b4903222-6b3d-42f1-a306-d5bd2f127a46"
      unitRef="usd">9502000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment
      contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNS0xLTEtMS0w_6fae2504-82d2-46e0-805a-e117b41f0b8f"
      unitRef="usd">148000</cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment>
    <us-gaap:PaymentsForRoyalties
      contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNi0xLTEtMS0w_0eeaf128-2547-47dc-8af7-4145bc889e55"
      unitRef="usd">1033108</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfNy0xLTEtMS0w_f5ed547c-787a-420d-a7ec-10d1999df9e9"
      unitRef="usd">-804167</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i1a16ef9573464482a030c11307d87377_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfOC0xLTEtMS0w_6e9550b1-fc9c-4c87-a01c-217ffcc0fa82"
      unitRef="usd">820864</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0ecf68fa0fa84ed4ae405f562df6d78e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfOS0xLTEtMS0w_146d365f-8960-4a71-a599-5f605cf7878e"
      unitRef="usd">8633589</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTAtMS0xLTEtMjg1MQ_8b9c750d-f304-40cb-8043-01b12579bc70"
      unitRef="usd">260735</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTEtMS0xLTEtMjg1MQ_1f825a98-234f-46b7-ab85-0275aaa3a668"
      unitRef="usd">-543006</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTItMS0xLTEtMjg1MQ_91df443b-83b9-4e96-9f99-85d9c296a8e4"
      unitRef="usd">0</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i71b25ac7991045ce8e15afc8083e3c2c_I20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjgzODk1YjE0ODY5ZTQ3YjBhZTM5ZTZhNTgwZDUzNWE4L3RhYmxlcmFuZ2U6ODM4OTViMTQ4NjllNDdiMGFlMzllNmE1ODBkNTM1YThfMTMtMS0xLTEtMjg1MQ_a623a6dd-2638-4683-9c46-850923fd0c56"
      unitRef="usd">7829848</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQ5Nw_2a29c494-32ad-40f7-9558-db0cfeec0831">&lt;div style="margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:75.923%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:20.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,624,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - unlabeled vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,970,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work in process - validation vials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,827,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,129,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21,550,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Intellectual property amortizable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total intangibles and goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,632,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,182,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMC0xLTEtMS0w_caee0fb7-405c-4802-adec-a8098d194cf6"
      unitRef="usd">6624000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMS0xLTEtMS0w_0ac9e45b-aa77-4c49-bd4f-5da62f429e62"
      unitRef="usd">3970000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMi0xLTEtMS0w_f221b10a-ed88-413e-acbe-25918b6cbd18"
      unitRef="usd">1827000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfMy0xLTEtMS0w_5f09b8ac-5c10-49fb-b3b1-626d4a9eab8e"
      unitRef="usd">9129000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfNC0xLTEtMS0w_1a10a46f-fc80-482f-9388-8fa035de4caf"
      unitRef="usd">21550000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfNi0xLTEtMS0w_70d20038-7f62-4c46-855a-7dfcf9d2f2ed"
      unitRef="usd">11750000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfNy0xLTEtMS0w_392ccfd4-e1ce-47e6-838e-bb5007aa5c58"
      unitRef="usd">882000</us-gaap:Goodwill>
    <cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfOC0xLTEtMS0w_c7283bec-7ce1-4458-b5ff-2b1ee54a97d3"
      unitRef="usd">12632000</cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i8444e0e8293a4f028089960cf516762d_I20181130"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RhYmxlOjEyMzBiYmQ3N2NlMTQ5ZTI5OTBmZTIxYWVhN2RjMTFlL3RhYmxlcmFuZ2U6MTIzMGJiZDc3Y2UxNDllMjk5MGZlMjFhZWE3ZGMxMWVfOS0xLTEtMS0w_8dea7ffd-546a-402c-8975-6284cb31bbaa"
      unitRef="usd">34182000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9ffe21db330645f5a121ce609572f5f2_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTE3Nw_cc504ee0-66a9-4ce8-8939-7d1b7244f31c"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i9ffe21db330645f5a121ce609572f5f2_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTIyMw_0c9b58a3-17b8-473f-a020-651c45c296c4"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i25267995c74748d6b1a05373c4e7820f_D20161101-20161130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTI1NQ_dfdae8b8-4fc1-4ce1-917a-452326042179"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i25267995c74748d6b1a05373c4e7820f_D20161101-20161130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTY3OA_dfdae8b8-4fc1-4ce1-917a-452326042179"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i4f6e5559b01349c0b2cb01a91818807a_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTc1Mg_28d03016-f51a-4afc-89c8-d961ddfd51eb"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5f4b8237d2904a1d9dd96818c23f441e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMjc0ODc3OTA3NTgzMg_69ce8623-bf3f-4e76-ab56-e8d706b9b510"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i667d0b68773d46a1a38eecfd7b6b8ff2_D20191001-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNDQwOA_0edc9c6e-b733-4691-9228-29c2764823a7"
      unitRef="usd">5000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i46788283ae334d9ea8d12af5a988a06f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMzg0ODI5MDcwOTk2Mw_73998ec1-43a8-42be-9627-dcc06adbaa91"
      unitRef="usd">800000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i46788283ae334d9ea8d12af5a988a06f_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfMzg0ODI5MDcxMDk3MA_73998ec1-43a8-42be-9627-dcc06adbaa91"
      unitRef="usd">800000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:Revenues
      contextRef="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc3OTU1NQ_bb8e330d-2d3b-47ab-b376-cc7da40cc337"
      unitRef="usd">3200000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzAxMg_537b4657-81fd-4355-b217-1316a936ba18"
      unitRef="usd">2000000.0</us-gaap:OperatingExpenses>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzAyNg_83ea48cb-698a-4177-addd-d086da72b9da"
      unitRef="usd">1100000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i81890f83a54f44bc874066750703bfcc_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81OC9mcmFnOjBkYzcyZmE3MWE4YzQyZmRhNzhjZDY2NWI5Njg3MWFlL3RleHRyZWdpb246MGRjNzJmYTcxYThjNDJmZGE3OGNkNjY1Yjk2ODcxYWVfNjU5NzA2OTc4MzA0MA_8ae75073-91f0-4537-90ea-fccaaa664d88"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NDAvZnJhZzo0NjRiYzQ4MmRmNTg0ZWMxYWIzZmEwYzYxNTFkMWUzOC90ZXh0cmVnaW9uOjQ2NGJjNDgyZGY1ODRlYzFhYjNmYTBjNjE1MWQxZTM4XzY1OTcwNjk3NzQ4Njg_50e4cb92-eed4-44a9-ac66-e7b4e727a28d">SUBSEQUENT EVENTS&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The PPP is administered by the U.S. Small Business Administration.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act.&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"&gt;  &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company intends to use the majority of the loan amount for such qualifying expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:8pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, thanks to assistance from the PPP loan, the Company currently does not foresee doing so. Cumberland will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="i92b3abff138f4568b1b90d05aff3cf8d_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NDAvZnJhZzo0NjRiYzQ4MmRmNTg0ZWMxYWIzZmEwYzYxNTFkMWUzOC90ZXh0cmVnaW9uOjQ2NGJjNDgyZGY1ODRlYzFhYjNmYTBjNjE1MWQxZTM4XzY1OTcwNjk3NzQ4NTE_8dc2b2e6-a544-4eae-ac47-c05d76b31ccb"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage
      contextRef="ic59f3a91d3c34c248c4b7251dabdddec_I20200420"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV81NDAvZnJhZzo0NjRiYzQ4MmRmNTg0ZWMxYWIzZmEwYzYxNTFkMWUzOC90ZXh0cmVnaW9uOjQ2NGJjNDgyZGY1ODRlYzFhYjNmYTBjNjE1MWQxZTM4XzY1OTcwNjk3NzQ4NjM_c82f57e7-fba1-442c-b28a-225c74651316"
      unitRef="number">0.010</cpix:CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6745946736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Operating Segments</a></td>
<td class="text">Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630535008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Product Revenues</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company accounts for revenues from contracts with customers under ASC 606, which became effective January 1, 2018. As part of the adoption of ASC 606, the Company applied the new standard on a modified retrospective basis analyzing open contracts as of January 1, 2018. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.321%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:13.058%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.891%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">713,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">849,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,311,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,307,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">208,763&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,096,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,317,074&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,425,755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,330,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,729,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Revenues</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has agreements with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is typically entitled to receive a non-refundable, up-front payment at the time each agreement is entered into as a result of providing the distinct intellectual property rights for the respective international territory. These agreements also provide for additional payments upon the partners' achievement of defined regulatory approvals, sales milestones or both. The Company may also be entitled to receive royalties on future sales of the products under the agreements and a transfer price on </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">supplies.  The contractual payments associated with the partners achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other revenues also include revenue generated by CET through grant funding from federal Small Business grant programs, and lease income generated by CET&#8217;s Life Sciences Center and contract services. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.2&#160;million and $0.6&#160;million for the three months ended March 31, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608785888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (&#8220;the Tax Act&#8221;).  The Tax Act makes broad and complex changes to the U.S. tax code, including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21%; (2) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how AMT credits can be realized; (3) capital expensing; and (4) creating new limitations on deductible interest expense and executive compensation.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The SEC staff issued Staff Accounting Bulletin (&#8220;SAB&#8221;) 118, providing guidance on applying the Tax Act.  SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.  In accordance with SAB 118, a company reflects the income tax effects of the Tax Act for which the accounting under ASC 740 is complete.  To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but a reasonable estimate is available, it must record the estimate in the financial statements.  If a company cannot determine an estimate, it should continue to apply ASC 740 on the basis of the tax laws that were in effect immediately prior to enactment of the Tax Act.  </span></div>As of March 31, 2020, the Company has approximately $44.1 million of net operating loss carryforwards resulting from the exercise of nonqualified stock options that have historically been used to significantly offset income tax obligations. The Company expects it will continue to pay minimal income taxes during 2020 and beyond, through the continued utilization of these net operating loss carryforwards, on any taxable income generated from our operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>88</ContextCount>
  <ElementCount>272</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statement of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity</Role>
      <ShortName>Condensed Consolidated Statement of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118106 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Shareholders' Equity and Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</Role>
      <ShortName>Shareholders' Equity and Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2126108 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129110 - Disclosure - Additions and Returns of Product Rights</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</Role>
      <ShortName>Additions and Returns of Product Rights</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319305 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Additions and Returns of Product Rights (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables</Role>
      <ShortName>Additions and Returns of Product Rights (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails</Role>
      <ShortName>Organization and Basis of Presentation Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments in Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual</Role>
      <ShortName>Earnings (Loss) Per Share (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesDetails</Role>
      <ShortName>Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Shareholders' Equity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails</Role>
      <ShortName>Shareholders' Equity and Debt (Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Change in Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails</Role>
      <ShortName>Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cpix-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SubsequentEvents</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cpix-20200331.htm">cpix-20200331.htm</File>
    <File>a2020q1-exhibit311.htm</File>
    <File>a2020q1-exhibit312.htm</File>
    <File>a2020q1-exhibit321.htm</File>
    <File>cpix-20200331.xsd</File>
    <File>cpix-20200331_cal.xml</File>
    <File>cpix-20200331_def.xml</File>
    <File>cpix-20200331_lab.xml</File>
    <File>cpix-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6922597024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Debt) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 17, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="nump">$ 18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Second Amendment | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit, maximum borrowing capacity</a></td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions', window );">Line of credit, maximum borrowing capacity upon satisfaction of certain conditions</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">3.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Line of Credit | Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate spread</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6921802592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Present value of remaining lease payments, percent</a></td>
<td class="nump">7.42%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6607562480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the relationship with the manufacturer or packager, the Company will either take title to the finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale. Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company continually evaluates inventory for potential losses due to excess, obsolete or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates that the carrying value may not be recoverable, a charge is taken to reduce the inventory to its current net realizable value.  At March 31, 2020 and December 31, 2019, there were no cumulative obsolescence and discontinuance losses necessary.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient (&#8220;API&#8221;) for Kristalose and maintains the inventory at the third-party manufacturer. As the API is consumed in production, the value of the API is transferred from raw materials to finished goods. API for the Company's Vaprisol brand is also included in the raw materials inventory total.  Consigned inventory represents Authorized Generic inventory stored until shipment.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories that are classified as non-current inventories.  During 2019, Cumberland also obtained $0.3&#160;million in non-current inventory for API related to its ifetroban clinical initiatives. At March 31, 2020 and December 31, 2019, total non-current inventory, including Vibativ and ifetroban, was $15.6&#160;million. The Company did not have any finished goods included in the non-current inventories at March 31, 2020 or December 31, 2019, respectively.  </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net inventories consisted of the following:</span></div><div style="text-align:center;margin-top:7pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:56.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.121%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.530%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.681%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.531%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials and work in process</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,456,867&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,345,723&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">245,354&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">416,468&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,017,923&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,664,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,720,144&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,426,246&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,569,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,554,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,150,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,871,254&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>26
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20200331.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 88,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml",
      "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd",
      "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd",
      "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 324,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2018-01-31": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 6
   },
   "keyCustom": 21,
   "keyStandard": 251,
   "memberCustom": 15,
   "memberStandard": 16,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Revenues",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Inventories",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118106 - Disclosure - Leases",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Shareholders' Equity and Debt",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt",
     "shortName": "Shareholders' Equity and Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126108 - Disclosure - Income Taxes",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Collaborative Agreements",
     "role": "http://www.cumberlandpharma.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129110 - Disclosure - Additions and Returns of Product Rights",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights",
     "shortName": "Additions and Returns of Product Rights",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - Subsequent Events",
     "role": "http://www.cumberlandpharma.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Basis of Presentation (Policies)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Investments in Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Revenues (Tables)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Inventories (Tables)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319305 - Disclosure - Leases (Tables)",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Additions and Returns of Product Rights (Tables)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables",
     "shortName": "Additions and Returns of Product Rights (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Basis of Presentation Organization (Details)",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails",
     "shortName": "Organization and Basis of Presentation Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Investments in Cash Equivalents and Marketable Securities (Details)",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Investments in Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Earnings (Loss) Per Share (Details)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Earnings (Loss) Per Share (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual",
     "shortName": "Earnings (Loss) Per Share (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Revenues (Details)",
     "role": "http://www.cumberlandpharma.com/role/RevenuesDetails",
     "shortName": "Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ib9cd9a66d5994c338329d9b7f23a56f2_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockNoParValue",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Inventories (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i1cbff9f699734f4fb0660403bd88bfc3_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Leases (Lease Position) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails",
     "shortName": "Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i4ed406cf09644236bcf2d718718fb69b_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails",
     "shortName": "Shareholders' Equity and Debt (Shareholders' Equity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i4ed406cf09644236bcf2d718718fb69b_I20160131",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Shareholders' Equity and Debt (Debt) (Details)",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails",
     "shortName": "Shareholders' Equity and Debt (Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i2b413e2b14ac4e75b23217f08d1a9c8d_I20181017",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - Additions and Returns of Product Rights - Narrative (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
     "shortName": "Additions and Returns of Product Rights - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i2cb927ffbf29488ab253abb5da0b6182_D20190101-20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i75c26a02dc094045bfcbdd64d34312fe_D20181101-20181130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i0fd95e6b7cef48a58cb8e905ab80f3d3_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:PaymentsForContingentConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (loss)",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9fe3919ad9c7434f9290fae098a242e4_I20181112",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - Additions and Returns of Product Rights - Change in Consideration (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
     "shortName": "Additions and Returns of Product Rights - Change in Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i1a16ef9573464482a030c11307d87377_D20190101-20191231",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "ifa55cb7eb5474354a2473e4ed21c98ea_I20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "role": "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
     "shortName": "Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i8444e0e8293a4f028089960cf516762d_I20181130",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i92b3abff138f4568b1b90d05aff3cf8d_D20200420-20200420",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.cumberlandpharma.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i92b3abff138f4568b1b90d05aff3cf8d_D20200420-20200420",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i1a78868ca68246878f4a228d9e2b4dc5_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statement of Equity",
     "role": "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
     "shortName": "Condensed Consolidated Statement of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i1a78868ca68246878f4a228d9e2b4dc5_I20181231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Investments in Cash Equivalents and Marketable Securities",
     "role": "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities",
     "shortName": "Investments in Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Earnings (Loss) Per Share",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20200331.htm",
      "contextRef": "i9cece6e6420548fd91b8e3046d72a6d9_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Acetadote",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Lease Position"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "label": "Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment",
        "terseLabel": "Adjustment to initial fair value of the contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory",
        "terseLabel": "Finished goods inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill",
        "terseLabel": "Total intangibles and goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials",
        "terseLabel": "Work in process - unlabeled vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials",
        "terseLabel": "Work in process - validation vials"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caldolor",
        "label": "Caldolor [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ClinigenHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Clinigen Healthcare Limited",
        "label": "Clinigen Healthcare Limited [Member]",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "ClinigenHealthcareLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "label": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "terseLabel": "Collaborative Arrangement, Federal Small Business Grant Programs"
       }
      }
     },
     "localname": "CollaborativeArrangementFederalSmallBusinessGrantProgramsMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Coronavirus Aid, Relief, and Economic Security Act, Debt Instrument, Interest Rate, Stated Percentage",
        "label": "Coronavirus Aid, Relief, and Economic Security Act, Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_EquityAndDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity and Debt [Abstract]",
        "label": "Equity and Debt [Abstract]"
       }
      }
     },
     "localname": "EquityAndDebtAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "xbrltype": "stringItemType"
    },
    "cpix_GloriaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gloria Pharmaceuticals",
        "label": "Gloria Pharmaceuticals [Member]",
        "terseLabel": "Gloria Pharmaceuticals"
       }
      }
     },
     "localname": "GloriaPharmaceuticalsMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "terseLabel": "WinHealth"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "IncreaseDecreaseInCurrentOperatingLiabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInCurrentOperatingLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Kristalose",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity Upon Satisfaction Of Certain Conditions",
        "terseLabel": "Line of credit, maximum borrowing capacity upon satisfaction of certain conditions"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityUponSatisfactionOfCertainConditions",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Omeclamox-Pak",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherLongTermObligationsExcludingCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long Term Obligations, Excluding Current Portion",
        "label": "Other Long Term Obligations, Excluding Current Portion",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLongTermObligationsExcludingCurrentPortion",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Products",
        "label": "Other Products [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PaymentsForContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Contingent Consideration",
        "label": "Payments for Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration - net sales royalty"
       }
      }
     },
     "localname": "PaymentsForContingentConsideration",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pinnacle Bank",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products.",
        "label": "Products [Abstract]",
        "verboseLabel": "Products:"
       }
      }
     },
     "localname": "ProductsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Second Amendment",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ShareholdersEquityTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shareholders Equity.",
        "label": "Shareholders Equity (Textual) [Abstract]",
        "verboseLabel": "Shareholders' Equity (Textual) [Abstract]"
       }
      }
     },
     "localname": "ShareholdersEquityTextualAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentCashContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Cash Contribution",
        "label": "Subsidiary Investment, Cash Contribution",
        "terseLabel": "Contribution of cash"
       }
      }
     },
     "localname": "SubsidiaryInvestmentCashContribution",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "label": "Subsidiary Investment, Conversion Of Intercompany Loans Payable",
        "terseLabel": "Conversion of intercompany loans payable"
       }
      }
     },
     "localname": "SubsidiaryInvestmentConversionOfIntercompanyLoansPayable",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Payments For Return Of Capital",
        "label": "Subsidiary Investment, Payments For Return Of Capital",
        "terseLabel": "Cash payments for return of shares"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subsidiary Investment, Purchase Of Shares",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "terseLabel": "Investment through purchase of shares of CET Stock"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Percentage of tiered royalty payments (up to)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaprisol",
        "label": "Vaprisol [Member]",
        "terseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20200331",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r57",
      "r91"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r123",
      "r154",
      "r156",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r31",
      "r155"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.",
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r68",
      "r85",
      "r212"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r85",
      "r139",
      "r141"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Common stock available for purchase through restricted stock awards and options (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetailsTextual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item is to be populated with the collective of (i) types (categories) of arrangements of the entity applicable to its revenue-generating activities or operations and non-arrangement transactions, including but not limited to, for instance, sales of product manufactured by the entity, if such comparison of arrangements as a component of all transactions is provided by the entity.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r120",
      "r229",
      "r245"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r56"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r13",
      "r14",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r162",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r176",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "verboseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r183",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r181",
      "r183",
      "r184",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liability recorded"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r84",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of contingent consideration included in operating expenses"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r182",
      "r185",
      "r189"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Additional liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ADDITIONS AND RETURN OF PRODUCT RIGHTS"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRights"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intellectual property amortizable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r178",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Total inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r17",
      "r41",
      "r87"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r87",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r210"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r12",
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r145",
      "r234",
      "r250"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, End of Period (in shares)",
        "periodStartLabel": "Balance, Beginning of Period (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u2014no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r61",
      "r197",
      "r198",
      "r204"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r61",
      "r196",
      "r204"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r230",
      "r231",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate spread"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r170"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r90",
      "r172",
      "r173"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r118"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DirectorMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Person serving on the board of directors (who collectively have responsibility for governing the entity).",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r65",
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "terseLabel": "Discontinued operations income"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r13",
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r95",
      "r98",
      "r100",
      "r101",
      "r102",
      "r105",
      "r239",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r95",
      "r98",
      "r100",
      "r101",
      "r102",
      "r105",
      "r239",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.",
        "label": "Excess Tax Benefit from Share-based Compensation, Operating Activities",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "ExcessTaxBenefitFromShareBasedCompensationOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Fair value of marketable securities, by type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r209",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r209",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r209",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r63",
      "r67",
      "r98",
      "r100",
      "r101",
      "r236",
      "r237",
      "r239",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r63",
      "r67",
      "r98",
      "r100",
      "r101",
      "r102",
      "r239",
      "r251",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Continuing operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r15",
      "r67",
      "r252"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r65",
      "r67",
      "r99",
      "r100",
      "r101",
      "r239",
      "r252",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - basic (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Earnings (loss) per share attributable to common shareholders - Discontinued operations - diluted (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r90",
      "r119",
      "r174"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r64",
      "r117",
      "r211",
      "r212",
      "r240"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r36",
      "r135"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Inventory, Gross, Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r18",
      "r53",
      "r134"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories classified as current",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net, Items Net of Reserve Alternative [Abstract]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetItemsNetOfReserveAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "Inventory, Noncurrent",
        "terseLabel": "Non-current inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r37",
      "r135"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r73",
      "r116"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r228",
      "r243",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "INVESTMENTS IN CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r233",
      "r248"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r13",
      "r14",
      "r142",
      "r144"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r44",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r44",
      "r92"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r49",
      "r147",
      "r148"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Loss Contingency Accrual [Roll Forward]",
        "terseLabel": "Loss Contingency Accrual [Roll Forward]"
       }
      }
     },
     "localname": "LossContingencyAccrualRollForward",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r52",
      "r232",
      "r247"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by (used in) operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r58",
      "r60",
      "r66",
      "r86",
      "r104",
      "r238",
      "r253"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss) attributable to common shareholders",
        "totalLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r60",
      "r200",
      "r203"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationOrganizationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "terseLabel": "Direct expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Lease Liabilities, Payments Due [Abstract]",
        "terseLabel": "Maturity of Leases Liabilities at March 31, 2020"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilitiesMaturityandFutureMinimumLeaseCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r214"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r217",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Present value of remaining lease payments, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r216",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r16",
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r46"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "terseLabel": "Cash payment during early 2019"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "negatedLabel": "Repurchase of subsidiary shares from noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r75",
      "r187"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payment to acquire business upon closing",
        "verboseLabel": "Payment to acquire business upon closing"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Financial consideration received in exchange for product license rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r58",
      "r60",
      "r80",
      "r120",
      "r122",
      "r196",
      "r199",
      "r201",
      "r203",
      "r204"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r24",
      "r25",
      "r143",
      "r249"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r169",
      "r257"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r32",
      "r150",
      "r246"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r152",
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenues",
        "verboseLabel": "Net revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r70",
      "r114",
      "r115",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Net Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r215",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of operating lease assets and liabilities through adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reporting scenario used to indicate financial results forecast for a future period.",
        "label": "Scenario, Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario, Unspecified [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r241",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r176",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsChangeinConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofInitialPaymentsandConsiderationDetails",
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsScheduleofPreliminaryPurchaseAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r176",
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Reconciliation of numerator and denominator"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Summary of net revenue"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r23",
      "r38",
      "r39",
      "r40"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r162",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock awards, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock granted in period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r160",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r51",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r29",
      "r30",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Unvested restricted shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r29",
      "r30",
      "r149",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r51",
      "r149",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Vested common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r29",
      "r30",
      "r150",
      "r161",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.",
        "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "verboseLabel": "Repurchase outstanding common shares"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r29",
      "r30",
      "r149",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of shares (in shares)",
        "terseLabel": "Repurchase of shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r29",
      "r30",
      "r149",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "negatedTerseLabel": "Repurchase of shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r33",
      "r34",
      "r125"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r194",
      "r195",
      "r202"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, End of Period",
        "periodStartLabel": "Balance, Beginning of Period",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND DEBT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AdditionsandReturnsofProductRightsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental non-cash operating, investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityandDebtShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InvestmentsinCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive effect of other securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r97",
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "- diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r96",
      "r102"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "- basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2018-01-31",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeloss",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27290-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27337-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27340-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27357-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109196918&loc=d3e11374-113907"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355146-122828"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=68078379&loc=d3e122625-111746"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r258": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r259": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r261": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r262": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r263": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868656-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1278-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6637772352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text">COLLABORATIVE AGREEMENTS<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The Company has determined that these collaborative agreements do not meet the criteria for accounting under ASC Topic 808, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Collaborative Agreements</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. Expenses incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the condensed consolidated statements of operations and comprehensive income (loss).</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>28
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MX7<1]H-U._>/C<^"NH5?=Z&_ %!+ P04    " "GB;90F5R<(Q &  "<)P
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M.ZV-L@M*[^Q2#K9;'@>5VIG^=FKOVVO+>!T8?1S:X63LR5=_ %!+ P04
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M)=<D:H^"46'N7G$5DK6VBD)IR=LX-IT9AW$EW5B;VQ!90S09PN1#0VP-\<*
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MM+)AYD8IK87Q-=!Q4>368$,%-%0 0T88*H*.5,JYLG(2 IWFW'"D9)1B.*3
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M_F2\QQ:62FKHK,2.&*AS^I <CFG(CPD_)8QV99/0R1GQ.3A?JISN@B!04+K
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M;#8D5#X<[_!LQS$;#6^ZZ0>Q^1OG_P!02P,$%     @ IXFV4-\8YE"U 0
MT@,  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6QM4]N.FS 0_17+'[ &
MDK;9") V6U6MU$K15MT^.S" M;Y0VX3MWW=L"*5;7FS/>,Z9,^-Q/AK[XCH
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MC0_'#WBVTYA-AC?]_(/8\HW+/U!+ P04    " "GB;90\OL/2K8!  #2 P
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MXS=_-N.8C8;#;OI!;/[&^3]02P,$%     @ IXFV4.,"S/ZW 0  T0,  !D
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M\6<S3MEH..RF#\3F7US\!5!+ P04    " "GB;90$Q#J@;8!  #2 P  &0
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M%N;7$12..4WH-? BF]:% "NR7C3P%=RW_F2\QQ:52FKHK,2.&*AS^I@<CFG
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M%7,@H+)^^^CV>AR8,;"JF]X",C](^6]02P,$%     @ IXFV4#^]1IVW 0
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M&A>.M_YLYC&;#8?#\H/8^HW+OU!+ P04    " "GB;90YMF&7\,!   W!
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MSZL]YXIJ4N]!&UWJ*\RX8'2OS#31<]&?X_U"\7:XHZ#QHE3\ U!+ P04
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MOJ:S1&6.@SINYJ [0C)ZX\(9*(8!8LI # .N(<USBM- $ !DI& %+*@ !17
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MW?O98% 9=WVR=S5._V@8V4V+C>=_E^PO4$L#!!0    ( *>)ME @1K;#*P,
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M<I!TK P"9%20J:0 =SBX#H=XXKL-N".!SI<&<$<"S)"F UW]%T*(1!2-I,&
MA!,J)[83P#T.KL<AGNH#<$=">(,TN"/!W1<1:2*GXC"2$1]_@A&<(!+HQ$<"
M<(>#ZW"()[8VP!T)X@9A<$>"NS\BPL1.:V(;?D(<85P<O\:U*06#+C-7Y:%I
MR"MOJ\^%J?NYP6S?]#] W:6.YM?V,-"V[A\T[4GB>U(>TJ+RGK6Q/7#3J>ZU
M-LJF2>[LFSO:PTL_R-3>U+?"WI=M!]\.C#YUIY.@/R*M_@%02P,$%     @
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M"!2(O$#\3H NHAQM4F_3>9L\CC')8$X,<F* $RTXHTURQR$DCO.\@$$)"$H
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M7]9[_KHA1=&<9[SSH6KZ'U!+ P04    " "GB;90AWW?9(L"  "="0  &0
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MU9K;\68WDG7#Y$;CYZ/\!U!+ P04    " "GB;90FA4GZZ "  #("   &0
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M3FIV4&98Z+'H+]=^HG@W?#<DX\?+\B]02P,$%     @ IXFV4'U%87QJ @
M;P@  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULC5;K;ILP%'X5Q ,4
M;'.-$J0U:-JD38HZK?OM)$Y !<QL)W1O/]L01+!I\R>^\%W..>38K#O*WGA!
MB'#>ZZKA&[<0HEUY'C\4I,;\B;:DD4].E-58R"4[>[QE!!\UJ:X\Z/N15^.R
M<;.UWMNQ;$TOHBH;LF,.O]0U9O^>246[C0O<V\9+>2Z$VO"R=8O/Y!<1O]L=
MDRMO5#F6-6EX21N'D=/&_0)6.0@402->2]+QR=Q1J>PI?5.+[\>-ZZN(2$4.
M0DE@.5S)EE254I)Q_!U$W=%3$:?SF_I7G;Q,9H\YV=+J3WD4Q<9-7.=(3OA2
MB1?:?2-#0J'K#-G_(%=22;B*1'H<:,7UKW.X<$'K046&4N/W?BP;/7:#_HUF
M)\"! $="7YQ% AH(Z%%",!""&<'K4]&UR;' V9K1SF']ZVVQ^A>!52"K?U";
MNMCZF2P/E[O7#"7)VKLJH0'SW&/@! /O$5L3$:;WD-R$H- ?,9X,<HP46B.%
M6@#="<1V 6050%H@F C$_BS3'A)I2*,A22)[: ;;?@J[BR:P1A,8T<!D02"T
M"H2/UR.R"D1&!"B9O[7(R#2*8+"8:FPUBDVC=%;2O,>$$R.4QOZB46(U2BQ&
M8&:4&$8@@?&B46HU2BU&LY[(4\,H!3!=- *^O3]]BQ6:]Y9O>$$0ALOE PN'
M ;"8!7,S8%80Q!^9V?L9P$_[,1\PX8.=!NR-#\S.1VDXMT)F6C!"'YC9^QJ8
MC8W2:&X6&'V% F#+S)L<Y.HJ_HG9N6RXLZ="W@GZY#Y1*HA4]9]D\(6\_<=%
M14Y"36,Y9_T5V"\$;8?KW1N_,;+_4$L#!!0    ( *>)ME!V:YACKP$  ,,#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;&U3VV[C(!#]%<0'%)NX
M31K9EC:M5KM2*T5=;?>9V.,8E8L72-S^?;FX5AKY!6:&,^?,#%".VKS9'L"A
M=RF4K7#OW+ EQ#8]2&9O] #*GW3:2.:\:X[$#@98&Y.D(#3+[HAD7.&ZC+&]
MJ4M]<H(KV!MD3U(R\[$#H<<*Y_@K\,*/O0L!4I<#.\(?<'^'O?$>F5E:+D%9
MKA4RT%7X1[[=%0$? :\<1GMAH]#)0>NWX/QN*YR%@D! XP(#\]L9'D"(0.3+
M^#]QXEDR)%[:7^P_8^^^EP.S\*#%/]ZZOL(;C%KHV$FX%SW^@JF?6XRFYI_@
M#,+#0R5>H]'"QA4U)^NTG%A\*9*]IYVKN(_II%A/:<L)=$J@<P)-O22A6/DC
M<ZPNC1Z12;,?6+CB?$O];)H0C*.(9[YXZZ/G>G6_+LDY$$V87<+0;YC-C"&>
M?Q:ABR(T$JR^$=PO$ZP6"5:1H+@@*++LJLJ$N8L8%3$TWZSS(EL6*A:%B@6A
M_$IH"4.O1,C%_,/S?F;FR)5%!^W\5<:!=UH[\'S9C7\SO?]1LR.@<\%<>]ND
M=Y4<IX?IRY#YW]:?4$L#!!0    ( *>)ME )XEC<KT4  $(& 0 4    >&PO
M<VAA<F5D4W1R:6YG<RYX;6SM?6ESV]B5Z.=YOP+E<::E*E#-12(I=R95M"1W
ME+AE1Y0[DTF]#R!Y*:%- @P 2F9J?OR<[6ZX $6Y.WDS];HJBT4 =SGWW+,O
MORW+*MIFZ=^VZB+?9M6_OSKM#EY%7]:KK/SW5P]5M7GS[;?E_$&MD_(DWZ@,
MGBSS8IU4\&=Q_VVY*52R*!^4JM:K;_O=[O#;=9)FKW[WVS+]W6^KWUWDCZJ(
M/B;W*NI$Y4-2J/*WWU:_^^VW^)A?&40_Y%GU4$97V4(MZD]_2(J3:-"+HWZW
MWPT?[J+>N/D9S_S7R:RLBF1>_=_Z\\M\OEVKK(KN=AM5?]CK=O[4^L&?MDE1
MJ6*UBV[5)B^J^HM5L0T&-!]_5$6:+W"OT652!>_I[?Z??_F7IDW911=)5J95
MFF<MBU@FJS(8_2JKTFH7O4M7*KK9KF>JJ+_1[?8Z@\%P,&KY]%;=IPA06,)-
ML@XFN*!!5PGL[B,<]CJ9JVV5SF$MT74V/VD9] )V5"0K>&6AOD1_5+MP5=U>
M=SSJGY^&$Q8%PN-=6L(LT5]44K3"MM/I]3N#7BM,W3'>P8\!IO:[O?/GOI;S
M;?S^3\'<$_ATP9^ODOL6\ #D\@+..,'CCJ-I!7N+\B*B"UL ^/)%L->[FY;!
M[I(OT?4"9DR7<"Z$0,V8,.QW>J/AV: ?;%E&FBP6<)O+6/\C>I]F*OJ0!6OI
MG_7/HC\K(#1X,I-'E87W8^^8=T]Y_?WI-@4@G)\%-Z0^T 7^!<"ZRY^R^KLW
M2?GPF*Y6SZ[&@/QCD3^FV?S9#S[F907(\)_IIO%T!J-^=Q"@,HT Y+3QDV'O
MK/[3^YP0[B'/VFYS_^RL R1YW';OY/(P!4FS>]IHB+=_"8FV04T@A$!=TT>%
M5R[10^XA/("W ,S[O AN^4V>=9+Y7,$[\,:"WVX9:;I.5JOH[;8$_"C;5G>U
M5L4];NO[(G^J'@"NZTV2!?/J(1\4#-GRSEU: <W,EU&O?S0[CJ9JOBW@HY#I
MK-=PH\HJGW^.HRR/-D!+'I-5B/! P!<$\=UZEJ^"<3Y>_T> \C)G=/5E_I!D
MP%&;*/#-9'HY"7B7/G!>WI27-R5V''W85H"L&:XFW Y0Y*R$LX!_E?DJ7=#!
MO$V PL\50DQ5)3#V3]/+Z.CU<4 ;U5SS[I!P:N1+RA(&>1,\AKL9(1^9XS_4
MW[8I@!'>#\YZ,I\C'2RC0LT5O#1;*8"\"E#P.@/"4^5%&B*SOQ0\Y040<Q!*
M4J!4BPC$'J:]P8<?"[5)T@6M,Z\> +?GWE#!H>=(%?:_@[= OY&VKQDH$2P+
MSA3G1O!LD(VT[!R.]SX%P,B4C6]]G^>+)R"&X2$N%:QF$57 .?9\_X&A!"B]
M4DFIHB*]?Z@Z^;*S+57+5C\0R/:!JOF9/J]5FLS2%4A!*L0?@Q:;9(<X<< 8
M+SCX^F:=49HW.0^GVX\<>UZ\58_YZI$F1^X(JY[#^:3AB=#,JSR[[P"57C\_
M]YX7D'*D%:)8R;>2@'2OLGGX,FH/;\H-R'[__@K4@U(5C^K5[Z* GB'Y><A7
M"U64__:OXWYO]!TA<K4+B8%#5NG5_G<N;?TNZG6[<9?_*UI&E&RK![@Y?U<+
M>'P6GYV=Q>/A&2T>_ASU!W%W=*9?3LL2#YSNL26'@'X(W3]L <J#+I&Q,;T#
MA$TAO]7$;10#]2DWBACA*N *MZH"G0C&!\DR@W%;P%^V J2!1N !%/EJA<M,
MD0N#?-4R;O,8P9$;2M+$U@[A T<?$T3=!T42_S'PA=?1MRU*'TE4)/@"@-^E
M&8R3HC"3BU+3KK?Y+-;@0'249M$" )(4<.?A:&C>@"7Y7P>H0J/PKX=]*HCS
MTL]<)-O[;2/<#? (/3\8*D4GB (,H!%\AD(9Z@YK ,XJ+\OC=D[M:-DAIY8Q
M[)&U'\Z-JN FD(3?0$)*(1[JRP9WU<#TX17<TJ;(%]LYO U[#BP"4\58CR.M
MD^*SJAHDEUL@.TDQ9Q%B 2M:Y<0@ ZZG,H6J)[Z6+-9I1MHM7N-054,9^>\$
MZ1;2'6RPG6VD[KDT,&RZS_)6ZV.9IN6\Y,R71;X6<KW%F2U3BV9JF1=*KP7X
M>[CB:_,L.I+ICN&[3"U#?J/G?6_GO;#S6C2-(T03.&;016/$T-66+L)'!#!<
ME4E5%>EL6R';CJH\JE$[O?TX(K '\LIA'!R7L/<0\(4C?N,XPC>BI(K*[:Q,
M%VD"6G=26V5V($T.)@Y&F@O%<-A!(,\+(]%#&(+W3Q\,:,I%(W)UHEE2IO,#
MZ?+/74/+J?^35_'/G*L-ZHMTM:V$)?V_A/L_=QTOF^W/"I43M>@DC[!BT*1#
MMAP8#YW#;>'6_BK:Q0&'/?]L0N /]X^@5YJWM2[[JX064N_?K?*G/>8#>F=)
M[Q SR0WW)(M3L]X7DM=V!ABP^,5/VU*4'(!0H>"K.=K*LQ<,2K"%]\ENL4%[
MX0)V/]M%1UN$29H='[:12P4 !Z&86"*))XX TL;Z/66]Y1W2NSJ S6I!QPKO
M- HUH.04I-P",F=HE, -&;VOPG\";LFVFS04?#]]1E:Q[STJ!GUT#[I2(]=D
MJU>)ZQ%+#8+%TV"62]3!['GL!W&#Z6B_]NY,F^^Q7=1M#PWVH3VJ]LW+D><%
M./X5HS]W+_GLGH/U8I&:^[%I-%X%)JXM"/" @$0P6-(G:)9L"&TVBLV56LBZ
MRH1-M@=]ZJTOK5O,6J$H@&N$P7-P6[+:NQ]N;_.BR)^(-<*UWV_PN56 <$)B
MGWN7%B.OTUL'7FR80XX%OW+XB[!0VED+;]D_ELOMG@=X$_":/EHX5&Q^J$VY
MU?B,/'6F[M,LHUNV1!DCS0,5=>_W"HE!VY?3[6:S(C8)3-=077,K8Q?18)R#
M4.@6^-A]QG85F-A><;9=MM#2ZJ'(M_>PC46^T9].IA?1^+3_4HZ/GUZ18:F=
MV3?J<J[M)+@8;'R*H[?N>8C[%<#L.A\"!]C>CQWI[=F!0'ME]#K2[/(8,8T\
M+"*R?:/W_M=;N _1N[QX2HI%8#II8\O[A,G:9>0;N.=]L^TKQD$+K;T&H);/
M:G Z;(@#3NME'^\YK4,WXB\^C+IX\?[#(3X4]TFFA3>\:F]!FR#&]A$MY'#=
MFXBM^U7L7"X]B/NM;TAUI.UV:]V'V^\G-]?_.;F[_G 336XNH[>3Z?4T^O N
M^GA[-;VZN:,G7_=5]$PH2'2$)NY^]SO[7DR_]+X#TJ,B_93=L>91CC*780+X
M(C(:]85HC'SSI,SK\LNV= >0'_-M(3_"E07Z%Z$!'V '-W7C+9BN(RPB6F)0
M!^JY/',RAWO-]NK8M3&*@V2]5@6.IT\=%C@K$HQQBM K,B]2IJO:V'D2W<&@
MLN%O0'@LTC4RUBHI[H&1L10#ZP2=^"$O-RGYQ^:@;P*7*5C&O$_@I'.%[#9?
MY?<[&A*(PQHD -R(WB')RO -D Y$#,6V;Q $"[5*V(>!<)U37$YE%XPNCQE)
M9-4#8'QEUPM<<94""$I83 9_ 'L#)8@_5BR5TZ@P1XFN^UBV!8]13 .Y(2_F
M"F#@H T<RH(6CF^QU @2*PL46?Y("[6F8EI1NL:75/2W+< = S^6#!P8'80=
MV+?V7R427[+-UFB+A*=YCA%=^)>&5H:BI+<B1@#00$AG* &#YHIDK77R)5VG
M?\>U,4[JPX=Q*PRV@7_!6O [O> 8$?D)0PZ24F,/?I^I)_T.PG)!S!3?AOF!
MTD<S4"18HLI@T':T@X\WAIM[N"6^);L4PH5UDFV7@ S;@E&A>DB+!?I7\/LX
M>GI(T9H.+V)<7:E4AB]9V)A!->A% !0SO1X;=PC3+@'V@/M #+R514]Y\1E0
M"'1L1):G%+=*9PMKZ>!:=NBA94,&W1WX*4,+$*#'.OFL/ A'R6.2KDCN%UKQ
M":0@+9C S-?\*\)=+B@L-+E7[$GG*RYW']>]S9+M@@:8&X%G[@H\2T-^2\_8
MX=Z3AP30<X;@VV#P0,'D)"'K4LFB=XD8PYO'+^O.QO/(6<8SD],U(@,[[ 51
MS5HX8CV9L-,\ XAG&-JY0GT8]%02*]T/,EA)61)-RJ-EDN*%V3 +HI6F&8>&
M(C!!IL1;!WL M5>EV4DT@?G+% 11##RCX ; 84U:$ZTRXXHQOK!$@1;5,0LP
MH#!KV&3%M'_N<D/&HJ\[H(8300L#+*A8D'O3G$2A[K<KL?+(L4Z-0DDK-Z$Y
MY"\G'(^.''8VO;K0/(=O]!S4X(3T1PLZ<EFE)=Z"+0IT=H%V6T"Q\G5:X:82
MLG3*'W1Q85E7%T3S",;I6I0-?5@69.77 JU\R+>K!1)ZC/^5\_AIF]&A68B]
M#%,SH)6EQE<:%"AL-,DR("D2I(:7!23H==3K=OY(6\1I=ABRJ8BUAK?%A3_]
MT#Z@/AM&)P#6=L4WV#'OZ3E!/U) -3ETF>?^@3R.6@0D8@E;,M<FA>N29L30
MD',)!NE9X$H!--%,-B<@R33(/)"!<70I;11E()1&MDBKY6A/HF?MM(:X+-"M
MBO055M!@V3Q\?W!D"- 3WPO@^*,G)2'RMD2D6FX+,H'!L=[ 00/ 06IBCH!Q
MW#A2[#);$F,(#0 T"<X!RV:R/[F'M1'/.WK5^/NK8\;!BQ60]GNX.;]7(/8\
MD"SP'J@(&>E?Z:>O2&=C#N?2ZD(!A#%N@P[B"Z E094BFTIMH-="GHJNJH>=
M,#PX##C&1K:#W^F)3^ 1J(@,;[C#AJPT;BJN"4=93L$]!%*,"%)(-H!T5RN*
M>$54D[_,?7299VR]Y[1F8)OK7$NJ*J6SDBU1_"SM2'"/%-1*F#DSVR4HMV2H
M"J]@7;)57]**#46X)C/"FJ)(--O=DCTJ JD325@B]Z.@2\M4KR56BUD(;S9X
M#B/J"V?)*D!IE0"Q7J96N =QQ5S15H*US/.*B1;>&F2P?!M+36E9<"W4<H7
M"Q954KBM3%,J1Q6X14,^.[_EJM ,8J2$E3@, T34#S]>7W: M'U$_6*=SJ-+
M?;'PQN)M97GFT\GT!$UB*V)S"?!FO!8L(RN,EE79?.<<)8E'VVH&1/ZSAL;1
M='([[5SD/W;ZR,0 #4$$C5#%3#.VXQ6PPL>TV(I0/D](:-:+Q&\P6BJ%\\A!
MEDA7*XSA]05!0&\@/2G&/M(RX&_0M+;,($4$MCMB,8=$8@;/:A<#D7/O"ZHE
MF)E"W%:M-ZM\!^2M3)9*S- HBG=FBHQL0 K0]+N"(3XKM=&0F$FXL6LEAR_)
MJ*P\10$%]4*M.>H+TV;H^/3W)/I7_FZUT94Q!CE!68KB(#S=IR*7**I4VKKV
M>R#@-+$.$F9QRY<]O\%9.)& U45GP294^D[-'S)4'E&D,3KZU9U1E37LW MT
M#V11R])X/[<9:@"P#Y3G$1" Q'@D?#-!N&?$>$K+!_,6QXN8%7V#UP(D15XI
M2/$YH8O67 %/038 65TT0Y06YXI/2<'"TKP@=^Z*3D @>$$LA2\K4%BRVUVP
MFG+B3\TZ:>X:;?!([<W5^@8PY15K@*(T>LI-[.FLOH2G=;PR 8#BKA!C_K95
MR*!/X$"?0+,KZ-:F!4T,6Z1%K%!Q7J'!/5V2I, ^&"0])1*O'%C)2FT>X/K,
MV<&"Q*>@/Y%AP>%PX@=>N2+!RYO,"W08TP'6#54)R)49"\*)U8V15I-3@I!
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MB.:AO^,88C3==( KI1CH9 0+1.2\-+"D &4+89B/'[MR&H.6?'1%_0L-@0%
M8.H%J]+P=!K*$6O8H(1CN"?;3A+:<QEI$,>AQYE ,(6S53=G,_&\Z AMIHG%
M8TKV7,00AA4G0Z*[3IYR<@&]3^N7Z'+B#C8,11BB1JN\,,CAWHP&YI<EE:@'
M3* TR_<520QER/)V"<3:/]S[4#:"J.G*\FQT7_S([NBG[>*>_F'LB2@$"YAA
M&\Y\R]P"('6E3! DT@RDYM4)H DA-,:W(,!HD4"1L%Y@N9W]I#@QCT+RPIF7
M#EC="6AZ(!>EMJ8[Z.9<$F,2=USP:;8 FEI(5!-A/VJM:X2;>TWDGC80@6L/
MV65.#)80O28&N=Q>TI7$4U9Y;'4W,@R7:(N$0^7CG4FAO*3\+,0A1J+V617?
M+D#L@,7ABG2)&"$? )Y=JE8+NC=U6ZHF)3:-!329.0ZKLOD#;@?SK1]Y&)=1
M;MA*0\HC;Y*,8867D^'!T41;H"**,'J;.)E 7FR/%A5]$=3DQ]AXC.9[3=+L
M+WFSR;EN([\Y\EC RV%8-I0;C:3B[T,HD*PB.E]5%R=803RB8$X>CCU<&$.B
M"#?8XK=$*FN51^WU%4Z&!YEFK0R5;[$3D,B4@CBQD8%\)15CQANI2HS@98+P
MS*RQF&Q5@O9+-LD"C7M3%U+#8'--+/2=YJCLYE\OZO+JZTB*V\&_3L_'<;<[
M]OYEG_;C'DC#P^[(^S</ZT.CF;[^W)G:R[=P\:>/L!M*:&U]T;RQ1YF^FMS>
M7-]\/X51/TRG,.K5;33]_>3VZN 7&[''U/5@[,E "*'80JD5AO<\H[^U8 :2
MRQQM_\H4>%&MY6I>'C[_!A;YW+N$6S=ZH6^BEU0Y@8,[ZL7C\2 ^[8V/^:_>
M>!2?G9T>M];O&??&<7\TB.#5TU'<&PP;IORJ^C+1>8SEH(\&L)QA][AQV.<+
M_M FNF=G\;#?I2V-!O%X!+N[M,?W)CJ@S ]C>N\[J>[3.XO[I]UXV#O%?YZ.
M^O'Y61^ A*'X0#C%\8-$AF0CYT8-!J-X>'X6 8SA\_&+YM98A64J1^-XT#W'
M?X[/>_!GMUT]9HT8@0K4EU7L?/Z98AS%7))KFV]NXP-.88Q^?\@C# ?Q.6"6
M7ILMPL#5"MVBEJ(+N^M'*4!(?>6E[;#ROP8IPAC_@IMCK\Q,480XNT(8PH8E
M8=C80L ?V/UN6RH-3A5+6;:N=3N-N;WZ\>KF4V!_,[^C%Y],L'HR3X@U:6ML
MN)4W]H:_F""E"PS^TF$="(.U:HM?Z(W)2N)%#=7*,M!8KL"A?4C:8V5$14HW
M!.F #1J%JFPDA&0A@JB\VOU=J$CF[$3JH=:7YD#$.%XRIQ*DDWFD=6=#DO^!
M]%).KGP33>;  A>82?$Z&O6 5)R?P[_&IT"+NOWHPQH3(M;YE\['Y'/4ZYW&
M([AVO7-X.AA%?T2I,B'O]2 >]'IPRX?XKR[<][-Q]&."QK@<N'IW'(^&@Z@_
M'L;#T3"Z2%:+? 6[ T)U/HS[YSWXUZ WBKNCT^C'=(:B&'#4T_Y9/#H[@W]U
MA]VX!Q3D@T12<"C5Z1DL8]B-1MWSN ]TA7F\!UW823P8=./1X)3^/>J?QV/X
MA =JQ%M4OA*=5R08ZB50V,Q:\E<T);/[$3)^R+4_EC.32+HL>))X)2.9^5A>
M+3>(,MI_J>.4)0$3G1ED0GO4/A,:P2964VJ.QC#S9BSR',^D(Q2RQ<H&8WO)
MQ93;06%O0M(L.:QM$$/$4\Y.\)5<G7%2VBVQHT,O&L=9H>]VR[D#MBR2=OV@
M9J&S3MU\L380![&XU6Z#MA?TDJ-'?:5SDDC6I_R=K%.H)9 EUEJVFPX0, H0
MY.I B6-B)PB:R7!X/TW/#S6SSGQR!U*R\;QJV;2DU6G(/ ML4]W 02]*V=$X
M5LN8,K61R*GOXMPW0,<?4#O3'M6%6I*!H0G?8L&)-0J059ZQ=HF^\/K1[W@Y
M,]4(^"+?224&#%#@(&A).UEZ^"P,@XB^LU/4I(V")5%_R+FW;-_EQ6C2O77W
M7W>R^=?/A\2!$*"PX=8-\95V_0<F8!>/@N+/"T5AB'AD%:NTA&]!G0FB7&1-
MAE-"<(AG<8E&QKGS@9Z"10D)F,<?"W%[)B2]8LH-XKKXCSWB*_BD$^CUB.RO
MU\&'5W>1+I5T3WUQ\"819Z,:7VI!]87]?A7R)L 3_K$6BK62,E4D"]?G,'SU
M?;I4T71.&2NE9#29BNQXU-H4(!C0^'XJUY1+),_Y1S%=2[!.B9]4::FY X8F
ME"1)+E>@\B-E7B6SB%R47@"@KHKA^"%F:>ZD1PF;^)Y X$4,5SH)DJ "(P"K
M0WQ!Q/M"KG4@8J^[)WU$O94FT?##T/SP<G'"EW(;?<OL/K^TD0_[_;\W=Q]N
M7^+1E?>?*X11#[P.DJ!@[,^H:2RQBO4#.O%R3$4E!IJ@4=JS67&I%V J#^G&
MT@%G3$HTES$+GZL0Z]0.4PPW(?*F;6FU^1/?0XOSF4!X_Q%Z)A_1@J%3@]W5
M^-2UPKC^)]((*;F4* ;/AW$SJV9.CJ9-TU%#&U KG3W#+J*""4I)"V0YB\0>
MQ'C'5TIO.+9HMM2:D+Y.FL7R+\S,6*OJ@9+T7:<TZ]W,F=D82**&QC>J66.J
MQX@;=K%5.G0:D]0X\(-[$Y6P^LXZ?V1M6X\RX\2YA")EF!P_ &ARL6OR+W"_
M?E)SHRMJLSV/0+F/V0+3F+ (QZ,06JEDX%HT:^'?R $-W9UCV1@6,!*)?R'A
M!+ G8[8(=$'5IL8H/XSBD:*93:=!$0"'^8XKSS9IXSF=\)FY22?4IX,_">Q-
M^1-*(H 7,E4O=^&$SR 623"@B>)A"<?)JL"/' 6#ZD,% EQ=&B9^[=1]XYFY
M&I)?N K. N,4J5""A$5//EZ;5%X<S)F=*_5H@=4_"7U3'<.T?SDG_ 4,K[.9
MMVOFL[)[BO/5=F^S;GE?RS&%-FH7R9,)\6.NXQ&5$_I0 \-J(48;(T@2GW,X
MN+%-^*.[^%:A1P<+K:7W&;VO'QD3>AE-;+L(:A^0SIWW\&HA.2 BI&E=H+UK
M_<\K(>:FQ>@(*]PF^7$P19J!27S8Z0QDO4%^G$+6W$C(I)<&!3<(5/E,HI>!
MK0X,6]4E@&O#,9'"-3HXC3<6A(ZJR&<)7!,L=<&X"-ND^U:^Y,[FIA!F?6XW
M:MS $P]=SQU3PL?KWIF5#WP*O$A9,.204DRG\CE7'6U:("K%_]S=8()YN!E/
MT*BYB+D0BQVSW61R@!?BUL/O)OQY'<&"3L^&\7@XXC\&I]05IQ'Y^_!L<'8:
MG?:&\>EPC'4&73B=QIA(=0X?G\;#X2D:9L5.X>ZH/X#QNW'O]!3&BT_[P[A_
M.N0XG#; 'J%%='@>GY_WC_F/LU/^(QR^%J0CHZ$]I'<&LY[UZ=_C42_NPT[J
M<MM[%+X#0R+_ND?<>W\UF1XHZ?&KR#ET48ZVI!^*AN[V3]P_G(#F0MF88**=
M1-^X"BG14:QAA64\)& .G;\ZO!($XOM:QCU5_6/=[-F:L"(ZSJ3O#[5]=:."
M<8#/:N<7)^'(::YE: WH;+^$]YU-:HYHQ,S$U&$'R;>AH1@K'K-5>E\KSK3B
M@_-QHE;XMJ4HGALI4O_"J()F#MJ*IY_T 4NQ"]7?MN0.4MSJ1&I9L+J$%9!T
MZ\DXNE,9ZH2*F3O).R;R$=/2_\;M9FFY&%I TPI^KRB5G,*U8- /\RKGK.9^
MGS<7;,!3:/?LHG<:]\-=/,'_F5(<C& ';8QUV%A<LS]1_%4G?T(B8SU(: JG
M\ D-=_'/H8;=I,4^#X\)H-V*\@Y.=%6JIHYMQCY1+!A1V/K"=>V,M,+E7.P
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M6Z5+-2Q3=TSW^HC#=WI:/N[F]>DJ^N0.MP>0N$V=C&_2Z9NGTV><OI/^5FV
M\!1;W["PUK4Y7*+*VH<"8?V]'TQG'(G,VDPTQ7[82_RF,9XX_4^0OK&:1>2
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MMR6I"4,B'Y[T@=?1;!0[0_<Q]N+IF=_Y7&:M3 B4#.F#1!>V6VB&PYS:K>*
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M(? UAL&]5.?:='^_D.[O>Y?@2@S.@X,6]*R!,$3<P"H8^!L]=MX*@A@KX)1
MDXFC[7G-&F3J+QUH_&NS\36=77@C#NQC'*.0.F^8C1K)MI&D:%]+V?I'?6XE
M&XVUU;[7CQ;)KJWM^I%OK#P('_2G+DZ%-CMC3D*$><>9]3](;P-^&^E;REQ]
M#W ]6:)E12\U705 :_XM8,=HPFKX;1!00F//:L9&'RM"^+JVK6>1+3!PO:@U
M*AQCP^.#\* 7_< H=H6.H0 &&SPWJ3(2R OYHWDXJC_\0Y+I$^\-PZ,&K7A
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ IXFV4,V ;W;N    *P(  !$
M             ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MIXFV4)E<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "GB;90"^K6=48#  "?#P  &
M    @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MIXFV4(F#P"*?!   "A4  !@              ( !<PP  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *>)ME Y8,=K\@$  ($%   8
M          "  4@1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "GB;90DS/ENWL$  #.%   &               @ %P$P  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ IXFV4+O_RX'_!   D!<
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M965T.2YX;6Q02P$"% ,4    " "GB;90\OL/2K8!  #2 P  &0
M    @ 'L)@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M *>)ME#C LS^MP$  -$#   9              "  =DH  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ IXFV4!,0ZH&V 0  T@,  !D
M             ( !QRH  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "GB;90-#=@D[8!  #2 P  &0              @ &T+   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *>)ME"V\B+=M@$
M -(#   9              "  :$N  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ IXFV4!!UU'.S 0  T@,  !D              ( !
MCC   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "GB;90
M5]@DRK8!  #2 P  &0              @ %X,@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( *>)ME#\-(F!M@$  -(#   9
M      "  64T  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ IXFV4 EZ25G. 0  G 0  !D              ( !4C8  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "GB;90/[U&G;<!  #2 P
M&0              @ %7.   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( *>)ME#%<V-%MP$  -(#   9              "  44Z  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ IXFV4)G%$,ZX
M 0  T@,  !D              ( !,SP  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "GB;90@VD35;8!  #2 P  &0
M@ $B/@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *>)
MME#FV89?PP$  #<$   9              "  0]   !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ IXFV4$3"-._5 0  G 0  !D
M         ( !"4(  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "GB;90NQJ^9+@!  #2 P  &0              @ $51   >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *>)ME!AJ3:'5@(  #0)
M   9              "  01&  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ IXFV4,B 5+"1 @  &@@  !D              ( !D4@
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "GB;90ZCZ_
M0N !  !I!   &0              @ %92P  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( *>)ME @1K;#*P,  "X-   9
M  "  7!-  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MIXFV4+70Z)[8 0  P@0  !D              ( !TE   'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "GB;902@$+9T("  "S!@  &0
M            @ 'A4@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( *>)ME"=W#LPI $  +T#   9              "  5I5  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ IXFV4#[W1M0* @
MA@4  !D              ( !-5<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "GB;902,]#C1X"   X!@  &0              @ %V
M60  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( *>)ME"@
MKH%O)P,  & -   9              "  <M;  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ IXFV4(=]WV2+ @  G0D  !D
M     ( !*5\  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *>)ME!]16%\:@(  &\(   9              "
M >9L  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ IXFV
M4'9KF&.O 0  PP,  !D              ( !AV\  'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " "GB;90">)8W*]%  !"!@$ %
M        @ %M<0  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " "G
MB;90G.W-,#$"  !]"0  #0              @ %.MP  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( *>)ME 78R3%KP,  "0<   /              "  :JY
M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "GB;90Y2$PY+ !   #&@
M&@              @ &&O0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " "GB;90,)0TP:\!  ! &@  $P              @ %NOP
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,P S -<-  !.P0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608782912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair value of marketable securities, by type</a></td>
<td class="text"><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the fair value of our marketable securities, by level within the fair value hierarchy, as of each period end:</span></div><div style="margin-top:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:27.368%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.160%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.162%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level 2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of marketable  securities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">498,008&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,119,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608318800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Lease Position</a></td>
<td class="text"><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March 31, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"><tr><td style="width:1.0%;"/><td style="width:29.316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.187%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.005%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,733,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"><tr><td style="width:1.0%;"/><td style="width:29.316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.187%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.005%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">943,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,831,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,775,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,996,903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:76.078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.971%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">844,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,100,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(325,616)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,775,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6899489248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (1,883,418)<span></span>
</td>
<td class="num">$ (1,187,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">818,273<span></span>
</td>
<td class="nump">1,147,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">9,525<span></span>
</td>
<td class="num">(33,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (1,055,620)<span></span>
</td>
<td class="num">$ (73,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">15,240,614<span></span>
</td>
<td class="nump">15,472,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive effect of other securities (in shares)</a></td>
<td class="nump">337,695<span></span>
</td>
<td class="nump">418,618<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">15,578,309<span></span>
</td>
<td class="nump">15,891,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630706992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:58.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.618%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.210%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,883,418)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,187,554)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">818,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,147,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,460)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,055,620)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73,878)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,240,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,472,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">418,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,578,309&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,891,570&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020 and 2019, restricted stock awards and options to purchase 431,226 and 263,919 shares of common stock, respectively, were outstanding but were not included in the computation of diluted earnings per share because the effect would be antidilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760058192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (1,065,145)<span></span>
</td>
<td class="num">$ (40,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations</a></td>
<td class="nump">818,273<span></span>
</td>
<td class="nump">1,147,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(1,883,418)<span></span>
</td>
<td class="num">(1,187,554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) from continuing operations to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,152,062<span></span>
</td>
<td class="nump">1,076,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">264,574<span></span>
</td>
<td class="nump">364,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(543,006)<span></span>
</td>
<td class="num">(269,422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">11,333<span></span>
</td>
<td class="nump">10,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Noncash investment gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(44,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,014,438<span></span>
</td>
<td class="num">(1,361,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">706,102<span></span>
</td>
<td class="nump">494,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current assets and other assets</a></td>
<td class="nump">1,093,517<span></span>
</td>
<td class="nump">134,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(2,394,824)<span></span>
</td>
<td class="nump">474,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(865,109)<span></span>
</td>
<td class="num">(353,925)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities from continuing operations</a></td>
<td class="num">(444,331)<span></span>
</td>
<td class="num">(618,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">1,332,870<span></span>
</td>
<td class="nump">232,942<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">888,539<span></span>
</td>
<td class="num">(385,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(22,726)<span></span>
</td>
<td class="num">(27,474)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,816,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,483,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(548,435)<span></span>
</td>
<td class="num">(363,711)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(571,161)<span></span>
</td>
<td class="num">(1,723,388)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">18,500,000<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(18,500,000)<span></span>
</td>
<td class="num">(19,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash payment of contingent consideration</a></td>
<td class="num">(260,735)<span></span>
</td>
<td class="num">(507,505)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Repurchase of subsidiary shares from noncontrolling interest</a></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(442,544)<span></span>
</td>
<td class="num">(712,919)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(1,503,279)<span></span>
</td>
<td class="num">(1,220,424)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(1,185,901)<span></span>
</td>
<td class="num">(3,329,545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">28,212,635<span></span>
</td>
<td class="nump">27,938,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">27,026,734<span></span>
</td>
<td class="nump">24,609,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental non-cash operating, investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of operating lease assets and liabilities through adoption of ASC 842</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,629,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11374-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6759089792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 18, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cumberland Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, no par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,230,746<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6923675888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br></strong></div></th>
<th class="th">
<div>Apr. 20, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="nump">$ 2,187,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security Act, Debt Instrument, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CoronavirusAidReliefAndEconomicSecurityActDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617401888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_EquityAndDebtAbstract', window );"><strong>Equity and Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY AND DEBT</a></td>
<td class="text">SHAREHOLDERS&#8217; EQUITY AND DEBT<div style="margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share repurchases</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations.  During the three months ended March 31, 2020 and March 31, 2019, the Company repurchased 164,876 shares and 121,466, respectively, of common stock for approximately $0.7 million and $0.7 million, respectively. </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share purchases and sales</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the Company's March 2020 trading window, several members of Cumberland's Board of Directors entered into share purchase agreements of the Company's stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934. These purchases are designed to increase ownership in the Company by the members of the Board.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Share Sale</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2017, the Company filed a Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018 including an At-The-Market ("ATM") feature enabling the Company to sell shares at market prices.  The Company did not issue any shares under the ATM during the three months ended March 31, 2020 or March 31, 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Share Grants </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2020, and March 31, 2019, the Company issued 229,141 shares and 222,269 shares of restricted stock to employees and directors, respectively. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant and for directors on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ4MzVlZDhhMzI2MTQ0NWNiMGVmZjAyM2EyZTJjYTFhL3NlYzo0ODM1ZWQ4YTMyNjE0NDVjYjBlZmYwMjNhMmUyY2ExYV80OS9mcmFnOmVlYTcxZmI2NTUwOTQ0OTQ5NTRjOGQxY2M0YjA0YWY4L3RleHRyZWdpb246ZWVhNzFmYjY1NTA5NDQ5NDk1NGM4ZDFjYzRiMDRhZjhfMjA0MA_be8c0114-58e3-40ca-8fab-05faba05647c">one</span>-year anniversary of the date of grant.  Stock compensation expense is presented as a component of general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cumberland Emerging Technologies</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, Cumberland Emerging Technologies ("CET"), our majority-owned subsidiary, entered into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">an agreement with WinHealth whereby WinHealth made a $1&#160;million investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1&#160;million investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals agreed to return it's shares in CET in exchange for consideration of  $0.8&#160;million.  </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Debt Agreement</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On May 10, 2019, the Company entered into a third amendment ("Third Amendment") to the Revolving Credit Loan Agreement, dated July 28, 2017, with Pinnacle Bank (&#8220;Pinnacle Agreement&#8221;). The Third Amendment extended the term of the Pinnacle Agreement through July 31, 2021 as well as modified certain definitions and terms of the existing financial covenants, including the definition of the Funded Debt Ratio and the compliance target of the Tangible Capital Ratio. Both Third Amendment modifications were related to the Vibativ transaction.  Under the Pinnacle Agreement, Cumberland was initially subject to one financial covenant, the maintenance of a Funded Debt Ratio, as such term is defined in the agreement and determined on a quarterly basis.  On August 14, 2018, the Company amended the Pinnacle Agreement ("First Amendment") to replace the single financial covenant with the maintenance of either the Funded Debt Ratio or a Tangible Capital Ratio, as defined in the First Amendment.  The Company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2020.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The initial revolving line of credit under the Pinnacle Agreement was for up to an aggregate principal amount of $12.0 million with the ability to increase the principal amount available for borrowing up to $20.0 million, upon the satisfaction of certain conditions.   On October 17, 2018, the Company entered into a second amendment (&#8220;Second Amendment&#8221;) which increased the maximum aggregate principal available for borrowing under the Pinnacle Agreement to $20.0 million.   </span></div>The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 3.73% at March 31, 2020).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  Borrowings under the line of credit are collateralized by substantially all of our assets. As of March 31, 2020  and December 31, 2019, the Company had $18.5 million in borrowings outstanding under our revolving credit facility.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EquityAndDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity and Debt [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EquityAndDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636935920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The PPP is administered by the U.S. Small Business Administration.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The loan matures April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly commencing during November 2020. The note may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company intends to use the majority of the loan amount for such qualifying expenses.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, thanks to assistance from the PPP loan, the Company currently does not foresee doing so. Cumberland will continue to monitor and evaluate changes to this program as they emerge and will take appropriate action, if necessary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638077712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liabilities Maturity and Future Minimum Lease Commitments) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Leases Liabilities at March 31, 2020</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 844,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">1,144,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">1,019,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">92,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">3,100,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(325,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,775,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6614994896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">$ 15,569,992<span></span>
</td>
<td class="nump">$ 15,554,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6760515440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Narrative (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 12, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Direct expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Discontinued operations income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Agreement | Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember', window );">Agreement | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Financial consideration received in exchange for product license rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Percentage of tiered royalty payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,829,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,633,589<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 9,034,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liability recorded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Vested common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Additional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Unvested restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_ClinigenHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630706992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care and gastroenterology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality control and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements of the Company have been prepared on a basis consistent with the December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly present the information set forth herein. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared in accordance with the regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and certain information and disclosures have been condensed or omitted as permitted by the SEC for interim period presentation. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2019 (the &#8220;2019 Annual Report on Form 10-K&#8221;). The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the entire fiscal year or any future period.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total comprehensive income (loss) consisted solely of net income (loss) for the three months ended March 31, 2020 and 2019.</span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Discontinued Operations</span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As discussed further in Note 10, during May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified on the face of the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 10, for additional information.</span></div><div style="text-align:justify;margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">COVID-19 Pandemic </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During March 2020, the U.S. declared a health care emergency following the outbreak of the (SARS-CoV-2), a novel strain of coronavirus that causes COVID-19, a respiratory illness.  The Company is monitoring this situation both in the U.S. and internationally, so Cumberland can maintain employee safety and well-being, while also keeping the business operating and secure.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has remained open for business, as the Company is considered to be essential by the United States Department of Homeland Security. All of the Company's corporate and Cumberland Emerging Technologies (&#8220;CET&#8221;) employees have been given the opportunity to work remotely, and those that wish to work from Cumberland's office and laboratories are encouraged to practice the behaviors outlined by the Centers for Disease Control.  Cumberland's sales organization has continued to make calls on medical professionals, providing information and product samples as requested. However, their contact has largely shifted from in person to telephonic and electronic communications.  Travel across the organization and attendance at medical meetings have largely been discontinued.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland relies on third-party organizations around the world to supply components, manufacture and distribute its products. The Company is aware that it may experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the ongoing COVID-19 pandemic. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During this national health care and economic crisis, Cumberland understands that the volume of patients seeking health care was negatively impacted by the stay-at-home orders across the country. Declines in hospital admissions, patient visits to physician offices and postponement of elective surgeries have all been reported. As a result, Cumberland is facing the same headwinds that are affecting all companies that rely on these factors to help drive revenue. While the Company expects these dynamics to improve as the country reopens, it cannot be determined at this time when and to what extent that improvement will occur.</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Given the uncertainty, magnitude and impact of such changes, the Company is unable to fully quantify the impact on the future results as of the date of this filing.</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Guidance</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Adopted Accounting Pronouncement</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2018, the FASB issued ASU No. 2018-18, &#8220;Collaboration Arrangements: Clarifying the Interaction between Topic 808 and Topic 606&#8221; (ASU 2018-18). The issuance of ASU 2014-09 raised questions about the interaction between the guidance on collaborative arrangements and revenue recognition. ASU 2018-18 addresses this uncertainty by (1) clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASU 2014-09 when the collaboration arrangement participant is a customer, (2) adding unit of account guidance to assess whether the collaboration arrangement or a part of the arrangement is with a customer and (3) precluding a company from presenting transactions with collaboration arrangement participants that are not directly related to sales to third parties together with revenue from contracts with customers. Cumberland adopted the standard effective January 1, 2020 with no impact on the Company's consolidated financial statements.</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2017, the FASB issued ASU No. 2017-04, &#8220;Simplifying the Test for Goodwill Impairment&#8221; (ASU 2017-04). The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation.  As a result of the revised guidance, a goodwill impairment will be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The new standard was adopted by Cumberland effective January 1, 2020 and was applied prospectively with no impact on the Company's consolidated financial statements. </span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;margin-top:7pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company will adopt both ASU 2016-13 and ASU 2019-05 on January 1, 2023 . The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accounting Policies:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration: underline;">Use of Estimates</span></div><div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory (3) assumptions used in estimating acquisition date fair value of assets acquired in business combinations and (4) valuation of contingent consideration liability associated with business combinations.</span></div>Operating SegmentsThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, has concluded that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States and total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6748663888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,318,529<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,318,529<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615041872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 8,330,734<span></span>
</td>
<td class="nump">$ 8,729,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">713,899<span></span>
</td>
<td class="nump">849,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">114,770<span></span>
</td>
<td class="nump">199,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">3,311,696<span></span>
</td>
<td class="nump">3,307,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">208,763<span></span>
</td>
<td class="nump">286,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">1,096,291<span></span>
</td>
<td class="nump">1,317,074<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">2,425,755<span></span>
</td>
<td class="nump">2,060,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">459,560<span></span>
</td>
<td class="nump">709,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant | Collaborative Arrangement, Federal Small Business Grant Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ProductsAbstract', window );"><strong>Products:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130543-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130539-203045<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630834272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Summary of net revenue</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s net revenues consisted of the following for the three months ended March 31, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.321%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="width:1.0%;"/><td style="width:13.058%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.891%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Products:</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acetadote</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">713,899&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">849,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Omeclamox-Pak</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">114,770&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">199,537&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Kristalose</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,311,696&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,307,658&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vaprisol</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">208,763&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,676&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Caldolor</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,096,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,317,074&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vibativ</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,425,755&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,060,195&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other revenue</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">459,560&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">709,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net revenues</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,330,734&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,729,860&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6921813888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation Organization (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6923010736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Change in Consideration (Details) - Vibativ - USD ($)<br></strong></div></th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualRollForward', window );"><strong>Loss Contingency Accrual [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 9,034,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,633,589<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment', window );">Adjustment to initial fair value of the contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,735)<span></span>
</td>
<td class="num">(1,033,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration included in operating expenses</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(543,006)<span></span>
</td>
<td class="num">(804,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued in operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">820,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 9,502,000<span></span>
</td>
<td class="nump">$ 7,829,848<span></span>
</td>
<td class="nump">$ 8,633,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Contingent Consideration, Liability, Initial Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationArrangementsContingentConsiderationLiabilityInitialFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6759179744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2018</a></td>
<td class="nump">$ 55,570,501<span></span>
</td>
<td class="nump">$ 51,098,613<span></span>
</td>
<td class="nump">$ 4,746,154<span></span>
</td>
<td class="num">$ (274,266)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,481,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">364,434<span></span>
</td>
<td class="nump">$ 364,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(703,790)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(121,466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(40,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,878)<span></span>
</td>
<td class="nump">33,460<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2019</a></td>
<td class="nump">55,190,727<span></span>
</td>
<td class="nump">$ 50,759,257<span></span>
</td>
<td class="nump">4,672,276<span></span>
</td>
<td class="num">(240,806)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,547,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, Beginning of Period at Dec. 31, 2019</a></td>
<td class="nump">$ 51,085,253<span></span>
</td>
<td class="nump">$ 49,914,478<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, Beginning of Period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,263,555<span></span>
</td>
<td class="nump">15,263,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="nump">$ 264,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">(441,624)<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,876)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,065,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,620)<span></span>
</td>
<td class="num">(9,525)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, End of Period at Mar. 31, 2020</a></td>
<td class="nump">$ 49,843,058<span></span>
</td>
<td class="nump">$ 49,737,428<span></span>
</td>
<td class="nump">$ 152,775<span></span>
</td>
<td class="num">$ (47,145)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, End of Period (in shares) at Mar. 31, 2020</a></td>
<td class="nump">15,318,529<span></span>
</td>
<td class="nump">15,318,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758786096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 27,026,734<span></span>
</td>
<td class="nump">$ 28,212,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">5,949,910<span></span>
</td>
<td class="nump">7,843,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,150,152<span></span>
</td>
<td class="nump">8,871,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="nump">1,291,359<span></span>
</td>
<td class="nump">2,477,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,318,862<span></span>
</td>
<td class="nump">2,757,456<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">44,737,017<span></span>
</td>
<td class="nump">50,163,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Non-current inventories</a></td>
<td class="nump">15,569,992<span></span>
</td>
<td class="nump">15,554,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">694,499<span></span>
</td>
<td class="nump">747,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">30,142,611<span></span>
</td>
<td class="nump">30,920,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">882,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">21,802<span></span>
</td>
<td class="nump">21,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,733,782<span></span>
</td>
<td class="nump">2,960,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,637,434<span></span>
</td>
<td class="nump">3,298,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">97,419,137<span></span>
</td>
<td class="nump">104,549,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,247,899<span></span>
</td>
<td class="nump">9,993,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="nump">1,247,011<span></span>
</td>
<td class="nump">1,918,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">943,807<span></span>
</td>
<td class="nump">920,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">8,933,874<span></span>
</td>
<td class="nump">11,317,358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">19,372,591<span></span>
</td>
<td class="nump">24,150,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">18,500,000<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,831,274<span></span>
</td>
<td class="nump">2,076,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_OtherLongTermObligationsExcludingCurrentPortion', window );">Other long-term liabilities</a></td>
<td class="nump">7,872,214<span></span>
</td>
<td class="nump">8,737,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">47,576,079<span></span>
</td>
<td class="nump">53,464,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;no par value; 100,000,000 shares authorized; 15,555,865 and 15,723,075 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">49,737,428<span></span>
</td>
<td class="nump">49,914,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">152,775<span></span>
</td>
<td class="nump">1,208,395<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">49,890,203<span></span>
</td>
<td class="nump">51,122,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(47,145)<span></span>
</td>
<td class="num">(37,620)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">49,843,058<span></span>
</td>
<td class="nump">51,085,253<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 97,419,137<span></span>
</td>
<td class="nump">$ 104,549,283<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherLongTermObligationsExcludingCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Long Term Obligations, Excluding Current Portion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherLongTermObligationsExcludingCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6922282960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of numerator and denominator</a></td>
<td class="text"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table reconciles the numerator and denominator used to calculate diluted earnings (loss) per share for the three months ended March 31, 2020 and 2019:</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.122%;"><tr><td style="width:1.0%;"/><td style="width:58.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.616%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.537%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.618%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:57.210%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:17.883%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.823%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.884%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) from continuing operations</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,883,418)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,187,554)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discontinued operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">818,273&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,147,136&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) at subsidiary attributable to noncontrolling interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,460)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss) attributable to common shareholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,055,620)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(73,878)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,240,614&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,472,952&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dilutive effect of other securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">337,695&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">418,618&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,578,309&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,891,570&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633371872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.631%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.369%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,034,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">508,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,502,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,033,108)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(804,167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">820,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,633,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(260,735)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(543,006)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,829,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6632947808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Details Textual) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock available for purchase through restricted stock awards and options (in shares)</a></td>
<td class="nump">431,226<span></span>
</td>
<td class="nump">263,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6632847168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Schedule of Preliminary Purchase Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="nump">$ 882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory', window );">Finished goods inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,624,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials', window );">Work in process - unlabeled vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials', window );">Work in process - validation vials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,827,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,129,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Total inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intellectual property amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill', window );">Total intangibles and goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,632,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finished Goods Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinishedGoodsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles and Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFiniteLivedIntangiblesAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Raw Materials Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRawMaterialsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Unlabeled Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryUnlabeledVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Work in Process Inventory, Validation Vials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWorkInProcessInventoryValidationVials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=108330185&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6607668464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases classified as operating leases. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company&#8217;s significant operating leases include the lease of approximately 25,500 square feet of office space in Nashville, Tennessee for its corporate headquarters.  This lease currently expires in October 2022.  The operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  This lease currently expires in April 2023. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating lease liabilities are recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms.  The weighted-average incremental borrowing rate used to discount the present value of the remaining lease payments is 7.42%. The weighted-average remaining lease term at March 31, 2020 is 2.7 years.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Lease Position</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At March 31, 2020 and December 31, 2019 , the Company's lease assets and liabilities were as follows:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"><tr><td style="width:1.0%;"/><td style="width:29.316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.187%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.005%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right-of-Use Assets</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,733,782&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,960,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:6pt;margin-bottom:6pt;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.637%;"><tr><td style="width:1.0%;"/><td style="width:29.316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:27.500%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.187%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.464%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:16.005%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease Liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance Sheet Classification</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other current liabilities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">943,807&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">920,431&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Noncurrent:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,831,274&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,076,472&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,775,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,996,903&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.368%;"><tr><td style="width:1.0%;"/><td style="width:76.078%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.751%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.971%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturity of Leases Liabilities at March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating Leases</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">844,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,144,889&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,019,313&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2023</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">92,478&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">After 2023</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,100,697&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Interest</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(325,616)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,775,081&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608785888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ADDITIONS AND RETURN OF PRODUCT RIGHTS</a></td>
<td class="text">ADDITIONS AND RETURN OF PRODUCT RIGHTS<div style="text-align:justify;margin-top:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Vibativ</span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, Food and Drug Administration ("FDA") approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $20.0 million at the closing of the transaction and a $5.0 million milestone payment in early April 2019. In addition, Cumberland has agreed to pay a royalty of up to 20% on future net sales of the product.  The future royalty payments are required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the initial payments and consideration for the business combination:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.631%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.369%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consideration:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid at closing</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment during early 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,000,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair value of contingent consideration - net sales royalty</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total consideration </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration liability represents the future net sales royalty payments discussed above.  Cumberland prepared the valuations of the contingent consideration liability and the intangible assets utilizing significant unobservable inputs.  As a result, the valuations are classified as Level 3 fair value measurements. </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at November 12, 2018</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,034,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(40,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">508,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,502,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment to initial fair value of the contingent consideration liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,033,108)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(804,167)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">820,864&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,633,589&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash payment of royalty during the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(260,735)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in fair value of contingent consideration included in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(543,006)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration earned and accrued in operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,829,848&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the final allocation of the fair values of the assets acquired as part of the acquisition of Vibativ:</span></div><div style="text-align:justify;margin-top:8pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:75.923%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:20.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,624,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - unlabeled vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,970,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work in process - validation vials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,827,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,129,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventory</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,550,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual property amortizable intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,750,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">882,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total intangibles and goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,632,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets acquired</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,182,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RediTrex</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In November 2016, the Company announced an Agreement to acquire the exclusive U.S. rights to Nordic Group B.V.&#8217;s ("Nordic") injectable methotrexate product line as an asset purchase. The products are designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the terms of the Agreement, Cumberland is responsible for the products&#8217; FDA submission and registration. As consideration for the license, at closing, Cumberland paid a deposit of $100,000.  The Company also recorded a liability of $0.9 million that was settled through 180,000 unvested restricted shares of Cumberland common stock.  These shares vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Nordic is responsible for manufacturing and supply of the products. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On November 27, 2019, Cumberland received FDA approval for the RediTrex product line and brand name. The 180,000 shares of restricted Cumberland common stock vested and were valued at $0.9 million on the vesting date. In addition, the FDA approval resulted in Cumberland recording an additional $1.0&#160;million other current liability due to Nordic that will be paid during 2020.    </span></div><div style="text-align:justify;margin-top:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Ethyol and Totect </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. The Dissolution Agreement originally resulted in a transition from the Company's current arrangement with Clinigen effective September 30, 2019.  In early September 2019, Clinigen and Cumberland completed an Amendment to the Dissolution Agreement whereby the transition date was changed to late December 2019. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products after December 31, 2019.  In exchange for the return of these product license rights and not competing with either product, Cumberland will receive $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date. Cumberland recorded the first installment of $0.8&#160;million during the quarter ended March 31, 2020 </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">as discontinued operations and will record each future quarterly installment over the two year period.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> There are no expenses associated with the installment payments under the Dissolution Agreement, resulting in $0.8&#160;million in discontinued operations income during the quarter ended March 31, 2020. </span></div><div style="text-align:justify;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Ethyol and Totect products provided $3.2&#160;million in revenue, $2.0&#160;million in direct expenses and $1.1&#160;million in discontinued operations income during the three months ended March 31, 2019. These direct expenses do not reflect the selling and marketing costs attributable to the individuals at Cumberland responsible for direct selling and promotion of the Products.  Those selling and marketing individuals who supported the Products continue to support Cumberland's other products.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 31, 2019 current assets of discontinued operations included $0.5&#160;million in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">inventory for the products sold back to Clinigen as part of the transaction. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020 and December 31, 2019 </span>the remaining balance of the current assets of discontinued operations were accounts receivable and the current liabilities of discontinued operations were accounts payable associated with Ethyol and Totect.   The accounts receivable and accounts payable balances were not sold or disposed of as part of the Dissolution Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615329440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additions and Returns of Product Rights - Schedule of Initial Payments and Consideration (Details) - Vibativ - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payment to acquire business upon closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Cash payment during early 2019</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_PaymentsForContingentConsideration', window );">Fair value of contingent consideration - net sales royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,182,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,182,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PaymentsForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PaymentsForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761145920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Debt (Shareholders' Equity) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 13, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentCashContribution', window );">Contribution of cash</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable', window );">Conversion of intercompany loans payable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">WinHealth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment through purchase of shares of CET Stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Cash payments for return of shares</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock granted in period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,141<span></span>
</td>
<td class="nump">222,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock awards, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cpix_ShareholdersEquityTextualAbstract', window );"><strong>Shareholders' Equity (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,876<span></span>
</td>
<td class="nump">121,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of shares, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (441,624)<span></span>
</td>
<td class="num">$ (703,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shareholders Equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentCashContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Cash Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentCashContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Conversion Of Intercompany Loans Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentConversionOfIntercompanyLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6748629968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 19,456,867<span></span>
</td>
<td class="nump">$ 19,345,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">245,354<span></span>
</td>
<td class="nump">416,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,017,923<span></span>
</td>
<td class="nump">4,664,055<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, Gross, Total</a></td>
<td class="nump">23,720,144<span></span>
</td>
<td class="nump">24,426,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, Noncurrent</a></td>
<td class="num">(15,569,992)<span></span>
</td>
<td class="num">(15,554,992)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories classified as current</a></td>
<td class="nump">$ 8,150,152<span></span>
</td>
<td class="nump">$ 8,871,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetItemsNetOfReserveAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
